var images_info;if (!images_info) images_info =[]; images_info["56"]={"56001":{"type":"graphic_picture","displayName":"Sarcoma botryoides","title":"Sarcoma botryoides","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Sarcoma botryoides</div><div class=\"cntnt\"><img style=\"width:503px; height:422px;\" src=\"images/OBGYN/56001_Sarcoma_botryoides.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) Sarcoma botryoides in situ. A 29 year old woman presented with the complaint that &quot;something is falling out of my vagina.&quot; Histology and hysteroscopy confirmed sarcoma botryoides, originating from the uterus. Panel B) Gross pathology specimen. Panel C) Hysteroscopic view of sarcoma botryoides.</div><div class=\"graphic_reference\">Courtesy of Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 56001 Version 2.0</div></div></div>"},"56002":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of fetal liver in CDH","title":"Ultrasound images of liver position in two fetuses with CDH","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ultrasound images&nbsp;of liver position in two fetuses with CDH</div><div class=\"cntnt\"><img style=\"width:504px; height:258px;\" src=\"images/OBGYN/56002_USfetalliverherniation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Left) High resolution fetal ultrasound demonstrates fetal stomach (ST) herniated into the left chest and fetal liver (FL) below the level of the diaphragm. (Right) Ultrasound demonstrates poor prognosis herniation of fetal liver (FL) into the left chest.</div><div class=\"graphic_reference\">Courtesy of Holly L Hedrick, MD.</div><div id=\"graphicVersion\">Graphic 56002 Version 4.0</div></div></div>"},"56004":{"type":"graphic_figure","displayName":"Anatomy of the mandible","title":"Anatomy of the mandible","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Anatomy of the mandible</div><div class=\"cntnt\"><img style=\"width:505px; height:378px;\" src=\"images/PEDS/56004_Anatomy_mandible_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fractures of the condyle are most common in children younger than 10 years, whereas fractures of the symphysis, body, and ramus are more common in older children. Fractures at multiple sites occur in approximately 40 to 60 percent of cases and are more common among children older than 13 years of age.</div><div id=\"graphicVersion\">Graphic 56004 Version 4.0</div></div></div>"},"56005":{"type":"graphic_table","displayName":"Gaucher disease classification","title":"Gaucher disease classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gaucher disease classification</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Type 1</td> <td class=\"subtitle1\">Type 2</td> <td class=\"subtitle1\">Type 3a</td> <td class=\"subtitle1\">Type 3b</td> <td class=\"subtitle1\">Type 3c</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Onset</strong></td> <td>Childhood to adult</td> <td>First year</td> <td>Childhood</td> <td>Childhood</td> <td>Childhood</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hematologic</strong></td> <td>Anemia, thrombocytopenia</td> <td>Minimal thrombocytopenia</td> <td>Anemia</td> <td>More severe anemia and thrombocytopenia</td> <td>Minimal</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Skeletal</strong></td> <td>Osteopenia, osteosclerosis, bone pain/crises</td> <td>Minimal</td> <td>Osteopenia, osteosclerosis</td> <td>Severe skeletal findings, including vertebral compression fractures and osteonecrosis of the long bones</td> <td>Minimal</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Neurologic</strong></td> <td>Parkinson disease, may have peripheral neuropathy</td> <td>Oculomotor dysfunction, generalized seizures, hypertonia, profound mental retardation, apnea</td> <td>Progressive dementia, ataxia, and myoclonus</td> <td>Supranuclear gaze palsy</td> <td>Supranuclear gaze palsy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Other systems</strong></td> <td>Hepatosplenomegaly, hepatic fibrosis, interstitial lung disease, pulmonary hypertension, hematologic maligancies, delayed growth and puberty</td> <td>Hepatosplenomegaly, congenital ichthyosis</td> <td>&nbsp;</td> <td>Hepatosplenomegaly, thoracic lymph node enlargement, pulmonary infiltrates</td> <td>Cardiac and vascular calcifications, mild splenomegaly</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Progression</strong></td> <td>Slow</td> <td>Rapid</td> <td>Variable</td> <td>Variable</td> <td>Variable</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Life span</strong></td> <td>Shortened, may be normal</td> <td>Death before 2 years of age</td> <td>20 to 30 years</td> <td>Shortened (third to fourth decade)</td> <td>Shortened (third to fourth decade)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Mutation association</strong></td> <td>c.1226A&#62;G (N370S allele)</td> <td>Diverse</td> <td>c.1448T&#62;C (L444P allele)</td> <td>Diverse</td> <td>c.1342G&#62;C (D409H allele)</td> </tr> <tr> <td><strong>Ethnic predilection</strong></td> <td>100 times more common in Ashkenazi Jews</td> <td>None</td> <td>Norrbottnian region, Sweden</td> <td>None</td> <td>Spanish?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56005 Version 8.0</div></div></div>"},"56007":{"type":"graphic_picture","displayName":"Adenovirus inclusions liver","title":"Adenoviral inclusions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adenoviral inclusions</div><div class=\"cntnt\"><img style=\"width:381px; height:252px;\" src=\"images/ID/56007_Adenovirus_inclusions_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of adenovirus type 5 hepatitis in a bone marrow transplant recipient who died from fulminant liver failure. Intranuclear viral inclusions are present within multiple hepatocytes, representing cells at different stages of infection with adenovirus (arrows). A &quot;smudge&quot; cell with a large inclusion that obscures the nucleus is present (center arrow).</div><div class=\"graphic_reference\">Courtesy of Phyllis Flomenberg, MD.</div><div id=\"graphicVersion\">Graphic 56007 Version 1.0</div></div></div>"},"56009":{"type":"graphic_movie","displayName":"TR four chamber color Doppler echo","title":"Tricuspid regurgitation in carcinoid","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tricuspid regurgitation in carcinoid</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/56009_4chcodtrconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:266px; height:449px;\" src=\"images/CARD/56009_4chcodtr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from 2-D echocardiogram with color flow Doppler shows severe tricuspid regurgitation. The patient had a carcinoid syndrome with fibrotic tricuspid valve leaflets that were stenotic and immobile, remaining opened during systole.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 56009 Version 2.0</div></div></div>"},"56013":{"type":"graphic_figure","displayName":"Ethylene glycol metabolism","title":"Ethylene glycol metabolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ethylene glycol metabolism</div><div class=\"cntnt\"><img style=\"width:394px; height:620px;\" src=\"images/EM/56013_Ethylene_glycol_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Blocked by ethanol and fomepizole.</div><div id=\"graphicVersion\">Graphic 56013 Version 1.0</div></div></div>"},"56014":{"type":"graphic_figure","displayName":"Proximal fifth metatarsal fracture zones","title":"Schematic representation of fracture zones for proximal fifth metatarsal fractures","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Schematic representation of fracture zones for proximal fifth metatarsal fractures</div><div class=\"cntnt\"><img style=\"width:590px; height:350px;\" src=\"images/EM/56014_prox_fifth_fx_scheme.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56014 Version 4.0</div></div></div>"},"56015":{"type":"graphic_table","displayName":"Characteristics of neuroendocrine tumors","title":"Characteristics of gastroenteropancreatic neuroendocrine tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of&nbsp;gastroenteropancreatic neuroendocrine&nbsp;tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"3\" width=\"26%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Foregut</td> <td class=\"subtitle1\">Midgut</td> <td class=\"subtitle1\">Hindgut</td> </tr> <tr> <td><strong>Localization</strong></td> <td>Stomach, duodenum, bronchus, thymus</td> <td>Jejunum, ileum, appendix, ascending colon</td> <td>Transverse, descending, and sigmoid colon, rectum, genitourinary</td> </tr> <tr> <td><strong>Secretory products</strong></td> <td>5-hydroxytryptophan, histamine, multiple polypeptides</td> <td>Serotonin prostaglandins, polypeptides</td> <td>Variable</td> </tr> <tr> <td><strong>Carcinoid syndrome</strong></td> <td>Rare, and atypical when it happens</td> <td>Classic</td> <td>Rare</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56015 Version 10.0</div></div></div>"},"56017":{"type":"graphic_diagnosticimage","displayName":"UGI-SMA syndrome II","title":"UGI dilated stomach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">UGI dilated stomach</div><div class=\"cntnt\"><img style=\"width:267px; height:411px;\" src=\"images/GAST/56017_UGI-SMA_syndrome_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is the UGI study on the same patient demonstrating the dilated stomach (open arrowhead) and a dilated proximal duodenum (closed arrowhead).</div><div class=\"graphic_reference\">Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.</div><div id=\"graphicVersion\">Graphic 56017 Version 2.0</div></div></div>"},"56018":{"type":"graphic_picture","displayName":"Mucoepidermoid CT","title":"Mucoepidermoid carcinoma of the trachea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucoepidermoid carcinoma of the trachea</div><div class=\"cntnt\"><img style=\"width:390px; height:454px;\" src=\"images/PULM/56018_Mucoepidermoid_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan demonstrates tracheal lesion and paramediastinal lung fibrosis from previous radiation therapy for invasive thymoma. Histology demonstrates a mixture of mucin-producing columnar cells, epidermoid (squamous) cells, and polygonal intermediate cells.</div><div id=\"graphicVersion\">Graphic 56018 Version 1.0</div></div></div>"},"56019":{"type":"graphic_table","displayName":"Clinical similarities between fibromyalgia and CFS/SEID","title":"Clinical similarities between fibromyalgia and chronic fatigue syndrome (CFS), also known as systemic exertion intolerance disease (SEID)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical similarities between fibromyalgia and chronic fatigue syndrome (CFS), also known as systemic exertion intolerance disease (SEID)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>80 to 90% women, usual ages 20 to 55 years</td> </tr> <tr> <td>Myalgias and fatigue in more than 90%</td> </tr> <tr> <td class=\"sublist1_start\">Associated common symptoms</td> </tr> <tr> <td class=\"sublist1\">Neurocognitive and mood disturbances</td> </tr> <tr> <td class=\"sublist1\">Headaches</td> </tr> <tr> <td class=\"sublist1\">Sleep disturbances</td> </tr> <tr> <td>No identifiable cause</td> </tr> <tr> <td class=\"sublist1_start\">Testing is normal</td> </tr> <tr> <td class=\"sublist1\">Physical examination usually normal except for tender points which are required for diagnosis of fibromyalgia and present in most patients with chronic fatigue</td> </tr> <tr> <td class=\"sublist1\">Normal laboratory and radiologic tests</td> </tr> <tr> <td>Chronic symptoms, no highly effective therapy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56019 Version 5.0</div></div></div>"},"56020":{"type":"graphic_algorithm","displayName":"Choosing a primary procedure for pelvic organ prolapse","title":"Choosing a primary procedure for pelvic organ prolapse: Major decision points","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choosing a primary procedure for pelvic organ prolapse: Major decision points</div><div class=\"cntnt\"><img style=\"width:440px; height:592px;\" src=\"images/OBGYN/56020_Primary_procedure_pelvic_prolapse.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56020 Version 3.0</div></div></div>"},"56021":{"type":"graphic_figure","displayName":"Congenital lipoid adrenal hyperplasia","title":"Congenital lipoid adrenal hyperplasia (StAR deficiency & CYP11A1 deficiency)","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Congenital lipoid adrenal hyperplasia (StAR deficiency &amp; CYP11A1 deficiency)</div><div class=\"cntnt\"><img style=\"width:602px; height:392px;\" src=\"images/ENDO/56021_Cong_lipoid_adren_hyperplas.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">StAR: steroidogenic acute regulatory protein; ACTH: corticotropin.</div><div id=\"graphicVersion\">Graphic 56021 Version 3.0</div></div></div>"},"56025":{"type":"graphic_figure","displayName":"Neonatal vertical suspension","title":"Neonatal vertical suspension","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Neonatal vertical suspension</div><div class=\"cntnt\"><img style=\"width:476px; height:674px;\" src=\"images/PEDS/56025_Vertical_suspension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vertical suspension measures the strength of the neonate's shoulder girdle. The examiner holds the infant in an upright position by placing the hands under the arms and around the chest with the feet unsupported. In infants with decreased tone of the shoulder girdle (shown in the inset of an abnormal response), the infant begins to slip through the examiner's hands and the legs are extended. Vertical suspension is also helpful in evaluating for subtle increases in muscle tone in the lower extremities. In the presence of lower extremity hypertonicity, there may be adduction at the hips combined with hyperextension at the knees and ankles. The lower extremities may appear to cross over each other (scissoring posture).</div><div id=\"graphicVersion\">Graphic 56025 Version 3.0</div></div></div>"},"56026":{"type":"graphic_table","displayName":"Diagnosis of acute scrotal pain","title":"Distinguishing conditions responsible for acute scrotal pain in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing conditions responsible for acute scrotal pain in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Symptom onset</td> <td class=\"subtitle1\">Pain location</td> <td class=\"subtitle1\">Cremasteric reflex</td> <td class=\"subtitle1\">Other clinical findings</td> </tr> <tr> <td>Appendiceal torsion</td> <td>Acute or subacute</td> <td>Upper pole of testis</td> <td>Positive</td> <td>Blue dot sign</td> </tr> <tr> <td>Epididymitis</td> <td>Acute or chronic</td> <td>Epididymis</td> <td>Positive</td> <td>Positive urinalysis, urine culture, or diagnostic tests for gonorrhea or <em>Chlamydia</em> infection</td> </tr> <tr> <td>Fournier's gangrene</td> <td>Acute</td> <td>Diffuse</td> <td>Positive</td> <td>Tense edema outside of involved skin, blisters/bullae, crepitus, fever, rigors, hypotension</td> </tr> <tr> <td>Testicular torsion</td> <td>Acute</td> <td>Testis</td> <td>Negative</td> <td>High-riding testis, bell clapper deformity, profound testicular swelling</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56026 Version 6.0</div></div></div>"},"56028":{"type":"graphic_table","displayName":"Common causes of granulomatous lung disease","title":"Common causes of granulomatous lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of granulomatous lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Exposures/toxins</td> </tr> <tr> <td>Drugs (eg, methotrexate, etanercept)</td> </tr> <tr> <td>Foreign body granulomatosis (eg, intravenous drug use)</td> </tr> <tr> <td>Hypersensitivity pneumonitis</td> </tr> <tr> <td>Pneumoconioses (eg, beryllium, cobalt, talc, zirconium)</td> </tr> <tr> <td class=\"subtitle1_single\">Immunodeficiency</td> </tr> <tr> <td>Chronic granulomatous disease</td> </tr> <tr> <td>Common variable immunodeficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory</td> </tr> <tr> <td>Bronchocentric granulomatosis</td> </tr> <tr> <td>Pulmonary Langerhans cell histiocytosis (eosinophilic granulomatosis)</td> </tr> <tr> <td>Lymphoid interstitial pneumonia</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Bacteria (eg, tuberculous/nontuberculous mycobacteria, <em>Brucella</em>)</td> </tr> <tr> <td>Fungi (eg, <em>Aspergillus</em>, <em>Histoplasma</em>, <em>Coccidioides</em>, <em>Blastomyces</em>)</td> </tr> <tr> <td>Parasites (eg, <em>Leishmania</em>, <em>Toxoplasma</em>, <em>Echinococcus</em>, <em>Schistosoma</em>)</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Lymphomatoid granulomatosis</td> </tr> <tr> <td class=\"subtitle1_single\">Vasculitis</td> </tr> <tr> <td>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56028 Version 5.0</div></div></div>"},"56029":{"type":"graphic_waveform","displayName":"Normal LV pressure","title":"Left ventricular pressure tracing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular pressure tracing</div><div class=\"cntnt\"><img style=\"width:324px; height:185px;\" src=\"images/CARD/56029_Normal_LV_pressure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal left ventricular pressure tracing recorded with a 40 mmHg scale; electrocardiographic leads II and aVL are recorded simultaneously. With rapid filling of the left ventricle at the onset of diastole, there is a gradual increase in pressure, culminating with left atrial contraction and an &quot;a&quot; wave. The pressure just prior to the onset of left ventricular systole is the left ventricular end-distolic pressure (LVEDP).</div><div class=\"graphic_reference\">Reproduced with permission from Kern MJ. ACC Current Journal Review, in press, 1997.</div><div id=\"graphicVersion\">Graphic 56029 Version 3.0</div></div></div>"},"56031":{"type":"graphic_table","displayName":"GnRH agonist dosing","title":"Recommended doses for GnRH-agonists","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended doses for GnRH-agonists</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Drug\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Trade name\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Dose\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Route of administration\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Goserelin acetate</td>\r\n  \r\n   <td>Zoladex</td>\r\n  \r\n   <td>3.6 milligrams every 28 days</td>\r\n  \r\n   <td>Subcutaneous</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Leuprolide acetate\r\n  \r\n   </td>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Lupron\r\n  \r\n   </td>\r\n  \r\n   <td>3.75 milligrams once per month</td>\r\n  \r\n   <td>Intramuscular</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>11.25 milligrams every three months</td>\r\n  \r\n   <td>Intramuscular</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nafarelin acetate</td>\r\n  \r\n   <td>Synarel</td>\r\n  \r\n   <td>200 micrograms twice daily</td>\r\n  \r\n   <td>Intranasal</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 56031 Version 1.0</div></div></div>"},"56032":{"type":"graphic_table","displayName":"SGA stillbirth association","title":"Relationship between selected first and second pregnancy outcomes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relationship between selected first and second pregnancy outcomes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Outcome of first pregnancy, live births only</td> <td class=\"subtitle1\">Odds ratio for stillbirth in second pregnancy (95% CI)</td> <td class=\"subtitle1\">Stillbirth rate per 1000 births</td> </tr> <tr> <td>AGA, term</td> <td>1.0</td> <td>2.4</td> </tr> <tr> <td>SGA, term</td> <td>2.0 (1.5 to 2.6)</td> <td>4.8</td> </tr> <tr> <td>SGA, moderately preterm</td> <td>4.0 (2.5 to 6.3)</td> <td>9.5</td> </tr> <tr> <td>SGA, very preterm</td> <td>8.0 (4.7 to 13.7)</td> <td>19.0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Analysis adjusted for factors such as cigarette smoking, maternal age, interpregnancy interval, and presence of hypertension or antepartum bleeding.</div><div class=\"graphic_footnotes\">AGA: weight appropriate for gestational age; SGA: weight small for gestational age (ie, birth weight &gt;2 standard deviations below the mean for gestational age [&lt;2.5<SUP>th</SUP> percentile]); moderately preterm: 32 to 36 weeks of gestation; very preterm: &lt;32 weeks of gestation.<br /></div><div class=\"graphic_reference\">Adapted from: Surkan PS, Stephansson O, Dickman PW, Cnattingius S. Previous preterm and small-for-gestational-age births and the subsequent risk of stillbirth. N Engl J Med 2004; 350:777.</div><div id=\"graphicVersion\">Graphic 56032 Version 4.0</div></div></div>"},"56033":{"type":"graphic_figure","displayName":"Anterior neck muscles B","title":"The prevertebral region and root of the neck, anterior view","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">The prevertebral region and root of the neck, anterior view</div><div class=\"cntnt\"><img style=\"width:531px; height:559px;\" src=\"images/PEDS/56033_Anterior_neck_muscles_B.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56033 Version 1.0</div></div></div>"},"56034":{"type":"graphic_diagnosticimage","displayName":"CXR bronchiect child","title":"Chest x-ray of a pediatric patient with bronchiectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest x-ray of a pediatric patient with bronchiectasis</div><div class=\"cntnt\"><img style=\"width:288px; height:266px;\" src=\"images/PEDS/56034_CXR_bronchiect_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The airways are dilated and thickened, as indicated by parallel linear opacities (tram tracking) when seen longitudinally, and ring shadows on cross section (arrows).</div><div class=\"graphic_reference\">Courtesy of: Drs. Khoulood Fakhoury and Adaobi Kanu.</div><div id=\"graphicVersion\">Graphic 56034 Version 2.0</div></div></div>"},"56037":{"type":"graphic_figure","displayName":"Lyme cases by age and sex","title":"Confirmed Lyme disease cases by age and sex - United States, 2001 to 2010","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Confirmed Lyme disease cases by age and sex - United States, 2001 to 2010</div><div class=\"cntnt\"><img style=\"width:612px; height:384px;\" src=\"images/ID/56037_Lyme_case_age_sex.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reported cases of Lyme disease are most common among boys aged 5 to 9 years.</div><div class=\"graphic_reference\">Reproduced from: United States Centers for Disease Control and Prevention. Lyme Disease Data. Available at: <A style=\"FONT-STYLE: italic\" href=\"http://www.cdc.gov/lyme/stats/chartstables/incidencebyagesex.html\" target=_blank>http://www.cdc.gov/lyme/stats/chartstables/incidencebyagesex.html</A>.</div><div id=\"graphicVersion\">Graphic 56037 Version 2.0</div></div></div>"},"56038":{"type":"graphic_diagnosticimage","displayName":"Cerebral angiography of developmental venous anomaly","title":"Cerebral angiography of a developmental venous anomaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cerebral angiography of a developmental venous anomaly</div><div class=\"cntnt\"><img style=\"width:353px; height:252px;\" src=\"images/NEURO/56038_DVA_angiography.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During the late capillary or venous phase of angiography, there is a paucity of normal veins in the region of a developmental venous anomaly and a characteristic &quot;caput medusae&quot; appearance of the radially arranged small medullary veins (arrow).</div><div class=\"graphic_reference\">Courtesy of Guy Rordorf, MD.</div><div id=\"graphicVersion\">Graphic 56038 Version 4.0</div></div></div>"},"56040":{"type":"graphic_table","displayName":"Disorders of carbohydrate metab","title":"Selected disorders of carbohydrate metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected disorders of carbohydrate metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Carbohydrate intolerance disorders</td> </tr> <tr> <td class=\"indent1\">Galactosemia</td> </tr> <tr> <td class=\"indent1\">Galactokinase deficiency</td> </tr> <tr> <td class=\"indent1\">UDP galactose epimerase deficiency</td> </tr> <tr> <td class=\"indent1\">Hereditary fructose intolerance</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of carbohydrate production or utilization</td> </tr> <tr> <td class=\"subtitle2_single\">Disorders of glycogenolysis (glycogen storage diseases, GSD)</td> </tr> <tr> <td class=\"indent1\">Liver glycogen synthase deficiency (GSD 0)</td> </tr> <tr> <td class=\"indent1\">Glucose-6-phosphatase deficiency (GSD I; von Gierke disease)</td> </tr> <tr> <td class=\"indent1\">Lysosomal acid maltase deficiency (GSD II; Pompe disease)</td> </tr> <tr> <td class=\"indent1\">Glycogen debrancher deficiency (GSD III; Cori/Forbes disease)</td> </tr> <tr> <td class=\"indent1\">Glycogen branching enzyme deficiency (GSD IV; Andersen disease)</td> </tr> <tr> <td class=\"indent1\">Muscle phosphorylase deficiency (GSD V; McArdle disease)</td> </tr> <tr> <td class=\"indent1\">Liver phosphorylase deficiency (GSD VI; Hers disease)</td> </tr> <tr> <td class=\"indent1\">Muscle phosphofructokinase deficiency (GSD VII; Tarui disease)</td> </tr> <tr> <td class=\"indent1\">Phosphoglycerate kinase and phosphoglycerate mutase deficiency</td> </tr> <tr> <td class=\"indent1\">Phosphorylase b kinase deficiency</td> </tr> <tr> <td class=\"subtitle2_single\">Disorders of gluconeogenesis</td> </tr> <tr> <td class=\"indent1\">Fructose 1,6-biphosphatase deficiency</td> </tr> <tr> <td class=\"indent1\">Pyruvate carboxylase deficiency</td> </tr> <tr> <td class=\"indent1\">Phosphoenolpyruvate carboxykinase (PEPCK) deficiency</td> </tr> <tr> <td class=\"indent1\">Pyruvate dehydrogenase deficiency</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UDP: uridine diphosphate.</div><div id=\"graphicVersion\">Graphic 56040 Version 3.0</div></div></div>"},"56041":{"type":"graphic_picture","displayName":"Neonatal HSV scalp vesicles","title":"Neonatal herpes simplex virus scalp vesicles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neonatal herpes simplex virus scalp vesicles</div><div class=\"cntnt\"><img style=\"width:400px; height:304px;\" src=\"images/PEDS/56041_Neonatal_HSV_scalp_vesicles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scalp lesions of neonate with skin, eye, and mouth neonatal herpes simplex virus (HSV)&nbsp;infection associated with fetal scalp monitor. Gram-stained smear and bacterial cultures were negative, and the lesions did not respond to topical and systemic antibiotics. Viral cultures grew HSV type 2, and the lesions responded to intravenous acyclovir.</div><div class=\"graphic_reference\">Courtesy of Jane Troendle-Atkins, MD, and Gail J Demmler-Harrison, MD, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 56041 Version 2.0</div></div></div>"},"56042":{"type":"graphic_picture","displayName":"Clostridium difficile","title":"<EM>Clostridium difficile</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Clostridium difficile</EM></div><div class=\"cntnt\"><img style=\"width:239px; height:194px;\" src=\"images/GAST/56042_Clostridium_difficile.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram-positive rods characteristic of <EM>Clostridium difficile</EM>.</div><div class=\"graphic_reference\">Courtesy of J Thomas LaMont, MD.</div><div id=\"graphicVersion\">Graphic 56042 Version 4.0</div></div></div>"},"56045":{"type":"graphic_figure","displayName":"Home O2 prescription form","title":"Home Oxygen prescription","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Home Oxygen prescription</div><div class=\"cntnt\"><img style=\"width:517px; height:417px;\" src=\"images/PULM/56045_Home_O2_prescription_form.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56045 Version 1.0</div></div></div>"},"56047":{"type":"graphic_figure","displayName":"Mechanism of blunt cerebrovascular injury","title":"Mechanism of blunt cerebrovascular injury","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Mechanism of blunt cerebrovascular injury</div><div class=\"cntnt\"><img style=\"width:526px; height:621px;\" src=\"images/SURG/56047_Blunt-cerebrovascular-injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cervical hyperextension stretches the internal carotid artery across the lateral articular processes of the first through third cervical vertebrae, causing intimal tearing.<br> (B) Cervical hyperflexion may directly compress the internal carotid artery between the mandible and the upper cervical vertebrae, causing intimal disruption or mural hematoma.<br> (C) Falling with a hard object in the mouth (eg, toothbrush) can lead to injury of the internal carotid artery at the angle of the jaw.</div><div id=\"graphicVersion\">Graphic 56047 Version 2.0</div></div></div>"},"56048":{"type":"graphic_algorithm","displayName":"SVT children algorithm","title":"Algorithm for differentiation of typical AVNRT and orthodromic AVRT in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for differentiation of typical AVNRT and orthodromic AVRT in children</div><div class=\"cntnt\"><img style=\"width:292px; height:292px;\" src=\"images/CARD/56048_SVTchildrenalgorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AVNRT: atrioventricular nodal reentrant tachycardia; AVRT: atrioventricular reentrant tachycardia.</div><div class=\"graphic_reference\">Adapted from: Jaeggi ET, Gilljam T, Bauersfeld U, et al. Electrocardiographic differentiation of typical atrioventricular node reentrant tachycardia from atrioventricular reciprocating tachycardia mediated by concealed accessory pathway in children. Am J Cardiol 2003; 91:1084.</div><div id=\"graphicVersion\">Graphic 56048 Version 4.0</div></div></div>"},"56049":{"type":"graphic_table","displayName":"Example of epinephrine infusion - Pediatric 10 kg","title":"Example of epinephrine infusion - Pediatric 10 kg","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of epinephrine infusion - Pediatric 10 kg</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"6\">Example of preparation of epinephrine infusion for refractory symptoms of anaphylaxis for pediatric patient of 10 kg body weight for emergency/critical care units</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"6\"> <p>Final concentration: Epinephrine 10 mcg/mL</p> Add 1 mg (1000 mcg) of epinephrine to 100 mL bag of 0.9% normal saline (NS) or 5% dextrose water (D5W)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Preparation</td> </tr> <tr> <td colspan=\"6\"> <ol> <li><strong>CHECK</strong> vial strength. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\"> <ol start=\"2\"> <li>To prepare epinephrine infusion for a final concentration of <strong>10</strong> mcg/mL, dilute <strong>10 mL</strong> of <strong>0.1 mg/mL</strong> epinephrine (may also be labeled 1:10,000) in <strong>100 mL</strong> bag of 0.9%&nbsp;NS or&nbsp;D5W <strong>OR</strong> <strong>1 mL</strong> of <strong>1 mg/mL</strong> epinephrine (may also be labeled 1:1000) in <strong>100 mL</strong> bag of 0.9% NS or D5W.* </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Administration</td> </tr> <tr> <td class=\"indent1\" colspan=\"6\"> <ul> <li>Infuse an initial dose of 0.1 mcg/kg/minute using a programmable infusion pump and titrate, as needed, while continuously monitoring the patient's cardiac rhythm and blood pressure. </li> <li>For detail on titrating the infusion based upon response, refer to the UpToDate topic on emergency treatment for anaphylaxis.</li> </ul> </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"3\">Pediatric dose for 10 kg child</td> <td class=\"subtitle2\" colspan=\"3\">Administration rate for infusion pump to deliver pediatric dose shown</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle3\">mcg per kg per minute</td> <td class=\"subtitle3\" rowspan=\"12\">Multiply by patient weight<br /> (10 kg)</td> <td class=\"subtitle3\">mcg per minute</td> <td class=\"subtitle3\">mL per <em>minute</em> for 10 kg child</td> <td class=\"subtitle3\" rowspan=\"12\">Multiply by 60 minutes</td> <td class=\"subtitle3\">mL per <em>hour</em> for 10 kg child</td> </tr> <tr> <td class=\"centered\">0.05</td> <td class=\"centered\">0.5</td> <td class=\"centered\">0.05</td> <td class=\"centered\">3</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">0.1</td> <td class=\"centered\">1</td> <td class=\"centered\">0.1</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"centered\">0.2</td> <td class=\"centered\">2</td> <td class=\"centered\">0.2</td> <td class=\"centered\">12</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">0.3</td> <td class=\"centered\">3</td> <td class=\"centered\">0.3</td> <td class=\"centered\">18</td> </tr> <tr> <td class=\"centered\">0.4</td> <td class=\"centered\">4</td> <td class=\"centered\">0.4</td> <td class=\"centered\">24</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">0.5</td> <td class=\"centered\">5</td> <td class=\"centered\">0.5</td> <td class=\"centered\">30</td> </tr> <tr> <td class=\"centered\">0.6</td> <td class=\"centered\">6</td> <td class=\"centered\">0.6</td> <td class=\"centered\">36</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">0.7</td> <td class=\"centered\">7</td> <td class=\"centered\">0.7</td> <td class=\"centered\">42</td> </tr> <tr> <td class=\"centered\">0.8</td> <td class=\"centered\">8</td> <td class=\"centered\">0.8</td> <td class=\"centered\">48</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">0.9</td> <td class=\"centered\">9</td> <td class=\"centered\">0.9</td> <td class=\"centered\">54</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td class=\"centered\">10</td> <td class=\"centered\">1</td> <td class=\"centered\">60</td> </tr> <tr> <td colspan=\"6\"> <ul> <li> <p>The above table is provided as an example. There are other acceptable concentrations.</p> </li> <li> <p>Intravenous epinephrine, like all vasopressors, can cause life-threatening hypertension, cardiac ischemia, and ventricular arrhythmias. It should be administered ONLY by clinicians trained and experienced in dose titration of intravenous epinephrine using continuous noninvasive electronic monitoring of heart rate and blood pressure. </p> </li> <li>Epinephrine is an ischemia-causing agent and vesicant. Monitor infusion site for extravasation. Central venous catheter administration is preferred when available.&nbsp;Refer to the&nbsp;Lexicomp drug reference for information on managing extravasation including infiltration of phentolamine. </li> <li>To reduce the risk of making a medication error, we suggest that centers have available an institutionally approved protocol for epinephrine infusion that includes steps on how to prepare and administer the infusion and standard concentration(s). </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Unused diluted solutions should be discarded within 24 hours or less of preparation depending on local standards.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gahart BL, Nazareno AR, Ortega MQ. Gahart's 2016 Intravenous Medications: A Handbook for Nurses and Health Professionals, 32nd ed, Elsevier-Mosby, St. Louis, MO 2016.</li>&#xD;&#xA;    <li>Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 56049 Version 11.0</div></div></div>"},"56050":{"type":"graphic_figure","displayName":"Geography PPD reactors USA","title":"Geographic distribution of PPD skin test reactors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Geographic distribution of PPD skin test reactors</div><div class=\"cntnt\"><img style=\"width:391px; height:578px;\" src=\"images/ID/56050_Geography_PPD_reactors_USA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Geographic variation in the frequency of reactors to PPD-S (top) and to PPD-B 9 (bottom).</div><div class=\"graphic_reference\">Redrawn from Edwards, et al, Am Rev Respir Dis 1969; 99(Suppl):1.</div><div id=\"graphicVersion\">Graphic 56050 Version 1.0</div></div></div>"},"56052":{"type":"graphic_table","displayName":"Risk of preterm delivery as a function of cervical length","title":"Relative risk of preterm delivery as a function of cervical length","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative risk of preterm delivery as a function of cervical length</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cervical length (mm)</td> <td class=\"subtitle1\">Centile</td> <td class=\"subtitle1\">Relative risk of PTD</td> <td class=\"subtitle1\">Confidence interval</td> </tr> <tr> <td class=\"centered\">&#8804;35</td> <td class=\"centered\">50</td> <td class=\"centered\">2.35</td> <td class=\"centered\">1.42 to 3.89</td> </tr> <tr> <td class=\"centered\">&#8804;30</td> <td class=\"centered\">25</td> <td class=\"centered\">3.79</td> <td class=\"centered\">2.32 to 6.19</td> </tr> <tr> <td class=\"centered\">&#8804;26</td> <td class=\"centered\">10</td> <td class=\"centered\">6.19</td> <td class=\"centered\">3.84 to 9.97</td> </tr> <tr> <td class=\"centered\">&#8804;22</td> <td class=\"centered\">5</td> <td class=\"centered\">9.49</td> <td class=\"centered\">5.95 to 15.15</td> </tr> <tr> <td class=\"centered\">&#8804;13</td> <td class=\"centered\">1</td> <td class=\"centered\">13.99</td> <td class=\"centered\">7.89 to 24.78</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Relative risk is in comparison to women whose cervical lengths were above the 75<sup>th</sup> percentile.<br />Data from an asymptomatic general obstetrical population evaluated between 22 and 30 weeks of gestation with exclusion of women with multiple gestations, fetal anomalies, cerclage, or placental previa.</div><div class=\"graphic_footnotes\">PTD: preterm delivery.</div><div class=\"graphic_reference\">Data from: Iams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med 1996; 334:567.</div><div id=\"graphicVersion\">Graphic 56052 Version 6.0</div></div></div>"},"56053":{"type":"graphic_table","displayName":"Overlooked sources of gluten or potential gluten","title":"Overlooked sources of gluten or potential gluten","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overlooked sources of gluten or potential gluten</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Foods and products that&nbsp;contain or&nbsp;MAY contain gluten, depending on their ingredients or how they are derived. This is not an all-inclusive list.</td> </tr> <tr> <td>Ales</td> </tr> <tr> <td>Beer/lagers</td> </tr> <tr> <td>Breading</td> </tr> <tr> <td>Brewer's yeast</td> </tr> <tr> <td>Broth/bouillon</td> </tr> <tr> <td>Brown rice syrup</td> </tr> <tr> <td>Cake frosting</td> </tr> <tr> <td>Candy</td> </tr> <tr> <td>Coating mixes</td> </tr> <tr> <td>Communion wafers</td> </tr> <tr> <td>Condiments</td> </tr> <tr> <td>Croutons</td> </tr> <tr> <td>Dates (if rolled in oat flour)</td> </tr> <tr> <td>Drink mixes</td> </tr> <tr> <td>Flavored teas and coffees</td> </tr> <tr> <td>Flavored spirits (eg, raspberry vodka)&nbsp;</td> </tr> <tr> <td>Flour or cereal products</td> </tr> <tr> <td>Gravies</td> </tr> <tr> <td>Imitation bacon</td> </tr> <tr> <td>Imitation seafood</td> </tr> <tr> <td>Licorice</td> </tr> <tr> <td>Marinades</td> </tr> <tr> <td>Malt, malt flavoring, and malt extract (avoid unless made from a gluten-free grain, such as rice malt, sorghum malt or corn malt; if so, it will be labeled as such)</td> </tr> <tr> <td>Malt vinegar</td> </tr> <tr> <td>Matzo/matzoh meal</td> </tr> <tr> <td>Medications (prescription and over the counter)</td> </tr> <tr> <td>Oats (avoid unless pure, uncontaminated, labeled gluten-free oats)</td> </tr> <tr> <td>Panko (Japanese bread crumbs)</td> </tr> <tr> <td>Pasta</td> </tr> <tr> <td>Play-Doh&#174;, paper mach&#233;, glue, and many art supplies* </td> </tr> <tr> <td>Processed luncheon meats</td> </tr> <tr> <td>Rice pilaf and other packaged rice mixtures</td> </tr> <tr> <td>Roux</td> </tr> <tr> <td>Salad dressing</td> </tr> <tr> <td>Sauces/spreads</td> </tr> <tr> <td>Seasonings (or spice blends)</td> </tr> <tr> <td>Seasoned chips, nuts, and seeds</td> </tr> <tr> <td>Self-basting poultry</td> </tr> <tr> <td>Smoke flavoring</td> </tr> <tr> <td>Soup stock</td> </tr> <tr> <td>Soy sauce (commonly made with both soy and wheat)</td> </tr> <tr> <td>Stuffing (for poultry)</td> </tr> <tr> <td>Supplements</td> </tr> <tr> <td class=\"subtitle1_single\">Not allowed in any form</td> </tr> <tr> <td>Wheat (einkorn, durum, faro, graham, kamut, semolina, spelt)</td> </tr> <tr> <td>Rye</td> </tr> <tr> <td>Barley</td> </tr> <tr> <td>Malt, malt flavoring, malt extract derived from barley</td> </tr> <tr> <td>Malt vinegar</td> </tr> <tr> <td>Triticale</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The gluten protein does not pass through the skin. Avoid cross contamination by washing hands after handling and before eating.</div><div class=\"graphic_reference\">Adapted from: Dennis M. Inadvertent gluten exposure. In: Real Life with Celiac Disease: Troubleshooting and Thriving Gluten-Free, Dennis M, Leffer D (Eds), AGA Press, Bethesda, MD 2010.</div><div id=\"graphicVersion\">Graphic 56053 Version 4.0</div></div></div>"},"56055":{"type":"graphic_picture","displayName":"Palpation of prepatellar bursa","title":"Palpation of the prepatellar bursa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the prepatellar bursa</div><div class=\"cntnt\"><img style=\"width:349px; height:289px;\" src=\"images/EM/56055_Palpation_of_prepatellar_bu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The prepatella bursa (arrow) is palpated for warmth, focal tenderness, and swelling, and the walls are squeezed between the fingertips to assess for bursal wall thickening. After assessing the acute and chronic inflammatory changes, the range of motion of the knee is assessed. The patient with prepatellar bursitis is able to fully extend the knee without increasing their symptoms.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 56055 Version 3.0</div></div></div>"},"56057":{"type":"graphic_picture","displayName":"Mechanics hands","title":"Mechanic's hands in a patient with polymyositis, and the anti-synthetase syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanic's hands in a patient with polymyositis, and the anti-synthetase syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:331px;\" src=\"images/RHEUM/56057_mechanics_hands.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John H. Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 56057 Version 2.0</div></div></div>"},"56058":{"type":"graphic_table","displayName":"Thromboelastography-guided transfusion parameters","title":"Thromboelastography-guided transfusion parameters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thromboelastography-guided transfusion parameters</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">r-TEG parameter</td> <td class=\"subtitle1\">Normal range</td> <td class=\"subtitle1\">Transfusion trigger</td> </tr> <tr> <td>TEG-ACT</td> <td>78-110 seconds</td> <td>&#62;120 seconds (FFP)</td> </tr> <tr> <td>Alpha angle</td> <td>66&#176;-82&#176;</td> <td>&#60;66&#176; (cryoprecipitate)</td> </tr> <tr> <td><em>K</em> value</td> <td>30-120 seconds</td> <td>&#62;120 seconds (cryoprecipitate)</td> </tr> <tr> <td>MA (maximum amplitude)</td> <td>54-72 mm</td> <td>&#60;54 mm (platelets)</td> </tr> <tr> <td><em>G</em> value</td> <td>5.3-12.4 dynes/second</td> <td>&#60;5.3 dynes/second*</td> </tr> <tr> <td>LY-30 (lysis at 30 min)</td> <td>0-8 percent</td> <td>&#62;8 percent<sup>​&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Values in the table are for non-citrated whole blood samples.</div><div class=\"graphic_footnotes\">r-TEG: rapid thromboelastography; ACT: activated clotting time; FFP: fresh frozen plasma.<br />* Reevaluate all parameters per massive transfusion algorithm-decision tree.<br />¶ Consider antifibrinolytic.</div><div class=\"graphic_reference\">Reproduced with permission from: Stahel PF, Moore EE, Schreier SL, et al. Transfusion strategies in postinjury coagulopathy. Curr Opin Anaesthesiol 2009; 22:289. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56058 Version 10.0</div></div></div>"},"56059":{"type":"graphic_figure","displayName":"Perforation of distal thoracic esophagus","title":"Perforation of distal thoracic esophagus - operative exposure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perforation of distal thoracic esophagus - operative exposure</div><div class=\"cntnt\"><img style=\"width:295px; height:247px;\" src=\"images/SURG/56059_Perf-distal-eso.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts facilitating exposure of the distal esophagus with a Penrose drain.</div><div id=\"graphicVersion\">Graphic 56059 Version 3.0</div></div></div>"},"56060":{"type":"graphic_diagnosticimage","displayName":"Toxocariasis - Chest images","title":"Toxocariasis - Chest images","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toxocariasis - Chest images</div><div class=\"cntnt\"><img style=\"width:390px; height:583px;\" src=\"images/ID/56060_Toxocariasis_chest_images.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Radiograph of a three-year-old girl with toxocariasis.<br />(B) Computed tomography scan of the same 3-year-old girl with toxocariasis as shown in panel A.</div><div class=\"graphic_reference\">Reproduced from: Ribeiro JD, Fischer GB. Eosinophilic lung disease. Paediatr Respir Rev 2002; 3:278. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 56060 Version 4.0</div></div></div>"},"56063":{"type":"graphic_movie","displayName":"Phonocardiogram calcific AS at 2nd right intercostal space","title":"Phoncardiogram of calcific aortic stenosis as recorded from 2nd right intercostal space","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phoncardiogram of calcific aortic stenosis as recorded from 2nd right intercostal space</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/56063_asc2ricsconv.mp4\" style=\"width:398px;height:478px\"></div><img style=\"width:385px; height:247px;\" src=\"images/CARD/56063_asc2rics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram and phonocardiogram of aortic stenosis due to valvular calcification as heard at the second right intercostal space. S1 (mitral and tricuspid valve closure) is followed by a mild systolic ejection murmur of aortic stenosis. A single S2 is from delayed aortic valve closure which occurs simultaneously with closure of the pulmonic valve.</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 56063 Version 4.0</div></div></div>"},"56064":{"type":"graphic_table","displayName":"Chronic migraine diagnostic criteria","title":"Chronic migraine diagnostic criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic migraine diagnostic criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Description:</td> </tr> <tr> <td class=\"indent1\">Headache occurring on 15 or more days per month for more than three months, which has the features of migraine headache on at least eight days per month.</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic criteria:</td> </tr> <tr> <td class=\"indent1\">A. Headache (tension-type-like and/or migraine-like) on 15 or more days per month for more than three months and fulfilling criteria B and C</td> </tr> <tr> <td class=\"sublist2_start\">B. Occurring in a patient who has had at least five attacks fulfilling the following criteria for migraine without aura (B1) and/or migraine with aura (B2)</td> </tr> <tr> <td class=\"sublist3_start\">B1. Migraine without aura:</td> </tr> <tr> <td class=\"indent3\">B1a. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)</td> </tr> <tr> <td class=\"sublist4_start\">B1b. Headache has at least two of the following characteristics:</td> </tr> <tr> <td class=\"sublist5_start\"> <ul> <li>Unilateral location </li> <li>Pulsating quality </li> <li>Moderate or severe pain intensity </li> <li>Aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs) </li> </ul> </td> </tr> <tr> <td class=\"sublist4_start\">B1c. During headache at least one of the following:</td> </tr> <tr> <td class=\"sublist5_start\"> <ul> <li>Nausea and/or vomiting </li> <li>Photophobia and phonophobia </li> </ul> </td> </tr> <tr> <td class=\"sublist3_start\">B2. Migraine with aura:</td> </tr> <tr> <td class=\"sublist4_start\">B2a. One or more of the following fully reversible aura symptoms:</td> </tr> <tr> <td class=\"sublist5_start\"> <ul> <li>Visual </li> <li>Sensory </li> <li>Speech and/or language </li> <li>Motor </li> <li>Brainstem </li> <li>Retinal </li> </ul> </td> </tr> <tr> <td class=\"sublist4_start\">B2b. At least two of the following characteristics:</td> </tr> <tr> <td class=\"sublist5_start\"> <ul> <li>At least one aura symptom spreads gradually over &#8805;5 minutes, and/or two or more symptoms occur in succession </li> <li>Each individual aura symptom lasts 5 to 60 minutes </li> <li>At least one aura symptom is unilateral </li> <li>The aura is accompanied, or followed within 60 minutes, by headache </li> </ul> </td> </tr> <tr> <td class=\"sublist2_start\">C. On eight days or more per month for more than three months, fulfilling any of the following:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Criteria B1b and B1c for migraine without aura </li> <li>Criteria B2a and B2b for migraine with aura </li> <li>Believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative </li> </ul> </td> </tr> <tr> <td class=\"indent1\">D. Not better accounted for by another ICHD-3 diagnosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICHD-3: International Classification of Headache Disorders, 3rd edition.</div><div class=\"graphic_reference\">Data from: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 56064 Version 9.0</div></div></div>"},"56066":{"type":"graphic_picture","displayName":"Dental enamel defects in a child with celiac disease","title":"Dental enamel defects in a child with celiac disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dental enamel defects in a child with celiac disease</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/PEDS/56066_Dental_celiac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dental enamel defects associated with celiac disease may consist of cream-, yellow-, or brown-colored opacities, loss of enamel glaze, horizontal grooves, or shallow pits.</div><div class=\"graphic_reference\">Courtesy of Lisa Papagiannoulis, DDS, MS, School of Dental Medicine, University of Athens, Greece.</div><div id=\"graphicVersion\">Graphic 56066 Version 2.0</div></div></div>"},"56067":{"type":"graphic_table","displayName":"Incidence CV disease","title":"Incidence of atherosclerotic cardiovascular events in the Framingham study*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of atherosclerotic cardiovascular events in the Framingham study*</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\" rowspan=\"2\">Age</td>\r\n                    <td class=\"subtitle1\" colspan=\"2\">Cardiovascular disease, all types</td>\r\n                    <td class=\"subtitle1\" colspan=\"2\">Coronary disease</td>\r\n                    <td class=\"subtitle1\" colspan=\"2\">Stroke and TIA</td>\r\n                    <td class=\"subtitle1\" colspan=\"2\">Heart failure</td>\r\n                    <td class=\"subtitle1\" colspan=\"2\">Peripheral artery disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2\">Men</td>\r\n                    <td class=\"subtitle2\">Women</td>\r\n                    <td class=\"subtitle2\">Men</td>\r\n                    <td class=\"subtitle2\">Women</td>\r\n                    <td class=\"subtitle2\">Men</td>\r\n                    <td class=\"subtitle2\">Women</td>\r\n                    <td class=\"subtitle2\">Men</td>\r\n                    <td class=\"subtitle2\">Women</td>\r\n                    <td class=\"subtitle2\">Men</td>\r\n                    <td class=\"subtitle2\">Women</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>35 to 64</td>\r\n                    <td>17</td>\r\n                    <td>9</td>\r\n                    <td>12</td>\r\n                    <td>5</td>\r\n                    <td>2</td>\r\n                    <td>2</td>\r\n                    <td>2</td>\r\n                    <td>1</td>\r\n                    <td>3</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>65 to 94</td>\r\n                    <td>44</td>\r\n                    <td>50</td>\r\n                    <td>27</td>\r\n                    <td>16</td>\r\n                    <td>13</td>\r\n                    <td>11</td>\r\n                    <td>12</td>\r\n                    <td>9</td>\r\n                    <td>8</td>\r\n                    <td>5</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">* Age-adjusted average annual incidence per 1000 persons free of the specified disease.</div><div id=\"graphicVersion\">Graphic 56067 Version 2.0</div></div></div>"},"56068":{"type":"graphic_diagnosticimage","displayName":"Normal finger radiographs","title":"Normal finger radiographs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal finger radiographs</div><div class=\"cntnt\"><img style=\"width:444px; height:388px;\" src=\"images/EM/56068_Finger_XR_normal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The three standard views (AP, lateral, and oblique) of the finger are shown here. Lateral is at the far left, oblique in the middle, and AP is on the right.</div><div class=\"graphic_footnotes\">AP: anterior-posterior.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 56068 Version 3.0</div></div></div>"},"56069":{"type":"graphic_table","displayName":"Causes of ascites","title":"Causes of ascites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of ascites</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Cirrhosis</strong></td> <td>81 percent</td> </tr> <tr> <td><strong>Cancer</strong></td> <td>10 percent</td> </tr> <tr> <td><strong>Heart failure</strong></td> <td>3 percent</td> </tr> <tr> <td><strong>Tuberculosis</strong></td> <td>2 percent</td> </tr> <tr> <td><strong>Dialysis</strong></td> <td>1 percent</td> </tr> <tr> <td><strong>Pancreatic disease</strong></td> <td>1 percent</td> </tr> <tr> <td><strong>Other</strong></td> <td>2 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Runyon BA, Montano AA, Akriviadis EA, et al. Ann Intern Med 1992; 117:215.</div><div id=\"graphicVersion\">Graphic 56069 Version 3.0</div></div></div>"},"56070":{"type":"graphic_figure","displayName":"Ligation of uterine artery","title":"Ligation of uterine artery during hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Ligation of uterine artery during hysterectomy</div><div class=\"cntnt\"><img style=\"width:488px; height:346px;\" src=\"images/OBGYN/56070_Ligation_of_uterine_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clamp placement is perpendicular to the uterine vasculature.</div><div id=\"graphicVersion\">Graphic 56070 Version 2.0</div></div></div>"},"56072":{"type":"graphic_diagnosticimage","displayName":"CT of a pulmonary arteriovenous malformation","title":"CT of a pulmonary arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of a pulmonary arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:337px; height:328px;\" src=\"images/PULM/56072_Arteriovenous_malformatio1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary arteriovenous malformation presenting as a solitary pulmonary nodule. Chest CT shows a nodule in the periphery of the right middle lobe (arrow) with a&nbsp;proximal tail-like extension corresponding to the supplying artery and the draining vein.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56072 Version 4.0</div></div></div>"},"56073":{"type":"graphic_figure","displayName":"Arterial catheter rapid flush test","title":"Arterial catheter rapid flush test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arterial catheter rapid flush test</div><div class=\"cntnt\"><img style=\"width:409px; height:161px;\" src=\"images/PULM/56073_Rapid_flush_test.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intravascular pressure tracings obtained during the rapid flushing of a monitoring catheter. A. Optimal damping in which rapid flushing produces a rapid upstroke in pressure followed by recovery characterized by a fall in pressure to below baseline with less than three beats of ringing. B. Overdamped system in which no ringing is seen. C. Underdamped system in which there is excessive ringing.</div><div class=\"graphic_reference\">Redrawn from Rippe, JM, Irwin, RS, Alpert, JS, Fink, MP (Eds), Intensive Care Medicine, 3rd ed, Little Brown, Boston, 1996.</div><div id=\"graphicVersion\">Graphic 56073 Version 2.0</div></div></div>"},"56074":{"type":"graphic_figure","displayName":"Port placement for foregut surgery","title":"Port placement for foregut surgery*","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Port placement for foregut surgery*</div><div class=\"cntnt\"><img style=\"width:457px; height:587px;\" src=\"images/SURG/56074_Port_lap_foregut.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Veres needle is placed in the upper abdomen to insufflate the peritoneal cavity. A 5 mm port is placed through the Veres tract and the laparoscope is placed. Additional ports are placed under direct vision. The 5 mm port in the subxiphoid region is used for a laparoscopic liver retractor. Right and left subcostal ports (5 mm) are placed and two additional ports are placed midway between these subcostal ports and the umbilicus. One of the midabdominal ports is used to pass the surgical stapler (12 mm) and/or special suturing instruments.<br> The surgeon stands on the patient's right side using the dissector and stapler through the right-sided ports (shown in red). The assistant stands on the patient's left side operating the laparoscope with his or her left hand through the 5 mm midabdominal port site, and provides counter-traction for the surgeon through the left subcostal port site (shown in blue). Alternatively, the patient can be placed in a split leg (ie, lithotomy) position, and the surgeon operates from a position between the legs.</div><div class=\"graphic_footnotes\">* Port placement and technique may vary amongst laparoscopic surgeons.</div><div id=\"graphicVersion\">Graphic 56074 Version 4.0</div></div></div>"},"56076":{"type":"graphic_figure","displayName":"Effects of vitamin D supplementation on total fracture","title":"Meta-analysis of randomized trials comparing the effects of vitamin D supplementation with placebo on total fracture","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Meta-analysis of randomized trials comparing the effects of vitamin D supplementation with placebo on total fracture</div><div class=\"cntnt\"><img style=\"width:645px; height:302px;\" src=\"images/ENDO/56076_EffectsvitaDsuptotalfx.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Chung M, Lee J, Terasawa T, et al. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:827. Copyright © 2011 American College of Physicians. All rights reserved.</div><div id=\"graphicVersion\">Graphic 56076 Version 12.0</div></div></div>"},"56077":{"type":"graphic_table","displayName":"Infxn acalculous cholecystitis","title":"Infections predisposing to acalculous cholecystitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infections predisposing to acalculous cholecystitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Ascaris lumbricoides</td> </tr> <tr> <td>Brucella species</td> </tr> <tr> <td>Campylobacter jejuni</td> </tr> <tr> <td>Candida species</td> </tr> <tr> <td>Coxiella burnetii</td> </tr> <tr> <td>Cryptosporidium</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td>Echinococcus granulosus</td> </tr> <tr> <td>Epstein-Barr virus</td> </tr> <tr> <td>Flavivirus</td> </tr> <tr> <td>Hepatitis A and B</td> </tr> <tr> <td>Isospora</td> </tr> <tr> <td>Leptospira species</td> </tr> <tr> <td>Mycobacterium tuberculosis</td> </tr> <tr> <td>Plasmodium species</td> </tr> <tr> <td>Salmonella species (S enterica, S typhi)</td> </tr> <tr> <td>Vibrio cholerae</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56077 Version 3.0</div></div></div>"},"56078":{"type":"graphic_table","displayName":"Bioterrorism agents CAP","title":"Bioterrorism agents that could cause outbreaks or clusters characterized by respiratory symptoms - differential diagnosis and key features ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bioterrorism agents that could cause outbreaks or clusters characterized by respiratory symptoms - differential diagnosis and key features </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Time to onset</td> <td class=\"subtitle1\">Chest radiograph</td> <td class=\"subtitle1\">Fatality</td> <td class=\"subtitle1\">Onset to respiratory failure</td> </tr> <tr> <td>Anthrax (inhalation)</td> <td>1 to 6 days</td> <td>Mediastinal widening, pleural effusions</td> <td>90 percent</td> <td>1 to 3 days</td> </tr> <tr> <td>Plague (pneumonic)</td> <td>2 to 3 days</td> <td>Bilateral infiltrates, may have pleural effusions</td> <td>90 percent</td> <td>Within 1 day</td> </tr> <tr> <td>Tularemia</td> <td>2 to 10 days</td> <td>Bilateral infiltrates hilar adenopathy</td> <td>30 percent without therapy, &#60;5 percent with therapy</td> <td>Low incidence</td> </tr> <tr> <td><em>Legionella</em></td> <td>2 to 10 days</td> <td>Variable, bilateral subsegmental infiltrates or consolidation</td> <td>15 percent</td> <td>Variable incidence</td> </tr> <tr> <td>Influenza</td> <td>1 to 2 days</td> <td>Variable bilateral interstitial or alveolar infiltrates</td> <td>10 to 25 percent in those with underlying diseases</td> <td>Variable incidence</td> </tr> <tr> <td>Ricin (inhalation)</td> <td>18 to 24 hours</td> <td>Likely bilateral infiltrates/acute respiratory distress syndrome</td> <td>High</td> <td>Likely within 30 hours</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Karwa M, Currie B, Kvetan V. Bioterrorism: Preparing for the impossible or the improbable. Crit Care Med 2005; 33:S75.</div><div id=\"graphicVersion\">Graphic 56078 Version 5.0</div></div></div>"},"56079":{"type":"graphic_table","displayName":"Spectrum of immune compromise","title":"Spectrum of immune compromise","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spectrum of immune compromise</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Significantly immunocompromising conditions include: </td> </tr> <tr> <td>Hematopoietic stem cell transplant (HCT) within the past two years</td> </tr> <tr> <td>Solid organ transplant (SOT) within the past year</td> </tr> <tr> <td>Treatment for rejection after SOT</td> </tr> <tr> <td>Active leukemia or lymphoma</td> </tr> <tr> <td>Generalized malignancy</td> </tr> <tr> <td>Aplastic anemia</td> </tr> <tr> <td>Graft-versus-host disease</td> </tr> <tr> <td>Congenital immunodeficiency</td> </tr> <tr> <td>Recent radiation therapy</td> </tr> <tr> <td>Significantly immunosuppressive medications</td> </tr> <tr> <td>AIDS with low CD4 count</td> </tr> <tr> <td class=\"subtitle1_single\">Moderately immunocompromising conditions include: </td> </tr> <tr> <td>Chronic hepatic disease (cirrhosis and alcoholism)</td> </tr> <tr> <td>Chronic renal disease</td> </tr> <tr> <td>Diabetes</td> </tr> <tr> <td>Asplenia</td> </tr> <tr> <td>Nutritional deficiencies (depending on the nature of the deficiency)</td> </tr> <tr> <td class=\"subtitle1_single\">Minimally immunocompromising conditions include: </td> </tr> <tr> <td>Chemotherapy for leukemia/lymphoma or cancer more than&nbsp;three months earlier</td> </tr> <tr> <td>Malignancy in remission</td> </tr> <tr> <td>High-dose steroid use more than a month earlier</td> </tr> <tr> <td>Mild steroid use including inhaled, topical, intraarticular, bursal, or tendon injection</td> </tr> <tr> <td>HIV with &#62;500 CD4 lymphocytes/mm<sup>3</sup></td> </tr> <tr> <td>HCT recipients more than&nbsp;two years post-transplant who are not on immunosuppressive drugs and do not have graft-versus-host disease</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Kotton CN,&nbsp;Freedman DO. Immunocompromised Travelers. In: CDC Health Information for International Travel 2014: The Yellow Book. Available at: <A href=\"http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-8-advising-travelers-with-specific-needs/immunocompromised-travelers\">http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-8-advising-travelers-with-specific-needs/immunocompromised-travelers</A>. (Accessed on November 17, 2014.)</LI></OL></div><div id=\"graphicVersion\">Graphic 56079 Version 5.0</div></div></div>"},"56080":{"type":"graphic_movie","displayName":"TEE LA appendage thrombus","title":"Left atrial appendage thrombus seen on TEE","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial appendage thrombus seen on TEE</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/56080_teethla1conv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:250px; height:199px;\" src=\"images/CARD/56080_teethla1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a stationary thrombus in the left atrial appendage. The mitral leaflets do not appear to open normally, suggesting the presence of mitral stenosis.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 56080 Version 3.0</div></div></div>"},"56081":{"type":"graphic_table","displayName":"Phosphorus foods 2 PI","title":"Table 20. Phosphorus content of protein-containing foods (cont'd)","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Table 20. Phosphorus content of protein-containing foods (cont'd)</div><div class=\"cntnt\"><img style=\"width:477px; height:585px;\" src=\"images/PI/56081_Phosphorus_foods_2_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A common way to determine a dietary phosphorus limit is to use an average of 10 to 12 mg/g of protein (multiply protein goal times 10 to 12 mg phosphorus). Thus, for a 70 kg individual requiring 84 g of protein, the phosphorus range is 840 to 1008 mg.<br />Considering all common sources of protein, the average phosphorus content per gram of protein is 17.8. If all diary products, nuts, beans, and seeds are eliminated, but meats and tofu are considered, the average phosphorus content per gram of protein is 10.3.</div><div class=\"graphic_footnotes\">FF: fast food; Tb: tablespoon.</div><div class=\"graphic_reference\">US Department of Agriculture, Agricultural Research Service. 2001. USDA Nutrient Database for Standard Reference, Release 14. Nutrient Data Laboratory Home Page, http://www.nalusda.gov/fnic/foodcomp.</div><div id=\"graphicVersion\">Graphic 56081 Version 8.0</div></div></div>"},"56082":{"type":"graphic_diagnosticimage","displayName":"Gluteal artery pseudoaneurysm","title":"Gluteal artery pseudoaneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gluteal artery pseudoaneurysm</div><div class=\"cntnt\"><img style=\"width:337px; height:514px;\" src=\"images/NEURO/56082_Gluteal_art_pseudoaneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) Pelvic computed tomography with intravenous contrast demonstrates a large intrapelvic hematoma (arrows) and pseudoaneurysm.</div><div class=\"graphic_reference\">Reproduced with permission from: Yurtseven T, Zileli M, Goker EN, et al. Gluteal artery pseudoaneurysm, a rare cause of sciatic pain: Case report and literature review. J Spinal Disord Tech 2002; 15:330. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56082 Version 11.0</div></div></div>"},"56083":{"type":"graphic_picture","displayName":"Rosacea erythema cheek","title":"Rosacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rosacea</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/56083_Rosaceaerythemacheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and telangiectasias on the cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56083 Version 5.0</div></div></div>"},"56084":{"type":"graphic_figure","displayName":"Augmented urethroplasty","title":"Augmented urethroplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Augmented urethroplasty</div><div class=\"cntnt\"><img style=\"width:395px; height:558px;\" src=\"images/SURG/56084_Augmented-urethroplasty.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56084 Version 1.0</div></div></div>"},"56085":{"type":"graphic_table","displayName":"Drug causes of pemphigoid","title":"Drugs that may induce bullous pemphigoid or mucous membrane pemphigoid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that may induce bullous pemphigoid or mucous membrane pemphigoid</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Systemic</td> </tr> <tr> <td class=\"indent1\">Actinomycin D</td> </tr> <tr> <td class=\"indent1\">Amlodipine</td> </tr> <tr> <td class=\"indent1\">Arsenic</td> </tr> <tr> <td class=\"indent1\">Azapropazone (NSAID, not currently available)</td> </tr> <tr> <td class=\"indent1\">Captopril (thiol*)</td> </tr> <tr> <td class=\"indent1\">Celecoxib</td> </tr> <tr> <td class=\"indent1\">Cephalexin</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin</td> </tr> <tr> <td class=\"indent1\">Clonidine</td> </tr> <tr> <td class=\"indent1\">Chloroquine</td> </tr> <tr> <td class=\"indent1\">Dipeptidyl peptidase-4 inhibitors (gliptins), including sitagliptin and vildagliptin</td> </tr> <tr> <td class=\"indent1\">Efalizumab</td> </tr> <tr> <td class=\"indent1\">Enalapril</td> </tr> <tr> <td class=\"indent1\">Erlotinib</td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> </tr> <tr> <td class=\"indent1\">Flupenthixol (thiol*)</td> </tr> <tr> <td class=\"indent1\">Furosemide (sulfonamide*)</td> </tr> <tr> <td class=\"indent1\">Gabapentin</td> </tr> <tr> <td class=\"indent1\">Galantamine hydrobromide</td> </tr> <tr> <td class=\"indent1\">Gold thiosulfate (thiol*)</td> </tr> <tr> <td class=\"indent1\">Hydrochlorothiazide</td> </tr> <tr> <td class=\"indent1\">Ibuprofen</td> </tr> <tr> <td class=\"indent1\">Interleukin-2</td> </tr> <tr> <td class=\"indent1\">Levetiracetam</td> </tr> <tr> <td class=\"indent1\">Levofloxacin</td> </tr> <tr> <td class=\"indent1\">Lisinopril</td> </tr> <tr> <td class=\"indent1\">Losartan</td> </tr> <tr> <td class=\"indent1\">Mefenamic acid</td> </tr> <tr> <td class=\"indent1\">Methyldopa</td> </tr> <tr> <td class=\"indent1\">Nadolol</td> </tr> <tr> <td class=\"indent1\">Nifedipine</td> </tr> <tr> <td class=\"indent1\">Omeprazole</td> </tr> <tr> <td class=\"indent1\">PD-1 and PD-L1&nbsp;monoclonal antibodies, including nivolumab, pembrolizumab, and&nbsp;durvalumab</td> </tr> <tr> <td class=\"indent1\">Penicillamine (thiol*)</td> </tr> <tr> <td class=\"indent1\">Penicillins, including amoxicillin and ampicillin</td> </tr> <tr> <td class=\"indent1\">Phenacetin</td> </tr> <tr> <td class=\"indent1\">Placental extracts</td> </tr> <tr> <td class=\"indent1\">Potassium iodide</td> </tr> <tr> <td class=\"indent1\">Practolol</td> </tr> <tr> <td class=\"indent1\">Psoralens with ultraviolet A (PUVA)</td> </tr> <tr> <td class=\"indent1\">Rifampin</td> </tr> <tr> <td class=\"indent1\">Risperidone</td> </tr> <tr> <td class=\"indent1\">Spironolactone</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine (sulfonamide*)</td> </tr> <tr> <td class=\"indent1\">Sulfamethoxazole (sulfonamide*)</td> </tr> <tr> <td class=\"indent1\">Terbinafine</td> </tr> <tr> <td class=\"indent1\">Tiopronin (thiol*)</td> </tr> <tr> <td class=\"indent1\">Tiobutarit, D Penicillamine analog (thiol*)</td> </tr> <tr> <td class=\"indent1\">Tolbutamide (sulfonamide*)</td> </tr> <tr> <td class=\"indent1\">Tumor necrosis factor-alpha inhibitors, including adalimumab and etanercept</td> </tr> <tr> <td class=\"indent1\">Ustekinumab</td> </tr> <tr> <td class=\"subtitle1_single\">Topical</td> </tr> <tr> <td class=\"indent1\">Anthralin</td> </tr> <tr> <td class=\"indent1\">Benzyl benzoate</td> </tr> <tr> <td class=\"indent1\">Coal tar</td> </tr> <tr> <td class=\"indent1\">5-fluorouracil</td> </tr> <tr> <td class=\"indent1\">Iodophor in adhesive bandage</td> </tr> <tr> <td class=\"indent1\">Epinephrine</td> </tr> <tr> <td class=\"indent1\">Idoxuridine</td> </tr> <tr> <td class=\"indent1\">Pilocarpine</td> </tr> <tr> <td class=\"indent1\">Timolol</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug; PD-1: programmed death; PD-L1; programmed death-ligand 1.<br />* Thiol compounds and sulfonamide derivatives are common inducers of pemphigoid.</div><div class=\"graphic_reference\">Original figure modified for this publication. Vassileva S. Drug-induced pemphigoid: Bullous and cicatricial. Clin Dermatol 1998; 16:379. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 56085 Version 6.0</div></div></div>"},"56086":{"type":"graphic_picture","displayName":"Histologic findings in GERD","title":"Histologic findings in GERD","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Histologic findings in GERD</div><div class=\"cntnt\"><img style=\"width:545px; height:366px;\" src=\"images/GAST/56086_histologic_find_GERD2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Increased basal layer thickness (noncornified stratified squamous).<br> (B) Papillary elongation (noncornified stratified squamous).</div><div class=\"graphic_footnotes\">GERD: gastrointestinal reflux disease.</div><div id=\"graphicVersion\">Graphic 56086 Version 1.0</div></div></div>"},"56087":{"type":"graphic_table","displayName":"Topical combination acne","title":"Topical combination products for acne vulgaris","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical combination products for acne vulgaris</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Benzoyl peroxide and topical antibiotic</td> <td class=\"subtitle1\">Trade names (United States)</td> </tr> <tr> <td>Benzoyl peroxide 5% and clindamycin 1% gel</td> <td>Benzaclin</td> </tr> <tr> <td>Benzoyl peroxide 5% and clindamycin 1.2% gel</td> <td>Duac, Neuac</td> </tr> <tr> <td>Benzoyl peroxide 3.75% and clindamycin 1.2% gel</td> <td>Onexton</td> </tr> <tr> <td>Benzoyl peroxide 2.5% and clindamycin 1.2% gel</td> <td>Acanya&nbsp;</td> </tr> <tr> <td>Benzoyl peroxide 5% and erythromycin 3% gel </td> <td>Benzamycin</td> </tr> <tr> <td class=\"subtitle1\">Topical retinoid and topical antimicrobial</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>Clindamycin 1.2% and tretinoin 0.025% gel</td> <td>Veltin, Ziana</td> </tr> <tr> <td>Benzoyl peroxide 2.5% and adapalene 0.1%</td> <td>Epiduo</td> </tr> <tr> <td>Benzoyl peroxide 2.5% and adapalene 0.3%*</td> <td>Epiduo Forte*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Expected to become available in the United States in 2015.</div><div id=\"graphicVersion\">Graphic 56087 Version 10.0</div></div></div>"},"56089":{"type":"graphic_figure","displayName":"Paravertebral sympathetic chain","title":"Brachial plexus and paravertebral sympathetic chain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brachial plexus and paravertebral sympathetic chain</div><div class=\"cntnt\"><img style=\"width:419px; height:246px;\" src=\"images/PULM/56089_Paravertebral_sympathetic_c.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram shows the interrelationships of the nerve roots, the sympathetic chain, and the peripheral nerves that can potentially be involved with superior sulcus tumors.</div><div id=\"graphicVersion\">Graphic 56089 Version 1.0</div></div></div>"},"56090":{"type":"graphic_figure","displayName":"Saw tooth pattern in OSA","title":"Flow-volume loop in obstructive sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow-volume loop in obstructive sleep apnea</div><div class=\"cntnt\"><img style=\"width:270px; height:262px;\" src=\"images/PULM/56090_Saw_tooth_pattern_OSA_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow-volume loop in obstructive sleep apnea showing a saw-tooth pattern. The intersections with the x-axis are at total lung capacity (TLC) on the left and residual volume (RV) on the right.</div><div id=\"graphicVersion\">Graphic 56090 Version 5.0</div></div></div>"},"56092":{"type":"graphic_picture","displayName":"Corn - plantar","title":"Corn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corn</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/56092_Corn_plantar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hyperkeratotic papule with a central &quot;core&quot; is present on the plantar surface near the base of the second toe.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56092 Version 4.0</div></div></div>"},"56093":{"type":"graphic_picture","displayName":"Visual inspect lugols","title":"Visual inspection with Lugol's iodine (VILI)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Visual inspection with Lugol's iodine (VILI)</div><div class=\"cntnt\"><img style=\"width:401px; height:607px;\" src=\"images/OBGYN/56093_Visual_inspect_lugols.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: IARC screening group. Testing and reporting the results of visual inspection with Lugol's iodine (VILI). In: Sankaranarayanan R, Wesley RS. A practical manual on visual screening for cervical neoplasia. IARC Press, Lyon, 2003. Copyright © 2003 IARC Press.</div><div id=\"graphicVersion\">Graphic 56093 Version 9.0</div></div></div>"},"56097":{"type":"graphic_picture","displayName":"Spitz nevus","title":"Spitz nevus (spindle-cell nevus, epithelioid-cell nevus)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spitz nevus (spindle-cell nevus, epithelioid-cell nevus)</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/56097_Spitz_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Smooth-surfaced, pink Spitz nevus.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 56097 Version 1.0</div></div></div>"},"56098":{"type":"graphic_table","displayName":"American Society of Anesthesiologists physical status scale","title":"American Society of Anesthesiologists physical status scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society of Anesthesiologists physical status scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">ASA class</td> <td class=\"subtitle1\">Physical status</td> <td class=\"subtitle1\">Functional status</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Risk status</td> </tr> <tr> <td>1</td> <td>Healthy, no disease outside surgical process</td> <td> <p>Can walk up one flight of stairs or two level city blocks without distress</p> <p>Little or no anxiety</p> </td> <td>&nbsp;</td> <td> <p>Little or no risk</p> <p><strong>Green flag for treatment</strong></p> </td> </tr> <tr> <td>2</td> <td>Mild to moderate systemic disease, medically well controlled, with no functional limitation</td> <td> <p>Can walk up one flight of stairs or two level city blocks but will have to stop after completion of the exercise because of distress</p> <p>ASA I with extreme anxiety and fear, a respiratory condition, pregnancy or active allergies</p> </td> <td>Well controlled disease states including diabetes, hypertension, obesity, epilepsy, asthma or thyroid conditions</td> <td> <p>Minimal risk</p> <p><strong>Yellow flag for treatment</strong></p> </td> </tr> <tr> <td>3</td> <td>Severe systemic disease that results in functional limitation</td> <td>Can walk up one flight of stairs or two level city blocks but will have to stop enroute because of distress</td> <td>History of angina pectoris, MI, CVA; HF &#62;6 months ago, COPD, diabetes with vascular complications, poorly controlled HTN, morbid obesity</td> <td><strong>Yellow flag for treatment</strong></td> </tr> <tr> <td>4</td> <td>Severe incapacitating disease process that is a constant threat to life</td> <td> <p>Unable to walk up one flight of stairs or two level city blocks</p> <p> Distress is present even at rest</p> </td> <td> <p>History of unstable angina, MI or CVA within last&nbsp;six months; severe HF, severe COPD; uncontrolled diabetes, HTN, epilepsy or thyroid condition</p> <p>Advanced pulmonary, renal or hepatic dysfunction</p> </td> <td> <p>The risk may be too great for elective surgical procedure</p> <p>Medical consultation needed for emergency treatment</p> <p><strong>Red flag for treatment</strong></p> </td> </tr> <tr> <td>5</td> <td>Moribund patient not expected to survive 24 hours without an operation</td> <td>&nbsp;</td> <td>Ruptured abdominal aneurysm, pulmonary embolus, head injury with increased intracranial pressure</td> <td> <p>Elective treatment is contraindicated; however, emergency surgery may be necessary</p> <p><strong>Red flag for treatment</strong></p> </td> </tr> <tr> <td>6</td> <td>A declared brain-dead patient being maintained for harvesting of organs</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>E</td> <td>Suffix to indicate emergency surgery for any class</td> <td>Any patient in whom an emergency operation is required</td> <td>Otherwise healthy young woman requiring D&#38;C for persistent vaginal bleeding</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MI: myocardial infarction; CVA: cerebrovascular accident; HF: heart failure; HTN: hypertension; D&amp;C: dilation and curettage.</div><div class=\"graphic_reference\">Adapted from: Cohen MM, Duncan PG, Tate RB. Does anesthesia contribute to operative mortality? JAMA 1988; 260:2859 and Malamed SF. Medical Emergencies in the Dental Office, Sixth Edition, Mosby Elsevier, St Louis 2007.</div><div id=\"graphicVersion\">Graphic 56098 Version 15.0</div></div></div>"},"56100":{"type":"graphic_picture","displayName":"Vaccinia virion on EM","title":"Poxvirus virions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Poxvirus virions</div><div class=\"cntnt\"><img style=\"width:210px; height:324px;\" src=\"images/ID/56100_EM_Vaccinia_virion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph shows intracellular brick-shaped vaccinia virions with dense central core and outer viral membranes (blue arrows). The electron microscopic image of variola virus would be identical to that seen here with vaccinia virus.</div><div class=\"graphic_reference\">Reproduced with permission from Herrera E, del mar Lorenzo M, Blasco R, Isaacs SN. J Virol 1998; 72:294.</div><div id=\"graphicVersion\">Graphic 56100 Version 3.0</div></div></div>"},"56105":{"type":"graphic_figure","displayName":"Nose external anatomy","title":"External anatomy of the nose","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">External anatomy of the nose</div><div class=\"cntnt\"><img style=\"width:542px; height:346px;\" src=\"images/ALLRG/56105_Nose_external_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomical structures of the nose. Bony components are shown in tan; cartilage is shown in blue.</div><div id=\"graphicVersion\">Graphic 56105 Version 2.0</div></div></div>"},"56106":{"type":"graphic_diagnosticimage","displayName":"Salter II ankle","title":"Salter-Harris II fracture of the distal fibula","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">Salter-Harris II fracture of the distal fibula</div><div class=\"cntnt\"><img style=\"width:785px; height:722px;\" src=\"images/EM/56106_Sltr_II_ankl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior posterior (A) and mortise (B) views in this patient show a nondisplaced Salter-Harris II fracture of the distal fibula with the characteristic triangular fragment, also known as the Thurston-Holland sign (arrows).</div><div class=\"graphic_reference\">Courtesy of Kathy Boutis, MD, FRCPC, FAAP, MSc.</div><div id=\"graphicVersion\">Graphic 56106 Version 5.0</div></div></div>"},"56108":{"type":"graphic_diagnosticimage","displayName":"Fluorosc looping guidewire","title":"EUS-guided pancreatic pseudocyst drainage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">EUS-guided pancreatic pseudocyst drainage</div><div class=\"cntnt\"><img style=\"width:360px; height:398px;\" src=\"images/GAST/56108_Fluorosc_looping_guidewire.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic image demonstrating looping of a guidewire in a pseudocyst under EUS-guidance.</div><div class=\"graphic_footnotes\">EUS: endoscopic ultrasound.</div><div class=\"graphic_reference\">Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.</div><div id=\"graphicVersion\">Graphic 56108 Version 3.0</div></div></div>"},"56109":{"type":"graphic_table","displayName":"5-FU treatment VAIN","title":"5-FU treatment of vaginal intraepithelial neoplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">5-FU treatment of vaginal intraepithelial neoplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Patients treated</td> <td class=\"subtitle1\">Recurred after first treatment (percent)</td> <td class=\"subtitle1\">Treatment schedule</td> <td class=\"subtitle1\">Follow-up range</td> </tr> <tr> <td>Woodruff</td> <td>1975</td> <td>9</td> <td>11</td> <td>Twice a day for 1 month then monthly</td> <td>6 weeks to 6 years</td> </tr> <tr> <td>Piver</td> <td>1979</td> <td>8</td> <td>38</td> <td>Once a day for five days per month for 2 to 3 months</td> <td>3 to 7 years</td> </tr> <tr> <td>Ballon</td> <td>1979</td> <td>12</td> <td>25</td> <td>Twice a day for 2 weeks</td> <td>6 to 30 months</td> </tr> <tr> <td>Daly</td> <td>1980</td> <td>17</td> <td>0</td> <td>Twice a day for 10 to 14 days</td> <td>2 to 5 years</td> </tr> <tr> <td>Petrilli</td> <td>1980</td> <td>15</td> <td>20</td> <td>Twice a day for 5 days</td> <td>2 to 60 months</td> </tr> <tr> <td>Caglar</td> <td>1981</td> <td>27</td> <td>15</td> <td>Once a day for 5 to 10 days</td> <td>3 to 48 months</td> </tr> <tr> <td>Kirwan</td> <td>1985</td> <td>14</td> <td>7</td> <td>Every week for 10 weeks</td> <td>4 to 42 months</td> </tr> <tr> <td>Krebs</td> <td>1989</td> <td>37</td> <td>19</td> <td>Every week for 10 weeks</td> <td>12 to 84 months</td> </tr> <tr> <td>Audet-LaPointe</td> <td>1990</td> <td>12</td> <td>17</td> <td>Once a day for 5 days</td> <td>9 to 42 months</td> </tr> <tr> <td>Dodge</td> <td>2001</td> <td>22</td> <td>59</td> <td>Not reported</td> <td>&#62;7 months</td> </tr> <tr> <td>Murta</td> <td>2005</td> <td>16</td> <td>38</td> <td>Every week for 10 weeks</td> <td>Not reported</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56109 Version 4.0</div></div></div>"},"56110":{"type":"graphic_picture","displayName":"Vulvar psoriasis","title":"Vulvar psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar psoriasis</div><div class=\"cntnt\"><img style=\"width:256px; height:391px;\" src=\"images/OBGYN/56110_Vulvar_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous and scaly plaques involving the labia majora and perineum in a patient with inverse psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from Ridley CM, Neill SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright © 1999 Blackwell Science. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 56110 Version 7.0</div></div></div>"},"56112":{"type":"graphic_picture","displayName":"Atherosclerotic plaque visualized by 3D TEE","title":"Atherosclerotic plaque visualized by 3D TEE","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atherosclerotic plaque visualized by 3D TEE</div><div class=\"cntnt\"><img style=\"width:504px; height:314px;\" src=\"images/SURG/56112_3D_TEE_Arth_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Protruding plaque in the aortic arch.<br> (B) Ulcerated plaque in the descending thoracica aorta.</div><div class=\"graphic_reference\">Courtesy of Dr. Muhamed Saric.</div><div id=\"graphicVersion\">Graphic 56112 Version 1.0</div></div></div>"},"56113":{"type":"graphic_picture","displayName":"Generalized morphea - trunk","title":"Generalized morphea on the trunk","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Generalized morphea on the trunk</div><div class=\"cntnt\"><img style=\"width:308px; height:360px;\" src=\"images/DERM/56113_Generalized_morphea_trunk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isomorphic, hyperpigmented, sclerotic plaques are present on the chest and abdomen.</div><div id=\"graphicVersion\">Graphic 56113 Version 2.0</div></div></div>"},"56114":{"type":"graphic_diagnosticimage","displayName":"Tube related complications after gastric banding","title":"Tube related complications after gastric banding","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Tube related complications after gastric banding</div><div class=\"cntnt\"><img style=\"width:507px; height:512px;\" src=\"images/SURG/56114_Disconnect_tubing_gast_band.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Disconnected tubing after gastric banding causing obstruction. Arrows are pointing to the port of an adjustable gastric band and the disconnected tubing.<BR>(B) Computed tomography (CT) scan&nbsp;with arrows&nbsp;pointing to the band tubing around dilated and then decompressed bowel near the transition point.</div><div id=\"graphicVersion\">Graphic 56114 Version 7.0</div></div></div>"},"56115":{"type":"graphic_figure","displayName":"Paragonimiasis life cycle","title":"Paragonimiasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Paragonimiasis life cycle</div><div class=\"cntnt\"><img style=\"width:553px; height:476px;\" src=\"images/ID/56115_Paragonimiasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The eggs are excreted unembryonated in the sputum, or, alternately, they are swallowed and passed with stool <strong>(1)</strong>. In the external environment, the eggs become embryonated <strong>(2)</strong>, and miracidia hatch and seek the first intermediate host, a snail, and penetrate its soft tissues <strong>(3)</strong>. Miracidia go through several developmental stages inside the snail <strong>(4)</strong>: sporocysts <strong>(4a)</strong>, rediae <strong>(4b)</strong>, with the latter giving rise to many cercariae <strong>(4c)</strong>, which emerge from the snail. The cercariae invade the second intermediate host, a crustacean, such as a crab or crayfish, where they encyst and become metacercariae. This is the infective stage for the mammalian host <strong>(5)</strong>. Human infection with <em>P. westermani</em> occurs by eating inadequately cooked or pickled crab or crayfish that harbor metacercariae of the parasite <strong>(6)</strong>. The metacercariae excyst in the duodenum <strong>(7)</strong>, penetrate through the intestinal wall into the peritoneal cavity, then through the abdominal wall and diaphragm into the lungs, where they become encapsulated and develop into adults <strong>(8)</strong> (7.5 to 12 mm by 4 to 6 mm). The worms can also reach other organs and tissues, such as the brain and striated muscles, respectively. However, when this takes place completion of the life cycles is not achieved, because the eggs laid cannot exit these sites. Time from infection to oviposition is 65 to 90 days. Infections may persist for 20 years in humans. Animals such as pigs, dogs, and a variety of feline species can also harbor <em>P. westermani</em>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Paragonimiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/paragonimiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/paragonimiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 56115 Version 4.0</div></div></div>"},"56116":{"type":"graphic_picture","displayName":"Polymorphic eruption of pregnancy abdomen thighs","title":"Polymorphic eruption of pregnancy (pruritic urticarial papules and plaques of pregnancy) ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymorphic eruption of pregnancy (pruritic urticarial papules and plaques of pregnancy)&nbsp;</div><div class=\"cntnt\"><img style=\"width:432px; height:479px;\" src=\"images/DERM/56116_PUPPP_abd_thighs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques are present in areas of striae in this woman with polymorphic eruption of pregnancy (PEP). This disorder is also&nbsp;called pruritic urticarial papules and plaques of pregnancy&nbsp;(PUPPP).</div><div class=\"graphic_reference\">Reproduced with permission from <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56116 Version 6.0</div></div></div>"},"56118":{"type":"graphic_figure","displayName":"Somatic sensory receptors","title":"Somatic sensory receptors in the skin","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Somatic sensory receptors in the skin</div><div class=\"cntnt\"><img style=\"width:533px; height:284px;\" src=\"images/PC/56118_Somatic_sensory_receptors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hairy and nonhairy skin have a variety of sensory receptors within the skin.</div><div class=\"graphic_reference\">Adapted with permission from: Bear MF, Connors BW, Paradiso MA. Neuroscience: Exploring the brain, Philadelphia: Williams &amp; Wilkins, 1996. Copyright © 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56118 Version 4.0</div></div></div>"},"56119":{"type":"graphic_table","displayName":"Criteria for adequate specimens","title":"Cytologic criteria for an \"adequate\" specimen during TBNA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytologic criteria for an &quot;adequate&quot; specimen during TBNA</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Bronchial epithelial cells should be absent or rare.</td>\n</tr>\n<tr>\n<td>A preponderance of lymphocytes should be found.</td>\n</tr>\n<tr>\n<td>Strict criteria for cytologic diagnosis of malignancy should be established and adhered to, and all samples should be classified as negative, suspicious, or definitely malignant.</td>\n</tr>\n<tr>\n<td>Only samples showing no evidence of pathology in the presence of lymphocytes should be considered true negatives.</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 56119 Version 1.0</div></div></div>"},"56120":{"type":"graphic_diagnosticimage","displayName":"Nodular pleural plaques CT","title":"Nodular pleural plaques","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Nodular pleural plaques</div><div class=\"cntnt\"><img style=\"width:521px; height:259px;\" src=\"images/PULM/56120_Nodular_pleural_plaques_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows bilateral nodular pleural plaques with small flecks of calcium.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56120 Version 3.0</div></div></div>"},"56121":{"type":"graphic_figure","displayName":"Outcome SWI VO2","title":"Stroke work index predicts outcome in patients with heart failure","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Stroke work index predicts outcome in patients with heart failure</div><div class=\"cntnt\"><img style=\"width:470px; height:222px;\" src=\"images/CARD/56121_OutcomeSWIVO2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 219 patients with heart failure followed for 19 months, a peak exercise stroke work index (peak ex SWI) &gt;30 gm/m<SUP>2</SUP>, derived from Swan-Ganz catheter measurements, was the most powerful predictor of two year survival (91 versus 54 percent for peak ex SWI ≤30 gm/m<SUP>2</SUP>). Among patients with a low peak V<SUB>O2</SUB> (&lt;14 mL/kg/min), those with a normal peak ex SWI (&gt;30 gm/m<SUP>2</SUP>) had an excellent survival (87 versus 58 percent for SWI &lt;30 gm/m<SUP>2</SUP>).</div><div class=\"graphic_reference\">Data from Metra M, Faggiano P, D'Aloia A, et al. J Am Coll Cardiol 1999; 33:943.</div><div id=\"graphicVersion\">Graphic 56121 Version 2.0</div></div></div>"},"56124":{"type":"graphic_diagnosticimage","displayName":"Thin intertwin membrane","title":"Monochorionic diamniotic pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Monochorionic diamniotic pregnancy</div><div class=\"cntnt\"><img style=\"width:414px; height:247px;\" src=\"images/OBGYN/56124_Thin_intertwin_membrane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow points to a thin intertwin membrane characteristic of monochorionic diamniotic twin pregnancy dividing sac A and sac B.</div><div id=\"graphicVersion\">Graphic 56124 Version 3.0</div></div></div>"},"56125":{"type":"graphic_table","displayName":"Paclitaxel and carboplatin for NSCLC","title":"Paclitaxel and carboplatin chemotherapy for non-small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paclitaxel and carboplatin chemotherapy for non-small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Every 21 days, for a maximum of six cycles. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Paclitaxel</td> <td>200 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (NS) and administer over one hour; special tubing needed.*</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Carboplatin</td> <td>AUC<sup>&#182;</sup> = 6 mg/mL per min IV</td> <td>Dilute in 250 mL NS<sup>&#916;</sup> and administer over 30 minutes.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Paclitaxel can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended (risk of febrile neutropenia approximately 2 to 4%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.<sup>&#182;</sup></li> <li>A lower starting dose of paclitaxel may be needed in patients with liver impairment.</li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes and liver and renal function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Treatment with paclitaxel and carboplatin should be delayed until the absolute neutrophil count is &#62;1500 cells/microL and platelet count is &#62;100,000/microL. If a patient developed severe neutropenia (&#60;500 cells/microL) for a week or longer, or febrile neutropenia during the prior course, then the paclitaxel and carboplatin doses should be reduced by 20 to 25% for subsequent courses.<sup>[2]</sup> An alternative to dose reduction is the institution of hematopoietic growth factor support. The carboplatin dose should be decreased by 25% in patients whose platelet count nadir is &#60;50,000/microL for longer than five days.<sup>[3]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Renal/hepatic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Alterations in renal function during therapy may require a recalculation of the carboplatin dose. Paclitaxel dose may need to be adjusted for hepatic impairment on day 1 of each cycle.</li> <li>Refer to UpToDate topics on \"Dosing of anticancer agents in adults\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For patients who develop severe neuropathy (grade 3 or 4) for a week or longer, the dose of paclitaxel should be reduced by 20% for subsequent courses.<sup>[4]</sup></li> </ul> </td> </tr> <tr class=\"divider_top divider_bottom\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Dose reductions may also be indicated if there are other grade 2 or higher nonhematologic toxicities. The dose reduction is at the discretion of the clinician, as formal guidelines are not available.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; GFR: glomerular filtration rate.<br />* Paclitaxel can be administered in NS, 5% dextrose in water (D5W), or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.<br />¶ AUC (area under the concentration × time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) × (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sandler A, et al. N Engl J Med 2006; 355:2542.</LI>&#xD;&#xA;<LI>Langer CT, et al. J Clin Oncol 1995; 13:1860.</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 56125 Version 27.0</div></div></div>"},"56126":{"type":"graphic_table","displayName":"Ataxias due to enzyme defects","title":"Major causes of hereditary ataxias due to known enzymatic defects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of hereditary ataxias due to known enzymatic defects</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\" colspan=\"2\">Gene locus and protein</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Intermittent ataxias</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Hyperammonemias and aminoacidurias</td> </tr> <tr> <td class=\"indent2\">Ornithine transcarbamylase deficiency</td> <td>Xp21.1</td> <td>Ornithine transcarbamylase</td> </tr> <tr> <td class=\"indent2\">Citrullinemia</td> <td>9q34</td> <td>Arginosuccinate synthetase</td> </tr> <tr> <td class=\"indent2\">Arginase deficiency</td> <td>6q23</td> <td>Arginase</td> </tr> <tr> <td class=\"indent2\">Argininosuccinic aciduria</td> <td>7cen-q11</td> <td>Arginosuccinate lyase</td> </tr> <tr> <td class=\"indent2\">Hyperornithemia-hyperammonemia- homocitrullinuria syndrome</td> <td>13q14</td> <td>Mitochondrial ornithine transporter</td> </tr> <tr> <td class=\"indent2\">Hartnup disease</td> <td>5p15.33</td> <td>Neutral amino acid transporter</td> </tr> <tr> <td class=\"indent2\">Isovaleric acidemia</td> <td>15q14</td> <td>Isovaleric acid CoA dehydrogenase</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Disorders of pyruvate and lactate metabolism</td> </tr> <tr> <td class=\"indent2\">Pyruvate dehydrogenase complex</td> <td>Xp22.2 (most common)</td> <td>E1-alpha subunit (most common)</td> </tr> <tr> <td class=\"indent2\">Multiple carboxylase deficiency</td> <td>21q22</td> <td>Holocarboxylase synthetase</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Progressive ataxias</td> </tr> <tr> <td class=\"indent1\">Tay-Sachs disease</td> <td>15q23-q24</td> <td>Alpha subunit of hexosaminidase A</td> </tr> <tr> <td class=\"indent1\">Sandhoff disease</td> <td>15q13</td> <td>Beta subunit of hexosaminidase A and B</td> </tr> <tr> <td class=\"indent1\">Niemann-Pick type A and B</td> <td>11p15.4-p15.1</td> <td>Acid sphingomyelinase</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Niemann-Pick type C</td> <td>18q11-q12</td> <td>NPC1</td> </tr> <tr> <td>14q24.3</td> <td>NPC2</td> </tr> <tr> <td class=\"indent1\">Metachromatic leukodystrophy</td> <td>22q13</td> <td>Arylsulfatase A</td> </tr> <tr> <td class=\"indent1\">Adrenomyeloneuropathy</td> <td>Xq28</td> <td>Adrenoleukodystrophy protein</td> </tr> <tr> <td class=\"indent1\">Abetalipoproteinemia</td> <td>4q22</td> <td>Microsomal triglyceride transfer protein</td> </tr> <tr> <td class=\"indent1\">Hypobetalipoproteinemia</td> <td>2p24</td> <td>Apolipoprotein B</td> </tr> <tr> <td class=\"indent1\">Cerebrotendinous xanthomatosis</td> <td>2q33</td> <td>Mitochondrial sterol 27-hydroxylase</td> </tr> <tr> <td class=\"indent1\">Ataxia with vitamin E deficiency</td> <td>8q13</td> <td>Alpha-tocopherol transfer protein</td> </tr> <tr> <td class=\"indent1\">Lesch-Nyhan syndrome</td> <td>Xq26</td> <td>Hypoxanthine-guanine phosphoribosyl- transferase</td> </tr> <tr> <td class=\"indent1\">Wilson disease</td> <td>13q14</td> <td>ATP7B (copper transporting ATPase)</td> </tr> <tr> <td class=\"indent1\">Ceroid lipofuscinosis</td> <td>Several variants</td> <td>Multiple gene products</td> </tr> <tr> <td class=\"indent1\">Refsum disease</td> <td>10pter</td> <td>Phytanoyl CoA hydroxylase</td> </tr> <tr> <td class=\"indent1\">X-linked ataxia, ichthyosis, and tapetoretinal dystrophy</td> <td>Xpter-p22</td> <td>Arylsulfatase C</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56126 Version 4.0</div></div></div>"},"56127":{"type":"graphic_figure","displayName":"Height measurement technique","title":"Height measurement technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Height measurement technique</div><div class=\"cntnt\"><img style=\"width:421px; height:441px;\" src=\"images/PEDS/56127_Height_measurement_techniqu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The child's shoes and any hats or hair ornaments are removed. The child faces away from the wall with the heels together and the back as straight as possible. The head, shoulders, buttocks, and heels should be in contact with the vertical surface. With the child looking straight ahead, the head projection is placed at the crown of the head. The child steps away from the wall, and the height measurement is recorded to the nearest 0.1 cm.</div><div id=\"graphicVersion\">Graphic 56127 Version 1.0</div></div></div>"},"56128":{"type":"graphic_picture","displayName":"RTT onset developmental arrest","title":"Rett syndrome, six to 18 months old","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rett syndrome, six to 18 months old</div><div class=\"cntnt\"><img style=\"width:378px; height:252px;\" src=\"images/PEDS/56128_RS_stage_I_develop_arrest_d.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At six to 18 months of age, she began to show signs of developmental arrest and a flaccid, calm appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright © 1997 Medscape.</div><div id=\"graphicVersion\">Graphic 56128 Version 4.0</div></div></div>"},"56130":{"type":"graphic_table","displayName":"Features of secondary hypertension","title":"Clinical features of the different causes of secondary hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of the different causes of secondary hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Suggestive clinical features</td> </tr> <tr> <td rowspan=\"4\">General</td> <td>Severe or resistant hypertension</td> </tr> <tr> <td>An acute rise in blood pressure over a previously stable value</td> </tr> <tr> <td>Proven age of onset before puberty</td> </tr> <tr> <td>Age less than 30 years with no family history of hypertension and no obesity</td> </tr> <tr> <td rowspan=\"5\">Renovascular disease</td> <td>An acute elevation in serum creatinine of at least 30% after administration of ACE inhibitor or ARB</td> </tr> <tr> <td>Moderate to severe hypertension in a patient with diffuse atherosclerosis, a unilateral small kidney, or asymmetry in renal size of more than 1.5 cm that cannot be explained by another reason</td> </tr> <tr> <td>Moderate to severe hypertension in patients with recurrent episodes of flash pulmonary edema</td> </tr> <tr> <td>Onset of stage II hypertension after age 55 years</td> </tr> <tr> <td>Systolic or diastolic abdominal bruit (not very sensitive)</td> </tr> <tr> <td rowspan=\"2\">Primary renal disease</td> <td>Elevated serum creatinine concentration</td> </tr> <tr> <td>Abnormal urinalysis</td> </tr> <tr> <td>Oral contraceptives</td> <td rowspan=\"5\">New elevation in blood pressure temporally related to use</td> </tr> <tr> <td>NSAIDs</td> </tr> <tr> <td>Stimulants (eg, cocaine, methylphenidate)</td> </tr> <tr> <td>Calcineurin inhibitors</td> </tr> <tr> <td>Antidepressants</td> </tr> <tr> <td rowspan=\"2\">Pheochromocytoma</td> <td>Paroxysmal elevations in blood pressure</td> </tr> <tr> <td>Triad of headache (usually pounding), palpitations, and sweating</td> </tr> <tr> <td>Primary aldosteronism</td> <td>Unexplained hypokalemia with urinary potassium wasting; however, more than one-half of patients are normokalemic</td> </tr> <tr> <td rowspan=\"2\">Cushing's syndrome</td> <td>Cushingoid facies, central obesity, proximal muscle weakness, and ecchymoses</td> </tr> <tr> <td>May have a history of glucocorticoid use</td> </tr> <tr> <td rowspan=\"3\">Sleep apnea syndrome</td> <td>Common in patients with resistant hypertension, particularly if overweight or obese</td> </tr> <tr> <td>Loud snoring or witnessed apneic episodes</td> </tr> <tr> <td>Daytime somnolence, fatigue, and morning confusion</td> </tr> <tr> <td rowspan=\"2\">Coarctation of the aorta</td> <td>Hypertension in the arms with diminished or delayed femoral pulses and low or unobtainable blood pressures in the legs</td> </tr> <tr> <td>Left brachial pulse is diminished and equal to the femoral pulse if origin of the left subclavian artery is distal to the coarct</td> </tr> <tr> <td rowspan=\"2\">Hypothyroidism</td> <td>Symptoms of hypothyroidism</td> </tr> <tr> <td>Elevated serum thyroid stimulating hormone</td> </tr> <tr> <td>Primary hyperparathyroidism</td> <td>Elevated serum calcium</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker; NSAID: nonsteroidal antiinflammatory drug.</div><div id=\"graphicVersion\">Graphic 56130 Version 10.0</div></div></div>"},"56132":{"type":"graphic_table","displayName":"Important mosquito vectors","title":"Important mosquito vector species in malarious areas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important mosquito vector species in malarious areas</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Region\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Species\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Remarks\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Tropics (sub-genera <em>Cellia</em> and <em>Nyssorhynchus</em>)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Tropical Africa\r\n  \r\n   </td>\r\n  \r\n   <td>\t<p><em>Anopheles gambiae</em> complex</p>\n\t<p>\t\t\t\t<em>Anopheles funestus</em></p>\n</td>\r\n  \r\n   <td>Highly anthropophilic and abundant in villages - very efficient vectors.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   South East Asia\r\n  \r\n   </td>\r\n  \r\n   <td>\t<p><em>Anopheles dirus</em></p>\n\t<p>\t\t\t\t<em>Anopheles minimus</em></p>\n</td>\r\n  \r\n   <td>Anthropophilic but breed in jungle pools and streams.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Indian subcontinent\r\n  \r\n   </td>\r\n  \r\n   <td>\t<p><em>Anopheles culicifacies</em></p>\n\t<p>\t\t\t\t<em>Anopheles stephensi</em></p>\n</td>\r\n  \r\n   <td><em>An. culicifacies</em> is rural; <em>An. stephensi</em> is mainly urban.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Brazilian Amazon\r\n  \r\n   </td>\r\n  \r\n   <td><em>Anopheles darlingi</em></td>\r\n  \r\n   <td>Biting time varies regionally.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Central America\r\n  \r\n   </td>\r\n  \r\n   <td><em>Anopheles albimanus</em></td>\r\n  \r\n   <td>Bites in the evening. Multiple insecticide resistance.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   New Guinea\r\n  \r\n   </td>\r\n  \r\n   <td><em>Anopheles punctulatus</em></td>\r\n  \r\n   <td>Malaria transmission in lowlands as intense as in Africa.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\">\r\n  \r\n   Temperate zone (sub-genus <em>Anopheles</em>)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   China\r\n  \r\n   </td>\r\n  \r\n   <td><em>Anopheles sinensis</em> group</td>\r\n  \r\n   <td>Breeds in rice fields.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Turkey and Central Asia\r\n  \r\n   </td>\r\n  \r\n   <td><em>Anopheles maculipennis</em> complex</td>\r\n  \r\n   <td>These mosquitoes were the vectors when there was malaria in Europe and they are still present today.</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=31098&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Important_mosquito_vectors.htm</title></head></div><div id=\"graphicVersion\">Graphic 56132 Version 1.0</div></div></div>"},"56133":{"type":"graphic_diagnosticimage","displayName":"Progressive primary TB","title":"Progressive primary tuberculosis in a toddler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Progressive primary tuberculosis in a toddler</div><div class=\"cntnt\"><img style=\"width:340px; height:432px;\" src=\"images/ID/56133_Progressive_primary_TB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Progressive primary tuberculosis in a toddler. There is extensive hilar adenopathy with subsequent collapse consolidation in the left lung and a miliary-like presentation in the right lung.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 56133 Version 3.0</div></div></div>"},"56135":{"type":"graphic_figure","displayName":"History physical exam B","title":"History and physical examination (cont)","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">History and physical examination (cont)</div><div class=\"cntnt\"><img style=\"width:497px; height:586px;\" src=\"images/OBGYN/56135_History_phys_exam_B_edt.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56135 Version 3.0</div></div></div>"},"56136":{"type":"graphic_picture","displayName":"TCu380A IUD","title":"TCu380A (ParaGard) intrauterine contraceptive device","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">TCu380A (ParaGard) intrauterine contraceptive device</div><div class=\"cntnt\"><img style=\"width:468px; height:287px;\" src=\"images/OBGYN/56136_Tcu-380A_IUD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This device consists of a T-shaped polyethylene frame with 380 mm<SUP>2</SUP> of exposed surface consisting of fine copper wire wound around the vertical stem and each of the horizontal arms. There is a 3 mm ball at the base of the stem to decrease the risk of cervical perforation. A white or clear polyethylene monofilament string is knotted through this ball.</div><div id=\"graphicVersion\">Graphic 56136 Version 3.0</div></div></div>"},"56137":{"type":"graphic_table","displayName":"HFE genotype in HH","title":"HFE genotype in patients with hereditary hemochromatosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">HFE genotype in patients with hereditary hemochromatosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tr>\n\t<td class=\"subtitle1\">&nbsp;</td>\n\t<td class=\"subtitle1\">Feder, et al</td>\n\t<td class=\"subtitle1\">Beutler, et al</td>\n\t<td class=\"subtitle1\">Jouanolle, et al</td>\n\t<td class=\"subtitle1\">Jazwinska, et al</td>\n\t<td class=\"subtitle1\">Carella, et al</td>\n\t<td class=\"subtitle1\">Nielsen, et al</td>\n\t</tr>\n\t<tr>\n\t<td class=\"subtitle2_left\">Country</td>\n\t<td>USA</td>\n\t<td>USA</td>\n\t<td>France</td>\n\t<td>Australia</td>\n\t<td>Italy</td>\n\t<td>Germany</td>\n\t</tr>\n\t\t\n\t<tr>\n\t<td class=\"subtitle2_left\">Number of patients</td>\n\t<td>178</td>\n\t<td>147</td>\n\t<td>65</td>\n\t<td>112*</td>\n\t<td>75</td>\n\t<td>92</td>\n\t</tr>\n\t\n\t<tr>\n\t<td colspan=\"7\" class=\"subtitle2_left\">Genotype, percent</td>\n\t</tr>\t\n\t\n\t<tr>\n\t<td class=\"indent1\"><p>C282Y</p>\n\t\t<p>C282Y</p></td>\n\t<td>83</td>\n\t<td>82</td>\n\t<td>91</td>\n\t<td>100</td>\n\t<td>64</td>\n\t<td>94.6</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\"><p>C282Y</p>\n\t\t<p>H63D</p></td>\n\t<td>4</td>\n\t<td>5</td>\n\t<td>5</td>\n\t<td>0</td>\n\t<td>7</td>\n\t<td>4.2</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\"><p>C282Y</p>\n\t\t<p>Wild type</p></td>\n\t<td>0.5</td>\n\t<td>1</td>\n\t<td>0</td>\n\t<td>0</td>\n\t<td>2.7</td>\n\t<td>1.2</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\"><p>H63D</p>\n\t\t<p>H63D</p></td>\n\t<td>0.5</td>\n\t<td>1</td>\n\t<td>1.5</td>\n\t<td>0</td>\n\t<td>1.3</td>\n\t<td>0</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\"><p>H63D</p>\n\t\t<p>Wild type</p></td>\n\t<td>4</td>\n\t<td>3</td>\n\t<td>3</td>\n\t<td>0</td>\n\t<td>4</td>\n\t<td>0</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\"><p>Wild type</p>\n\t\t<p>Wild type</p></td>\n\t<td>7</td>\n\t<td>7</td>\n\t<td>0</td>\n\t<td>0</td>\n\t<td>21</td>\n\t<td>0</td>\n\t</tr>\n\t</table></div><div class=\"graphic_footnotes\">* All patients had a positive family history of iron overload.</div><div id=\"graphicVersion\">Graphic 56137 Version 1.0</div></div></div>"},"56138":{"type":"graphic_picture","displayName":"Nonproliferative diabetic retinopathy","title":"Nonproliferative diabetic retinopathy: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonproliferative diabetic retinopathy: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:396px; height:296px;\" src=\"images/ENDO/56138_Nonprolifdiabretinopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph of nonproliferative diabetic retinopathy showing retinal hemorrhages, yellow lipid exudates, and dull white cotton wool spots (nerve fiber layer infarcts).</div><div id=\"graphicVersion\">Graphic 56138 Version 4.0</div></div></div>"},"56139":{"type":"graphic_diagnosticimage","displayName":"Ultrasound acute appendicitis","title":"Ultrasound acute appendicitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound acute appendicitis</div><div class=\"cntnt\"><img style=\"width:291px; height:203px;\" src=\"images/GAST/56139_Appendicitis_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute appendicitis. Image from an abdominal&nbsp;ultrasound with Doppler shows a thickened appendix (calipers) with hypervascular wall.&nbsp;Diagnosis was surgically confirmed.</div><div class=\"graphic_reference\">Courtesy of Christoph F Dietrich, MD.</div><div id=\"graphicVersion\">Graphic 56139 Version 6.0</div></div></div>"},"56142":{"type":"graphic_table","displayName":"Surgical options for UC","title":"Choice of operation for ulcerative colitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Choice of operation for ulcerative colitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Operation</td>\n\n      <td class=\"subtitle1\">Advantages</td>\n\n      <td class=\"subtitle1\">Disadvantages</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Rectal mucosectomy with ileal pouch-anal canal anastomosis</td>\n\n      <td colspan=\"1\" rowspan=\"1\">Complete excision of large intestinal disease<br />Transanal defecation and fecal continence preserved<br />No ileostomy</td>\n\n      <td colspan=\"1\" rowspan=\"1\">Two operations required<br />At risk for pouchitis<br />Nocturnal fecal spotting present</td>\n\n    </tr>\n\n\n    \n\n\n    \n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Stapled, ileal pouch-distal rectal anastomosis</td>\n\n      <td colspan=\"1\" rowspan=\"1\">Transanal defecation and fecal continence preserved<br />No ileostomy<br />Easier technically</td>\n\n      <td>At risk for pouchitis and cancer from residual rectal mucosa</td>\n\n    </tr>\n\n\n    \n\n    \n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Continent ileostomy</td>\n\n      <td colspan=\"1\" rowspan=\"1\">Complete excision of large intestinal disease<br />Fecal continence preserved<br />No external appliance</td>\n\n      <td colspan=\"1\" rowspan=\"1\">Stoma present<br />Intubation of pouch required<br />At risk for pouchitis and need for valve revision</td>\n\n    </tr>\n\n\n    \n\n    \n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Brooke ileostomy</td>\n\n      <td>Complete excision of large intestinal disease<br />One operation</td>\n\n      <td>Stoma present, risk of parastomal hernia<br />Incontinent for feces<br />Need of external appliance</td>\n\n    </tr>\n\n    \n\n    \n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Ileorectal anastomosis</td>\n\n      <td>Transanal defecation and fecal continence preserved<br />No ileostomy</td>\n\n      <td>Diseased rectum remains to produce symptoms, require treatment and predispose to cancer</td>\n\n    </tr>\n\n    \n\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 56142 Version 1.0</div></div></div>"},"56143":{"type":"graphic_table","displayName":"ACC AHA Prevention of critical limb ischemia","title":"ACC/AHA guideline summary: Prevention of critical limb ischemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Prevention of critical limb ischemia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Class I - There is evidence and/or general\nagreement for the following approach to the prevention of critical limb\nischemia</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Patients at risk of CLI, defined as an diabetic patient with known lower extremity peripheral arterial disease or an ABI less than 0.4 in a nondiabetic patient, should undergo regular inspection of the feet to detect objective signs of CLI.</td>\n</tr>\n\n\n<tr>\n<td>&#8226;&nbsp; The feet should be examined with shoes and socks removed.</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; Patients who have been successfully treated for CLI are at relatively high risk for recurrence. They should be evaluated at least twice yearly by a vascular specialist and be given verbal and written instructions for self-surveillance for recurrence.</td>\n</tr>\n\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Hirsch, AT, Haskal, ZJ, Hertzer, NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.</div><div id=\"graphicVersion\">Graphic 56143 Version 2.0</div></div></div>"},"56146":{"type":"graphic_picture","displayName":"Congenital histiocytosis foot","title":"Congenital self-healing reticulohistiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital self-healing reticulohistiocytosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/56146_Congenital_histio_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ulcerated nodule is present on the foot of this young infant with congenital self-healing reticulohistiocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56146 Version 5.0</div></div></div>"},"56147":{"type":"graphic_picture","displayName":"Distal interphalangeal finger joint splint","title":"Distal interphalangeal finger joint splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal interphalangeal finger joint splint</div><div class=\"cntnt\"><img style=\"width:396px; height:272px;\" src=\"images/EM/56147_Dip_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 56147 Version 3.0</div></div></div>"},"56148":{"type":"graphic_table","displayName":"Paraphimosis reduction summary","title":"Paraphimosis reduction: Procedure summary","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paraphimosis reduction: Procedure summary</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Remove any foreign bodies or constricting bands.</td> </tr> <tr> <td>2. Inspect the penis for signs of glans penis necrosis (blue/black color and firmness to palpation).</td> </tr> <tr> <td>3. If necrosis or urinary obstruction&nbsp;is present, emergently consult urology and prepare for immediate reduction utilizing procedural sedation in the ED or general anesthesia in the OR.</td> </tr> <tr> <td class=\"sublist1_start\">4. If glans penis necrosis is not present (glans penis is pink and soft), provide pain control (eg, topical or infiltrated local anesthetic) and proceed with manual reduction:</td> </tr> <tr> <td class=\"sublist2\">a. Apply methods to reduce swelling&nbsp;(ice, compression bandages, and/or osmotic agents).</td> </tr> <tr> <td class=\"sublist2\">b. Ensure efficacy of chosen method of pain control.</td> </tr> <tr> <td class=\"sublist2\">c. Perform manual reduction by providing manual circumferential compression for several minutes followed by manual reduction.</td> </tr> <tr> <td class=\"sublist1_start\">5. If paraphimosis is still not reduced, advance to a dorsal slit procedure (consult an urologist or surgeon with similar expertise although a knowledgeable physician may perform this procedure if specialty care is not available and emergency reduction is required). Regional anesthesia with a dorsal penile block and, in young children and otherwise uncooperative patients, procedural sedation are typically needed for adequate analgesia.</td> </tr> <tr> <td class=\"sublist1_start\">&nbsp;6. Alternative invasive procedures include (refer to UpToDate topics on treatment of paraphimosis):</td> </tr> <tr> <td class=\"sublist2\">a. Multiple puncture of the foreskin with a 25 gauge or smaller needle after ensuring appropriate pain control with local or parenteral medications followed by repeated manual reduction.</td> </tr> <tr> <td class=\"sublist2\">b. Reduction after applying Adson or Babcock forceps to the swollen foreskin.</td> </tr> <tr> <td class=\"sublist2\">c.&nbsp;Needle aspiration of the glans penis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ED: emergency department; OR: operating room.</div><div id=\"graphicVersion\">Graphic 56148 Version 9.0</div></div></div>"},"56149":{"type":"graphic_diagnosticimage","displayName":"Blurred spine in osteomalacia","title":"Hypophosphatemic osteomalacia: Radiographic findings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypophosphatemic osteomalacia: Radiographic findings</div><div class=\"cntnt\"><img style=\"width:422px; height:288px;\" src=\"images/ENDO/56149_Blurred_spine_in_osteomalac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spine films in a 37-year-old man with osteomalacia. The main findings are decreased bone density, with blurring and deformity of the spine. The blurring makes the films appear of low quality.</div><div class=\"graphic_reference\">Courtesy of CJ Menkes, MD.</div><div id=\"graphicVersion\">Graphic 56149 Version 3.0</div></div></div>"},"56150":{"type":"graphic_diagnosticimage","displayName":"Fetal ascites","title":"Longitudinal view of fetal abdomen showing fetal ascites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal view of fetal abdomen showing fetal ascites</div><div class=\"cntnt\"><img style=\"width:360px; height:252px;\" src=\"images/OBGYN/56150_Fetal_ascites.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Svena Julien, MD and Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 56150 Version 3.0</div></div></div>"},"56152":{"type":"graphic_diagnosticimage","displayName":"Chordoma MRI","title":"Chordoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chordoma</div><div class=\"cntnt\"><img style=\"width:320px; height:576px;\" src=\"images/ONC/56152_Chordoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI and CT studies on a 70-year-old woman with chordoma. The patient had undergone subtotal resection of the lesion and received postoperative fractionated radiation therapy. Top panel: A sagittal, contrast-enhanced MRI demonstrates recurrent chordoma in the sacral region (arrow). Bottom panel: A contrast-enhanced axial CT scan also shows recurrent tumor (arrow). The patient underwent stereotactic radiosurgery but the tumor progressed.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of William Welch, MD.</div><div id=\"graphicVersion\">Graphic 56152 Version 3.0</div></div></div>"},"56153":{"type":"graphic_diagnosticimage","displayName":"Metastatic ependymoma MRI","title":"Metastatic ependymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastatic ependymoma</div><div class=\"cntnt\"><img style=\"width:237px; height:425px;\" src=\"images/ONC/56153_Metastatic_ependymoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MR image of a spinal cord ependymoma (upper arrow) discovered to be metastatic to multiple sites within the neuraxis (lower arrows) at diagnosis.</div><div class=\"graphic_reference\">Courtesy of Mark Kieran, MD.</div><div id=\"graphicVersion\">Graphic 56153 Version 2.0</div></div></div>"},"56155":{"type":"graphic_diagnosticimage","displayName":"M-mode echo normal aorta and left atrium","title":"M-mode echocardiogram of normal aorta and left atrium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of normal aorta and left atrium</div><div class=\"cntnt\"><img style=\"width:326px; height:252px;\" src=\"images/CARD/56155_Mmodeaortaleftatrium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode echocardiogram is obtained from the long axis parasternal two dimensional view (panel A); the dotted line represents the M-mode beam passing through the aortic root, the right (R) and noncoronary (N) cusps of the aortic valve, and the left atrium (LA). The atrium is measured at end systole (arrows) when the descent of the left ventricle base has resulted in maximal filling.</div><div id=\"graphicVersion\">Graphic 56155 Version 5.0</div></div></div>"},"56156":{"type":"graphic_picture","displayName":"Diabetic nephropathy Light","title":"Diabetic nephropathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diabetic nephropathy</div><div class=\"cntnt\"><img style=\"width:377px; height:279px;\" src=\"images/NEPH/56156_Diabetic_nephropathy_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing diffuse and nodular (N) glomerulosclerosis in diabetic nephropathy. Note the dense appearance of the deposits and the rim of cells around the nodules, which distinguish this disorder on light microscopy from fibrillary glomerulonephritis or amyloidosis.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 56156 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"56160":{"type":"graphic_table","displayName":"Urinary patterns associated with different kidney diseases","title":"Urinary patterns associated with different kidney diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urinary patterns associated with different kidney diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Urinary pattern</td> <td class=\"subtitle1\">Kidney disease suggested by pattern</td> </tr> <tr class=\"divider_bottom\"> <td>Hematuria with dysmorphic red blood cells, red blood cell casts, varying degrees of albuminuria</td> <td>Proliferative glomerulonephritis (eg, IgA nephropathy, ANCA-associated vasculitis, lupus nephritis)</td> </tr> <tr class=\"divider_bottom\"> <td>Heavy albuminuria with minimal or absent hematuria</td> <td>Nonproliferative glomerulopathy (eg, diabetes, amyloidosis, membranous nephropathy, focal segmental glomerulosclerosis, minimal change)</td> </tr> <tr class=\"divider_bottom\"> <td>Multiple granular and epithelial cell casts with free epithelial cells</td> <td>Acute tubular necrosis in a patient with underlying acute kidney injury</td> </tr> <tr class=\"divider_bottom\"> <td>Isolated pyuria</td> <td>Infection (bacterial, mycobacterial) or tubulointerstitial disease</td> </tr> <tr> <td rowspan=\"2\">Normal urinalysis with few cells, no casts, and no or minimal proteinuria</td> <td>In presence of acute kidney injury: prerenal disease, urinary tract obstruction, hypercalcemia, acute phosphate nephropathy, myeloma cast nephropathy</td> </tr> <tr> <td>In presence of chronic kidney disease: ischemic nephropathy, hypertensive nephrosclerosis, urinary tract obstruction, hepato renal disease, cardiorenal disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgA: immunoglobulin A; ANCA: antineutrophil cytoplasmic antibody.</div><div id=\"graphicVersion\">Graphic 56160 Version 10.0</div></div></div>"},"56162":{"type":"graphic_picture","displayName":"Condylomata lata on vulva","title":"Condylomata lata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Condylomata lata</div><div class=\"cntnt\"><img style=\"width:247px; height:360px;\" src=\"images/ID/56162_Condyloma_lata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flat condylomata lata lesions which are moist in a woman with secondary syphilis.</div><div class=\"graphic_reference\">Courtesy of David H Martin and Tomasz F Mroczkowski. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 56162 Version 7.0</div></div></div>"},"56163":{"type":"graphic_figure","displayName":"Unobstructed blood flow predicts TMLR outcome","title":"Unobstructed blood flow predicts TMLR outcome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unobstructed blood flow predicts TMLR outcome</div><div class=\"cntnt\"><img style=\"width:376px; height:278px;\" src=\"images/CARD/56163_Blood_flow_after_TMLR_outco.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier curves show that survival after transmyocardial laser revascularization (TMLR) is strongly affected by the overall anatomic myocardial perfusion index score (AMP); patients with a score of 1, which indicates unobstructed blood flow to a major vessel in at least one vascular territory, had a lower mortality than those who did not have adequate blood flow to any region (AMP score = 0).</div><div class=\"graphic_reference\">Data from Burkhoff D, Wesley MN, Rear JR, Lansing AM. J Am Coll Cardiol 1999; 34:55.</div><div id=\"graphicVersion\">Graphic 56163 Version 3.0</div></div></div>"},"56166":{"type":"graphic_diagnosticimage","displayName":"Brain MRI adult vanishing white matter disease","title":"Conventional cerebral MRI imaging in adult-onset vanishing white matter disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Conventional cerebral MRI imaging in adult-onset vanishing white matter disease</div><div class=\"cntnt\"><img style=\"width:408px; height:408px;\" src=\"images/NEURO/56166_MRI_adult_VWM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T2-weighted (A) and axial fluid-attenuated inversion recovery (FLAIR) (B) are shown. Virtually, all hemispheric white matter appeared homogeneously hyperintense on T2-weighted and hypointense on T1-weighted (not shown) with atrophy of the corpus callosum. On FLAIR, large part of the white matter has a signal identical to CSF, surrounded by a rim of hyperintensity demonstrating the cavitated breakdown of the white matter.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CSF: cerebrospinal fluid.</div><div class=\"graphic_reference\">Reproduced with permission from: Denier C, Orgibet A, Roffi F. Adult-Onset vanishing white matter leukoencephalopathy presenting as psychosis. Neurology 2007; 68:1538. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56166 Version 13.0</div></div></div>"},"56168":{"type":"graphic_picture","displayName":"Darier disease - light skin","title":"Darier disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Darier disease</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/56168_Darier_disease_light_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple yellow-brown, hyperkeratotic papules are present on the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56168 Version 6.0</div></div></div>"},"56169":{"type":"graphic_diagnosticimage","displayName":"Endovascular repair of AAA with common iliac aneurysm","title":"Endovascular repair of AAA with common iliac aneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endovascular repair of AAA with common iliac aneurysm</div><div class=\"cntnt\"><img style=\"width:232px; height:354px;\" src=\"images/SURG/56169_Endovasc_repair_AAA_iliac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal aortic aneurysm and left common iliac artery aneurysm treated with internal iliac artery coiling and endograft extension into the external iliac artery.</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm.</div><div id=\"graphicVersion\">Graphic 56169 Version 2.0</div></div></div>"},"56170":{"type":"graphic_table","displayName":"Glycemic index of foods","title":"Glycemic index of foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glycemic index of foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Glycemic index</td> </tr> <tr> <td>Baked russet potato</td> <td class=\"centered\">135</td> </tr> <tr> <td>Cornflakes</td> <td class=\"centered\">119</td> </tr> <tr> <td><strong>White bread</strong></td> <td class=\"centered\"><strong>100</strong></td> </tr> <tr> <td>Whole meal bread</td> <td class=\"centered\">99</td> </tr> <tr> <td>Brown rice</td> <td class=\"centered\">96</td> </tr> <tr> <td>Raisins</td> <td class=\"centered\">93</td> </tr> <tr> <td>White rice</td> <td class=\"centered\">83</td> </tr> <tr> <td>Banana (raw)</td> <td class=\"centered\">79</td> </tr> <tr> <td>All-Bran</td> <td class=\"centered\">73</td> </tr> <tr> <td>Sweet potato</td> <td class=\"centered\">70</td> </tr> <tr> <td>Spaghetti (white)</td> <td class=\"centered\">66</td> </tr> <tr> <td>Spaghetti (whole wheat)</td> <td class=\"centered\">61</td> </tr> <tr> <td>Baked beans (tinned)</td> <td class=\"centered\">60</td> </tr> <tr> <td>Ice cream, yogurt, whole milk, apple (raw)</td> <td class=\"centered\">49 to 53</td> </tr> <tr> <td>Red lentils</td> <td class=\"centered\">43</td> </tr> <tr> <td>Soya beans (tinned)</td> <td class=\"centered\">20</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Glycemic content of an assortment of foods, with white bread representing the standard value of 100. Values below 100 will produce a lesser rise in the blood glucose (for the same level of carbohydrate intake) than white bread.</div><div class=\"graphic_reference\">Data from: Jenkins DJ, Wolever TM, Jenkins AL, et al. The glycaemic response to carbohydrate foods. Lancet 1984; 2:388.</div><div id=\"graphicVersion\">Graphic 56170 Version 3.0</div></div></div>"},"56172":{"type":"graphic_figure","displayName":"Pathogenesis of AMM","title":"Pathogenesis of myelofibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of myelofibrosis</div><div class=\"cntnt\"><img style=\"width:443px; height:242px;\" src=\"images/HEME/56172_Pathogenesis_of_AMM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the currently held opinion on the factors contributing to the pathogenesis of bone marrow fibrosis in myeloid metaplasia.</div><div class=\"graphic_footnotes\">TGF-&#946;: transforming growth factor; PDGF: platelet derived growth factor; EGF: epidermal growth factor; bFGF: basic fibroblast growth factor.</div><div id=\"graphicVersion\">Graphic 56172 Version 1.0</div></div></div>"},"56174":{"type":"graphic_figure","displayName":"Smoking trajectories","title":"Trajectories for smoking continuation or cessation among adolescent smokers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trajectories for smoking continuation or cessation among adolescent smokers</div><div class=\"cntnt\"><img style=\"width:444px; height:302px;\" src=\"images/PEDS/56174_Smoking_trajectories.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Predicted smoking quantity-frequency for each smoking trajectory group in a sample of adolescents and young adults in the United States.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: Costello, DM, Dierker, LC, Jones, BL, Rose, JS. Trajectories of smoking from adolescence to early adulthood and their psychosocial risk factors. Health Psychol 2008; 27:811. Copyright &#169; 2008 American Psychological Association.</div><div id=\"graphicVersion\">Graphic 56174 Version 1.0</div></div></div>"},"56176":{"type":"graphic_diagnosticimage","displayName":"NSCLC malig pl eff post rx","title":"Malignant pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant pleural effusion</div><div class=\"cntnt\"><img style=\"width:432px; height:410px;\" src=\"images/PULM/56176_NSCLC_malig_pl_eff_post_rx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT image of the effusion following thoracentesis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 56176 Version 3.0</div></div></div>"},"56177":{"type":"graphic_figure","displayName":"NYHA repair vs replacement MV","title":"Survival after mitral valve surgery is better for patients in NYHA class I/II independent of procedure","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Survival after mitral valve surgery is better for patients in NYHA class I/II independent of procedure</div><div class=\"cntnt\"><img style=\"width:510px; height:271px;\" src=\"images/CARD/56177_NYHA_repair_vs_replacement.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-term patient survival after mitral valve surgery for chronic mitral regurgitation is better in those with NYHA class I/II compared to those in class III/IV at the time of surgery. This benefit is independent of the type of procedure performed (replacement versus repair), although the outcomes are better in those undergoing repair.</div><div class=\"graphic_reference\">Data from Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Circulation 1999; 99:400.</div><div id=\"graphicVersion\">Graphic 56177 Version 2.0</div></div></div>"},"56178":{"type":"graphic_figure","displayName":"Clinical response to gold RA","title":"Beneficial response to gold in RA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Beneficial response to gold in RA</div><div class=\"cntnt\"><img style=\"width:444px; height:386px;\" src=\"images/RHEUM/56178_Clinical_response_to_gold_R.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plots of treatment variables from the start of intramuscular gold to the completion of 12 months therapy in 98 patients with rheumatoid arthritis.</div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate.</div><div class=\"graphic_reference\">Data from Wolfe, F, Hawley, DJ, Cathey MA, J Rheumatol 1993; 20:797.</div><div id=\"graphicVersion\">Graphic 56178 Version 1.0</div></div></div>"},"56179":{"type":"graphic_diagnosticimage","displayName":"CPA radiograph","title":"Chronic cavitary aspergillosis transformed from allergic bronchopulmonary aspergillosis (ABPA)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic cavitary aspergillosis transformed from allergic bronchopulmonary aspergillosis (ABPA)</div><div class=\"cntnt\"><img style=\"width:360px; height:321px;\" src=\"images/ID/56179_CPA_radiograph_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longstanding asthma, ABPA with chronic cavitary pulmonary aspergillosis. The patient suffered a long history of severe steroid-dependent asthma with recurrent infective exacerbations culture positive for <EM>Aspergillus fumigatus</EM> and <EM>Pseudomonas aeruginosa</EM>. An <EM>Aspergillus </EM>precipitins test was positive with an elevated total IgE level. Despite initial treatment with oral itraconazole, chest radiograph deteriorated, showing cystic cavities in both apices and&nbsp;a&nbsp;computed tomography&nbsp;scan showing a right upper lobe mycetoma (fungal ball). She developed respiratory failure and was established on long-term oxygen therapy of 2 L/min via an oxygen concentrator at home and oxygen conserver when mobile. Systemic steroids, nebulizers, and long-term itraconazole did not prevent disease progression of ABPA to chronic cavitary aspergillosis. She&nbsp;was treated with voriconazole for &gt;5 years with some benefit, although very slow deterioration requiring 4 L/min oxygen 24 hours a day.</div><div class=\"graphic_reference\">Reproduced with permission from:The Aspergillus Website (http://www.aspergillus.org.uk/). Copyright © 2010.</div><div id=\"graphicVersion\">Graphic 56179 Version 5.0</div></div></div>"},"56181":{"type":"graphic_table","displayName":"Empiric treatment for pyelonephritis in pregnancy","title":"Parenteral regimens for empiric treatment of pyelonephritis in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral regimens for empiric treatment of pyelonephritis in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Dose, interval</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mild to moderate pyelonephritis</td> </tr> <tr> <td class=\"indent1\">Ceftriaxone</td> <td>1 g every 24 hours</td> </tr> <tr> <td class=\"indent1\">Cefepime</td> <td>1 g every 12 hours</td> </tr> <tr> <td class=\"indent1\">Aztreonam*</td> <td>1 g every 8 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Ampicillin</p> <p>PLUS</p> Gentamicin<sup>&#182;</sup></td> <td> <p>1-2 g every 6 hours</p> <p>&nbsp;</p> 1.5 mg/kg every 8 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Severe pyelonephritis with an impaired immune system and/or incomplete urinary drainage</td> </tr> <tr> <td class=\"indent1\">Piperacillin-tazobactam</td> <td>3.375 g every 6 hours</td> </tr> <tr> <td class=\"indent1\">Meropenem </td> <td>1 g&nbsp;every 8 hours</td> </tr> <tr> <td class=\"indent1\">Ertapenem</td> <td>1 g every 24 hours</td> </tr> <tr> <td class=\"indent1\">Doripenem</td> <td>500 mg every 8 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Doses are for patients with normal renal function.<br />If methicillin-resistant S. aureus (MRSA) is known or suspected, see treatment regimens outlined separately in topics addressing MRSA management.</div><div class=\"graphic_footnotes\">* Alternative in the setting of beta lactam allergy.<br />&para; Aminoglycosides have been associated with fetal ototoxicity; this regimen should be used only if intolerance precludes the use of less toxic agents.</div><div id=\"graphicVersion\">Graphic 56181 Version 11.0</div></div></div>"},"56183":{"type":"graphic_diagnosticimage","displayName":"Typical carcinoid RML CT","title":"Typical carcinoid tumor presenting as a RML nodule","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Typical carcinoid tumor presenting as a RML nodule</div><div class=\"cntnt\"><img style=\"width:504px; height:249px;\" src=\"images/ONC/56183_Typical_carcinoid_RML_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial noncontrasted CT image of a typical bronchial carcinoid involving the right middle lobe (RML). The image on the left, which was obtained with lung-window settings, shows a lobulated nodule in the RML (arrow). The image on the right depicts this mass with mediastinal soft-tissue-window settings, which shows that the nodule is soft tissue density without any calcification and therefore indeterminate.</div><div class=\"graphic_reference\">Courtesy of Charles F Thomas, Jr, MD.</div><div id=\"graphicVersion\">Graphic 56183 Version 3.0</div></div></div>"},"56186":{"type":"graphic_figure","displayName":"Elastic tape method","title":"Elastic tape (or string wrap) method","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elastic tape (or string wrap) method</div><div class=\"cntnt\"><img style=\"width:307px; height:243px;\" src=\"images/EM/56186_Elastictapemethod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apply a blood pressure cuff to the affected extremity and inflate it to the patient's systolic blood pressure plus 100 mmHg. Tightly wrap a Penrose drain or 1 inch elastic band (eg, intravenous tourniquet) from the tip of the digit proximally and elevate the extremity above the heart for 15 minutes. Assess for reduction of edema and reapply the elastic wrap, if necessary. Keep the blood pressure cuff inflated while attempting manual removal. Total tourniquet time should not exceed two hours.</div><div class=\"graphic_reference\">Reproduced with permission from: Fuchs SM. Ring removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56186 Version 10.0</div></div></div>"},"56188":{"type":"graphic_figure","displayName":"Platelet aggregometry","title":"Platelet aggregometry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Platelet aggregometry</div><div class=\"cntnt\"><img style=\"width:446px; height:474px;\" src=\"images/HEME/56188_Platelet_aggregometry.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of results of platelet aggregometry. The test substance is added to platelet-rich plasma at the point shown by the arrow. Time progresses to the right; an upward deflection of the curve represents a decrease in optical density due to platelet aggregation, allowing more light to pass through the solution. Three examples are shown: Curve A: A normal response to addition of adenosine diphosphate (ADP) is shown, with a first and second wave (phase) of aggregation. Curve B: Only a first phase of aggregation is seen. This pattern is seen in platelets taken from a patient with a storage pool defect after addition of an intermediate dose of ADP. Curve C: No response. This pattern is seen in platelets from a patient with Bernard-Soulier syndrome after addition of ristocetin or in patients with Glanzmann thrombasthenia after addition of all agonists except ristocetin.</div><div id=\"graphicVersion\">Graphic 56188 Version 1.0</div></div></div>"},"56189":{"type":"graphic_figure","displayName":"Sinus tarsi anatomy","title":"Sinus tarsi anatomy","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Sinus tarsi anatomy</div><div class=\"cntnt\"><img style=\"width:519px; height:448px;\" src=\"images/PEDS/56189_Sinus_tarsi_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sinus tarsi is the space between the medial neck of the talus and the superior aspect of the anterior calcaneus. It runs an oblique course between the talus and calcaneus from lateral to medial coursing anterior to posterior. It is the lateral extension of the tarsal canal.</div><div class=\"graphic_footnotes\">* Facet on talus for spring lig.</div><div id=\"graphicVersion\">Graphic 56189 Version 1.0</div></div></div>"},"56190":{"type":"graphic_figure","displayName":"Inflammatory follicle in acne PI","title":"Inflammatory follicle response in acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory follicle response in acne</div><div class=\"cntnt\"><img style=\"width:420px; height:450px;\" src=\"images/PI/56190_Inflamm_follicle_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">How acne develops. Inflammatory response in follicle.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright © 2008 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 56190 Version 6.0</div></div></div>"},"56191":{"type":"graphic_figure","displayName":"Outcome AS valve calcification","title":"Outcome of asymptomatic severe aortic stenosis is related to the degree of valve calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Outcome of asymptomatic severe aortic stenosis is related to the degree of valve calcification</div><div class=\"cntnt\"><img style=\"width:445px; height:345px;\" src=\"images/CARD/56191_Outcome_AS_valve_calcificat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 126 patients with asymptomatic severe aortic stenosis followed for a mean of 22 months, Kaplan-Meier analysis shows that event-free survival (death or aortic valve replacement) is related to the degree of aortic valve calcification observed on echocardiography.</div><div class=\"graphic_reference\">Data from Rosenhek R, Binder T, Porenta G, et al. N Engl J Med 2000; 343:611.</div><div id=\"graphicVersion\">Graphic 56191 Version 2.0</div></div></div>"},"56193":{"type":"graphic_picture","displayName":"Disseminated histo bone marrow","title":"Bone marrow biopsy findings from a patient with disseminated histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Bone marrow biopsy findings from a patient with disseminated histoplasmosis</div><div class=\"cntnt\"><img style=\"width:511px; height:190px;\" src=\"images/ID/56193_Dis_histo_bone_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bone marrow biopsy specimen showing numerous oval-shaped intracellular and extracellular microorganisms (A and B).<br> (A) Hematoxylin and eosin stain, x1000.<br> (B) Periodic acid-Schiff stain, x1000.</div><div class=\"graphic_reference\">Reproduced from: Lai CH, Huang CK, Chin C, et al. Indigenous case of disseminated histoplasmosis, Taiwan. Emerg Infect Dis 2007; 13:127.</div><div id=\"graphicVersion\">Graphic 56193 Version 3.0</div></div></div>"},"56194":{"type":"graphic_table","displayName":"Nocardia treatment regimens","title":"Empiric antibiotic regimens for the treatment of nocardiosis in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric antibiotic regimens for the treatment of nocardiosis in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Non-severe infection</td> </tr> <tr> <td rowspan=\"3\">Isolated cutaneous infection</td> <td>TMP-SMX 5 to 10 mg/kg orally of the trimethoprim component per day in two divided doses (first-line regimen)</td> </tr> <tr> <td><strong>OR</strong></td> </tr> <tr> <td>Minocycline 100 mg orally twice daily (alternative regimen)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Non-severe mycetoma</td> <td>TMP-SMX 10 mg/kg orally of the trimethoprim component per day in two divided doses <strong>+/-</strong></td> </tr> <tr> <td>Dapsone 100 mg orally once daily</td> </tr> <tr class=\"divider_top\"> <td>Mild or moderate pulmonary disease in immunocompetent hosts</td> <td>TMP-SMX 5 to 10 mg/kg orally of the trimethoprim component per day in two divided doses </td> </tr> <tr class=\"divider_top\"> <td>Mild or moderate pulmonary disease in immunocompromised hosts</td> <td>TMP-SMX 15 mg/kg orally of the trimethoprim component per day in three or four divided doses </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Severe infection</td> </tr> <tr> <td rowspan=\"2\">Severe mycetoma</td> <td>Imipenem 500 mg IV every 6 hours <strong>+/-</strong></td> </tr> <tr> <td>Amikacin 7.5 mg/kg IV every 12 hours</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Severe pulmonary or disseminated disease (without CNS involvement)</td> <td>TMP-SMX 15 mg/kg IV of the trimethoprim component per day in three or four divided doses <strong>PLUS</strong></td> </tr> <tr> <td>Amikacin 7.5 mg/kg IV every 12 hours (first-line regimen)</td> </tr> <tr> <td><strong>OR</strong></td> </tr> <tr> <td>Imipenem 500 mg IV every 6 hours <strong>PLUS</strong></td> </tr> <tr> <td>Amikacin 7.5 mg/kg IV every 12 hours (alternative regimen)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Involvement of &#8805;2 sites in immunocompromised hosts (without CNS involvement)</td> <td>TMP-SMX 15 mg/kg IV of the trimethoprim component per day in&nbsp;three or four divided doses <strong>PLUS</strong></td> </tr> <tr> <td>Amikacin 7.5 mg/kg IV every 12 hours (first-line regimen)</td> </tr> <tr> <td><strong>OR</strong></td> </tr> <tr> <td>Imipenem 500 mg IV every 6 hours <strong>PLUS</strong></td> </tr> <tr> <td>Amikacin 7.5 mg/kg IV every 12 hours (alternative regimen)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Isolated CNS disease</td> <td>TMP-SMX 15 mg/kg IV of the trimethoprim component per day in three or four divided doses <strong>PLUS</strong></td> </tr> <tr> <td>Imipenem 500 mg IV every 6 hours</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">CNS disease with multiorgan involvement (ie, at least one other site)</td> <td>TMP-SMX 15 mg/kg IV of the trimethoprim component per day in&nbsp;three or four divided doses <strong>PLUS</strong></td> </tr> <tr> <td>Imipenem 500 mg IV every 6 hours <strong>PLUS</strong></td> </tr> <tr> <td>Amikacin 7.5 mg/kg IV every 12 hours</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Life-threatening disease</td> <td>TMP-SMX 15 mg/kg IV of the trimethoprim component per day in&nbsp;three or four divided doses <strong>PLUS</strong></td> </tr> <tr> <td>Imipenem 500 mg IV every 6 hours <strong>PLUS</strong></td> </tr> <tr> <td>Amikacin 7.5 mg/kg IV every 12 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; TMP-SMX: trimethoprim-sulfamethoxazole.<br> * Antibiotic dosing must be adjusted in patients with impaired renal function.</div><div id=\"graphicVersion\">Graphic 56194 Version 6.0</div></div></div>"},"56195":{"type":"graphic_diagnosticimage","displayName":"CT pulmonary aspergillosis","title":"Computed tomography (CT) pulmonary aspergillosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography (CT) pulmonary aspergillosis</div><div class=\"cntnt\"><img style=\"width:342px; height:576px;\" src=\"images/ID/56195_CT_pulmonary_aspergillosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Halo sign (A) converting to an air-crescent sign (B) after neutrophil recovery.</div><div class=\"graphic_reference\">Reproduced with permission from: Maertens J, Meersseman W, Van Bleyenbergh P. New therapies for fungal pneumonia. Curr Opin Infect Dis 2009; 22:183. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56195 Version 12.0</div></div></div>"},"56196":{"type":"graphic_picture","displayName":"Encysted Trichinella larvae","title":"Encysted <EM>Trichinella </EM>larvae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Encysted <EM>Trichinella </EM>larvae</div><div class=\"cntnt\"><img style=\"width:430px; height:288px;\" src=\"images/ID/56196_Encysted_Trichinella_larvae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing encysted <EM>Trichinella</EM> larvae in skeletal muscle cells. This process occurs with all <EM>Trichinella</EM> species except <EM>T. pseudospiralis </EM>and <EM>T. papuae</EM>.</div><div class=\"graphic_reference\">Courtesy of Peter F Weller, MD.</div><div id=\"graphicVersion\">Graphic 56196 Version 4.0</div></div></div>"},"56197":{"type":"graphic_waveform","displayName":"Basic case 1 with answer","title":"LVH with repolarization abnormalities","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">LVH with repolarization abnormalities</div><div class=\"cntnt\"><img style=\"width:540px; height:328px;\" src=\"images/CARD/56197_Basic_case_1_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Precordial leads in a hypertensive patient with left ventricular hypertrophy (LVH). The ECG far exceeds commonly used voltage criteria for LVH in the precordial leads: the S in V1 plus the R in V5 equals 50 mm (upper limit of normal 35 mm). Voltage criteria alone may not be diagnostic of LVH. However, the associated repolarization abnormality (formerly referred to as a &quot;strain&quot; pattern) in leads V5 and V6, characterized by downward sloping ST segment depression and T wave inversion, make LVH highly likely. Left atrial abnormality consistent with enlargement is also present as shown by the biphasic P wave with a broad negative deflection in lead V1. These changes can be induced by a chronic pressure load (hypertension or aortic stenosis) or a chronic volume load (aortic or mitral regurgitation or dilated cardiomyopathy).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 56197 Version 2.0</div></div></div>"},"56200":{"type":"graphic_diagnosticimage","displayName":"Traumatic epidural hematoma","title":"Traumatic epidural hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic epidural hematoma</div><div class=\"cntnt\"><img style=\"width:380px; height:450px;\" src=\"images/NEURO/56200_TBI_epidural_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan demonstrating a right epidural hematoma (EDH, arrow). Note the lenticular shape.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: J Claude Hemphill III, MD and Nicholas Phan, MD, FRCSC.</div><div id=\"graphicVersion\">Graphic 56200 Version 4.0</div></div></div>"},"56201":{"type":"graphic_diagnosticimage","displayName":"Abscess cavity","title":"Anaerobic pulmonary abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anaerobic pulmonary abscess</div><div class=\"cntnt\"><img style=\"width:396px; height:292px;\" src=\"images/PULM/56201_Abscess_cavity_final.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, thick-walled cavity in the right middle lobe due to an anaerobic pulmonary abscess.</div><div id=\"graphicVersion\">Graphic 56201 Version 3.0</div></div></div>"},"56203":{"type":"graphic_diagnosticimage","displayName":"EUS anorectum","title":"Endoscopic ultrasound of the anal sphincter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound of the anal sphincter</div><div class=\"cntnt\"><img style=\"width:335px; height:304px;\" src=\"images/GAST/56203_EUS_anorectum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound image demonstrating the internal (IAS) and external (EAS) anal sphincters.</div><div class=\"graphic_reference\">Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 56203 Version 3.0</div></div></div>"},"56204":{"type":"graphic_figure","displayName":"Complete transverse vag septum","title":"Transverse vaginal septum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse vaginal septum</div><div class=\"cntnt\"><img style=\"width:386px; height:319px;\" src=\"images/OBGYN/56204_Completetransversevagsep.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56204 Version 12.0</div></div></div>"},"56206":{"type":"graphic_figure","displayName":"Laryngeal musculature","title":"Intrinsic laryngeal musculature with relative positions of the thyroid, cricoid, and arytenoid cartilages","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Intrinsic laryngeal musculature with relative positions of the thyroid, cricoid, and arytenoid cartilages</div><div class=\"cntnt\"><img style=\"width:516px; height:344px;\" src=\"images/PC/56206_Laryngeal_musculature.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Garrett CG, Ossoff RH. Hoarseness. Med Clin N Am 1999; 83:115. Copyright 1999 W.B. Saunders Company.</div><div id=\"graphicVersion\">Graphic 56206 Version 2.0</div></div></div>"},"56208":{"type":"graphic_table","displayName":"Cytokine assays","title":"Cytokine assays","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytokine assays</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bioassays</td> </tr> <tr> <td>Sensitive</td> </tr> <tr> <td>Less specific</td> </tr> <tr> <td>Inhibitors interfere with assay</td> </tr> <tr> <td class=\"subtitle1_single\">Immunoassays, including multiplex techniques</td> </tr> <tr> <td>Less sensitive but improving</td> </tr> <tr> <td>Very specific</td> </tr> <tr> <td>Rheumatoid factors, soluble receptors can interfere</td> </tr> <tr> <td class=\"subtitle1_single\">Messenger RNA assays</td> </tr> <tr> <td>Complex procedures</td> </tr> <tr> <td>Not always correlated with cytokine protein release</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RNA: ribonucleic acid.</div><div id=\"graphicVersion\">Graphic 56208 Version 3.0</div></div></div>"},"56209":{"type":"graphic_picture","displayName":"Simple anal fistula","title":"Simple anal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Simple anal fistula</div><div class=\"cntnt\"><img style=\"width:351px; height:203px;\" src=\"images/SURG/56209_AU_Simple_ARF_fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This intraoperative photograph shows the primary internal opening and the secondary external opening of the simple anal fistula.</div><div class=\"graphic_reference\">Courtesy of Bradley J Champagne, MD.</div><div id=\"graphicVersion\">Graphic 56209 Version 5.0</div></div></div>"},"56210":{"type":"graphic_picture","displayName":"Pathology of granuloma annulare - perforating","title":"Pathology of granuloma annulare (H&E 100x)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathology of granuloma annulare (H&amp;E 100x)</div><div class=\"cntnt\"><img style=\"width:426px; height:314px;\" src=\"images/DERM/56210_Perforating.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This fully formed necrobiotic granuloma is situated in the upper dermis and the acellular material can be seen to perforate the epidermis (perforating granuloma annulare) at the right side of the photomicrograph (H&amp;E 100x).</div><div id=\"graphicVersion\">Graphic 56210 Version 1.0</div></div></div>"},"56211":{"type":"graphic_picture","displayName":"Darkfield Treponema pallidum","title":"Treponoma pallidum by darkfield microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treponoma pallidum by darkfield microscopy</div><div class=\"cntnt\"><img style=\"width:360px; height:252px;\" src=\"images/ID/56211_Darkfield_Treponema_pallidu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Darkfield examination of an exudate from a penile ulcer in a patient with syphilis. When viewed in a fresh specimen, Treponema pallidum moves with a characteristic forward and backward motion with rotation around the longitudinal axis.</div><div class=\"graphic_reference\">Courtesy of Charles B Hicks, MD.</div><div id=\"graphicVersion\">Graphic 56211 Version 2.0</div></div></div>"},"56212":{"type":"graphic_table","displayName":"Echinocandins PK","title":"Selected pharmacokinetic characteristics of the echinocandins in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected pharmacokinetic characteristics of the echinocandins in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Caspofungin</td> <td class=\"subtitle1\">Micafungin</td> <td class=\"subtitle1\">Anidulafungin</td> </tr> <tr> <td>Elimination half-life adult* (hours)</td> <td>27 to 50</td> <td>14 to 17.2</td> <td>40 to 50</td> </tr> <tr> <td>Metabolism</td> <td>Hepatic: slow peptide hydrolysis and N-acetylation, with some spontaneous degradation to peptide product</td> <td>Hepatic: catechol-O-methytransferase (COMT) and to a lesser extent, CYP1A2, 2B6, 2C, and 3A4</td> <td>Not metabolized: undergoes slow spontaneous degradation to inactive metabolites</td> </tr> <tr> <td>Dose adjustment for hepatic insufficiency</td> <td> <ul> <li>Mild (Child-Pugh 5 to 6): none </li> <li>Moderate (Child-Pugh 7 to 9): decrease maintenance dose to 35 mg/day </li> <li>Severe (Child-Pugh &#62;9): no data </li> </ul> </td> <td> <ul> <li>Mild and Moderate (Child-Pugh 5 to 9): none </li> <li>Severe (Child-Pugh &#62;9): no data </li> </ul> </td> <td>Not necessary</td> </tr> <tr> <td>Dose adjustment for renal insufficiency</td> <td>Not necessary</td> <td>Not necessary</td> <td>Not necessary</td> </tr> <tr> <td>Drug interactions</td> <td> <ul> <li>Cyclosporine increases caspofungin AUC by approximately 35 percent </li> <li>Potent inducers of metabolism (eg, rifampin, efavirenz, nevirapine, phenytoin, dexamethasone, carbemazepine) reduce caspofungin AUC by 15 to 30 percent </li> <li>Caspofungin reduces tacrolimus AUC by&nbsp;approximately 20 percent </li> </ul> </td> <td>N/A</td> <td>N/A</td> </tr> <tr> <td>CSF penetration (percent of plasma)</td> <td>&#60;0.1</td> <td>&#60;0.1</td> <td>&#60;0.1</td> </tr> <tr> <td>Fraction urine excretion (percent)</td> <td>1.4</td> <td>0.7</td> <td>&#60;1</td> </tr> <tr> <td>Protein binding (percent)</td> <td>96 to 97</td> <td>99.8</td> <td>84</td> </tr> <tr> <td>Vd (L/kg)</td> <td>0.14</td> <td>0.22 to 0.24</td> <td>0.50</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AUC: area under curve; CYP: cytochrome P; N/A: not applicable; CSF: cerebrospinal fluid; Vd: volume of distribution.<br> * Half-life of caspofungin and micafungin may be reduced in young children and infants compared with adults due to more rapid clearance.</div><div class=\"graphic_reference\">Sources:<br /><OL>&#xD;&#xA;<LI>US Food and Drug Administration-approved product information. </LI>&#xD;&#xA;<LI>Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739. </LI>&#xD;&#xA;<LI>Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48:815. </LI>&#xD;&#xA;<LI>Dodds Ashley E, Lewis R, Lewis J, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43 Suppl 1:S28. </LI>&#xD;&#xA;<LI>Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacotherapy 2009; 43:1647. </LI></OL></div><div id=\"graphicVersion\">Graphic 56212 Version 16.0</div></div></div>"},"56213":{"type":"graphic_figure","displayName":"Beta blocker ACEI HF mort","title":"Beta blockers and ACE inhibitors have synergistic effects in asymptomatic LV dysfunction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Beta blockers and ACE inhibitors have synergistic effects in asymptomatic LV dysfunction</div><div class=\"cntnt\"><img style=\"width:431px; height:225px;\" src=\"images/CARD/56213_BetablockerACEIHFmort.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the SOLVD-prevention trial of 4223 patients with mostly asymptomatic left ventricular (LV) dysfunction, those receiving a beta blocker and enalapril had a significantly lower all-cause mortality compared with those receiving beta blocker or enalapril alone (relative risk 0.7); this was due to a significant reduction in death from arrhythmia or pump failure.</div><div class=\"graphic_reference\">Data from: Exner DV, Dries DL, Waclawiw MA, et al. J Am Coll Cardiol 1999; 33:916.</div><div id=\"graphicVersion\">Graphic 56213 Version 3.0</div></div></div>"},"56214":{"type":"graphic_picture","displayName":"Shigella and actin EM","title":"Shigella and actin filaments on electron microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shigella and actin filaments on electron microscopy</div><div class=\"cntnt\"><img style=\"width:281px; height:220px;\" src=\"images/ID/56214_Shigella_and_actin_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning electron microscopy of HeLa cell infected by Shigella flexneri. The cytoskeleton has been insolubilized, and the host cell membrane has been removed. A dividing bacterium is seen with tight bundles of actin filaments at one extremity (arrow).</div><div class=\"graphic_reference\">Redrawn from Prevost MC, Lesourd M, Arpin M, et al. Infect Immun 1992; 60:4088.</div><div id=\"graphicVersion\">Graphic 56214 Version 2.0</div></div></div>"},"56216":{"type":"graphic_table","displayName":"Adjuvant analgesics","title":"Adjuvant analgesics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjuvant analgesics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">For neuropathic pain</td> </tr> <tr> <td class=\"indent1\">Desipramine</td> </tr> <tr> <td class=\"indent1\">Nortriptyline</td> </tr> <tr> <td class=\"indent1\">Duloxetine</td> </tr> <tr> <td class=\"indent1\">Milnacipran</td> </tr> <tr> <td class=\"indent1\">Venlafaxine</td> </tr> <tr> <td class=\"indent1\">Gabapentin</td> </tr> <tr> <td class=\"indent1\">Pregabalin</td> </tr> <tr> <td class=\"indent1\">Baclofen</td> </tr> <tr> <td class=\"indent1\">Mexiletine</td> </tr> <tr> <td class=\"indent1\">Clonidine</td> </tr> <tr> <td class=\"indent1\">Tizanidine</td> </tr> <tr> <td class=\"indent1\">Ketamine</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids (eg, dexamethasone, prednisone)</td> </tr> <tr> <td class=\"indent1\"><strong>Topical agents</strong></td> </tr> <tr> <td class=\"indent2\">Capsaicin</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Lidocaine patch</td> </tr> <tr> <td class=\"subtitle1_single\">For bone pain</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids (eg, dexamethasone, prednisone)</td> </tr> <tr> <td class=\"indent1\"><strong>Osteoclast inhibitors</strong></td> </tr> <tr> <td class=\"indent2\">Bisphosphonates (eg, ibandronate, pamidronate, zoledronic acid)</td> </tr> <tr> <td class=\"indent2\">Denosumab</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Calcitonin</td> </tr> <tr> <td class=\"subtitle1_single\">For bowel obstruction</td> </tr> <tr> <td class=\"indent1\"><strong>Anticholinergics</strong></td> </tr> <tr> <td class=\"indent2\">Glycopyrrolate</td> </tr> <tr> <td class=\"indent2\">Scopolamine</td> </tr> <tr> <td class=\"indent1\"><strong>Somatostatin analog</strong></td> </tr> <tr> <td class=\"indent2\">Octreotide</td> </tr> <tr> <td class=\"indent1\"><strong>Glucocorticoids</strong></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56216 Version 3.0</div></div></div>"},"56217":{"type":"graphic_figure","displayName":"Relationship between EPEC and STEC","title":"Relationship between EPEC and STEC","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Relationship between EPEC and STEC</div><div class=\"cntnt\"><img style=\"width:459px; height:297px;\" src=\"images/ID/56217_Relationship_betw_EPEC_STEC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Venn diagram illustrating the relationship between enteropathogenic Escherichia coli (EPEC) and Shiga toxin-producing E. coli (STEC) strains. Both the EPEC and the enterohemorrhagic E. coli (EHEC) subsets of STEC strains are capable of the attaching and effacing effect and are sometimes referred to as attaching and effacing E. coli (AEEC). The O157:H7 serotype is the most important clone of EHEC. EPEC can be divided into typical strains that produce bundle-forming pili and exhibit localized adherence and atypical strains with neither of these properties.</div><div class=\"graphic_reference\">Reproduced from: Donnenberg MS. Enterobacteriaceae. In: Principles and Practice of Infectious Diseases, 6th ed. Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia, PA 2005. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 56217 Version 1.0</div></div></div>"},"56218":{"type":"graphic_table","displayName":"Irritant contact dermatitis occupational exposures","title":"Occupations at high risk for irritant contact dermatitis and common irritants encountered","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Occupations at high risk for irritant contact dermatitis and common irritants encountered</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Occupation</td> <td class=\"subtitle1\">Common irritants encountered</td> </tr> <tr> <td>Agriculture</td> <td> <p>Oils</p> <p>Solvents</p> <p>Fertilizers and pesticides</p> <p>Cleansers and detergents</p> <p>Plants</p> <p>Animal hair, saliva, secretions</p> <p>Wet work</p> </td> </tr> <tr class=\"divider_top\"> <td>Automobile industry</td> <td> <p>Oils (cutting oils)</p> <p>Solvents and paints</p> <p>Cleansers and detergents</p> </td> </tr> <tr class=\"divider_top\"> <td>Cement and construction industry</td> <td> <p>Cement</p> <p>Wood preservatives</p> <p>Oils</p> <p>Acids and alkalis</p> <p>Fiberglass</p> <p>Adhesives and glues</p> </td> </tr> <tr class=\"divider_top\"> <td>Cleaners and housework</td> <td> <p>Wet work</p> <p>Cleansers and detergents</p> <p>Abrasives</p> </td> </tr> <tr class=\"divider_top\"> <td>Electrical/electronics</td> <td> <p>Solvents</p> <p>Soldering flux</p> <p>Cleansers and detergents</p> <p>Acids and alkalis</p> <p>Adhesives and glues</p> </td> </tr> <tr class=\"divider_top\"> <td>Food industry</td> <td> <p>Wet work</p> <p>Cleansers and detergents</p> <p>Foods (especially acidic foods and food enzymes)</p> </td> </tr> <tr class=\"divider_top\"> <td>Hairdressing/beautician</td> <td> <p>Wet work</p> <p>Shampoos</p> <p>Permanent wave solutions</p> <p>Oxidizing agents, bleaching agents</p> </td> </tr> <tr class=\"divider_top\"> <td>Health care and dental</td> <td> <p>Cleansers and detergents</p> <p>Wet work</p> <p>Alcohol and other disinfectants</p> <p>Medications</p> </td> </tr> <tr class=\"divider_top\"> <td>Painting</td> <td> <p>Solvents and paints</p> <p>Cleansers and detergents</p> <p>Acids and alkalis</p> </td> </tr> <tr class=\"divider_top\"> <td>Metal industry</td> <td> <p>Solvents</p> <p>Cleansers and detergents</p> <p>Paints</p> <p>Glues and adhesives</p> <p>Oils and cutting fluids</p> </td> </tr> <tr class=\"divider_top\"> <td>Plastic industry</td> <td> <p>Plastics</p> <p>Solvents</p> <p>Fiberglass</p> <p>Acids</p> </td> </tr> <tr class=\"divider_top\"> <td>Rubber industry</td> <td> <p>Solvents</p> <p>Cleansers and detergents</p> <p>Frictional/mechanical factor</p> </td> </tr> <tr class=\"divider_top\"> <td>Woodwork</td> <td> <p>Plastics</p> <p>Solvents</p> <p>Wood preservatives</p> <p>Detergents</p> <p>Sawdust and other</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Chew AL, Maibach HI. Occupational issues of irritant contact dermatitis. Int Arch Occup Environ Health 2003; 76:339, with kind permission from: Springer Science + Business Media B.V. Copyright © 2003.</div><div id=\"graphicVersion\">Graphic 56218 Version 7.0</div></div></div>"},"56219":{"type":"graphic_table","displayName":"Heart in hyperthyroidism","title":"Cardiovascular effects of hyperthyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiovascular effects of hyperthyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Finding</td> </tr> <tr> <td>Heart rate</td> <td>Increased</td> </tr> <tr> <td>Pulmonary artery pressure</td> <td>Increased</td> </tr> <tr> <td>Systemic vascular resistance</td> <td>Decreased</td> </tr> <tr> <td>Cardiac output</td> <td>Increased</td> </tr> <tr> <td>Ejection fraction</td> <td>Increased</td> </tr> <tr> <td>Diastolic relaxation</td> <td>Increased</td> </tr> <tr> <td>Diastolic blood pressure</td> <td>Decreased</td> </tr> <tr> <td>Myocardial oxygen consumption</td> <td>Increased</td> </tr> <tr> <td>Anginal syndrome</td> <td>Can induce or worsen</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56219 Version 2.0</div></div></div>"},"56220":{"type":"graphic_picture","displayName":"Esophageal adenocarcinoma CPC Light","title":"Histologic appearance of an esophageal adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of an esophageal adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/GAST/56220_Esoph_adenoca_CPC_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a biopsy specimen from the mass revealed poorly differentiated carcinoma in the lamina propria, infiltrating beneath an unremarkable squamous epithelium. The malignancy consists of sheets of neoplastic cells. However, focal gland formation is identified (arrow), allowing classification as poorly differentiated adenocarcinoma.</div><div class=\"graphic_reference\">Courtesy of Maria Botero, MD and Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 56220 Version 3.0</div></div></div>"},"56224":{"type":"graphic_table","displayName":"Features of JIA subtypes","title":"Features of three of the major subtypes of juvenile idiopathic arthritis (JIA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of three of the major subtypes of juvenile idiopathic arthritis (JIA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Systemic JIA</td> <td class=\"subtitle1\">Oligoarticular JIA</td> <td class=\"subtitle1\">Polyarticular JIA</td> </tr> <tr> <td><strong>Percent of JIA patients</strong></td> <td>10 to 15</td> <td>50</td> <td>30 to 40</td> </tr> <tr> <td><strong>Sex</strong></td> <td>F = M</td> <td>F&#62;M</td> <td>F&#62;M</td> </tr> <tr> <td><strong>Age</strong></td> <td>Any &#60;17 years</td> <td>Peak 2 to 3 years, rare &#62;10</td> <td>Peaks 2 to 5, 10 to 14 years</td> </tr> <tr> <td><strong>Joints</strong></td> <td>Any number and any joint</td> <td>Large joints, but rarely hips</td> <td>Any, usually symmetrical and rare to start in hips</td> </tr> <tr> <td><strong>Fever, rash, lymphadenopathy, hepatosplenomegaly</strong></td> <td>Yes</td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Uveitis</strong></td> <td>Rare</td> <td>20%, most common in patients who are ANA positive</td> <td>Less frequently seen than in oligoarticular JIA</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\"><strong>Laboratory abnormalities</strong></td> </tr> <tr> <td class=\"sublist1\">- Leukocytosis</td> <td class=\"sublist_other\">Marked</td> <td class=\"sublist_other\">No</td> <td class=\"sublist_other\">No</td> </tr> <tr> <td class=\"sublist1\">- Anemia</td> <td class=\"sublist_other\">Marked</td> <td class=\"sublist_other\">No</td> <td class=\"sublist_other\">Mild</td> </tr> <tr> <td class=\"sublist1\">- Elevated ESR</td> <td class=\"sublist_other\">Marked</td> <td class=\"sublist_other\">Mild</td> <td class=\"sublist_other\">Mild</td> </tr> <tr> <td class=\"sublist1\">- ANA</td> <td class=\"sublist_other\">Absent</td> <td class=\"sublist_other\">Low titer common</td> <td class=\"sublist_other\">Low titer common in younger</td> </tr> <tr> <td class=\"sublist1\">- Rheumatoid factor</td> <td class=\"sublist_other\">Rare</td> <td class=\"sublist_other\">Absent</td> <td class=\"sublist_other\">10 to 20% in those &#62;10 years</td> </tr> <tr> <td class=\"sublist1\">- Elevated ferritin</td> <td class=\"sublist_other\">Marked</td> <td class=\"sublist_other\">No</td> <td class=\"sublist_other\">Mild</td> </tr> <tr> <td><strong>Destructive arthritis</strong></td> <td>&#62;50%</td> <td>Rare</td> <td>&#62;50%</td> </tr> <tr> <td><strong>Response to methotrexate</strong></td> <td>Poor to moderate</td> <td>Excellent</td> <td>Excellent</td> </tr> <tr> <td><strong>Response to biologic drugs</strong></td> <td> <p>Poor to TNF inhibitors</p> Excellent to IL-1 and IL-6 inhibitors</td> <td> <p>Excellent to TNF inhibitors and IL-6 inhibitors (although not commonly used)&nbsp;</p> Poor to IL-1 inhibitors</td> <td> <p>Excellent to TNF inhibitors and IL-6 inhibitors</p> Poor to IL-1 inhibitors</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">F: female; M: male; ANA: antinuclear antibody; ESR: erythrocyte-sedimentation rate; TNF: tumor necrosis factor; IL: interleukin.</div><div id=\"graphicVersion\">Graphic 56224 Version 12.0</div></div></div>"},"56225":{"type":"graphic_table","displayName":"Counseling women with pseudocyesis","title":"Factors relevant to pseudocyesis that can be a focus of counseling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors relevant to pseudocyesis that can be a focus of counseling</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Contributory factors</td> <td class=\"subtitle1\">Focus of counseling</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Strong desire for a baby</td> <td>Identify what fuels the wish; redirect energy toward other ways to achieve similar goals</td> <td>Helping a socially isolated woman focus on making new friends<sup>[1]</sup></td> </tr> <tr> <td>Misconceptions about fertility</td> <td>Psychoeducation</td> <td>Teaching a woman that it is the man's sperm that determines a baby's sex, so she is not \"to blame\" for having only girl babies<sup>[2]</sup></td> </tr> <tr> <td>Lack of awareness of emotions; use of denial as a primary coping mechanism</td> <td>Help patient recognize and articulate emotions</td> <td>Helping a woman voice anger at her husband for pressuring her to have a tubal ligation<sup>[3]</sup></td> </tr> <tr> <td>Helplessness - eg, due to poverty and/or abuse</td> <td>Focus on aspects of her life that patient can control</td> <td>Helping a woman find resources to leave an abusive relationship<sup>[4]</sup></td> </tr> <tr> <td>Low self esteem</td> <td>Help patient identify her strengths</td> <td>Helping a woman notice how she has social value without being pregnant<sup>[5]</sup></td> </tr> <tr> <td>Losses</td> <td>Grief counseling</td> <td>Working through suppressed feelings about a past miscarriage<sup>[1]</sup></td> </tr> <tr> <td>Cognitive bias - \"jumping to conclusions\" and not questioning conclusions</td> <td>Cognitive reframing</td> <td>Helping a woman consider other explanations for physical sensations<sup>[2]</sup></td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br> <ol> <li>Whelan, CI, Stewart, DE. Pseudocyesis--a review and report of six cases. Int J Psychiatry Med 1990; 20:97. </li> <li>Ahuja, N, Moorhead, S, Lloyd, AJ, et al. Antipsychotic-induced hyperprolactinemia and delusion of pregnancy. Psychosomatics 2008; 49:163. </li> <li>Bianchi-Demicheli, F, L&#252;dicke, F, Chardonnens, D. Imaginary pregnancy 10 years after abortion and sterilization in a menopausal woman: a case report. Maturitas 2004; 48:479. </li> <li>Ibekwe, PC, Achor, JU. Psychosocial and cultural aspects of pseudocyesis. Indian J Psychiatry 2008; 50:112. </li> <li>O'Grady, JP, Rosenthal, M. Pseudocyesis: a modern perspective on an old disorder. Obstet Gynecol Survey 1988; 44:500. </li> </ol></div><div id=\"graphicVersion\">Graphic 56225 Version 2.0</div></div></div>"},"56226":{"type":"graphic_picture","displayName":"Sarcoidosis - papules on neck","title":"Cutaneous sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/56226_Sarcoidosispapulesneck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple skin-colored papules are present on the posterior neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56226 Version 3.0</div></div></div>"},"56227":{"type":"graphic_diagnosticimage","displayName":"Aortic stenosis CW Doppler","title":"Aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic stenosis</div><div class=\"cntnt\"><img style=\"width:278px; height:238px;\" src=\"images/CARD/56227_Aortic_stenosis_CW_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous wave Doppler shows a peak velocity across the aortic valve of 4.6 m/sec or a gradient of 85 mmHg compatible with severe aortic stenosis. No aortic regurgitation is present.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 56227 Version 2.0</div></div></div>"},"56229":{"type":"graphic_picture","displayName":"Buccal hyperpigmentation PI","title":"Buccal hyperpigmentation due to ACTH excess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Buccal hyperpigmentation due to ACTH excess</div><div class=\"cntnt\"><img style=\"width:360px; height:230px;\" src=\"images/PI/56229_Buccal_hyperpigmentation_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows the inner lip of a man with adrenal insufficiency. The lip has darkened areas caused by a hormone imbalance.</div><div class=\"graphic_footnotes\">ACTH: corticotropin.</div><div class=\"graphic_reference\">Reprinted with permission from: Williams Textbook of Endocrinology, 8th ed, Foster, DW, Wilson, JD (Eds), WB Saunders, Philadelphia, 1996.</div><div id=\"graphicVersion\">Graphic 56229 Version 2.0</div></div></div>"},"56231":{"type":"graphic_figure","displayName":"Cholesteatoma mechanisms","title":"Mechanism of acquired retraction pocket cholesteatoma formation","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Mechanism of acquired retraction pocket cholesteatoma formation</div><div class=\"cntnt\"><img style=\"width:454px; height:305px;\" src=\"images/ALLRG/56231_Retxnpocketmechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As a retraction pocket is progressively drawn in, it forms a large pouch with a narrow neck that traps desquamating cells.<br> (A) Normal drum in cross-section.<br> (B) Shallow focal retraction.<br> (C) Deep retraction with collection of keratin debris.<br> (D) Infected cholesteatoma with granulation at its mouth.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 120, Pages 603-8, Copyright © 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 56231 Version 15.0</div></div></div>"},"56232":{"type":"graphic_picture","displayName":"Fungal otitis externa","title":"Fungal otitis externa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fungal otitis externa</div><div class=\"cntnt\"><img style=\"width:350px; height:238px;\" src=\"images/PC/56232_Fungal_otitis_externa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">External auditory canal with purulent debris coated with fungal filaments and spores.</div><div class=\"graphic_reference\">Courtesy of Laura A Goguen, MD.</div><div id=\"graphicVersion\">Graphic 56232 Version 1.0</div></div></div>"},"56233":{"type":"graphic_picture","displayName":"Gastric cardia","title":"Endoscopic appearance of gastric cardia after gastric banding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic appearance of gastric cardia after gastric banding</div><div class=\"cntnt\"><img style=\"width:324px; height:326px;\" src=\"images/GAST/56233_Gastric_cardia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retroflexed endoscopic appearance of the gastric cardia after laparoscopic adjustable gastric banding.</div><div class=\"graphic_reference\">Courtesy of Christopher S Huang, MD.</div><div id=\"graphicVersion\">Graphic 56233 Version 3.0</div></div></div>"},"56234":{"type":"graphic_picture","displayName":"Defibulation 4","title":"Defibulation (reversal of female genital infibulation)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Defibulation (reversal of female genital infibulation)</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/OBGYN/56234_Defibulation_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Step 4: View of the introitus and urethra after incising coapted labia.</div><div id=\"graphicVersion\">Graphic 56234 Version 2.0</div></div></div>"},"56235":{"type":"graphic_diagnosticimage","displayName":"Langerhans sternum CT","title":"Langerhans cell histiocytosis of bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Langerhans cell histiocytosis of bone</div><div class=\"cntnt\"><img style=\"width:360px; height:433px;\" src=\"images/HEME/56235_Langerhans_sternum_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This section from a thoracic CT scan shows a solitary osteolytic lesion of the sternum (arrow) with sclerotic margins (arrowhead) in a 38-year-old woman presenting with chest pain. A bone scan was positive in this area, as well. The resected surgical specimen showed Langerhans cell histiocytosis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Fazio N, Spaggiari L, Pelosi G, et al. Langerhans' cell histiocytosis. Lancet 2005; 365:598. Copyright &copy; 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 56235 Version 4.0</div></div></div>"},"56237":{"type":"graphic_figure","displayName":"Sternal wiring","title":"Sternal wiring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sternal wiring</div><div class=\"cntnt\"><img style=\"width:310px; height:333px;\" src=\"images/SURG/56237_Sternal_wiring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wire cerclage technique passes wires around the sternum (peristernal) instead of through it (transsternal).</div><div class=\"graphic_reference\">Reproduced from: Fawzy H, Alhodaib N, Mazer CD, et al. Sternal plating for primary and secondary sternal closure; can it improve sternal stability? J Cardiothorac Surg 2009; 4:19. Copyright © 2009 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 56237 Version 4.0</div></div></div>"},"56238":{"type":"graphic_table","displayName":"Classification of morphea","title":"Classification of morphea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of morphea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Morphea&nbsp;subtype</td> <td class=\"subtitle1\">Modifiers</td> <td class=\"subtitle1\">Clinical</td> </tr> <tr> <td rowspan=\"2\"><strong>Circumscribed</strong></td> <td>Superficial</td> <td>Single or multiple oval/round lesions limited to epidermis and dermis</td> </tr> <tr> <td>Deep</td> <td>Single or multiple oval/round lesions involving subcutaneous tissue, fascia or muscle</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Linear</strong></td> <td>Trunk/limbs</td> <td>Linear lesions involving possible primary site of involvement in subcutaneous tissue without involvement of skin, dermis, subcutaneous tissue, muscle or bone</td> </tr> <tr> <td>Head</td> <td>En coup de sabre, progressive facial hemiatrophy, linear lesions of the face (may involve underlying bone)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">Generalized</td> </tr> <tr> <td class=\"indent1\">1. Coalescent plaque</td> <td>&nbsp;</td> <td>&#8805;4 plaques in at least 2 of 7 anatomic sites (head-neck, right/left upper extremity, right/left lower extremity, anterior/posterior trunk); isomorphic pattern: coalescent plaques inframammary fold, waistline, lower abdomen, proximal thighs; symmetric pattern: symmetric plaques circumferential around breasts, umbilicus, arms, and legs</td> </tr> <tr> <td class=\"indent1\">2. Pansclerotic</td> <td>&nbsp;</td> <td>Circumferential involvement of majority of body surface area (sparing fingertips and toes), affecting skin, subcutaneous tissue, muscle or bone; no internal organ involvement</td> </tr> <tr class=\"divider_top\"> <td><strong>Mixed</strong></td> <td>&nbsp;</td> <td>Combination of any above subtype (eg, linear-circumscribed)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">21</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=84895&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Adapted with permission from: Laxer RM, Zulian FB. Localized scleroderma. Curr Opin Rheumatol 2006; 18:606. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56238 Version 9.0</div></div></div>"},"56239":{"type":"graphic_picture","displayName":"Examination of the hand for malrotation","title":"Examination of the hand for malrotation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examination of the hand for malrotation</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/SURG/56239_Exam_hand_malrotation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Assessment of rotational deformity after a hand fracture can be accomplished by observing the orientation of the fingernails to assess rotatory displacement. Normally, all fingers are directed toward the scaphoid and there should be no overlap or rotation as shown here.</div><div id=\"graphicVersion\">Graphic 56239 Version 3.0</div></div></div>"},"56240":{"type":"graphic_table","displayName":"AIM 60_6","title":"Doxorubicin (Adriamycin), ifosfamide, and mesna (AIM 60/6) for advanced soft tissue sarcoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doxorubicin (Adriamycin), ifosfamide, and mesna (AIM 60/6) for advanced soft tissue sarcoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Doxorubicin</td> <td>20 mg/m<sup>2</sup> per day IV</td> <td>Dilute with 1000 mL normal saline (NS) and administer as a continuous IV infusion over 24 hours daily.</td> <td>Days 1 through 3</td> </tr> <tr> <td>Ifosfamide</td> <td>1500 mg/m<sup>2</sup> per day IV</td> <td>Dilute with 500 mL NS to a final concentration of 0.6 to 20 mg/mL and administer over two hours daily.</td> <td>Days 1 through 4</td> </tr> <tr class=\"divider_bottom\"> <td>Mesna*</td> <td>Total daily dose 900 mg/m<sup>2</sup> IV</td> <td>Administer 300 mg/m<sup>2</sup> in NS or 5% dextrose (D5W) in water over one hour prior to each daily dose of ifosfamide. Total concentration of mesna should not exceed 20 mg/mL. Repeat at four and eight hours after the initiation of each dose of ifosfamide daily.</td> <td>Days 1 through 4</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Adequate hydration (at least two liters of oral or IV fluids per day) should be maintained with ifosfamide to reduce the risk of bladder toxicity.<sup>[2]</sup> Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> <li>The choice of hydration fluid is empiric and may vary by institution and protocol. The original protocol administered 500 mL of D5W containing electrolytes (sodium acetate 120 mEq/L [equal to 120 mmol/L], magnesium sulfate 500 mg/L [equal to 2.03 mmol/L], and potassium acetate 40 mEq/L [equal to 40 mmol/L]) over one hour before the start of each dose of ifosfamide, and maintenance hydration of the same hydration fluid over one hour at the completion of each ifosfamide dose; IV fluid was discontinued after completion of the eight-hour dose of mesna on each treatment day.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% risk of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> <li>Concomitant administration of aprepitant may increase the risk of ifosfamide neurotoxicity;<sup>[3-5]</sup> its use is avoided at some institutions. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is a vesicant; avoid extravasation. Infusional regimens should be administered through a central venous line. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>This regimen was designed to include primary prophylaxis with a granulocyte colony stimulating factor in all cycles.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower initial ifosfamide dose may be needed for patients with preexisting renal or liver impairment.<sup>[2]</sup> A lower starting dose of doxorubicin may be needed for patients with preexisting liver impairment.<sup>[6]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is associated with cardiomyopathy, the incidence of which is related to the cumulative dose. Assess baseline LVEF prior to administration. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines.<sup>[6]</sup> </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Ifosfamide is associated with cumulative nephrotoxicity, mostly at a total dose above 60 g/m<sup>2</sup>. Clinical manifestations may include hypophosphatemia, renal potassium wasting, metabolic acidosis with a normal ion gap, and rarely, polyuria due to nephrogenic diabetes insipidus. Assess creatinine and electrolytes, including potassium and phosphate, daily during treatment and prior to each subsequent treatment cycle. </li> <li>Refer to UpToDate topic on \"Ifosfamide nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Mesna does not prevent hemorrhagic cystitis in all patients.<sup>[7]</sup> Monitor a morning specimen of urine for hematuria daily, on days 1 through 4. </li> <li>Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for ifosfamide neurotoxicity (confusion, coma, rarely seizures, weakness, neuropathy, ataxia, cranial nerve dysfunction) daily on days 1 through 4. Central nervous system side effects may be especially problematic in those over age 60. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assay liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor cumulative doxorubicin dose. Reassess LVEF periodically during therapy as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment cycle until the absolute neutrophil count is &#8805;1500 cells/microL and platelet count is &#8805;100,000/microL.<sup>[1]</sup> Discontinue for &#62;2 week delay in recovery. Reduce doses of doxorubicin and ifosfamide by 10% for febrile neutropenia despite the use of hematopoietic growth factors. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Although formal guidelines are not provided by the manufacturer, reduce the ifosfamide dose or administer the same dose over a greater number of days for reversible grade 2 central nervous system toxicity. Discontinue for &#8805;grade 3 toxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Renal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, a 50% dose reduction for ifosfamide was recommended for creatinine rise to 1.5 times ULN during therapy; treatment was discontinued or rise of &#62;1.5 times ULN.<sup>[1]</sup> In addition, among patients with a normal baseline serum creatinine level, we suggest ifosfamide dose reduction for a day 1 serum creatinine of 1.8 mg/dL or greater. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Bladder toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For microscopic hematuria (greater than 10 RBC per high power field) despite mesna, withhold ifosfamide until complete resolution. Although formal guidelines are not available from the US FDA, reduce ifosfamide dose for grade 3 or worse hemorrhagic cystitis not responding to an increase in IV fluids and mesna. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; ULN: upper limit of normal; RBC: red blood cells.<br />* This regimen was designed to be used in the outpatient setting. If necessary, oral mesna may be used; however, oral mesna is not recommended for the initial dose.<SUP>[8]</SUP> If the oral route is chosen, patients should receive an initial IV dose of mesna (300 mg/m<SUP>2</SUP> [20% of the total daily ifosfamide dose]) prior to each day's ifosfamide administration, followed by oral mesna tablets at 40% of the daily ifosfamide dose (600 mg/m<SUP>2</SUP> per dose), administered at two and six hours after the initiation of each dose of ifosfamide.<SUP>[8]</SUP> This same dosing schedule is repeated on each day that ifosfamide is administered. The total daily mesna dose is 100% of the ifosfamide dose when the oral route is used.<SUP>[9]</SUP> If patients vomit within two hours of taking a dose of mesna, they should repeat the dose or receive an IV dose of mesna.<SUP>[9]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Worden FP, et al. J Clin Oncol 2005; 23:105.</LI>&#xD;&#xA;<LI>Ifosfamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).</LI>&#xD;&#xA;<LI>Durand JP, et al. Ann Oncol 2007; 18:808.</LI>&#xD;&#xA;<LI>Jarkowski A. Am J Health-Syst Pharm 2008; 65:2229.</LI>&#xD;&#xA;<LI>Howell JE, et al. J Oncol Pharm Practice 2008; 14:157.</LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).</LI>&#xD;&#xA;<LI>MESNA injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).</LI>&#xD;&#xA;<LI>Hensley ML, et al. J Clin Oncol 2009; 27:127.</LI>&#xD;&#xA;<LI>Mesna tablets. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 56240 Version 18.0</div></div></div>"},"56241":{"type":"graphic_picture","displayName":"Lupus miliaris disseminatus faciei","title":"Lupus miliaris disseminatus faciei","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Lupus miliaris disseminatus faciei</div><div class=\"cntnt\"><img style=\"width:468px; height:504px;\" src=\"images/DERM/56241_Lupus_miliar_dis_faci_crop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous to yellow-brown papules are present on the central face.</div><div class=\"graphic_reference\">Reproduced with permisison from: the Dermatology Online Atlas, <a href=\"http://www.dermis.net/\" target=\"_blank\">www.dermis.net</a>. Copyright &#169; 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 56241 Version 1.0</div></div></div>"},"56242":{"type":"graphic_picture","displayName":"Medullary thyroid cancer FNA","title":"Medullary thyroid cancer: Findings on fine needle aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medullary thyroid cancer: Findings on fine needle aspirate</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ENDO/56242_Medullary_thyroid_carcino1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fine needle aspirate with immunostaining for calcitonin in medullary cancer of the thyroid. The nuclei of the tumor cells are placed eccentrically and are larger and more pleomorphic than those of normal follicular cells. Immunocytologic staining for calcitonin is positive (brown staining which is best seen at the arrow). The background contains many red cells that nonspecifically take up the stain.</div><div id=\"graphicVersion\">Graphic 56242 Version 4.0</div></div></div>"},"56243":{"type":"graphic_table","displayName":"Effect of antiplatelet therapy on vascular events","title":"Effect of antiplatelet therapy on vascular events","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effect of antiplatelet therapy on vascular events</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category of trial</td> <td class=\"subtitle1\">Number of trials with data</td> <td class=\"subtitle1\">Anti-platelet, percent*</td> <td class=\"subtitle1\">Adjusted controls, percent*</td> <td class=\"subtitle1\">Odds reduction, percent<sup>&#182;</sup></td> </tr> <tr> <td>Prior MI</td> <td>12</td> <td>13.5</td> <td>17</td> <td>25&#177;4</td> </tr> <tr> <td>Acute MI</td> <td>15</td> <td>10.4</td> <td>14.2</td> <td>30&#177;4</td> </tr> <tr> <td>Prior stroke/TIA</td> <td>21</td> <td>17.8</td> <td>21.4</td> <td>22&#177;4</td> </tr> <tr> <td class=\"sublist1_start\">Acute stroke</td> <td class=\"sublist_other_start\">7</td> <td class=\"sublist_other_start\">8.2</td> <td class=\"sublist_other_start\">9.1</td> <td class=\"sublist_other_start\">11&#177;3</td> </tr> <tr> <td class=\"sublist1_start\">Other high risk</td> <td>140</td> <td>8</td> <td>10.2</td> <td>26&#177;3</td> </tr> <tr> <td class=\"sublist1\">Unstable angina</td> <td class=\"sublist_other\">12</td> <td class=\"sublist_other\">8</td> <td class=\"sublist_other\">13.3 </td> <td class=\"sublist_other\">46&#177;7</td> </tr> <tr> <td class=\"sublist1\">Stable angina/CHD</td> <td class=\"sublist_other\">7</td> <td class=\"sublist_other\">9.9 </td> <td class=\"sublist_other\">14.1</td> <td class=\"sublist_other\">33&#177;9</td> </tr> <tr> <td class=\"sublist1\">Peripheral arterial disease</td> <td class=\"sublist_other\">42</td> <td class=\"sublist_other\">5.8</td> <td class=\"sublist_other\">7.1</td> <td class=\"sublist_other\">23&#177;8</td> </tr> <tr> <td>All trials (high or low risk)</td> <td>195</td> <td>10.7</td> <td>13.2</td> <td>22&#177;2</td> </tr> <tr> <td>All low risk<sup>&#916;</sup> (primary prevention)</td> <td>3</td> <td>4.5</td> <td>4.9</td> <td>10</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Percent of patients suffering vascular events who are treated with antiplatelet agents or placebo; the duration of treatment was two years with a prior MI or stroke/TIA, 30 days with an acute MI, three weeks with an acute stroke, and two years for other high-risk patients.<br />&para; Odds reduction of vascular events due to antiplatelet therapy.<br />&Delta; Data from: Antiplatelet Trialists' Collaboration, BMJ 1994; 308:81.</div><div id=\"graphicVersion\">Graphic 56243 Version 5.0</div></div></div>"},"56245":{"type":"graphic_table","displayName":"Chemo dose adj renal","title":"Chemotherapy agents that may require dose reduction in patients with renal insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy agents that may require dose reduction in patients with renal insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Conventional cytotoxic agents</td> <td class=\"subtitle1\">Molecularly targeted agents</td> </tr> <tr> <td>Arsenic trioxide</td> <td>Afatinib</td> </tr> <tr> <td>Bendamustine</td> <td>Bosutinib</td> </tr> <tr> <td>Bleomycin</td> <td>Brentuximab</td> </tr> <tr> <td>Capecitabine</td> <td>Crizotinib</td> </tr> <tr> <td>Carboplatin</td> <td>Imatinib</td> </tr> <tr> <td>Carmustine (BiCNU)</td> <td>Lenvatinib&nbsp;</td> </tr> <tr> <td>Cisplatin</td> <td>Olaparib&nbsp;</td> </tr> <tr> <td>Cladribine</td> <td>Sorafenib</td> </tr> <tr> <td>Clofarabine&nbsp;</td> <td>Sunitinib</td> </tr> <tr> <td>Cyclophosphamide</td> <td>Vandetanib</td> </tr> <tr> <td>Cytarabine (high dose)</td> <td>&nbsp;</td> </tr> <tr> <td>Daunorubicin</td> <td>&nbsp;</td> </tr> <tr> <td>Epirubicin</td> <td>&nbsp;</td> </tr> <tr> <td>Eribulin</td> <td>&nbsp;</td> </tr> <tr> <td>Etoposide</td> <td>&nbsp;</td> </tr> <tr> <td>Fludarabine</td> <td>&nbsp;</td> </tr> <tr> <td>Hydroxyurea</td> <td>&nbsp;</td> </tr> <tr> <td>Ifosfamide</td> <td>&nbsp;</td> </tr> <tr> <td>Irinotecan (controversial)</td> <td>&nbsp;</td> </tr> <tr> <td>Ixazomib&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Lenalidomide</td> <td>&nbsp;</td> </tr> <tr> <td>Lomustine (CCNU)</td> <td>&nbsp;</td> </tr> <tr> <td>Melphalan</td> <td>&nbsp;</td> </tr> <tr> <td>Methotrexate</td> <td>&nbsp;</td> </tr> <tr> <td>Mitomycin</td> <td>&nbsp;</td> </tr> <tr> <td>Oxaliplatin</td> <td>&nbsp;</td> </tr> <tr> <td>Pemetrexed</td> <td>&nbsp;</td> </tr> <tr> <td>Pentostatin</td> <td>&nbsp;</td> </tr> <tr> <td>Pomalidomide&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Pralatrexate&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Streptozocin</td> <td>&nbsp;</td> </tr> <tr> <td>Topotecan</td> <td>&nbsp;</td> </tr> <tr> <td>Trabectedin&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Vinorelbine</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56245 Version 14.0</div></div></div>"},"56246":{"type":"graphic_figure","displayName":"Back anatomy PI","title":"Anatomy of the back","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Anatomy of the back</div><div class=\"cntnt\"><img style=\"width:543px; height:572px;\" src=\"images/PI/56246_Back_anatomy_PI_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low back pain can be caused by problems with the muscles, ligaments, discs, bones (vertebrae), or nerves. Often, back pain is caused by strains or sprains involving the muscles or ligaments. These problems cannot always be seen on imaging tests, such as MRI or CT scans.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 56246 Version 5.0</div></div></div>"},"56247":{"type":"graphic_table","displayName":"ROS joint pain swell child","title":"Examples of review of systems in the differential diagnosis of childhood joint pain and swelling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of review of systems in the differential diagnosis of childhood joint pain and swelling</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Affected system </td> <td class=\"subtitle1\">Diagnosis </td> <td class=\"subtitle1\">Manifestation </td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">Dermatologic </td> <td>SLE</td> <td>Malar rash and hair loss</td> </tr> <tr> <td>Dermatomyositis</td> <td>Gottron's papules</td> </tr> <tr> <td>Systemic JIA</td> <td>Evanescent pink macular rash</td> </tr> <tr> <td>IgAV (HSP)</td> <td>Lower extremity purpuric lesions</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">Ophthalmologic </td> <td>Oligoarthritis or psoriatic JIA</td> <td>Asymptomatic chronic anterior uveitis</td> </tr> <tr> <td>Enthesitis-related arthritis</td> <td>Acute symptomatic uveitis (pain, redness)</td> </tr> <tr> <td>Kawasaki disease</td> <td>Conjunctival injection without discharge</td> </tr> <tr> <td>Sj&#246;gren's syndrome</td> <td>Dry eyes with keratitis</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Oral </td> <td>SLE</td> <td>Painless oral ulcers on palate</td> </tr> <tr> <td>Beh&#231;et disease</td> <td>Large extremely painful oral ulcers</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"5\">Respiratory </td> <td>CF or immunodeficiency</td> <td>Recurrent pneumonia</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> <td>Destructive upper tract lesions</td> </tr> <tr> <td>SLE or systemic JIA</td> <td>Pleuritis</td> </tr> <tr> <td>SLE or scleroderma</td> <td>Interstitial lung disease</td> </tr> <tr> <td>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> <td>Eosinophilic pneumonia</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">Cardiovascular </td> <td>ARF or endocarditis</td> <td>New heart murmur</td> </tr> <tr> <td>SLE, systemic JIA, or ARF</td> <td>Pericarditis</td> </tr> <tr> <td>SLE or scleroderma</td> <td>Raynaud phenomenon</td> </tr> <tr> <td>Takayasu arteritis</td> <td>Absent pulses</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">Gastrointestinal </td> <td>IBD, SLE, or vasculitis</td> <td>Weight loss or poor growth</td> </tr> <tr> <td>IBD</td> <td>Diarrhea and abdominal pain</td> </tr> <tr> <td>Reactive arthritis</td> <td>Preceding infectious gastroenteritis</td> </tr> <tr> <td>IgAV (HSP)</td> <td>Intermittent colicky abdominal pain</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"3\">Genitourinary </td> <td>Gonococcal arthritis</td> <td>Pustular urethritis or cervicitis</td> </tr> <tr> <td>Reactive arthritis</td> <td>Nongonococcal urethritis</td> </tr> <tr> <td>Behcet disease or IBD</td> <td>Large painful genital ulcerations</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"3\">Hematologic </td> <td>SLE or hemoglobinopathy (eg, SCD)</td> <td>Hemolytic anemia</td> </tr> <tr> <td>SLE</td> <td>Pancytopenia</td> </tr> <tr> <td>Bleeding disorders</td> <td>Hemarthrosis</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"5\">Neurologic </td> <td>SLE</td> <td>Seizures and psychosis</td> </tr> <tr> <td>SLE or fibromyalgia</td> <td>Difficulty concentrating</td> </tr> <tr> <td>SLE, vasculitis, or hypercoagulability</td> <td>Stroke</td> </tr> <tr> <td>Vasculitis</td> <td>Asymmetric polyneuropathy</td> </tr> <tr> <td>Dermatomyositis and polymyositis</td> <td>Proximal muscle weakness</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematous; JIA: juvenile&nbsp;idiopathic arthritis<FONT color=black>; IgAV (HSP): immunoglobulin A vasculitis (Henoch-Schönlein purpura); CF: cystic fibrosis;</FONT> ARF: acute rheumatic fever; IBD: inflammatory bowel disease; SCD: sickle cell disease.</div><div class=\"graphic_reference\">Courtesy of Yukiko Kimura, MD&nbsp;and Taunton R Southwood, MD, FRACP, FRCPA, FRCP, FRCPCH.</div><div id=\"graphicVersion\">Graphic 56247 Version 9.0</div></div></div>"},"56248":{"type":"graphic_picture","displayName":"Gingival enlargement","title":"Drug-influenced gingival enlargement","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Drug-influenced gingival enlargement</div><div class=\"cntnt\"><img style=\"width:575px; height:368px;\" src=\"images/PC/56248_Gingival_enlargement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cyclosporine-induced in a young adult who received a kidney transplant.</div><div id=\"graphicVersion\">Graphic 56248 Version 1.0</div></div></div>"},"56249":{"type":"graphic_picture","displayName":"GAVE post bipolar probe endosc","title":"Thermal coagulation of gastric antral vascular ectasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thermal coagulation of gastric antral vascular ectasia</div><div class=\"cntnt\"><img style=\"width:300px; height:252px;\" src=\"images/GAST/56249_GAVE_post_gold_probe_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance after bipolar probe thermal coagulation of gastric antral vascular ectasia (watermelon stomach). Coagulation with the bipolar probe eventually obliterated the vascular ectasia.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD and Dennis M Jensen, MD.</div><div id=\"graphicVersion\">Graphic 56249 Version 2.0</div></div></div>"},"56250":{"type":"graphic_figure","displayName":"Uterine coring technique during vaginal hysterectomy","title":"Uterine coring technique during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Uterine coring technique during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:581px; height:663px;\" src=\"images/OBGYN/56250_Core_uterine_morcellation_t.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) Intramyometrial coring technique.</div><div id=\"graphicVersion\">Graphic 56250 Version 4.0</div></div></div>"},"56251":{"type":"graphic_figure","displayName":"Excision rectovaginal fistula","title":"Repair of a small rectovaginal fistula through a transvaginal approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of a small rectovaginal fistula through a transvaginal approach</div><div class=\"cntnt\"><img style=\"width:330px; height:403px;\" src=\"images/OBGYN/56251_Excision_rectovaginal_fistu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fistula tract is excised, including the adjacent vaginal and rectal mucosa.</div><div id=\"graphicVersion\">Graphic 56251 Version 1.0</div></div></div>"},"56252":{"type":"graphic_table","displayName":"Risk factors VTE","title":"Genetic and acquired risk factors for a first episode of venous thromboembolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic and acquired risk factors for a first episode of venous thromboembolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition/risk factor(s)</td> <td class=\"subtitle1\">Relative risk</td> <td class=\"subtitle1\">Incidence, percent per year</td> </tr> <tr> <td>Normal</td> <td>1</td> <td>0.008</td> </tr> <tr> <td>Prothrombin&nbsp;G20210A mutation</td> <td>2.8</td> <td>0.02</td> </tr> <tr> <td>Oral contraceptives</td> <td>4</td> <td>0.03</td> </tr> <tr> <td>Factor V Leiden mutation&nbsp;(heterozygous)</td> <td>7</td> <td>0.06</td> </tr> <tr> <td>Oral contraceptives plus heterozygous factor V Leiden mutation</td> <td>35</td> <td>0.29</td> </tr> <tr> <td>Factor V Leiden mutation&nbsp;(homozygous)</td> <td>80</td> <td>0.5 to 1.0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for further information. These risks were derived from the Leiden thrombophilia study; other studies have found slightly different risk estimates.</div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine,</EM> Bauer KA, The thrombophilias: Well-defined risk factors with uncertain therapeutic implications, vol. 135, p. 367. Copyright © 2001 American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 56252 Version 11.0</div></div></div>"},"56253":{"type":"graphic_table","displayName":"Cetuximab for recurrent and-or metastatic head and neck cancer","title":"Cetuximab for recurrent and/or metastatic head and neck cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cetuximab for recurrent and/or metastatic head and neck cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Weekly. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cetuximab</td> <td>400 mg/m<sup>2</sup> IV</td> <td>The appropriate dose should be withdrawn from the vials (supplied in a concentration of 2 mg/mL) and aseptically transferred into an empty sterile IV bag without further dilution. The initial dose should be infused over 120 minutes.*<sup>&#182;</sup></td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Cetuximab</td> <td>250 mg/m<sup>2</sup> IV</td> <td>If Day 1 is tolerated, subsequent doses may be administered over 60 minutes.</td> <td>Weekly, beginning day 8</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedication with diphenhydramine with or without a glucocorticoid at least prior to the first infusion.<sup>[2]</sup></li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (including creatinine, magnesium, calcium, and potassium) prior to each dose.</li> <li>Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of therapy.<sup>[2]</sup></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for skin rash.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dematologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Severe dermatologic reactions, such as acneiform rash, require delayed administration of cetuximab and/or dose reduction.</li> <li>Refer to UpToDate topic on \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Cetuximab should be administered with an infusion or syringe pump, using a low protein-binding 0.22 micron in line filter. Do not shake or dilute. Flush line with normal saline.<br />¶ A slower infusion rate should be considered in areas with a high incidence of infusion reactions (such as the southeast United States). Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used in cancer therapy\".</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Vermorken JB, et al. J Clin Oncol 2007; 25:2171.</LI>&#xD;&#xA;<LI>Cetuximab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 56253 Version 17.0</div></div></div>"},"56255":{"type":"graphic_table","displayName":"Intratumoral heterogeneity Ki67 grades","title":"Intratumoral heterogeneity of well-differentiated neuroendocrine tumors metastatic to the liver based on the mean and highest Ki67 grades on whole-slide subsections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intratumoral heterogeneity of well-differentiated neuroendocrine tumors metastatic to the liver based on the mean and highest Ki67 grades on whole-slide subsections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Tumor grade</td> <td class=\"subtitle1\">Homogeneous<br /> (n = 24, 53 percent)</td> <td class=\"subtitle1\">Heterogeneous<br /> (n = 21, 47 percent)</td> </tr> <tr> <td rowspan=\"2\"><strong>Mean Ki67</strong></td> <td>G1 (82 percent)</td> <td>22 (59 percent)</td> <td>15 (41 percent)</td> </tr> <tr> <td>G2 (18 percent)</td> <td>2 (25 percent)</td> <td>6 (75 percent)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Highest Ki67</strong></td> <td>G1 (49 percent)</td> <td>22 (100 percent)</td> <td>0 (0 percent)</td> </tr> <tr> <td>G2 (51 percent)</td> <td>2 (9 percent)</td> <td>21 (91 percent)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=93431&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">The percentage of G1 or G2 cases is based on the total number of cases. The percentage of homogeneous or heterogeneous cases in G1 (low grade) or G2 (intermediate grade) group is based on the number of cases in that particular grade.</div><div class=\"graphic_reference\">Reproduced with permission from: Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 2011; 35:853. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56255 Version 7.0</div></div></div>"},"56256":{"type":"graphic_picture","displayName":"Renal pathology of late diffuse mesangial sclerosis","title":"Renal pathology of late diffuse mesangial sclerosis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Renal pathology of late diffuse mesangial sclerosis</div><div class=\"cntnt\"><img style=\"width:540px; height:352px;\" src=\"images/PEDS/56256_Renal_path_late_diff_mesang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathologic specimen from a patient with diffuse mesangial sclerosis demonstrating the characteristic contraction of the glomerular tuft into sclerotic masses.</div><div id=\"graphicVersion\">Graphic 56256 Version 2.0</div></div></div>"},"56257":{"type":"graphic_picture","displayName":"Parallel pattern and pseudonetwork","title":"Dermoscopic structures of melanocytic lesions seen on volar and facial skin","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Dermoscopic structures of melanocytic lesions seen on volar and facial skin</div><div class=\"cntnt\"><img style=\"width:582px; height:233px;\" src=\"images/DERM/56257_Para_pattern_pseudonetwork.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Parallel pattern, typically seen in melanocytic lesions on palms and soles (volar surfaces).<br> (B) Pseudonetwork pattern seen in pigmented facial lesions.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 56257 Version 2.0</div></div></div>"},"56258":{"type":"graphic_figure","displayName":"EUS normal layers","title":"Diagram of the five-layer echo pattern of the normal gastrointestinal wall","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Diagram of the five-layer echo pattern of the normal gastrointestinal wall</div><div class=\"cntnt\"><img style=\"width:491px; height:324px;\" src=\"images/GAST/56258_EUS_normal_layers.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mary Lee Krinsky, DO and Kenneth Binmoeller, MD.</div><div id=\"graphicVersion\">Graphic 56258 Version 1.0</div></div></div>"},"56259":{"type":"graphic_table","displayName":"Carbapenemase subgroups","title":"Carbapenemase subgroups of the OXA family of beta-lactamases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carbapenemase subgroups of the OXA family of beta-lactamases</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cluster </td> <td class=\"subtitle1\">Enzyme subfamily </td> <td class=\"subtitle1\">Additional OXA member(s) </td> </tr> <tr> <td>1</td> <td>OXA-23 (ARI-1)</td> <td> <p>OXA-27</p> <p>OXA-49</p> </td> </tr> <tr> <td>2</td> <td>OXA-24/OXA-40</td> <td> <p>OXA-25</p> <p>OXA-26</p> <p>OXA-72</p> </td> </tr> <tr> <td>3</td> <td>OXA-51</td> <td> <p>OXA-64 through OXA-71</p> <p>OXA-75 through OXA-78</p> <p>OXA-83</p> <p>OXA-84</p> <p>OXA-86 through OXA-89</p> <p>OXA-91</p> <p>OXA-92</p> <p>OXA-94</p> <p>OXA-95</p> </td> </tr> <tr> <td>4</td> <td>OXA-58</td> <td> <p>OXA-96</p> <p>OXA-97</p> </td> </tr> <tr> <td>5</td> <td>OXA-48&nbsp;</td> <td> <p>OXA-162</p> <p>OXA-163</p> <p>OXA-181</p> <p>OXA-204</p> <p>OXA-232&nbsp;</p> </td> </tr> <tr> <td>6&nbsp;</td> <td> <p>OXA-143&nbsp;</p> </td> <td> <p>OXA-231</p> <p>OXA-253</p> <p>OXA-255</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20:440. Copyright ©2007 American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 56259 Version 3.0</div></div></div>"},"56260":{"type":"graphic_table","displayName":"Empiric IV rx pneumonia in children","title":"Parenteral empiric antibiotics for inpatient treatment of pediatric pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral empiric antibiotics for inpatient treatment of pediatric pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"35%\"></colgroup><colgroup width=\"65%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age group and suspected pathogens</td> <td class=\"subtitle1\">Suggested empiric regimens*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">1 to 6 months<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Bacterial (not <em>Chlamydia trachomatis</em> or <em>Staphylococcus aureus</em>)</td> <td> <p>Ceftriaxone 50 to 100<sup>&#916;</sup> mg/kg per day in 1 or 2 divided doses (2 doses should be used for severe infection or substantial local penicillin resistance), <strong>OR</strong></p> Cefotaxime 150 mg/kg per day in 3 or 4 divided doses (4 doses should be used for severe infection or substantial local penicillin resistance)</td> </tr> <tr> <td class=\"indent1\"><em>Chlamydia trachomatis</em></td> <td>Azithromycin 10 mg/kg on days 1 and 2 of therapy; transition to oral therapy if possible</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">&#62;6 months<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Uncomplicated bacterial (not <em>Mycoplasma pneumoniae</em>, <em>Chlamydia pneumoniae</em>, or <em>S. aureus</em>)</td> <td> <p>Ampicillin<sup>&#9674;</sup> 150 to 200 mg/kg per day in 4 divided doses (MAX 12 g/day), <strong>OR</strong></p> <p>Penicillin G<sup>&#9674;</sup> 200,000 to 250,000 units/kg per day in 4 or 6 divided doses, <strong>OR</strong></p> <p>Cefotaxime<sup>&#167;</sup> 150 mg/kg per day in 3 divided doses (MAX 8 g/day or 10 g/day divided in 4 doses for severe infection or substantial local penicillin resistance), <strong>OR</strong></p> Ceftriaxone<sup>&#167;</sup> 50 to 100<sup>&#916;</sup> mg/kg per day in 1 or 2 divided doses (MAX 2 g/day or 4 g/day divided in 2 doses for severe infection or substantial local penicillin resistance)</td> </tr> <tr> <td class=\"indent1\"><em>M. pneumoniae</em> or <em>C. pneumoniae</em></td> <td> <p>Azithromycin 10 mg/kg once per day for two days (MAX 500 mg/day); transition to oral therapy at 5 mg/kg per day as soon as clinically appropriate, <strong>OR</strong></p> <p>Erythromycin<sup>&#165;</sup> 20 mg/kg per day in 4 divided doses (MAX 4 g/day), <strong>OR</strong></p> Levofloxacin 16 to 20 mg/kg per day in 2 divided doses for children 6 months to 5 years; 8 to 10 mg/kg per day for children 5 to 16 years (MAX 750 mg)</td> </tr> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Suggested empiric regimens<sup>&#135;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Severe pneumonia<sup>&#182;&#134;</sup> (Refer to UpToDate topic on inpatient treatment of pneumonia in children for clinical features)</td> <td> <p>Either ceftriaxone 100 mg/kg per day in 2 divided doses (MAX 4 g/day), <strong>OR </strong>cefotaxime 150 mg/kg per day in 4 divided doses (MAX 10 g/day)</p> <strong>PLUS one of the following:</strong> <ul class=\"decimal_heading\"> <li>Azithromycin 10 mg/kg once per day for two days (MAX 500 mg/day); transition to oral therapy at 5 mg/kg per day as soon as clinically appropriate, <strong>OR</strong> </li> <li>Erythromycin<sup>&#165;</sup> 20 mg/kg per day in 4 divided doses (MAX 4 g/day), <strong>OR</strong> </li> <li>Doxycycline 4 mg/kg per day in 2 divided doses (MAX 200 mg/day); transition to oral therapy as soon as clinically appropriate </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Severe pneumonia requiring ICU admission<sup>**</sup> (refer to UpToDate topic on inpatient treatment of pneumonia in children for details)</td> <td> <p>Vancomycin 40 to 60 mg/kg per day in 3 or&nbsp;4 divided doses (MAX 4 g/day) <strong>PLUS either:</strong></p> <p>Ceftriaxone 100 mg/kg per day in 2 divided doses (MAX 4 g/day) <strong>OR</strong> cefotaxime 150 mg/kg per day in 4 divided doses (MAX 10 g/day)</p> <p><strong>PLUS</strong></p> <p>Azithromycin 10 mg/kg once per day for two days (MAX 500 mg/day); transition to oral therapy at 5 mg/kg per day as soon as clinically appropriate</p> <p><strong>PLUS (if necessary)</strong></p> <p>Nafcillin<sup>&#182;&#182;</sup> 150 mg/kg per day in 4 or 6 divided doses (MAX 12 g/day)</p> <p><strong>PLUS (if indicated)</strong></p> Antiviral treatment for influenza</td> </tr> <tr class=\"divider_bottom\"> <td>Complicated pneumonia/abscess<sup>&#916;&#916;</sup></td> <td> <p>Either ceftriaxone 100 mg/kg per day in 2 divided doses (MAX 4 g/day) <strong>OR</strong> cefotaxime 150 mg/kg per day in 4 divided doses (MAX 10 g/day)</p> <p><strong>PLUS (if necessary)<sup></sup></strong><sup>&#9674;&#9674;</sup></p> <p>Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 3.6 g/day) <strong>OR, for patients allergic to clindamycin or if clindamycin-resistant <em>S. aureus</em> is prevalent</strong><sup>&#167;&#167;</sup> <strong>in the community,</strong></p> Vancomycin 40 to 60 mg/kg per day in 3 or 4 divided doses (MAX 4 g/day)</td> </tr> <tr class=\"divider_bottom\"> <td>Nosocomial (hospital-acquired) pneumonia<sup>&#165;&#165;</sup></td> <td>Either gentamicin<sup>&#135;&#135;</sup> 7.5 mg/kg per day divided in 3 doses for children &#60;5 years; 6 to 7.5 mg/kg per day divided in 3 doses for children &#8805;5 years <strong>OR</strong> amikacin 15 to 22.5 mg/kg per day divided in 3 doses, <strong>PLUS one of the following:</strong> <ul class=\"decimal_heading\"> <li>Piperacillin-tazobactam 300 mg/kg per day in 4 divided doses (MAX 16 g/day), <strong>OR</strong> </li> <li>Meropenem 60 mg/kg per day in 3 divided doses (MAX 3 g/day), <strong>OR</strong> </li> <li>Ceftazidime 125 to 150 mg/kg per day in 3 divided doses (MAX 6 g/day), <strong>OR</strong> </li> <li>Cefepime 150 mg/kg per day in 3 divided doses (MAX 4 g/day), <strong>OR</strong> </li> <li>Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 3.6 g/day) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Community-acquired aspiration pneumonia<sup>&#134;&#134;</sup></td> <td> <p>Ampicillin-sulbactam 150 to 200 mg/kg per day in 4 divided doses (MAX 8 g/day of ampicillin component)</p> <p><strong>OR, if MRSA is a consideration,</strong></p> <p>Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 3.6 g/day)</p> </td> </tr> <tr> <td>Hospital-acquired aspiration pneumonia in patients colonized with unusual gram-negative pathogens<sup>&#134;&#134;,</sup>***</td> <td> <p>Piperacillin-tazobactam 300 mg/kg per day in 4 divided doses (MAX 16 g/day), <strong>OR</strong></p> Meropenem 60 mg/kg per day in 3 divided doses (MAX 3 g/day)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>MAX: maximum dose; ICU: intensive care unit; MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* Consultation with a specialist in infectious diseases for children is suggested for children with severe hypersensitivity to beta-lactam antibiotics (eg, penicillins and cephalosporins).<br />¶ Add vancomycin 40 to 60 mg/kg per day in 3 or 4 divided doses or clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses for suspected community-associated MRSA pneumonia.<br />Δ The 100 mg/kg per day dose of ceftriaxone should be used only if local rates of penicillin resistance to <EM>Streptococcus pneumoniae</EM> are substantial (≥25 percent).<br /><FONT class=lozenge>◊</FONT> Fully immunized with conjugate vaccines for <EM>Haemophilus influenzae</EM> type b (Hib) and <EM>S. pneumoniae</EM> in communities where penicillin resistance in invasive strains of pneumococcus is insignificant.<br />§ Not fully immunized with conjugate vaccines for Hib and <EM>S. pneumoniae</EM> or in communities where penicillin resistance in invasive strains of pneumococcus is significant.<br />¥ Parenteral erythromycin is associated with phlebitis, prokinetic and, rarely, cardiotoxic effects.<br />‡ Dosages recommended are for patients with normal renal function.<br />† Children of any age with severe infection may benefit from broad-spectrum therapy that addresses both atypical and typical pathogens.<br />**&nbsp;These recommendations are for children of any age.<br />¶¶&nbsp;If <EM>S. aureus</EM> is likely, since methicillin-sensitive <EM>S. aureus</EM> is more rapidly killed by nafcillin than by vancomycin.<br />ΔΔ&nbsp;Pneumonia complicated by significant parapneumonic effusion or necrotizing process (<EM>S. pneumoniae</EM>, <EM>S. aureus</EM>, and <EM>Streptococcus pyogenes</EM> are possible pathogens).<br />◊◊&nbsp;If MRSA is a consideration.<br />§§&nbsp;The threshold prevalence of clindamycin-resistant MRSA (constitutive plus inducible) for choosing vancomycin varies from center to center, usually ranging from 10 to 25 percent, trying to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community.<br />Additional considerations in the decision to choose vancomycin include the prevalence of MRSA in the community, the severity of illness, and the turn-around time for susceptibilities.<br />¥¥&nbsp;The amikacin/meropenem combination should be used if extended-spectrum gram-negative rods are a consideration.&nbsp;Either amikacin/meropenem or amikacin/cefepime should be used if AmpC beta-lactamase-producing gram-negative rods are a consideration. The aminoglycoside/cephalosporin combination should <STRONG>not</STRONG> be used if aspiration pneumonia is a possibility. Vancomycin should be <STRONG>added</STRONG> to the empiric regimen if MRSA is a consideration. An agent other than piperacillin-tazobactam should be chosen as the second agent, if feasible,&nbsp;if vancomycin is added because the combination of vancomycin and piperacillin-tazobactam has been associated with increased risk of acute kidney injury.<br />‡‡&nbsp;Gentamicin dosage is adjusted for peak concentration of 7 to 9 mcg/mL and trough of &lt;2 mcg/mL.<br />††&nbsp;Patients with severe hypersensitivity reaction to beta-lactam antibiotics can be treated with a combination of clindamycin plus an aminoglycoside.<br />***&nbsp;Vancomycin should be added to the empiric regimen if MRSA is a consideration. </FONT><FONT color=red><FONT color=black>Meropenem&nbsp;may be preferred for&nbsp;gram-negative coverage if vancomycin is added because the combination of vancomycin and piperacillin-tazobactam has been associated with increased risk of acute kidney injury. However, this risk must be weighed against the development of meropenem resistance, especially in closed units</FONT>.</FONT></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429. </LI>&#xD;&#xA;<LI>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Cinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25. </LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS. (Eds), American Academy of Pediatrics, 2015. p.871.</LI>&#xD;&#xA;<LI><FONT color=black>Downes KJ, Cowden C, Laskin BL, et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children. JAMA Pediatr 2017; 171:e173219.</FONT></LI></OL></div><div id=\"graphicVersion\">Graphic 56260 Version 28.0</div></div></div>"},"56261":{"type":"graphic_diagnosticimage","displayName":"Fibrous dysplasia femur","title":"Fibrous dysplasia of the proximal femur","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrous dysplasia of the proximal femur</div><div class=\"cntnt\"><img style=\"width:350px; height:491px;\" src=\"images/PEDS/56261_Fibrous_dysplasia_femur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sclerosis around a focus of fibrous dysplasia of the proximal femur.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56261 Version 2.0</div></div></div>"},"56262":{"type":"graphic_table","displayName":"Reducing pediatric lead exposure","title":"Provider steps in reducing continued lead exposure in children with elevated blood lead levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Provider steps in reducing continued lead exposure in children with elevated blood lead levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Report to appropriate health authorities (eg, city, county, or state health department).</td> </tr> <tr> <td>2. Take emergency measures to reduce lead exposure. Relocate the child and family to lead-free housing if necessary.</td> </tr> <tr> <td>3. Initiate intensive blood lead screening and/or chelation as determined by the degree of the child's blood lead elevation.*</td> </tr> <tr> <td>4. Educate the family about sources of lead exposure so that they can be eliminated.*</td> </tr> <tr> <td>5. Follow-up on long-term abatement procedures to reduce lead exposure.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For recommendations applicable to specific blood lead levels or signs and symptoms of pediatric lead poisoning and for specific family education content, refer to UpToDate topics on the management of childhood lead poisoning. </div><div id=\"graphicVersion\">Graphic 56262 Version 5.0</div></div></div>"},"56263":{"type":"graphic_figure","displayName":"IUGR morbidity and mortality","title":"Perinatal morbidity and mortality in fetuses with intrauterine growth restriction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perinatal morbidity and mortality in fetuses with intrauterine growth restriction</div><div class=\"cntnt\"><img style=\"width:388px; height:348px;\" src=\"images/PEDS/56263_SGA_morbidity_mortality_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Manning FA. Intrauterine growth retardation. In: Fetal Medicine: Principles and Practice, Appleton &amp; Lange, Norwalk, CT 1995. p.312.</div><div id=\"graphicVersion\">Graphic 56263 Version 6.0</div></div></div>"},"56265":{"type":"graphic_diagnosticimage","displayName":"Fibroid embolization 4d","title":"Right uterine angiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right uterine angiogram</div><div class=\"cntnt\"><img style=\"width:389px; height:399px;\" src=\"images/OBGYN/56265_Fibroid_embolization_4d.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right uterine angiogram before uterine fibroid embolization demonstrates dilated branches of the right uterine artery supplying multiple hypervascular uterine fibroids (arrows) on the right.</div><div id=\"graphicVersion\">Graphic 56265 Version 2.0</div></div></div>"},"56266":{"type":"graphic_diagnosticimage","displayName":"Postoperative ileus on plain abdominal radiograph","title":"Postoperative ileus on plain abdominal radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postoperative ileus on plain abdominal radiograph</div><div class=\"cntnt\"><img style=\"width:396px; height:482px;\" src=\"images/OBGYN/56266_KUB_postoperative_ileus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain abdominal radiograph&nbsp;shows a pattern suggestive of ileus with dilated colon on the right in a patient with spinal fixation devices</div><div class=\"graphic_reference\">Reproduced with permission from: Deborah Levine, MD. Copyright © Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 56266 Version 3.0</div></div></div>"},"56268":{"type":"graphic_figure","displayName":"Regulation ferritin and TfR","title":"Regulation of transferrin receptor and ferritin synthesis by iron","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Regulation of transferrin receptor and ferritin synthesis by iron</div><div class=\"cntnt\"><img style=\"width:532px; height:414px;\" src=\"images/HEME/56268_Regulation_ferritin_and_TfR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representations of the regulation of transferrin receptor and ferritin synthesis through translational controls operated by the iron-responsive elements (IREs) and the iron regulatory proteins IRP1 and IRP2. Only one IRE is present in the 5'-untranslated region (UTR) of ferritin mRNA, which is shown on the upper two diagrams. When cellular iron is scarce (upper left diagram), iron regulatory protein (IRP) molecules (shown as the pac-man-like circles) are available for binding the 5' IRE; initiation of translation is prevented and ferritin synthesis is inhibited. By contrast, presence of abundant intracellular iron prevents binding of IRP2 to the 5' IRE (upper right) and allows efficient mRNA translation to proceed. Five IREs are present in the 3'-UTR of transferrin receptor (TfR) mRNA, shown on the two lower diagrams. When cellular iron is scarce (lower left diagram), binding of IRPs to the IREs in the 3'-UTR stabilizes TfR mRNA and increases TfR translation. Conversely, when iron is abundant (right lower diagram), IREs are not occupied by IRPs, and TfR mRNA is rapidly degraded.</div><div id=\"graphicVersion\">Graphic 56268 Version 5.0</div></div></div>"},"56269":{"type":"graphic_figure","displayName":"Great toe amputation","title":"Great toe amputation","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Great toe amputation</div><div class=\"cntnt\"><img style=\"width:508px; height:681px;\" src=\"images/SURG/56269_Great_toe_amputation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56269 Version 3.0</div></div></div>"},"56270":{"type":"graphic_table","displayName":"Questions to consider","title":"Questions to consider when interpreting a systematic review","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Questions to consider when interpreting a systematic review</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Was the meta-analysis performed according to an explicitly defined protocol?</td> </tr> <tr> <td>Were the key questions well-formulated, and would their answers be clinically useful?</td> </tr> <tr> <td>Did the authors have a perspective or source of financing that may have biased the results?</td> </tr> <tr> <td>Did the authors clearly define the populations included?</td> </tr> <tr> <td>Were the subjects included similar to those seen in clinical practice?</td> </tr> <tr> <td>Were the treatments and comparators explicitly defined?</td> </tr> <tr> <td>Were the treatments used in a similar fashion to how they are used in clinical practice?</td> </tr> <tr> <td>Were the study outcomes well-defined and relevant to clinical practice?</td> </tr> <tr> <td>Were the analyzed outcomes relevant to clinical practice?</td> </tr> <tr> <td>Were the study designs of included trials appropriate for the key questions being addressed?</td> </tr> <tr> <td>Were the study eligibility criteria appropriate to capture all studies relevant to the questions?</td> </tr> <tr> <td>Was a thorough literature search done and the search strategy reported in sufficient detail that it could be reproduced?</td> </tr> <tr> <td>Were adequate explanations given for exclusion of studies?</td> </tr> <tr> <td>Were important sources of \"grey\" literature included?</td> </tr> <tr> <td>Was publication bias considered?</td> </tr> <tr> <td>Were the studies used in the meta-analysis assessed for their quality and was the quality of the studies considered in formulating conclusions?</td> </tr> <tr> <td>Were the characteristics of the individual studies listed with sufficient detail to allow an assessment of the appropriateness of their inclusion?</td> </tr> <tr> <td>Were primary results reported for each included study sufficiently that the reader can understand the results of the individual studies?</td> </tr> <tr> <td>Were the statistical methods for combining results (meta-analysis) described?</td> </tr> <tr> <td>Were confidence intervals, rather than p values, given for the overall estimates?</td> </tr> <tr> <td>Were study heterogeneity assessed and appropriate sensitivity and subgroup analyses performed?</td> </tr> <tr> <td>Were limitations of the meta-analysis discussed?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56270 Version 1.0</div></div></div>"},"56271":{"type":"graphic_picture","displayName":"Thenar space abscess","title":"Thenar space abscess","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Thenar space abscess</div><div class=\"cntnt\"><img style=\"width:548px; height:357px;\" src=\"images/SURG/56271_Thenar_space_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A thenar space abscess is characterized by a widely abducted thumb and fullness on the dorsum of the first web space as shown in the photograph.</div><div id=\"graphicVersion\">Graphic 56271 Version 1.0</div></div></div>"},"56272":{"type":"graphic_picture","displayName":"Palpable purpura on legs","title":"Palpable purpura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpable purpura</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/56272_Palpable_purpura_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpable purpura are present in this patient with cutaneous small vessel vasculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56272 Version 1.0</div></div></div>"},"56274":{"type":"graphic_picture","displayName":"Glycogen acanthosis Endosc","title":"Esophageal glycogen acanthosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal glycogen acanthosis</div><div class=\"cntnt\"><img style=\"width:252px; height:260px;\" src=\"images/GAST/56274_GlycogenacanthosisEndosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy revealed multiple elevated gray-white nodules (white arrows) in the upper and middle third of the esophagus. A long segment of salmon colored mucosa was seen in the distal esophagus.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Kenneth Falchuk, MD.</div><div id=\"graphicVersion\">Graphic 56274 Version 2.0</div></div></div>"},"56276":{"type":"graphic_table","displayName":"Energy intake CKD children","title":"Equations to estimate energy requirements for children with chronic kidney disease at healthy weights","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Equations to estimate energy requirements for children with chronic kidney disease at healthy weights</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Age</td>\r\n                    <td class=\"subtitle1\">Estimated energy requirement (EER) (kcal/day) = total energy expenditure + energy deposition</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>0 to 3 months</td>\r\n                    <td>EER = [89 x weight (kg) - 100] + 175</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>4 to 6 months</td>\r\n                    <td>EER = [89 x weight (kg) - 100] + 56</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>7 to 12 months</td>\r\n                    <td>EER = [89 x weight (kg) - 100] + 22</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>13 to 35 months</td>\r\n                    <td>EER = [89 x weight (kg) - 100] + 20</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">3 to 8 years</td>\r\n                    <td>Boys: EER = 88.5 - 61.9 x age (years) + PA x [26.7 x weight (kg) + 903 x height (m)] + 20</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Girls: EER = 135.3 - 30.8 x age (years) + PA x [10 x weight (kg) + 934 x height (m)] + 20</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">9 to 18 years</td>\r\n                    <td>Boys: EER = 88.5 - 61.9 x age (years) + PA x [26.7 x weight (kg) + 903 x height (m)] + 25</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Girls: EER = 135.3 - 30.8 x age (years) + PA x [10 x weight (kg) + 934 x height (m)] + 25</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; PA: physical activity coefficient.</div><div class=\"graphic_reference\">Reproduced with permission from: National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009; 53:S11. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 56276 Version 4.0</div></div></div>"},"56277":{"type":"graphic_algorithm","displayName":"Fatty diarrhea child","title":"Algorithm for evaluation of a child with fatty diarrhea","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of a child with fatty diarrhea</div><div class=\"cntnt\"><img style=\"width:534px; height:290px;\" src=\"images/PEDS/56277_Fatty_diarrhea_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm shows a typical diagnostic pathway for many patients in this age group. Other sequences of testing may be appropriate in some cases.</div><div class=\"graphic_footnotes\">IgA: immunoglobulin A; CT: computerized tomography.</div><div id=\"graphicVersion\">Graphic 56277 Version 4.0</div></div></div>"},"56279":{"type":"graphic_table","displayName":"Testing for type 2 diabetes mellitus in children","title":"Testing for type 2 diabetes mellitus in asymptomatic children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Testing for type 2 diabetes mellitus in asymptomatic children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Overweight&nbsp;or obese&nbsp;(any of the following):</td> </tr> <tr> <td class=\"indent1\">Body mass index &#8805;85th percentile for age and gender</td> </tr> <tr> <td class=\"indent1\">Weight for height &#8805;85th percentile</td> </tr> <tr> <td class=\"indent1\">Weight &#8805;120 percent of ideal for height</td> </tr> <tr> <td class=\"subtitle1_single\">Plus one or more of the following additional&nbsp;risk factors<sup>*</sup>:</td> </tr> <tr> <td class=\"indent1\">Family history of type 2 diabetes mellitus in a 1<sup>st</sup> or 2<sup>nd</sup> degree relative</td> </tr> <tr> <td class=\"indent1\">High-risk race/ethnicity (Native American, African-American, Latino, Asian American, Pacific Islander)</td> </tr> <tr> <td class=\"indent1\">Signs of insulin resistance on physical examination or conditions associated with insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational age birthweight)</td> </tr> <tr> <td class=\"indent1\">Maternal history of diabetes or gestational diabetes mellitus during the child's gestation</td> </tr> <tr> <td class=\"subtitle1_single\">Screening frequency</td> </tr> <tr> <td class=\"indent1\">Begin screening at age 10 years, or at onset of puberty if this occurs less than 10 years old</td> </tr> <tr> <td class=\"indent1\">Repeat screening every three years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This criterion has been updated to match the 2018 version of the Standards of Medical Care in Diabetes<SUP>[1]</SUP>.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018; 41 Suppl 1:S13.</LI></OL>From: American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care 2014; 37 Suppl 1:S14. American Diabetes Association, 2014. Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 56279 Version 12.0</div></div></div>"},"56280":{"type":"graphic_figure","displayName":"Variations in the origin and course of the cystic artery","title":"Variations in the origin and course of the cystic artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variations in the origin and course of the cystic artery</div><div class=\"cntnt\"><img style=\"width:319px; height:355px;\" src=\"images/SURG/56280_Varorgcourcystartedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Variation in the origin and course of the cystic artery. The cystic artery usually arises from the right hepatic artery. Variations in the origin and course of the cystic artery occur in about 25% of <span style=\"white-space: nowrap;\">people<sup>[1,2]</sup></span>, which is of clinical significance during surgical removal of the gallbladder.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Anson BJ. Anatomical considerations in surgery of the gallbladder. Q Bull Northwest Univ Med Sch 1956; 30:250.</li>&#xD;&#xA;    <li>Michel NA. The hepatic, cystic and retroduodenal arteries and their relations to the biliary ducts with samples of the entire celiacal blood supply. Ann Surg 1951; 133:503.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 4th ed, Lippincott Williams &amp; Wilkins, Baltimore 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56280 Version 3.0</div></div></div>"},"56282":{"type":"graphic_picture","displayName":"Lymphocyte and monocyte","title":"Cells in peripheral smear","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cells in peripheral smear</div><div class=\"cntnt\"><img style=\"width:370px; height:252px;\" src=\"images/HEME/56282_Lymphocyte_and_monocyte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear shows four different leukocytes: a band form, a lymphocyte, a monocyte, and a metamyelocyte. The lymphocyte is a small cell with a heavily stained condensed nucleus and a small rim of blue cytoplasm. The monocyte has an irregular nucleus with grayish, blue cytoplasm that has few granules. The metamyelocyte has a kidney bean-shaped nucleus with a granulated cytoplasm.</div><div class=\"graphic_reference\">Courtesy of David Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 56282 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"56284":{"type":"graphic_table","displayName":"Rai staging system CLL","title":"Modified Rai clinical staging system for chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Rai clinical staging system for chronic lymphocytic leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk</td> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td>Low</td> <td>0</td> <td>Lymphocytosis in blood or bone marrow</td> </tr> <tr> <td rowspan=\"2\">Intermediate</td> <td>I</td> <td>Lymphocytosis + enlarged lymph nodes</td> </tr> <tr> <td>II</td> <td>Lymphocytosis + enlarged liver or spleen with or without lymphadenopathy</td> </tr> <tr> <td rowspan=\"2\">High</td> <td>III</td> <td>Lymphocytosis + anemia (Hgb &#60;11 g/dL) with&nbsp;or without enlarged liver, spleen, or lymph lnodes</td> </tr> <tr> <td>IV</td> <td>Lymphocytosis + thrombocytopenia (platelet count &#60;100,000/microL) with or without anemia or enlarged liver, spleen, or lymph nodes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56284 Version 2.0</div></div></div>"},"56285":{"type":"graphic_diagnosticimage","displayName":"Sacroiliitis grade 1 and 2","title":"Sacroiliitis grade 1 and 2","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Sacroiliitis grade 1 and 2</div><div class=\"cntnt\"><img style=\"width:541px; height:395px;\" src=\"images/RHEUM/56285_Sacroiliitis_grade_1_and_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right sacroiliitis is grade 1 (suspicious of sacroiliitis). Left sacroiliitis is grade 2 (minimal changes of sacroiliitis).</div><div class=\"graphic_reference\">Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität, Herne, Germany.</div><div id=\"graphicVersion\">Graphic 56285 Version 4.0</div></div></div>"},"56286":{"type":"graphic_table","displayName":"Categories for albuminuria and proteinuria","title":"Categories for albuminuria and proteinuria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories for albuminuria and proteinuria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Normal to mildly increased</td> <td class=\"subtitle1\">Moderately increased</td> <td class=\"subtitle1\">Severely increased</td> </tr> <tr> <td><strong>AER (mg/day)</strong></td> <td>&#60;30</td> <td>30 to 300</td> <td>&#62;300</td> </tr> <tr> <td><strong>PER (mg/day)</strong></td> <td>&#60;150</td> <td>150 to 500</td> <td>&#62;500</td> </tr> <tr> <td><strong>ACR (mg/g)</strong></td> <td>&#60;30</td> <td>30 to 300</td> <td>&#62;300</td> </tr> <tr> <td><strong>PCR (mg/g)</strong></td> <td>&#60;150</td> <td>150 to 500</td> <td>&#62;500</td> </tr> <tr> <td><strong>Protein dipstick</strong></td> <td>Negative to trace</td> <td>Trace to 1+</td> <td>&#62;1+</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Normal urine contains small amounts of albumin, low-molecular-weight serum proteins, and proteins derived from renal tubules and the lower urinary tract. Albuminuria and proteinuria can be measured using excretion rates in timed urine collections, ratio of concentrations to creatinine concentration in spot urine samples, and semiquantitative dipsticks in spot urine samples. Relationships among measurement methods within a category are not exact.<br />Normal albumin and protein excretion rates are &lt;10 mg/day and &lt;50 mg/day, respectively. In most kidney diseases, albumin is the predominant urine protein, comprising approximately 60 to 90 percent of urine protein when protein excretion rate is very high. Urine albumin excretion rate of 30 to 300 and &gt;300 mg/day correspond to moderately increased albuminuria (formerly \"microalbuminuria\") and severely increased albuminuria (formerly \"macroalbuminuria\"), respectively. Urine albumin and protein excretion rates of &gt;2200 mg/day and &gt;3500 mg/day are usually accompanied by signs and symptoms of nephrotic syndrome (hypoalbuminemia, hypercholesterolemia, and edema).<br />Albuminuria and proteinuria may be assessed from ACR and PCR. ACR and PCR are best determined by repeated measurement in morning first voided urine. In general, for clinical decision-making, ACR and PCR are sufficient, but AER and PER can be measured as a confirmatory test. Relationships between AER and ACR and between PER and PCR are based on the assumption that average creatinine excretion rate is 1 g/day. Creatinine excretion varies with age, sex, race and diet; therefore, the relationship among these categories is approximate only. ACR &lt;10 mg/g (&lt;1.1 mg/mmol) is considered normal; ACR 10 to 29 mg/g (1.1 to 3.3 mg/mmol) is considered \"mildly increased.\"<br />Proteinuria may be assessed from semiquantitative urine dipsticks. The relationship between urine dipstick results and other measures depends upon urine concentration. In particular, a \"trace\" result can correspond to the \"normal to mildly increased\" category or low range of the \"moderately increased\" category. Positive dipstick tests can be confirmed by ACR, PCR, AER, or PER.<br />For ACR and PCR, to convert from mg/g creatinine to mg/mmol of creatinine, multiply by 0.113.</div><div class=\"graphic_footnotes\">AER: albumin excretion rate; PER: protein excretion rate; ACR: albumin/creatinine ratio; PCR: protein/creatinine ratio.</div><div class=\"graphic_reference\">Data from: KDIGO. Summary of recommendation statements. Kidney Int 2013; 3(Suppl):5.</div><div id=\"graphicVersion\">Graphic 56286 Version 8.0</div></div></div>"},"56287":{"type":"graphic_picture","displayName":"Pterygium with vascularity","title":"Vascularized pterygium approaching visual axis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Vascularized pterygium approaching visual axis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PC/56287_Highly_vascular_pterygium.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56287 Version 6.0</div></div></div>"},"56288":{"type":"graphic_picture","displayName":"Shoulder and upper arm stretch","title":"Flexibility exercise: Shoulder and upper arm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexibility exercise: Shoulder and upper arm</div><div class=\"cntnt\"><img style=\"width:374px; height:306px;\" src=\"images/PC/56288_Shoulder_upper_arm_stret_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise to increase flexibility in your shoulders and upper arms will help make it easier to reach for your seatbelt. If you have shoulder problems, talk with your doctor before trying this stretch.   <OL>  <LI>Stand with feet shoulder-width apart. </LI>  <LI>Hold one end of a towel in your right hand. </LI>  <LI>Raise and bend your right arm to drape the towel down your back. Keep your right arm in this position and continue holding on to the towel. </LI>  <LI>Reach behind your lower back and grasp the towel with your left hand. </LI>  <LI>To stretch your right shoulder, pull the towel down with your left hand. Stop when you feel a stretch or slight discomfort in your right shoulder. </LI>  <LI>Repeat at least three to five times. </LI>  <LI>Reverse positions, and repeat at least three to five times. </LI></OL></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 56288 Version 3.0</div></div></div>"},"56289":{"type":"graphic_figure","displayName":"Abdominal aortic aneurysm repair","title":"Abdominal aortic aneurysm repair","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Abdominal aortic aneurysm repair</div><div class=\"cntnt\"><img style=\"width:464px; height:705px;\" src=\"images/SURG/56289_Abd_aortic_aneurysm_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Top) For open surgical repair of abdominal aortic aneurysm, the aorta is clamped and the aneurysm sac opened. A graft is sutured into the aorta proximally and distally. A tube graft (illustrated) or a bifurcated graft is used depending upon the extent of iliac artery disease (aneurysm or stenosis). Once the graft is in place, the aneurysm sac and retroperitoneum are closed over the graft.<BR>(Bottom) For endovascular repair, the folded endograft is introduced through the femoral (or iliac) artery and, once it is properly posititioned, the self-expanding endograft is deployed. Iliac artery extensions are positioned and deployed to complete the repair.</div><div id=\"graphicVersion\">Graphic 56289 Version 1.0</div></div></div>"},"56290":{"type":"graphic_diagnosticimage","displayName":"Gestational sac TAUS","title":"Gestational sac (transabdominal ultrasound)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gestational sac (transabdominal ultrasound)</div><div class=\"cntnt\"><img style=\"width:244px; height:226px;\" src=\"images/OBGYN/56290_Gestational_sac_TAUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal sagittal image shows a fluid collection in the uterus (G) suggestive of a gestational sac.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 56290 Version 2.0</div></div></div>"},"56292":{"type":"graphic_figure","displayName":"US reported cases of chancroid","title":"US reported cases of chancroid","html":"<div class=\"graphic\"><div style=\"width: 693px\" class=\"figure\"><div class=\"ttl\">US reported cases of chancroid</div><div class=\"cntnt\"><img style=\"width:673px; height:296px;\" src=\"images/ID/56292_US_rprt_cases_chncrd.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. 2013 Sexually Transmitted Diseases Surveillance. Available at: <a href=\"http://www.cdc.gov/std/stats13/figures/46.htm\" target=\"_blank\">http://www.cdc.gov/std/stats13/figures/46.htm</a> (Accessed on: September 25, 2015).</div><div id=\"graphicVersion\">Graphic 56292 Version 3.0</div></div></div>"},"56293":{"type":"graphic_figure","displayName":"HR and BP response in tilt table test","title":"Heart rate and blood pressure patterns observed in head-up tilt table testing","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Heart rate and blood pressure patterns observed in head-up tilt table testing</div><div class=\"cntnt\"><img style=\"width:551px; height:348px;\" src=\"images/NEURO/56293_HR_BP_response_tilt_table.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are the heart rate and blood pressure responses seen during tilt table testing in patients with various etiologies of syncope, including autonomic failure, neurally mediated syncope, and postural tachycardia syndrome (POTS). The absence of an appropriate reflex-induced increase in heart rate as the blood pressure falls is a useful clue to the presence of autonomic failure. During neurally mediated syncope, parasympathetic (vagal) activity increases as blood pressure declines, slowing the heart. With POTS, tilt table testing typically reproduces the clinical symptoms in association with a heart rate increase ≥30 beats/min or a maximum heart rate ≥120 beats/min within the first 10 minutes; these changes are not associated with hypotension.</div><div id=\"graphicVersion\">Graphic 56293 Version 2.0</div></div></div>"},"56294":{"type":"graphic_table","displayName":"Effect of selecting different risk cut-offs for Down syn screen","title":"The effect of selecting different risk cut-offs for Down syndrome screening","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The effect of selecting different risk cut-offs for Down syndrome screening</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Down syndrome screening test</td> <td class=\"subtitle1\">Term risk cutoff*</td> <td class=\"subtitle1\">Detection rate (%)</td> <td class=\"subtitle1\">False-positive rate (%)</td> <td class=\"subtitle1\">Positive predictive value (%)<sup>&#182;</sup></td> </tr> <tr> <td class=\"centered\">Quadruple</td> <td class=\"centered divider_bottom\" rowspan=\"3\">1:350</td> <td class=\"centered\">88</td> <td class=\"centered\">7.7</td> <td class=\"centered\">2.5 (1:39)</td> </tr> <tr> <td class=\"centered\">Combined<sup>&#916;</sup></td> <td class=\"centered\">86</td> <td class=\"centered\">6.4</td> <td class=\"centered\">3 (1:33)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">Integrated<sup>&#916;</sup></td> <td class=\"centered\">92</td> <td class=\"centered\">3.9</td> <td class=\"centered\">5 (1:19)</td> </tr> <tr> <td class=\"centered\">Quadruple</td> <td class=\"centered divider_bottom\" rowspan=\"3\">1:300</td> <td class=\"centered\">86</td> <td class=\"centered\">6.6</td> <td class=\"centered\">3 (1:34)</td> </tr> <tr> <td class=\"centered\">Combined<sup>&#916;</sup></td> <td class=\"centered\">84</td> <td class=\"centered\">5.5</td> <td class=\"centered\">3 (1:29)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">Integrated<sup>&#916;</sup></td> <td class=\"centered\">91</td> <td class=\"centered\">3.4</td> <td class=\"centered\">6 (1:17)</td> </tr> <tr> <td class=\"centered\">Quadruple</td> <td class=\"centered divider_bottom\" rowspan=\"3\">1:250</td> <td class=\"centered\">84</td> <td class=\"centered\">5.7</td> <td class=\"centered\">3 (1:30)</td> </tr> <tr> <td class=\"centered\">Combined<sup>&#916;</sup></td> <td class=\"centered\">83</td> <td class=\"centered\">4.7</td> <td class=\"centered\">4 (1:25)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">Integrated<sup>&#916;</sup></td> <td class=\"centered\">90</td> <td class=\"centered\">3.0</td> <td class=\"centered\">7 (1:14)</td> </tr> <tr> <td class=\"centered\">Quadruple</td> <td class=\"centered divider_bottom\" rowspan=\"3\">1:200</td> <td class=\"centered\">82</td> <td class=\"centered\">4.7</td> <td class=\"centered\">4 (1:25)</td> </tr> <tr> <td class=\"centered\">Combined<sup>&#916;</sup></td> <td class=\"centered\">81</td> <td class=\"centered\">3.8</td> <td class=\"centered\">5 (1:21)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">Integrated<sup>&#916;</sup></td> <td class=\"centered\">89</td> <td class=\"centered\">2.4</td> <td class=\"centered\">8 (1:12)</td> </tr> <tr> <td class=\"centered\">Quadruple</td> <td class=\"centered divider_bottom\" rowspan=\"3\">1:150</td> <td class=\"centered\">79</td> <td class=\"centered\">3.6</td> <td class=\"centered\">5 (1:20)</td> </tr> <tr> <td class=\"centered\">Combined<sup>&#916;</sup></td> <td class=\"centered\">78</td> <td class=\"centered\">2.8</td> <td class=\"centered\">6 (1:16)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">Integrated<sup>&#916;</sup></td> <td class=\"centered\">87</td> <td class=\"centered\">1.9</td> <td class=\"centered\">9 (1:10)</td> </tr> <tr> <td class=\"centered\">Quadruple</td> <td class=\"centered\" rowspan=\"3\">1:100</td> <td class=\"centered\">74</td> <td class=\"centered\">2.5</td> <td class=\"centered\">7 (1:15)</td> </tr> <tr> <td class=\"centered\">Combined<sup>&#916;</sup></td> <td class=\"centered\">75</td> <td class=\"centered\">1.9</td> <td class=\"centered\">8 (1:11)</td> </tr> <tr> <td class=\"centered\">Integrated<sup>&#916;</sup></td> <td class=\"centered\">85</td> <td class=\"centered\">1.3</td> <td class=\"centered\">12 (1:7)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Source of estimates are from the parameters/tables from the SURUSS study and a birth prevalence of Down syndrome of 1:450. Quadruple refers to second-trimester AFP, uE3, total/intact hCG (or the free beta subunit), and inhibin A. Combined refers to first-trimester NT, PAPP-A, and total/intact hCG (or the free beta subunit). Integrated refers to first-trimester NT, PAPP-A, and second-trimester Quadruple test.</div><div class=\"graphic_footnotes\">AFP: alpha-fetoprotein; uE3: unconjugated estriol; hCG: human chorionic gonadotropin; NT: nuchal translucency; PAPP-A: pregnancy-associated plasma protein A.<br />* The approximate age cutoff equivalent for 1:350, 1:250, 1:200, 1:150, and 1:100 are 35, 36, 37, 38, and 39 years of age, respectively (eg, 1:350 is approximately the same as the age-associated risk of a group of women delivering at age 35).<br />¶ The positive predictive value as a percentage and the associated odds in parentheses.<br />Δ First-trimester sample obtained at 12 weeks of gestation. Performance will differ slightly at other weeks of gestation between 9 and 13.</div><div class=\"graphic_reference\">Data from: Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: The results of the Serum, Urine, and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003; 7:1.</div><div id=\"graphicVersion\">Graphic 56294 Version 2.0</div></div></div>"},"56295":{"type":"graphic_table","displayName":"Classification thymic neuroendocrine tumors","title":"Classification of thymic neuroendocrine carcinomas (NEC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of thymic neuroendocrine carcinomas (NEC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Well differentiated NEC</td> <td class=\"subtitle1\" colspan=\"2\">Poorly differentiated NEC</td> </tr> <tr> <td class=\"subtitle2\">Typical carcinoid</td> <td class=\"subtitle2\">Atypical carcinoid</td> <td class=\"subtitle2\">LCNEC</td> <td class=\"subtitle2\">SCC, neuroendocrine type</td> </tr> <tr> <td>No necrosis; &#60;2 mitoses per 2 mm<sup>2</sup> (10 HPF)</td> <td>Necrosis present and/or 2-10 mitoses per 2 mm<sup>2</sup> (10 HPF)</td> <td>Non-small cell NEC with &#62;10 mitoses per 2 mm<sup>2</sup> (10 HPF)</td> <td>Small cell cytology</td> </tr> <tr> <td colspan=\"2\"> <p><strong>Morphological variants:</strong></p> <ul> <li>Spindle cell type </li> <li>Pigmented type </li> <li>With amyloid (extrathyroidal medullary carcinoma) </li> <li>Oncocytic/oxyphilic type </li> <li>Mucinous </li> <li>Angiomatoid type </li> <li>Combinations of the above variants </li> </ul> </td> <td>&nbsp;</td> <td> <p><strong>Variants:</strong></p> <ul> <li>SCNEC combined with non-NECs </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <p>Thymic NECs with shared features of (atypical) carcinoid and LCNEC/SCC</p> Carcinoid with sarcomatous change (\"metaplastic NEC\") </td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=63761&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">LCNEC: large cell neuroendocrine carcinoma; SCC: small cell carcinoma; HPF: high power field.</div><div class=\"graphic_reference\">Reproduced with permission from: World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart, Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds), IARC Press, Lyon, 2004. Copyright © 2004 IARC Press.</div><div id=\"graphicVersion\">Graphic 56295 Version 9.0</div></div></div>"},"56296":{"type":"graphic_waveform","displayName":"M mode MV annular calcification","title":"M-mode echocardiogram of mitral annular calcification","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of mitral annular calcification</div><div class=\"cntnt\"><img style=\"width:473px; height:198px;\" src=\"images/CARD/56296_MmodeMVannularcalcifica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient, mitral annular calcification (MAC) is seen in association with aortic valve stenosis. An M-mode tracing (panel A) of the aortic root (Ao) shows a thickened aortic valve (AV). Panel B shows a dense band of echoes from the mitral annulus, due to MAC, which are located posterior to the anterior leaflet of the mitral valve (ALMV); the posterior mitral valve leaflet is not seen because it is obscured by the artifacts that arise from the highly reflective, calcified annulus.</div><div id=\"graphicVersion\">Graphic 56296 Version 3.0</div></div></div>"},"56297":{"type":"graphic_picture","displayName":"Insemination catheter","title":"Insemination catheter","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Insemination catheter</div><div class=\"cntnt\"><img style=\"width:463px; height:98px;\" src=\"images/OBGYN/56297_Insemination_catheter.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56297 Version 1.0</div></div></div>"},"56298":{"type":"graphic_diagnosticimage","displayName":"Pancoast tumor MRI I","title":"Pancoast tumor on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancoast tumor on MRI</div><div class=\"cntnt\"><img style=\"width:260px; height:360px;\" src=\"images/PULM/56298_Pancoast_tumor_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T1-weighted section through the lung mass shows extension through the apical fat pad into the base of the neck (arrow). The mass partially surrounds a patent left subclavian artery (arrowhead) and obliterates the tissue plane containing the brachial plexus. The left brachiocephalic vein is occluded and cannot be seen. A corresponding section from the right side of the neck is included for comparison.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56298 Version 3.0</div></div></div>"},"56301":{"type":"graphic_figure","displayName":"Dissection of the left mesocolon from Gerota fascia","title":"Dissection of the left mesocolon from Gerota's fascia","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Dissection of the left mesocolon from Gerota's fascia</div><div class=\"cntnt\"><img style=\"width:479px; height:473px;\" src=\"images/SURG/56301_Left-mesocolon-Gerota's-fascia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The splenic flexure is mobilized by dissecting the left mesocolon from Gerota's fascia.</div><div id=\"graphicVersion\">Graphic 56301 Version 3.0</div></div></div>"},"56302":{"type":"graphic_figure","displayName":"Anatomy wrist radial","title":"Anatomy of the radial aspect of the wrist","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Anatomy of the radial aspect of the wrist</div><div class=\"cntnt\"><img style=\"width:460px; height:585px;\" src=\"images/EM/56302_Anatomy_wrist_radial.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56302 Version 2.0</div></div></div>"},"56303":{"type":"graphic_table","displayName":"IDUS accuracy versus EUS","title":"Diagnostic accuracy of endoscopic ultrasound (EUS) and intraductal ultrasound (IDUS) for bile duct strictures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic accuracy of endoscopic ultrasound (EUS) and intraductal ultrasound (IDUS) for bile duct strictures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">EUS (percent)</td> <td class=\"subtitle1\">IDUS (percent)</td> <td class=\"subtitle1\">p value</td> </tr> <tr> <td><strong>Sensitivity</strong></td> <td>76</td> <td>91</td> <td>&#60;0.002</td> </tr> <tr> <td><strong>Specificity</strong></td> <td>75</td> <td>80</td> <td>NS</td> </tr> <tr> <td><strong>Positive predictive value</strong></td> <td>93</td> <td>95</td> <td>NS</td> </tr> <tr> <td><strong>Negative predictive value</strong></td> <td>40</td> <td>67</td> <td>NS</td> </tr> <tr> <td><strong>Accuracy</strong></td> <td>76</td> <td>89</td> <td>&#60;0.002</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Menzel J, Poremba C, Dietl KH, Domschke W. Scand J Gastroenterol 2000; 35:77.</div><div id=\"graphicVersion\">Graphic 56303 Version 3.0</div></div></div>"},"56307":{"type":"graphic_diagnosticimage","displayName":"Amniotic band sequence involving GI tract and a limb","title":"Two images from fetal a survey at 20 weeks of gestation in a fetus with amniotic band sequence","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Two images from fetal a survey at 20 weeks of gestation in a fetus with amniotic band sequence</div><div class=\"cntnt\"><img style=\"width:521px; height:264px;\" src=\"images/OBGYN/56307_Amniotic_band_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first image, which was obtained during a fetal survey,&nbsp;(A) shows an anterior abdominal wall defect adjacent to the cord insertion site, with free floating loops of bowel in the amniotic fluid. This is the appearance of a gastroschisis. The second image (B) shows the leg with a constriction band. There were many other regions of amputations and constriction bands in this fetus, leading to the diagnosis of amniotic band sequence.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 56307 Version 6.0</div></div></div>"},"56308":{"type":"graphic_diagnosticimage","displayName":"SVC invasion by lung ca MRI","title":"Magnetic resonance imaging (MRI) study demonstrating superior vena cava (SVC) invasion by lung carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging (MRI) study demonstrating superior vena cava (SVC) invasion by lung carcinoma</div><div class=\"cntnt\"><img style=\"width:360px; height:241px;\" src=\"images/ONC/56308_SVC_invasion_by_lung_ca_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gradient echo T1-weighted axial MRI image demonstrates a right paratracheal soft tissue mass which appears to invade or invaginate into the SVC, giving the appearance of an intraluminal mass (white arrow).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56308 Version 2.0</div></div></div>"},"56309":{"type":"graphic_table","displayName":"Diff dx appendicitis","title":"Differential diagnosis of acute appendicitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of acute appendicitis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n\t\n   <tr>\n   <td  class=\"subtitle1_single\">Abdominal Causes</td>\n   </tr>\n\n   <tr>\n   <td  class=\"subtitle2_single\">Gastrointestinal</td>\n   </tr>\n\n   <tr>\n   <td  class=\"indent1\">\n   Appendiceal neoplasm\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Gastroenteritis (Salmonella, Yersinia, Campylobacter)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Mesenteric adenitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Omental torsion\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Constipation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Perforated ulcer\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Intussusception\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Small bowel obstruction\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Crohn's disease\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Meckel diverticulitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Cecal diverticulitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Typhlitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Pancreatitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Gynecological\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Ectopic pregnancy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Pelvic inflammatory disease\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Ruptured ovarian follicle or cyst (Mittelschmerz)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Ovarian torsion\n   </td>\n   </tr>\n  <tr>\n   <td  class=\"subtitle2_single\">Obstetrical</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">Placental abruption</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">Uterine rupture</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">Labor</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">Severe preeclampsia and HELLP syndrome (midline or right upper quadrant pain)</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">Intraamniotic infection</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">Round ligament pain</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Genitourinary\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Testicular torsion\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Nephritis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Urinary tract infection\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Renal colic (stone, UPJ obstruction)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Other\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Sickle cell crisis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Mesenteric adenitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Primary peritonitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Extra-Abdominal Causes\n   </td>\n   </tr>\n   <tr>\n   <td>Pneumonia</td>\n   </tr>\n   <tr>\n   <td>Hemolytic uremic syndromes</td>\n   </tr>\n   <tr>\n   <td>Diabetic ketoacidosis</td>\n   </tr>\n   <tr>\n   <td>Henoch Schoenlein purpura</td>\n   </tr>\n   <tr>\n   <td>Streptococcal pharyngitis</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 56309 Version 1.0</div></div></div>"},"56310":{"type":"graphic_table","displayName":"Failure to respond to iron","title":"Causes for failure to respond to oral iron therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes for failure to respond to oral iron therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Coexisting disease interfering with marrow response</td> </tr> <tr> <td class=\"indent1\">Infection</td> </tr> <tr> <td class=\"indent1\">Inflammatory disorder (eg, rheumatoid arthritis)</td> </tr> <tr> <td class=\"indent1\">Concomitant malignancy</td> </tr> <tr> <td class=\"indent1\">Coexisting folate and/or vitamin B12 deficiency</td> </tr> <tr> <td class=\"indent1\">Bone marrow suppression from another cause</td> </tr> <tr> <td class=\"subtitle1_single\">Patient is not iron deficient, possible correct diagnoses include</td> </tr> <tr> <td class=\"indent1\">Thalassemia</td> </tr> <tr> <td class=\"indent1\">Lead poisoning</td> </tr> <tr> <td class=\"indent1\">Anemia of (chronic) inflammation</td> </tr> <tr> <td class=\"indent1\">Copper deficiency (zinc toxicity)</td> </tr> <tr> <td class=\"indent1\">Myelodysplastic syndrome/refractory sideroblastic anemia</td> </tr> <tr> <td class=\"subtitle1_single\">Patient is not taking the medication</td> </tr> <tr> <td class=\"indent1\">Prescription has not been filled</td> </tr> <tr> <td class=\"indent1\">Prescription has been filled but patient is no longer taking the medication</td> </tr> <tr> <td class=\"subtitle1_single\">Medication is being taken but is not being absorbed</td> </tr> <tr> <td class=\"indent1\">Rapid intestinal transport bypasses area of maximum absorption</td> </tr> <tr> <td class=\"indent1\">Enteric coated product: coating is not dissolving</td> </tr> <tr> <td class=\"indent1\">Patient has acquired malabsorption for iron (eg, sprue, atrophic or autoimmune gastritis, H. pylori infection)</td> </tr> <tr> <td class=\"indent1\">Medication taken in association with an agent interfering with absorption (eg, antacids, tetracycline, tea)</td> </tr> <tr> <td class=\"indent1\">Congenital cause for iron malabsorption (eg, iron-resistant iron deficiency anemia, IRIDA)</td> </tr> <tr> <td class=\"subtitle1_single\">Continued blood loss or need in excess of iron dose ingested</td> </tr> <tr> <td class=\"sublist2_start\">Cause of blood loss treatable (eg, bleeding peptic ulcer)</td> </tr> <tr> <td class=\"sublist2\">Initiate appropriate treatment</td> </tr> <tr> <td class=\"sublist2_start\">Cause of blood loss not treatable (eg, hereditary hemorrhagic telangiectasia [Osler-Weber-Rendu syndrome]) or need cannot be met by oral iron preparation (eg, renal failure or malignancy being treated with erythropoietin)</td> </tr> <tr> <td class=\"sublist2\">Switch patient to intravenous iron product</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Assumes that original diagnosis was iron deficiency anemia with hypochromic microcytic red blood cells, low ferritin, and low transferrin saturation.</div><div id=\"graphicVersion\">Graphic 56310 Version 4.0</div></div></div>"},"56311":{"type":"graphic_figure","displayName":"FL pathogenesis","title":"Overview of common mechanisms for the pathogenesis of follicular lymphoma","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Overview of common mechanisms for the pathogenesis of follicular lymphoma</div><div class=\"cntnt\"><img style=\"width:535px; height:682px;\" src=\"images/HEME/56311_FL_pathogenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The molecular pathogenesis of follicular lymphoma (FL) is a complex, multistep process leading to the replication of a malignancy clone of germinal B cell origin. While some steps in this pathway have been elucidated, many remain unknown. The majority of FL tumors demonstrate translocations or mutations that result in the increased expression of the B cell lymphoma 2 (BCL-2) gene. Approximately 85 percent demonstrate a translocation between the long arm of chromosome 18 and the immunoglobulin heavy chain gene on chromosome 14, resulting in the t(14;18)(q32;q21). BCL-2 is an anti-apoptotic factor that prevents caspase activation, thereby resulting in prolonged cell survival. Overexpression of BCL-2 is not sufficient to cause FL, and additional factors, such as the tumor microenvironment and other genetic lesions, likely contribute to the pathogenesis.</div><div id=\"graphicVersion\">Graphic 56311 Version 1.0</div></div></div>"},"56312":{"type":"graphic_movie","displayName":"Ultrasound of filarial dance","title":"Ultrasound of filarial dance","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of filarial dance</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ID/56312_USfilarialdancevideo.mp4\" style=\"width:320px;height:272px\"></div><img style=\"width:367px; height:263px;\" src=\"images/ID/56312_USfilarialdanceimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse scan of left testis. In para-testicular position an enlarged lymphatic vessel can be seen (arrow). One or more adult worms are detectable by their typical movements (filaria dance sign). The following m-mode imaging presents the dilated lymphatic vessels, containing moving adult worms, as a section marked by the cursor in the b-mode image.</div><div class=\"graphic_reference\">Reproduced from: Mand S, Marfo-Debrekyei Y, Dittrich M, et al. Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis. Filaria J 2003; 2:3. Available at: <a href=\"http://www.filariajournal.com/content/2/1/3\" target=\"_blank\">http://www.filariajournal.com/content/2/1/3</a>. Copyright &copy; 2003 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 56312 Version 1.0</div></div></div>"},"56313":{"type":"graphic_figure","displayName":"Fracture classification one","title":"Fracture classification: Part one","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Fracture classification: Part one</div><div class=\"cntnt\"><img style=\"width:581px; height:646px;\" src=\"images/EM/56313_Fracture_patterns_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Johnson, TR, Steinbach, LS (Eds): Essentials of Musculoskeletal imaging. Rosemonst, IL, American Academy of Orthopaedic Surgeons, 2004, p. 40-41. Copyright ©2004 American Academy of Orthopaedic Surgeons.</div><div id=\"graphicVersion\">Graphic 56313 Version 2.0</div></div></div>"},"56314":{"type":"graphic_table","displayName":"Interpretation laboratory tests","title":"Hypoglycemia: Interpretation of laboratory tests*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypoglycemia: Interpretation of laboratory tests*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptoms, signs, or both</td> <td class=\"subtitle1\">Glucose (mg/dL)/(mmol/L)</td> <td class=\"subtitle1\">Insulin (microU/mL)/(pmol/L)</td> <td class=\"subtitle1\">C-peptide (nmol/L)/(ng/mL)</td> <td class=\"subtitle1\">Proinsulin (pmol/L)</td> <td class=\"subtitle1\">Beta-hydroxybutyrate (mmol/L)</td> <td class=\"subtitle1\">Glucose increase after glucagon (mg/dL)/(mmol/L)</td> <td class=\"subtitle1\">Circulating oral hypoglycemic agent</td> <td class=\"subtitle1\">Antibody to insulin</td> <td class=\"subtitle1\">Diagnostic interpretation</td> </tr> <tr> <td>No</td> <td>&#60;55/3</td> <td>&#60;3/20.8</td> <td>&#60;0.2/0.6</td> <td>&#60;5</td> <td>&#62;2.7</td> <td>&#60;25/1.4</td> <td>No</td> <td>No</td> <td>Normal</td> </tr> <tr> <td>Yes</td> <td>&#60;55</td> <td>&#62;&#62;3</td> <td>&#60;0.2</td> <td>&#60;5</td> <td>&#8804;2.7</td> <td>&#62;25</td> <td>No</td> <td>Neg (Pos)</td> <td>Exogenous insulin</td> </tr> <tr> <td>Yes</td> <td>&#60;55</td> <td>&#8805;3</td> <td>&#8805;0.2</td> <td>&#8805;5</td> <td>&#8804;2.7</td> <td>&#62;25</td> <td>No</td> <td>Neg</td> <td>Insulinoma, NIPHS, PGBH</td> </tr> <tr> <td>Yes</td> <td>&#60;55</td> <td>&#8805;3</td> <td>&#8805;0.2</td> <td>&#8805;5</td> <td>&#8804;2.7</td> <td>&#62;25</td> <td>Yes</td> <td>Neg</td> <td>Oral hypoglycemic agent</td> </tr> <tr> <td>Yes</td> <td>&#60;55</td> <td>&#62;&#62;3</td> <td>&#62;&#62;0.2<sup>&#182;</sup></td> <td>&#62;&#62;5<sup>&#182;</sup></td> <td>&#8804;2.7</td> <td>&#62;25</td> <td>No</td> <td>Pos</td> <td>Insulin autoimmune</td> </tr> <tr> <td>Yes</td> <td>&#60;55</td> <td>&#60;3</td> <td>&#60;0.2</td> <td>&#60;5</td> <td>&#8804;2.7</td> <td>&#62;25</td> <td>No</td> <td>Neg</td> <td>IGF<sup>&#916;</sup></td> </tr> <tr> <td>Yes</td> <td>&#60;55</td> <td>&#60;3</td> <td>&#60;0.2</td> <td>&#60;5</td> <td>&#62;2.7</td> <td>&#60;25</td> <td>No</td> <td>Neg</td> <td>Not insulin (or IGF)-mediated</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Neg: negative; Pos: positive; NIPHS: noninsulinoma pancreatogenous hypoglycemia syndrome; PGBH: post-gastric bypass hypoglycemia; IGF: insulin-like growth factor.<br />* Patterns of findings during fasting or after a mixed meal in normal individuals with no symptoms or signs despite relatively low plasma glucose concentrations (ie, Whipple's triad not documented) and in individuals with hyperinsulinemic (or IGF-mediated) hypoglycemia or hypoglycemia caused by other mechanisms.<br />¶ Free C-peptide and proinsulin concentrations are low.<br />Δ Increased pro-IGF-2, free IGF-2, IGF-2/IGF-1 ratio.</div><div class=\"graphic_reference\">Original table modified for this publication to include mmol/L equivalent data. Reproduced with permission from: Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94:709. Copyright &copy; 2009 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 56314 Version 16.0</div></div></div>"},"56315":{"type":"graphic_figure","displayName":"Bleeding after medical abortion","title":"Types of vaginal bleeding as recorded by women from day 1 (administration of mifepristone) to day 15","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Types of vaginal bleeding as recorded by women from day 1 (administration of mifepristone) to day 15</div><div class=\"cntnt\"><img style=\"width:474px; height:319px;\" src=\"images/OBGYN/56315_Bleeding_after_medical_abor.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The data are from 1506 women who did not undergo surgical termination of pregnancy and who recorded the types of bleeding they had from study day 1 to day 15 on menstrual diary cards. Bleeding was characterized as spotting, as similar to normal menstrual bleeding (normal), or as heavier than normal menstrual bleeding (heavy).</div><div class=\"graphic_reference\">Data from Spitz, IM, Bardin, CW, Benton, L, Robbins, A. N Engl J Med 1998; 388:1241.</div><div id=\"graphicVersion\">Graphic 56315 Version 1.0</div></div></div>"},"56316":{"type":"graphic_waveform","displayName":"Advanced case 13 with answer","title":"Atrial fibrillation and nonsustained ventricular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Atrial fibrillation and nonsustained ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:505px; height:127px;\" src=\"images/CARD/56316_Advancedcase13withanswe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonsustained ventricular tachycardia in a patient with underlying atrial fibrillation. The ventricular arrhythmia consists of nine consecutive beats at an approximate rate of 170 beats/min.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 56316 Version 3.0</div></div></div>"},"56317":{"type":"graphic_table","displayName":"Headache database","title":"Headache database","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Headache database</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Do you have one or two types of headache?</td>\n</tr>\n<tr>\n<td>How did the headaches begin?</td>\n</tr>\n<tr>\n<td>How long has the headache been present?</td>\n</tr>\n<tr>\n<td>Are the headaches static, intermittent or progressive?</td>\n</tr>\n<tr>\n<td>How often does the headache occur?</td>\n</tr>\n<tr>\n<td>How long does the headache last?</td>\n</tr>\n<tr>\n<td>Do the headaches occur at any special time or under special circumstances?</td>\n</tr>\n<tr>\n<td>Are the headaches related to specific foods, medication or activities?</td>\n</tr>\n<tr>\n<td>Are there warning symptoms?</td>\n</tr>\n<tr>\n<td>Where is the pain located?</td>\n</tr>\n<tr>\n<td>What is the quality of the pain?</td>\n</tr>\n<tr>\n<td>Are there associated symptoms during the headache?</td>\n</tr>\n<tr>\n<td>What do you do during the headache?</td>\n</tr>\n<tr>\n<td>What makes the headache better?</td>\n</tr>\n<tr>\n<td>What makes the headache worse?</td>\n</tr>\n<tr>\n<td>Do symptoms continue in between the headaches?</td>\n</tr>\n<tr>\n<td>Are you being treated for any other medical problems?</td>\n</tr>\n<tr>\n<td>Do you take any medication for any reason regularly or intermittently?</td>\n</tr>\n<tr>\n<td>Does anyone in your family have headaches?</td>\n</tr>\n<tr>\n<td>What do you think is causing your headaches, and why do you have them?</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from De Benedittis, G, Lorenzetti, A. Headach 1992; 32:330.</div><div id=\"graphicVersion\">Graphic 56317 Version 1.0</div></div></div>"},"56318":{"type":"graphic_figure","displayName":"Suicide rates adolescents","title":"Suicide rates per 100,000 population, ages 10-24 in 1997: National Center for Health Statistics (1999)","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Suicide rates per 100,000 population, ages 10-24 in 1997: National Center for Health Statistics (1999)</div><div class=\"cntnt\"><img style=\"width:506px; height:385px;\" src=\"images/PEDS/56318_Suicide_rates_adolescents.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56318 Version 1.0</div></div></div>"},"56319":{"type":"graphic_table","displayName":"Asthma adherence II","title":"Identifying problems in taking medicines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Identifying problems in taking medicines</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\" rowspan=\"1\" colspan=\"3\">During the week, did you miss or were you late in taking your medicine because:</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"3\">1. You felt good and decided you didn't need your medicine.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Often </td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\">2. You felt good and forgot.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Often </td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n      <td colspan=\"3\" rowspan=\"1\">3. You were involved in an activity and forgot.</td>\n    </tr>\n    <tr>\n\n      <td>Often </td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"3\">4. You were interrupted and forgot.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Often </td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"3\">5. There was a planned change in your normal routine.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Often</td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"3\">6. There was some unexpected change in your normal routine.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Often</td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"3\">7. Your medicine caused you to be sick (side effects).</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Often</td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\">8. You ran out of medicine.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Often</td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"3\">9. You felt the medicine may not work as well if you used it too much.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Often</td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n      <td colspan=\"3\" rowspan=\"1\">10. You felt that the medicine wasn't working.</td>\n    </tr>\n    <tr>\n\n      <td>Often</td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n      <td colspan=\"3\" rowspan=\"1\">11. It was inconvenient.</td>\n    </tr>\n    <tr>\n\n      <td>Often</td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"3\">12. You were confused about what medicine you should take.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Often</td>\n\n      <td>Sometimes</td>\n\n      <td>Never</td>\n\n    </tr>\n<tr><td colspan=\"3\">Look back over your week's records and your answers to the questions above. Use this information to identify the problems you have most often in taking medicine as prescribed.</td>\n\t</tr>\n\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 56319 Version 1.0</div></div></div>"},"56320":{"type":"graphic_figure","displayName":"Lung function smokers with COPD","title":"Lung function decline over 5 years in smokers with COPD in the lung health study","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Lung function decline over 5 years in smokers with COPD in the lung health study</div><div class=\"cntnt\"><img style=\"width:471px; height:410px;\" src=\"images/PULM/56320_Lung_function_smokers_with.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FEV<sub>1</sub> undergoes a one time change during the first year of follow up and then declines linearly. Patients who received ipratropium in addition to smoking intervention had a small increase in FEV<sub>1</sub> in the first year but then showed the same rate of decline as the others. This improvement in lung function with ipratropium was lost within a few weeks of stopping the medication at the end of the study (not shown).</div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Redrawn from: Anthonisen NR, Connett JE, Kiley JP, et al. JAMA 1994; 272:1497.</div><div id=\"graphicVersion\">Graphic 56320 Version 2.0</div></div></div>"},"56321":{"type":"graphic_table","displayName":"Stages of sarcoidosis","title":"Stages of radiographic involvement in pulmonary sarcoidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of radiographic involvement in pulmonary sarcoidosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Radiographic findings</td> </tr> <tr> <td>I</td> <td>Bilateral hilar adenopathy</td> </tr> <tr> <td>II</td> <td>Bilateral hilar adenopathy and reticular opacities (predominantly in upper lobes)</td> </tr> <tr> <td>III</td> <td>Reticular opacities (predominantly in upper lobes) with shrinking hilar lymph nodes</td> </tr> <tr> <td>IV</td> <td>Reticular opacities, volume loss, conglomerated masses with traction bronchiectasis. Calcification and cavitation or cyst formation may be present.</td> </tr> <tr> <td>Nodular sarcoid</td> <td>Multiple, bilateral lung nodules and minimal hilar adenopathy</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=80350&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Stages_of_sarcoidosis.htm</title></head></div><div class=\"graphic_reference\">Data from: Scadding JG. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years' observation. Br Med J 1961; 2:1165.</div><div id=\"graphicVersion\">Graphic 56321 Version 2.0</div></div></div>"},"56322":{"type":"graphic_table","displayName":"Acquired causes of low complement values","title":"Acquired causes of low complement values","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acquired causes of low complement values</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Number of cases</td> <td class=\"subtitle1\">Percent of total</td> </tr> <tr> <td>Systemic lupus erythematosus</td> <td>72</td> <td>65</td> </tr> <tr> <td>Parvovirus infection</td> <td>9</td> <td>8</td> </tr> <tr> <td>Rheumatoid arthritis-associated vasculitis</td> <td>8</td> <td>7</td> </tr> <tr> <td>Liver failure*</td> <td>6</td> <td>5</td> </tr> <tr> <td>Autoimmune hemolytic anemia</td> <td>6</td> <td>5</td> </tr> <tr> <td>IgG<sub>4</sub>-positive multiorgan lymphoproliferative syndrome</td> <td>6</td> <td>5</td> </tr> <tr> <td>Cryoglobulinemia</td> <td>3</td> <td>3</td> </tr> <tr> <td>Membranoproliferative glomerulonephritis</td> <td>3</td> <td>3</td> </tr> <tr> <td>Acute glomerulonephritis</td> <td>3</td> <td>3</td> </tr> <tr> <td>Autoimmune pancreatitis</td> <td>2</td> <td>2</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table depicts various causes of acquired hypocomplementemia and the relative frequency of each disorder in a study of 121 Japanese patients. Patients had to have a low C4, C3, and total hemolytic complement (THC) to be included. A cause was determined in 111. By requiring both a low C4 and C3, the authors selected for patients with classical pathway activation. The antiphospholipid syndrome is also commonly associated with low C4 and C3 (in the presence or absence of systemic lupus erythematosus).</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G.<br />* Mechanism of hypocomplementemia in this situation is reduced hepatic synthesis while the others represent accelerated consumption.</div><div class=\"graphic_reference\">Data from: Saeki T, Ito T, Yamazaki H, et al. Hypocomplementemia of unknown etiology: an opportunity to find cases of IgG4-positive multi-organ lymphoproliferative syndrome. Rheumatol Int 2009; 30:99.</div><div id=\"graphicVersion\">Graphic 56322 Version 9.0</div></div></div>"},"56323":{"type":"graphic_figure","displayName":"Atenolol dose in angina","title":"Dose-dependence of efficacy of atenolol in stable angina","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Dose-dependence of efficacy of atenolol in stable angina</div><div class=\"cntnt\"><img style=\"width:552px; height:307px;\" src=\"images/CARD/56323_Atenolol_dose_in_angina.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of different daily doses of atenolol (25, 50, 100, and 200 mg) in patients with stable angina. There was a tendency toward increasing efficacy with increasing dose. Only the 100 and 200 mg doses were significantly effective at trough levels with respect to exercise time and ST depression.</div><div class=\"graphic_reference\">Data from Jackson G, Schwartz J, Kates RE, et al. Circulation 1980; 61:555.</div><div id=\"graphicVersion\">Graphic 56323 Version 2.0</div></div></div>"},"56326":{"type":"graphic_diagnosticimage","displayName":"Second trimester nuchal fold","title":"Thickened fetal nuchal skin fold in the second trimester","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thickened fetal nuchal skin fold in the second trimester</div><div class=\"cntnt\"><img style=\"width:389px; height:263px;\" src=\"images/OBGYN/56326_Second_trimester_nuchal_fol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonogram obtained during the second trimester of pregnancy to measure the thickness of the nuchal skin fold. Nuchal skin-fold thickness is measured by placing the calipers at the outer edges of the occipital bone and skin surface. The correct level is the transaxial plane containing the cavum septi pellucidum (CSP) and the cerebellar hemisphere (H).</div><div id=\"graphicVersion\">Graphic 56326 Version 2.0</div></div></div>"},"56327":{"type":"graphic_picture","displayName":"Reactivity of paraneoplastic antibodies","title":"Reactivity of paraneoplastic antineuronal antibodies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reactivity of paraneoplastic antineuronal antibodies</div><div class=\"cntnt\"><img style=\"width:403px; height:306px;\" src=\"images/ONC/56327_ReactivityparaneoplasticA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reactivity of different paraneoplastic antibodies with the nervous system. <br />(A) Reactivity of anti-Hu antibodies with human cerebral cortex. There is predominant staining of the nuclei of the neurons (with sparing of the nucleoli), and milder staining of the cytoplasm. Glial cells are not immunoreactive. <br />(B) Reactivity of anti-Yo antibodies with rat cerebellum. There is intense immunolabeling of the cytoplasm of the Purkinje cells and of neurons of the molecular layer. <br />(C) Reactivity of anti-Tr antibodies with rat cerebellum. There is a characteristic dot-like immunolabeling of the cytoplasm of Purkinje cells and the neuropil of the molecular layer of cerebellum.<br />(D) Reactivity of anti-Ma2 (Ta) antibodies with human cerebral cortex. This antibody reacts with the nucleoli of the neurons, and shows mild immunolabeling of the cytoplasm; glial cells are not immunoreactive.</div><div class=\"graphic_reference\">Courtesy of Josep Dalmau, MD, PhD.</div><div id=\"graphicVersion\">Graphic 56327 Version 3.0</div></div></div>"},"56328":{"type":"graphic_diagnosticimage","displayName":"Ultrasound hip dysplasia","title":"Ultrasound hip dysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound hip dysplasia</div><div class=\"cntnt\"><img style=\"width:346px; height:523px;\" src=\"images/PEDS/56328_US_hip_dysplasia_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This coronal ultrasound image of the hip demonstrates that the femoral head is less than 50% covered by the bony acetabulum and that the alpha angle measures less than 60&#176;. Normally, the femoral head is greater than 50% covered by the acetabulum, and the alpha angle measures greater than 60&#176;. The alpha angle is formed by the acetabular roof and the vertical cortex of the ilium.</div><div class=\"graphic_reference\">Reproduced with permission from: Jeanne Chow, MD. Children's Hospital-Boston, Copyright &copy; Jeanne Chow, MD.</div><div id=\"graphicVersion\">Graphic 56328 Version 6.0</div></div></div>"},"56329":{"type":"graphic_table","displayName":"Variants hereditary hemochromatosis","title":"Genetic causes of hemochromatosis, iron overload, and hyperferritinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic causes of hemochromatosis, iron overload, and hyperferritinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"12%\"></colgroup><colgroup width=\"64%\"></colgroup><colgroup width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Clinical characteristics</td> <td class=\"subtitle1\">Genetic defect(s)</td> </tr> <tr> <td class=\"centered\">I</td> <td class=\"centered\">AR</td> <td>Low penetrance, clinical onset in adults: <strong>\"Classical hereditary hemochromatosis.\"</strong></td> <td>HFE protein</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">II</td> <td class=\"centered\" rowspan=\"2\">AR</td> <td rowspan=\"2\">Rapid iron loading, full penetrance, and early onset of hypogonadism and cardiac complications. Liver disease less prominent. Also termed <strong>\"juvenile hemochromatosis.\"</strong> Onset in children or young adults.</td> <td>Hemojuvelin (IIA)</td> </tr> <tr> <td>Hepcidin (IIB)</td> </tr> <tr> <td class=\"centered\">III</td> <td class=\"centered\">AR</td> <td>Rare condition described in only eight families to date. Clinically similar to classical HH, but with onset in young adults.</td> <td>Transferrin receptor 2</td> </tr> <tr> <td class=\"centered\">IV</td> <td class=\"centered\">AD</td> <td>Variable dominant disorder: <ul class=\"decimal_heading\"> <li>Families with loss-of-function mutations have high ferritin levels, increased macrophage iron, reduced transferrin saturation, mild anemia and minimal hepatic iron deposition <strong>(\"ferroportin disease\")</strong> </li> <li>Families with the less common gain-of-function ferroportin mutations have findings similar to classical HH </li> </ul> </td> <td>Ferroportin 1</td> </tr> <tr> <td class=\"centered\">V</td> <td class=\"centered\">AD</td> <td>Found in four of seven members in a single Japanese family.</td> <td>H-ferritin</td> </tr> <tr> <td class=\"centered\">VI</td> <td class=\"centered\">AD</td> <td>High levels of ferritin in association with bilateral congenital cataract; no iron deposition. Also termed <strong>\"hereditary hyperferritinemia-cataract syndrome.\"</strong> Other mutations may lead to \"benign hyperferritinemia\" without other manifestations.</td> <td>L-ferritin</td> </tr> <tr> <td class=\"centered\">&ndash;&ndash;</td> <td class=\"centered\">AR</td> <td>Absence of ceruloplasmin <strong>(aceruloplasminemia)</strong> leads to anemia, diabetes mellitus, neurodegeneration, and iron deposition in various organs, including the liver and basal ganglia.</td> <td>Ceruloplasmin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AR: autosomal recessive; AD: autosomal dominant; HH: hereditary hemochromatosis.</div><div class=\"graphic_reference\">Compiled from multiple sources. Refer to topics for details and references.</div><div id=\"graphicVersion\">Graphic 56329 Version 9.0</div></div></div>"},"56331":{"type":"graphic_waveform","displayName":"MS pulsed wave Doppler echo","title":"Pulsed wave Doppler echocardiogram in mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulsed wave Doppler echocardiogram in mitral stenosis</div><div class=\"cntnt\"><img style=\"width:387px; height:248px;\" src=\"images/CARD/56331_MS_pulsed_wave_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulsed wave Doppler in a patient with mitral stenosis shows reduced diastolic flow after the E point (ie, reduced E-F slope), indicating reduced excursion of the mitral valve leaflet. The peak velocity is increased to over 2 m/sec, translating into a transvalvular gradient of 16 mmHg. There is also an increase in the amplitude of the A wave.</div><div class=\"graphic_reference\">Provided by Thomas Binder, et al. Interactive Echocardiography, A Clinical Atlas, Futura, 1997.</div><div id=\"graphicVersion\">Graphic 56331 Version 3.0</div></div></div>"},"56332":{"type":"graphic_picture","displayName":"Intraocular juvenile xanthogranuloma","title":"Intraocular juvenile xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraocular juvenile xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/56332_Intraocular_juv_xanthogran.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56332 Version 3.0</div></div></div>"},"56333":{"type":"graphic_picture","displayName":"Pemphigus vulgaris on gingiva","title":"Pemphigus vulgaris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus vulgaris</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/56333_Pemph_vulgaris_gingiva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gingival erosions are present in this patient with pemphigus vulgaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56333 Version 3.0</div></div></div>"},"56334":{"type":"graphic_picture","displayName":"PDR neovascularization disc","title":"Proliferative diabetic retinopathy displaying prominent neovascularization at the disc (NVD): Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proliferative diabetic retinopathy displaying prominent neovascularization at the disc (NVD): Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:396px; height:333px;\" src=\"images/ENDO/56334_PDR_neovasc_disc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph of proliferative diabetic retinopathy displaying prominent neovascularization at the disc (NVD).</div><div id=\"graphicVersion\">Graphic 56334 Version 3.0</div></div></div>"},"56337":{"type":"graphic_table","displayName":"Causes of heme-negative red urine","title":"Causes of heme-negative red urine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of heme-negative red urine</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td>Doxorubicin</td> </tr> <tr> <td>Chloroquine</td> </tr> <tr> <td>Deferoxamine</td> </tr> <tr> <td>Ibuprofen</td> </tr> <tr> <td>Iron sorbitol</td> </tr> <tr> <td>Nitrofurantoin</td> </tr> <tr> <td>Phenazopyridine</td> </tr> <tr> <td>Phenolphthalein</td> </tr> <tr> <td>Rifampin</td> </tr> <tr> <td class=\"subtitle1_single\">Food dyes</td> </tr> <tr> <td>Beets (in selected patients)</td> </tr> <tr> <td>Blackberries</td> </tr> <tr> <td>Food coloring</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolites</td> </tr> <tr> <td>Bile pigments</td> </tr> <tr> <td>Homogentisic acid</td> </tr> <tr> <td>Melanin</td> </tr> <tr> <td>Methemoglobin</td> </tr> <tr> <td>Porphyrin</td> </tr> <tr> <td>Tyrosinosis</td> </tr> <tr> <td>Urates</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56337 Version 3.0</div></div></div>"},"56339":{"type":"graphic_picture","displayName":"Arteriovenous anastomosis postablation 3","title":"Arteriovenous anastomosis postablation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous anastomosis postablation</div><div class=\"cntnt\"><img style=\"width:288px; height:292px;\" src=\"images/OBGYN/56339_Tx_TTTS6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ablated (blanched) area between the recipient vein at 12 o'clock and the donor artery at 5 o'clock.</div><div class=\"graphic_reference\">Courtesy of Kenneth J Moise, Jr, MD and Anthony Johnson, DO.</div><div id=\"graphicVersion\">Graphic 56339 Version 5.0</div></div></div>"},"56342":{"type":"graphic_figure","displayName":"Alcohol intake stroke risk","title":"Light alcohol consumption reduces the risk of stroke","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light alcohol consumption reduces the risk of stroke</div><div class=\"cntnt\"><img style=\"width:419px; height:547px;\" src=\"images/CARD/56342_Alcoholintakestrokerisk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relationship between stroke of various etiologies and alcohol consumption was evaluated in 26,556 male cigarette smokers; relative risks were adjusted for age, body mass index, serum total cholesterol, number of cigarettes smoked daily, history of diabetes, history of heart disease, education, leisure-time activity, and supplementation with an antioxidant. Systolic blood pressure (SBP) and HDL cholesterol (HDLC) were added separately. Light alcohol intake reduced the risk of a stroke, while moderate and heavy consumption increased the risk.</div><div class=\"graphic_reference\">Data from Leppala, JM, Paunio, M, Virtamo, J, et al, Circulation 1999; 100:1209.</div><div id=\"graphicVersion\">Graphic 56342 Version 1.0</div></div></div>"},"56343":{"type":"graphic_figure","displayName":"Cardiac examination for VSD","title":"Cardiac examination for VSD","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Cardiac examination for VSD</div><div class=\"cntnt\"><img style=\"width:622px; height:560px;\" src=\"images/CARD/56343_Cardiac_examination_VSD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Graphic illustration of the cardiac examination in ventricular septal defect (VSD).<br />  (A) Holosystolic murmur of VSD.<br />  (B) Shortened systolic murmur of muscular (VSD).<br />  (C) Typical murmur of VSD with mild pulmonary stenosis (PS) showing the delayed pulmonary closure sound (P<sub>2</sub>).<br />  (D) Systolic ejection murmur of severe pulmonary stenosis with delayed and reduced P<sub>2</sub>.<br />  (E) Eisenmenger complex with absence of the holosystolic murmur of VSD (see text), a loud P<sub>2</sub> secondary to pulmonary hypertension, and pulmonary regurgitation (PR) diastolic murmur.<br />  (F) VSD murmur followed by diastolic murmur of aortic regurgitation (AR).</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; A<sub>2</sub>: aortic closure sound.</div><div class=\"graphic_reference\">Reprinted with permission Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes, CA (Ed). © 2009 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 56343 Version 5.0</div></div></div>"},"56344":{"type":"graphic_picture","displayName":"EBV gene expression in Reed-Sternberg cells","title":"Epstein-Barr virus gene expression in Reed-Sternberg cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epstein-Barr virus gene expression in Reed-Sternberg cells</div><div class=\"cntnt\"><img style=\"width:316px; height:469px;\" src=\"images/HEME/56344_EBVgeneexpRdSternbrg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polymerase III transcript (EBER) in situ hybridization demonstrates Epstein-Barr virus gene expression in Reed-Sternberg cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Ambinder RF, Weiss LM. Association of Epstein-Barr Virus with Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al, (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56344 Version 6.0</div></div></div>"},"56346":{"type":"graphic_figure","displayName":"EHL sequential views","title":"Electrohydraulic lithotripsy of a bile duct stone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrohydraulic lithotripsy of a bile duct stone</div><div class=\"cntnt\"><img style=\"width:402px; height:666px;\" src=\"images/GAST/56346_EHL_sequential_views.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential fluoroscopic and endoscopic views during electrohydraulic lithotripsy (EHL) for giant extrahepatic bile duct stones.<br />(A) Giant common and left hepatic duct stones (arrows).<br />(B) Daughter scope inserted, stone fragmentation with EHL.<br />(C) Stone fragments being removed with a basket (white arrow), stone in the duodenal lumen (green arrow), fluoroscopic view demonstrating clearance of the stones.</div><div class=\"graphic_reference\">Courtesy of Isaac Raijman, MD and Susana Escalante, MD.</div><div id=\"graphicVersion\">Graphic 56346 Version 3.0</div></div></div>"},"56347":{"type":"graphic_table","displayName":"Frequency gallbladder polyps","title":"Relative frequency of the different pathologic types of gallbladder polyps","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative frequency of the different pathologic types of gallbladder polyps</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type </td> <td class=\"subtitle1\">Frequency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Benign polyps</td> </tr> <tr> <td class=\"indent1\">Cholesterol polyps</td> <td>60%</td> </tr> <tr> <td class=\"indent1\">Adenomyomas</td> <td>25%</td> </tr> <tr> <td class=\"indent1\">Inflammatory polyps</td> <td>10%</td> </tr> <tr> <td class=\"indent1\">Adenomas</td> <td>4%</td> </tr> <tr> <td class=\"sublist2_start\">Miscellaneous:</td> <td rowspan=\"4\">1%</td> </tr> <tr> <td class=\"sublist2\">Leiomyomas</td> </tr> <tr> <td class=\"sublist2\">Fibromas</td> </tr> <tr> <td class=\"sublist2\">Lipomas, etc</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Malignant polyps</td> </tr> <tr> <td class=\"indent1\">Adenocarcinoma</td> <td>80%</td> </tr> <tr> <td class=\"sublist2_start\">Miscellaneous:</td> <td class=\"sublist_other_start\" rowspan=\"4\">20%</td> </tr> <tr> <td class=\"sublist2\">Mucinous cystadenomas</td> </tr> <tr> <td class=\"sublist2\">Squamous cell carcinoma</td> </tr> <tr> <td class=\"sublist2\">Adenoacanthomas</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Weedon, D. Benign mucosal polyps. In pathology of the gallbladder, Mason, New York 1984. p.195. and Laitio, M, Pathol Res Pract 1983; 178:57.</div><div id=\"graphicVersion\">Graphic 56347 Version 2.0</div></div></div>"},"56349":{"type":"graphic_form","displayName":"Teacher questionnaire A","title":"Speech and language evaluation teacher questionnaire","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Speech and language evaluation teacher questionnaire</div><div class=\"cntnt\"><img style=\"width:614px; height:794px;\" src=\"images/PEDS/56349_Teacher_questionnaire_A.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 56349 Version 3.0</div></div></div>"},"56351":{"type":"graphic_table","displayName":"Medications causing sweating","title":"Medications that may cause sweating or flushing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications that may cause sweating or flushing</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Antidepressants </td> </tr> <tr> <td>Bupropion</td> </tr> <tr> <td>SSRIs</td> </tr> <tr> <td>Tricyclic antidepressants</td> </tr> <tr> <td>SSNRIs</td> </tr> <tr> <td class=\"subtitle1_single\">Anti-migraine drugs </td> </tr> <tr> <td>\"Triptans\" serotonin 5-HT (lb/ld) agonists</td> </tr> <tr> <td class=\"subtitle1_single\">Antipyretics </td> </tr> <tr> <td>Acetaminophen</td> </tr> <tr> <td>Aspirin</td> </tr> <tr> <td>NSAIDs</td> </tr> <tr> <td class=\"subtitle1_single\">Cholinergic agonists </td> </tr> <tr> <td>Bethanechol</td> </tr> <tr> <td>Pilocarpine</td> </tr> <tr> <td>Pyridostigmine</td> </tr> <tr> <td class=\"subtitle1_single\">Hormonal agents </td> </tr> <tr> <td class=\"subtitle2_single\">GnRH agonists </td> </tr> <tr> <td class=\"indent1\">Gonadorelin </td> </tr> <tr> <td class=\"indent1\">Goserelin </td> </tr> <tr> <td class=\"indent1\">Histrelin </td> </tr> <tr> <td class=\"indent1\">Leuprolide </td> </tr> <tr> <td class=\"indent1\">Nafarelin </td> </tr> <tr> <td class=\"subtitle2_single\">Aromatase inhibitors </td> </tr> <tr> <td class=\"indent1\">Anastrazole </td> </tr> <tr> <td class=\"indent1\">Exemestane </td> </tr> <tr> <td class=\"indent1\">Letrozole </td> </tr> <tr> <td class=\"subtitle2_single\">Receptor blockers </td> </tr> <tr> <td class=\"indent1\">Flutamide </td> </tr> <tr> <td class=\"subtitle2_single\">SERMs </td> </tr> <tr> <td class=\"indent1\">Raloxifene </td> </tr> <tr> <td class=\"indent1\">Tamoxifen</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hypoglycemic agents </td> </tr> <tr> <td>Insulin</td> </tr> <tr> <td>Sulfonylureas</td> </tr> <tr> <td>Thiazolidinediones</td> </tr> <tr> <td class=\"subtitle1_single\">Sympathomimetic agents </td> </tr> <tr> <td>Beta-agonists</td> </tr> <tr> <td>Phenylephrine</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous </td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Beta blockers</td> </tr> <tr> <td>Bromocriptine</td> </tr> <tr> <td>Calcium channel blockers</td> </tr> <tr> <td>Clozapine</td> </tr> <tr> <td>Cyclosporine</td> </tr> <tr> <td>Donepezil</td> </tr> <tr> <td>Fluvoxamine</td> </tr> <tr> <td>Hydralazine</td> </tr> <tr> <td>Imatinib</td> </tr> <tr> <td>Infliximab</td> </tr> <tr> <td>Interferon alfa-2b</td> </tr> <tr> <td>Morphine</td> </tr> <tr> <td>Niacin</td> </tr> <tr> <td>Nitroglycerin</td> </tr> <tr> <td>Omeprazole</td> </tr> <tr> <td>Opioids</td> </tr> <tr> <td>Protease inhibitors</td> </tr> <tr> <td>Rituximab</td> </tr> <tr> <td>Ropinirole</td> </tr> <tr> <td>Sildenafil</td> </tr> <tr> <td>Tamoxifen</td> </tr> <tr> <td>Theophylline</td> </tr> <tr> <td>Tramadol</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SSRI: selective serotonin reuptake inhibitor; SSNRI: serotonin-norepinephrine reuptake inhibitor; NSAIDs: nonsteroidal antiinflammatory drugs; GnRH: gonadotropin-releasing hormone; SERM: selective estrogen receptor modulator.</div><div id=\"graphicVersion\">Graphic 56351 Version 5.0</div></div></div>"},"56352":{"type":"graphic_figure","displayName":"LVEF predicts one-year mortality after thrombolysis","title":"LVEF after thrombolysis predicts one-year mortality","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LVEF after thrombolysis predicts one-year mortality</div><div class=\"cntnt\"><img style=\"width:415px; height:265px;\" src=\"images/CARD/56352_LVEF_outcome_thrombolysis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the GUSTO-I trial of 11,228 patients, the only predictor of mortality at one year was the left ventricular ejection fraction (LVEF) measured at the time of first catheterization; the relationship between LVEF and one year mortality was continuous. The red line is the point estimate; the blue lines are 95 percent confidence intervals.</div><div class=\"graphic_reference\">Data from Puma JA, Sketch MH Jr, Thompson TD, et al. J Am Cardiol 1999; 83:482.</div><div id=\"graphicVersion\">Graphic 56352 Version 3.0</div></div></div>"},"56355":{"type":"graphic_table","displayName":"Skin ulcers in travelers","title":"Skin ulcers in travelers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Skin ulcers in travelers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp; </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Bacteria </td> </tr> <tr> <td class=\"indent1\">Anthrax </td> <td>Hemorrhagic ulcer with surrounding edema; eschar</td> </tr> <tr> <td class=\"indent1\">Chancroid </td> <td>Painful genital ulcer; single or multiple</td> </tr> <tr> <td class=\"indent1\">Diphtheria </td> <td>Shallow ulcer</td> </tr> <tr> <td class=\"indent1\">Granuloma inguinale </td> <td>Painless genital ulcer</td> </tr> <tr> <td class=\"indent1\">Leprosy </td> <td>Neuropathic ulcers</td> </tr> <tr> <td class=\"indent1\">Lymphogranuloma venereum </td> <td>Late ulceration</td> </tr> <tr> <td class=\"indent1\">Melioidosis </td> <td>Necrotic ulcer with local cellulitis</td> </tr> <tr> <td class=\"indent1\">Mycetoma </td> <td>Ulcers with sinus tracts</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Mycobacteria </td> </tr> <tr> <td class=\"sublist2\"><em>M. marinum </em></td> <td class=\"sublist_other\">Nodules may ulcerate </td> </tr> <tr> <td class=\"sublist2\"><em>M. tuberculosis</em> </td> <td class=\"sublist_other\">Nodule ulcerates at site of primary inoculation </td> </tr> <tr> <td class=\"sublist2\"><em>M. ulcerans</em> </td> <td class=\"sublist_other\">Deep ulcer with undermined edges (Buruli) </td> </tr> <tr> <td class=\"indent1\">Plague </td> <td>Breakdown of bubo</td> </tr> <tr> <td class=\"indent1\">Pyoderma </td> <td>Crusted ulcer associated with staphylococci and streptococci</td> </tr> <tr> <td class=\"indent1\">Rickettsial infections </td> <td>Eschar at inoculation site for some rickettsiae; may be multiple</td> </tr> <tr> <td class=\"indent1\">Syphilis </td> <td>Painless ulcer with indurated edge</td> </tr> <tr> <td class=\"indent1\">Tropical ulcer </td> <td>Painful ulcer, necrotic</td> </tr> <tr> <td class=\"indent1\">Tularemia </td> <td>Ulceroglandular; ulcer at site of inoculation</td> </tr> <tr> <td class=\"indent1\">Yaws </td> <td>Papule ulcerates</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Protozoa </td> </tr> <tr> <td class=\"indent1\">Amebiasis </td> <td>Rapidly growing, painful necrotic ulcers</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis </td> <td>Painless, rolled edge; chronic; single or multiple</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other </td> </tr> <tr> <td class=\"indent1\">Brown recluse spider bite </td> <td>Painful, edema, erythema; necrotic eschar</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56355 Version 2.0</div></div></div>"},"56356":{"type":"graphic_figure","displayName":"Clopidogrel outcome in CURE","title":"Clopidogrel improves outcome in an acute coronary syndrome","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Clopidogrel improves outcome in an acute coronary syndrome</div><div class=\"cntnt\"><img style=\"width:522px; height:324px;\" src=\"images/CARD/56356_Clopidogrel_outcome_in_CURE.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the CURE trial, 12,562 patients with an acute coronary syndrome were randomly assigned to clopidogrel or placebo in combination with aspirin. After a one-year follow-up, the incidence of the first primary outcome (cardiovascular death, nonfatal myocardial infarction, or stroke) was significantly lower with clopidogrel (9.3 versus 11.4 percent for placebo). This benefit was largely due to fewer nonfatal infarctions.</div><div class=\"graphic_reference\">Data from Yusuf S, Zhao F, Mehta HR, et al. N Engl J Med 2001; 345:494</div><div id=\"graphicVersion\">Graphic 56356 Version 3.0</div></div></div>"},"56359":{"type":"graphic_diagnosticimage","displayName":"Serial MRI sCJD","title":"Serial MRI of sporadic CJD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serial MRI of sporadic CJD</div><div class=\"cntnt\"><img style=\"width:433px; height:441px;\" src=\"images/NEURO/56359_Serial_MRI_sCJD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Head MRI of a 34-year-old woman with pathologically proven sporadic CJD. The initial T2 MRI (Figure A) shows barely perceptible asymmetric hyperintensity in the bilateral caudate and putamen, more prominent on the right. Initial diffusion-weighted MRI (DWI) shows more obvious hyperintensity in the bilateral caudate and putamen, again more prominent on the right (Figure B). DWI also shows slight hyperintensity in the medial frontal lobe cortices (Figure C). MRI two weeks later shows more apparent increased signal intensity within the bilateral basal ganglia on T2 (Figure D) and especially FLAIR images (Figure G) with characteristic posterior progression and involvement of the putamen. DWI images show increased signal intensity within the left basal ganglia (Figure E) and medial frontal lobe cortices (Figure F), with new involvement of the posterior right frontal lobe (Figure F). The FLAIR image (Figure H) shows slightly increased signal intensity in the medial frontal lobes and possibly in the posterior right frontal lobe, but the conspicuity of these abnormal regions is better appreciated on the corresponding DWI image (Figure F).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CJD: Creutzfeldt-Jakob disease; FLAIR: fluid-attenuated&nbsp;inversion recovery. </div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 56359 Version 3.0</div></div></div>"},"56360":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CXR V","title":"Right paratracheal bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right paratracheal bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:413px;\" src=\"images/PULM/56360_Med_bronchogen_cyst_CXR_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a mass in the right tracheobronchial angle that mimics an enlarged azygos vein.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56360 Version 2.0</div></div></div>"},"56361":{"type":"graphic_figure","displayName":"PCOS androstenedione on OC versus OC-metformin","title":"Serum androstenedione on OC versus OC-metformin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum androstenedione on OC versus OC-metformin</div><div class=\"cntnt\"><img style=\"width:328px; height:412px;\" src=\"images/ENDO/56361_OCP_metformin_adione.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">OC: oral contraceptive pill.</div><div class=\"graphic_reference\">Data from: Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002; 17:1729.</div><div id=\"graphicVersion\">Graphic 56361 Version 4.0</div></div></div>"},"56362":{"type":"graphic_diagnosticimage","displayName":"Cytology bile duct strictures","title":"Cytologic brushing of bile duct strictures","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Cytologic brushing of bile duct strictures</div><div class=\"cntnt\"><img style=\"width:574px; height:270px;\" src=\"images/GAST/56362_Cytology_bile_duct_strictur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiographic picture of cytologic brushing of a distal bile duct stricture secondary to pancreatic cancer (A). Cholangiographic picture of cytologic brushing of a proximal common hepatic duct stricture secondary to metastatic breast cancer (B).</div><div class=\"graphic_reference\">Courtesy of Isaac Raijman, MD and Susana Escalante-Glorsky, MD.</div><div id=\"graphicVersion\">Graphic 56362 Version 2.0</div></div></div>"},"56364":{"type":"graphic_figure","displayName":"Activation of leflunomide","title":"Activation of leflunomide","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Activation of leflunomide</div><div class=\"cntnt\"><img style=\"width:414px; height:326px;\" src=\"images/RHEUM/56364_Activationleflunomideedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leflunomide is converted into its active metabolite A77 1726 (teriflunomide).</div><div class=\"graphic_reference\">Data from: Fox RI, J Rheumatol 1998; 25:20.</div><div id=\"graphicVersion\">Graphic 56364 Version 3.0</div></div></div>"},"56365":{"type":"graphic_table","displayName":"Evaluation metabolic myopathy","title":"Evaluation of the patient with suspected metabolic myopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of the patient with suspected metabolic myopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General investigations</td> </tr> <tr> <td class=\"subtitle2_single\">Blood</td> </tr> <tr> <td class=\"indent1\">Creatinine kinase blood level (at rest, during episodes)</td> </tr> <tr> <td class=\"indent1\">Lactate, pyruvate, LDH, LFTs, uric acid</td> </tr> <tr> <td class=\"indent1\">CBC, electrolytes, glucose</td> </tr> <tr> <td class=\"indent1\">Lactate, pyruvate, and lactate/pyruvate ratio</td> </tr> <tr> <td class=\"indent1\">ALT, AST, LDH</td> </tr> <tr> <td class=\"indent1\">Carnitine - free, total, and free/total ratio</td> </tr> <tr> <td class=\"indent1\">Ketones</td> </tr> <tr> <td class=\"indent1\">Myoglobin</td> </tr> <tr> <td class=\"indent1\">Ca, K, PO4</td> </tr> <tr> <td class=\"subtitle2_single\">Urine</td> </tr> <tr> <td class=\"indent1\">Myoglobin</td> </tr> <tr> <td class=\"indent1\">Ketones</td> </tr> <tr> <td class=\"subtitle1_single\">Specific investigations</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac evaluation</td> </tr> <tr> <td class=\"indent1\">Electrocardiography</td> </tr> <tr> <td class=\"indent1\">Echocardiography</td> </tr> <tr> <td class=\"subtitle2_single\">Lipid metabolism defects</td> </tr> <tr> <td class=\"indent1\">Plasma carnitine - free, total, free/total ratio</td> </tr> <tr> <td class=\"indent1\">Serum acylcarnitines, free fatty acids</td> </tr> <tr> <td class=\"indent1\">Serum glucose, ammonia, ketones</td> </tr> <tr> <td class=\"indent1\">Serum free fatty acid/ketone ratio</td> </tr> <tr> <td class=\"indent1\">Urine dicarboxylic acids</td> </tr> <tr> <td class=\"indent1\">Urine acylglycines and organic acids</td> </tr> <tr> <td class=\"indent1\">Skin fibroblast culture for enzyme assay</td> </tr> <tr> <td class=\"indent1\">Electromyography and nerve conduction studies</td> </tr> <tr> <td class=\"indent1\">Biochemical and/or molecular studies</td> </tr> <tr> <td class=\"subtitle2_single\">Glycolytic/glycogenolytic defects</td> </tr> <tr> <td class=\"indent1\">CBC, reticulocyte count, bilirubin</td> </tr> <tr> <td class=\"indent1\">Electromyography and nerve conduction studies</td> </tr> <tr> <td class=\"indent1\">Muscle and skin biopsies for histology and enzyme assays</td> </tr> <tr> <td class=\"indent1\">Biochemical and/or molecular studies</td> </tr> <tr> <td class=\"subtitle2_single\">Mitochondrial defects</td> </tr> <tr> <td class=\"indent1\">Other system evaluation (eg, endocrine, cardiac)</td> </tr> <tr> <td class=\"indent1\">Serum lactate, pyruvate, lactate/pyruvate ratio</td> </tr> <tr> <td class=\"indent1\">CSF lactate, pyruvate, and lactate/pyruvate ratio</td> </tr> <tr> <td class=\"indent1\">Urine organic acids</td> </tr> <tr> <td class=\"indent1\">MRI spectroscopy of muscle and brain</td> </tr> <tr> <td class=\"indent1\">Electromyography and nerve conduction studies</td> </tr> <tr> <td class=\"indent1\">Muscle and skin biopsies for histology and enzyme assays </td> </tr> <tr> <td class=\"indent1\">Biochemical and/or molecular studies</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: serum alanine aminotransferase; AST: serum aspartate aminotransferase; CBC: complete blood count; CSF: cerebrospinal fluid; LDH: lactate dehydrogenase; LFT: liver function tests; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 56365 Version 2.0</div></div></div>"},"56367":{"type":"graphic_picture","displayName":"Necrolytic migratory erythema perineum","title":"Necrolytic migratory erythema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrolytic migratory erythema</div><div class=\"cntnt\"><img style=\"width:400px; height:519px;\" src=\"images/DERM/56367_Necrolytic_migratory_erythema_perineum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous patches and erosions with peripheral crusts on the perineum in a&nbsp;patient with necrolytic migratory erythema.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56367 Version 5.0</div></div></div>"},"56368":{"type":"graphic_picture","displayName":"Ankle position for US","title":"Positions for puncture of tibiotalar joint with ultrasound guidance","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Positions for puncture of tibiotalar joint with ultrasound guidance</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/RHEUM/56368_Ankle_pos_US_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient and needle positioning for puncture of tibio-talar joint.</div><div class=\"graphic_reference\">Reproduced with permission from: George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 56368 Version 1.0</div></div></div>"},"56369":{"type":"graphic_waveform","displayName":"J wave","title":"J or Osborn wave","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">J or Osborn wave</div><div class=\"cntnt\"><img style=\"width:418px; height:266px;\" src=\"images/EM/56369_Jwave.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ECG change with hypothermia, including presence of J wave.</div><div class=\"graphic_reference\">Reproduced with permission from: Hickey R, De Caen A. Warming Procedures. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56369 Version 11.0</div></div></div>"},"56371":{"type":"graphic_movie","displayName":"Aortic regurgitation as heard at the apex","title":"Phonocardiogram of aortic regurgitation as heard at the apex","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phonocardiogram of aortic regurgitation as heard at the apex</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/56371_aorapexconv.mp4\" style=\"width:410px;height:474px\"></div><img style=\"width:404px; height:247px;\" src=\"images/CARD/56371_aorapex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carotid artery pulse tracing and phonocardiogram of aortic regurgitation as heard at the apex. There is a fourth heart sound (S4) heard prior to S1 (mitral and tricuspid valve closure) and the upstroke of the carotid arterial pulses. This is the result of atrial contraction into the \"stiffened\" left ventricle. Following S1 is a short systolic ejection murmur&nbsp;that results from the large stroke volume seen in aortic regurgitation.</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 56371 Version 4.0</div></div></div>"},"56374":{"type":"graphic_figure","displayName":"Complement pathways","title":"Complement pathways","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Complement pathways</div><div class=\"cntnt\"><img style=\"width:512px; height:494px;\" src=\"images/ALLRG/56374_Complementpathways.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are three major independent yet overlapping pathways for complement activation. In the classical pathway, immune complexes (Ag-Ab complexes) bind C1 via its C1q subcomponent, while its C1s protease subunit cleaves C4 and C2. The large C4b fragment binds to a target and subsequently captures the large fragment of C2 (C2a). This bimolecular complex forms an enzyme (the C3 convertase, C4bC2a) that cleaves C3 to C3b and releases the anaphylatoxin, C3a<FONT color=black>. The binding of another C3b to the convertase (C4bC2aC3b) generates the C5 convertase.</FONT><br />The lectin pathway is an analogous system, except that the initiating step is the binding by lectins to repetitive sugars on microbial surfaces. <FONT color=black>Mannose</FONT><FONT color=black>-</FONT>associated serine proteases (MASPs) take the place of the C1 proteases.<br />The alternative pathway (AP) continuously self-activates at a low level (a process called C3 tickover) to generate C3b that deposits on pathogens or debris. C3b engages the alternative pathway components, factors B (FB) and D (FD), to form a C3 convertase (C3bBb), which in turn cleaves more C3 to C3b. The binding by another C3b to the C3 convertase generates the C5 convertase (C3bBbC3b). Properdin (P) is a positive regulator that stabilizes both the AP C3 and C5 convertases. The latter subsequently cleaves C5 to release the potent anaphylatoxin C5a, while C5b engages the terminal pathway and initiates the formation of the lytic membrane attack complex (MAC). The complement system is designed to function most efficiently on a biologic membrane.</div><div id=\"graphicVersion\">Graphic 56374 Version 7.0</div></div></div>"},"56375":{"type":"graphic_table","displayName":"Causes of third nerve palsy","title":"Acquired third nerve lesions: most common causes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acquired third nerve lesions: most common causes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Location of the lesion</td>\n\t\t\t\t\t<td class=\"subtitle1\">Associated symptoms/signs</td>\n\t\t\t\t\t<td class=\"subtitle1\">Most common causes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Nucleus</td>\n\t\t\t\t\t<td>Complete ipsilateral third plus contralateral ptosis and contralateral superior rectus weakness</td>\n\t\t\t\t\t<td><p>Infarction</p>\n\t\t\t\t\t\t<p>Hemorrhage</p>\n\t\t\t\t\t\t<p>Tumor</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Fascicles</td>\n\t\t\t\t\t<td><p>Contralateral hemiparesis (Weber's syndrome)</p>\n\t\t\t\t\t\t<p>Contralateral tremor (Benedikt's syndrome)</p>\n\t\t\t\t\t\t<p>Ipsilateral ataxia (Nothnagel's syndrome)</p></td>\n\t\t\t\t\t<td><p>Infarction</p>\n\t\t\t\t\t\t<p>Hemorrhage</p>\n\t\t\t\t\t\t<p>Tumor</p>\n\t\t\t\t\t\t<p>Demyelination</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Subarachnoid space</td>\n\t\t\t\t\t<td><p>Typically isolated</p>\n\t\t\t\t\t\t<p>May present with headaches or orbital pain</p></td>\n\t\t\t\t\t<td><p>ICA/Pcom A/Basilar/PCA Aneurysm</p>\n\t\t\t\t\t\t<p>Microvascular (ischemic)</p>\n\t\t\t\t\t\t<p>Tumor (pituitary, carcinomatous meningitis)</p>\n\t\t\t\t\t\t<p>Meningitis</p>\n\t\t\t\t\t\t<p>Herniation</p>\n\t\t\t\t\t\t<p>Trauma</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cavernous sinus</td>\n\t\t\t\t\t<td><p>Cranial nerves IV, VI, V1, V2</p>\n\t\t\t\t\t\t<p>Oculosympathetic dysfunction (Horner)</p>\n\t\t\t\t\t\t<p>Pain may be prominent</p></td>\n\t\t\t\t\t<td><p>Tumor</p>\n\t\t\t\t\t\t<p>Inflammation</p>\n\t\t\t\t\t\t<p>Carotid aneurysm</p>\n\t\t\t\t\t\t<p>Microvascular (ischemic)</p>\n\t\t\t\t\t\t<p>Thrombosis</p>\n\t\t\t\t\t\t<p>Arteriovenous fistula</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Orbital apex</td>\n\t\t\t\t\t<td><p>Proptosis</p>\n\t\t\t\t\t\t<p>Visual loss</p>\n\t\t\t\t\t\t<p>Cranial nerves IV, VI, V1, V2</p>\n\t\t\t\t\t\t<p>Oculosympathetic dysfunction (Horner)</p>\n\t\t\t\t\t\t<p>Pain may be prominent</p></td>\n\t\t\t\t\t<td><p>Trauma</p>\n\t\t\t\t\t\t<p>Tumor</p>\n\t\t\t\t\t\t<p>Inflammation</p>\n\t\t\t\t\t\t<p>Infection (fungus)</p></td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">ICA: internal carotid artery; Pcom A: posterior communicating artery; PCA: posterior cerebral artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Biousse V, Newman NJ. Third Nerve Palsies. Semin Neurol 2000; 20:55. Copyright &#169; 2000 Theime Medical Publishers.</div><div id=\"graphicVersion\">Graphic 56375 Version 6.0</div></div></div>"},"56376":{"type":"graphic_diagnosticimage","displayName":"Hip osteoarthritis","title":"Hip osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip osteoarthritis</div><div class=\"cntnt\"><img style=\"width:261px; height:323px;\" src=\"images/RHEUM/56376_Hip_osteoarthritis_x_ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph of the right hip joint demonstrates marked joint space narrowing, sclerosis about opposing joint space margins, and periarticular osteophyte formation. These features are all characteristic of osteoarthritis.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 56376 Version 2.0</div></div></div>"},"56377":{"type":"graphic_table","displayName":"Anticoagulation regimens in pregnancy","title":"Anticoagulation regimen definitions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticoagulation regimen definitions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Management type</td> <td class=\"subtitle1\">Dosage</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Prophylactic LMWH*</td> <td>Enoxaparin, 40 mg SC once daily</td> </tr> <tr> <td>Dalteparin, 5000 units SC once daily</td> </tr> <tr> <td class=\"divider_bottom\">Tinzaparin, 4500 units SC once daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Therapeutic LMWH<sup>&#182;</sup> (also referred to as weight-adjusted, full-treatment dose)</p> </td> <td>Enoxaparin, 1 mg/kg every 12 hours</td> </tr> <tr> <td>Dalteparin, 200 units/kg once daily</td> </tr> <tr> <td>Tinzaparin, 175 units/kg once daily</td> </tr> <tr> <td class=\"divider_bottom\">Dalteparin, 100 units/kg every 12 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Minidose prophylactic UFH</td> <td>UFH, 5000 units SC every 12 hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Prophylactic UFH</td> <td>UFH, 5000 to 10,000 units SC every 12 hours</td> </tr> <tr> <td>UFH, 5000 to 7500 units SC every 12 hours in first trimester</td> </tr> <tr> <td>UFH, 7500 to 10,000 units SC every 12 hours in the second trimester</td> </tr> <tr> <td class=\"divider_bottom\">UFH, 10,000 units SC every 12 hours in the third trimester, unless the aPTT is elevated</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Therapeutic UFH (also referred to as weight-adjusted, full-treatment dose)</p> </td> <td>UFH, 10,000 units or more SC every 12 hours in doses adjusted to target aPTT in the therapeutic range (1.5 to 2.5) six hours after injection</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Postpartum anticoagulation</td> <td>Prophylactic LMWH/UFH for four to six weeks</td> </tr> <tr> <td><strong>OR</strong></td> </tr> <tr> <td class=\"divider_bottom\">Vitamin K antagonists for four to six weeks with a target INR of 2.0 to 3.0, with initial UFH or LMWH therapy overlap until the INR is 2.0 or more for two days</td> </tr> <tr> <td>Surveillance<sup>&#916;</sup></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In addition, the American College of Chest Physicians (ACCP) provides the option of intermediate dosing. Intermediate-dose UFH refers to doses adjusted to target a specific anti-Xa UFH level. Examples of intermediate-dose LMWH include dalteparin 5000 units subcutaneously every 12 hours or enoxaparin 40 mg subcutaneously every 12 hours. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. February 2012.<br />NOTE: Tinzaparin is not available in the United States.<br />The role and frequency of anti-Xa level testing for management of therapeutic dosing of LMWH in pregnancy are reviewed in the UpToDate topic on anticoagulation in pregnancy.</div><div class=\"graphic_footnotes\">LMWH: low molecular weight heparin; SC: subcutaneously; UFH: unfractionated heparin; aPTT: activated partial thromboplastin time; INR: international normalized ratio.<br />* Although at extremes of body weight, modification of dose may be required.<br />&para; May target an anti-Xa level in the therapeutic range of 0.6 to 1.0 units/mL for twice daily regimen; slightly higher doses may be needed for a once-daily regimen.<br />&Delta; Clinical vigilance and appropriate objective investigation of women with symptoms suspicious of deep vein thrombosis or pulmonary embolism may be needed.</div><div class=\"graphic_reference\">Reprinted with permission from Thromboembolism in pregnancy. Practice Bulletin No. 138. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013; 122:706-17. Copyright © 2013.</div><div id=\"graphicVersion\">Graphic 56377 Version 19.0</div></div></div>"},"56381":{"type":"graphic_algorithm","displayName":"Dx biliary obstruction","title":"Evaluation of suspected biliary obstruction after liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation of suspected biliary obstruction after liver transplantation</div><div class=\"cntnt\"><img style=\"width:432px; height:474px;\" src=\"images/GAST/56381_Dx_biliary_obstruction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagnostic algorithm for the evaluation of suspected biliary obstruction after liver transplantation.</div><div class=\"graphic_footnotes\">HA: hepatic artery; CT: computed tomography; RUQ: right upper quadrant; US: ultrasound; MRCP: magnetic resonance cholangiopancreatography; ERC: endoscopic retrograde cholangiography; PTC: percutaneous transhepatic cholangiography.<br />* Abnormal liver enzymes include: aspartate aminotransferase; alanine aminotransferase; total bilirubin; alkaline phosphatase, and gamma glutamyltransferase.</div><div class=\"graphic_reference\">Courtesy of Andres C&aacute;rdenas, MD, MMSc.</div><div id=\"graphicVersion\">Graphic 56381 Version 2.0</div></div></div>"},"56383":{"type":"graphic_figure","displayName":"Transcervical CVS","title":"Technique for transcervical chorionic villus sampling (CVS)","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Technique for transcervical chorionic villus sampling (CVS)</div><div class=\"cntnt\"><img style=\"width:534px; height:483px;\" src=\"images/OBGYN/56383_Transcervical_CVS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the transcervical CVS technique, the physician guides a cannula (a small tube used for collection of the chorionic villi) through the vagina into the placenta under ultrasound guidance.</div><div id=\"graphicVersion\">Graphic 56383 Version 3.0</div></div></div>"},"56384":{"type":"graphic_waveform","displayName":"ECG Mahaim fiber tachycardia","title":"12-lead electrocardiogram (ECG) consistent with Mahaim fiber tachycardia","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) consistent with Mahaim fiber tachycardia</div><div class=\"cntnt\"><img style=\"width:498px; height:269px;\" src=\"images/CARD/56384_Mahaim_fiber_tachycardia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram from a patient with an atrioventricular reentrant tachycardia due to a Mahaim accessory pathway. The QRS complexes are wide with a left bundle branch block morphology and left axis deviation; these changes are characteristic of a Mahaim fiber tachycardia.</div><div id=\"graphicVersion\">Graphic 56384 Version 3.0</div></div></div>"},"56387":{"type":"graphic_diagnosticimage","displayName":"Pleural hematoma II CT","title":"Pleural hematoma in right hemithorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural hematoma in right hemithorax</div><div class=\"cntnt\"><img style=\"width:360px; height:285px;\" src=\"images/PULM/56387_Pleural_hematoma_II_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spontaneous hemorrhage in an anticoagulated patient. The right effusion has high attenuation due to the fresh blood. The left pleural effusion is transudative and has lower attenuation.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56387 Version 2.0</div></div></div>"},"56391":{"type":"graphic_figure","displayName":"External ventricular device","title":"External ventricular drain","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">External ventricular drain</div><div class=\"cntnt\"><img style=\"width:534px; height:452px;\" src=\"images/NEURO/56391_External_ventricular_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An external ventricular drain (EVD) is a small catheter inserted through the skull usually into the lateral ventricle, which is typically connected to a closed collecting device to allow for drainage of cerebrospinal fluid. The EVD can also be connected to a transducer that records intracranial pressure.</div><div id=\"graphicVersion\">Graphic 56391 Version 1.0</div></div></div>"},"56392":{"type":"graphic_table","displayName":"PA catheter insertion sites","title":"Comparison among pulmonary artery (PA) catheter insertion sites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison among pulmonary artery (PA) catheter insertion sites</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"3\" width=\"8%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Insertion site</td> <td class=\"subtitle1\" colspan=\"3\">Distance (cm) to:</td> <td class=\"subtitle1\" rowspan=\"2\">Advantages</td> <td class=\"subtitle1\" rowspan=\"2\">Disadvantages</td> </tr> <tr> <td class=\"subtitle2\">RA</td> <td class=\"subtitle2\">RV</td> <td class=\"subtitle2\">PA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Internal jugular (IJ)</td> <td class=\"divider_bottom centered\" rowspan=\"3\">15 to 20</td> <td class=\"divider_bottom centered\" rowspan=\"3\">30</td> <td class=\"divider_bottom centered\" rowspan=\"3\">40</td> <td>Easy to float, esp from right</td> <td>Puncture of carotid relatively common</td> </tr> <tr> <td>Easy to cannulate</td> <td>Risk of pneumothorax</td> </tr> <tr class=\"divider_bottom\"> <td>Easy to see and compress on ultrasound</td> <td>Higher likelihood of contamination with respiratory secretions</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Subclavian</td> <td class=\"divider_bottom centered\" rowspan=\"2\">15 to 20</td> <td class=\"divider_bottom centered\" rowspan=\"2\">30</td> <td class=\"divider_bottom centered\" rowspan=\"2\">40</td> <td>Easy to float, esp from left</td> <td class=\"divider_bottom\" rowspan=\"2\">Higher risk of pneumothorax than with IJ approach</td> </tr> <tr class=\"divider_bottom\"> <td>Easy to cannulate</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Femoral</td> <td class=\"divider_bottom centered\" rowspan=\"2\">45</td> <td class=\"divider_bottom centered\" rowspan=\"2\">55</td> <td class=\"divider_bottom centered\" rowspan=\"2\">65</td> <td>Easy to cannulate</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>More difficult to float catheter (may require fluoroscopy)</p> <p>Higher risk of infection</p> Higher risk of DVT</td> </tr> <tr class=\"divider_bottom\"> <td>Fewer major complications</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"6\">Brachial</td> </tr> <tr> <td class=\"indent1\">Right</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td>Few major complications</td> <td>More time-consuming</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Left</td> <td class=\"centered\" rowspan=\"3\">50</td> <td class=\"centered\" rowspan=\"3\">60</td> <td class=\"centered\" rowspan=\"3\">70</td> <td>Safer if bleeding diathesis or coagulopathy</td> <td>Difficult to float catheter</td> </tr> <tr> <td rowspan=\"2\">May be easiest in morbidly obese patients</td> <td>Lower rate of successful cannulation</td> </tr> <tr> <td>Limited to 72 hour duration due to phlebitis and infection risk</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RA: right atrium; RV: right ventricle; PA: pulmonary artery; DVT: deep vein thrombosis.</div><div id=\"graphicVersion\">Graphic 56392 Version 3.0</div></div></div>"},"56393":{"type":"graphic_figure","displayName":"Antibody (immunoglobulin) structure","title":"Antibody (immunoglobulin) structure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Antibody (immunoglobulin) structure</div><div class=\"cntnt\"><img style=\"width:356px; height:261px;\" src=\"images/ALLRG/56393_Antibodystructureedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An immunoglobulin molecule is composed of four chains: two identical light chains, shown on the inner aspects of the molecule (in blue and gray), and two identical heavy chains, shown along the outer aspect of the molecule (in red and tan). Each chain is made up of immunoglobulin domains, represented as circles, and contains an internal disulfide bond (not shown). There are usually multiple disulfide bonds linking the two H chains in the hinge region and also a disulfide linking the H and L chains. Only IgG, IgA, and IgD have distinct hinge regions, and only IgM and IgE have four H chain domains. The points of cleavage of the enzymes pepsin and papain are shown. The CS is formed by structures contributed by the variable regions of both the heavy chain (VH) and light chain (VL).</div><div class=\"graphic_footnotes\">VL: variable region of the light chain; CS: combining site; CL: constant region of the light chain; VH: variable region of the heavy chain; CH: constant region of the heavy chain; Ig: immunoglobulin.</div><div id=\"graphicVersion\">Graphic 56393 Version 12.0</div></div></div>"},"56394":{"type":"graphic_figure","displayName":"Fat distribution and NIDDM","title":"Obesity and fat distribution impair glucose tolerance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Obesity and fat distribution impair glucose tolerance</div><div class=\"cntnt\"><img style=\"width:450px; height:247px;\" src=\"images/ENDO/56394_Fat_distribution_and_NIDDM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serial changes in blood glucose concentrations during an oral glucose tolerance test in nine patients with upper body obesity, 16 patients with lower body obesity, and nine normal subjects. Both obese groups had impaired glucose tolerance, but the abnormality was more pronounced in the group with upper body obesity. The degree of glucose intolerance underestimated the degree of insulin resistance, since peak serum insulin concentrations were also much higher in the group with upper body obesity (225 µU/mL versus 115 and 65 µU/mL in the other two groups). To convert blood glucose to mmol/L, divide by 18; to convert serum insulin to pmol/L, multiply by 6.</div><div class=\"graphic_reference\">Data from: Kissebah A, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54:254.</div><div id=\"graphicVersion\">Graphic 56394 Version 2.0</div></div></div>"},"56396":{"type":"graphic_algorithm","displayName":"Dx workup FM","title":"Recommended diagnostic workup for fibromyalgia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Recommended diagnostic workup for fibromyalgia</div><div class=\"cntnt\"><img style=\"width:375px; height:269px;\" src=\"images/RHEUM/56396_Dx_workup_FM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Establishing the diagnosis is an essential component of FM management. Diagnostic criteria for FM include the ACR and the Canadian Consensus Guidelines. A complete history, physical exam, and laboratory testing should be done to exclude diseases that may mimic or complicate FM. Each patient should be assessed for a ≥three-month history of chronic widespread pain; patient self-report should be used as an index of pain. The presence of tender points should be confirmed. However, tenderness is subjective and depends upon the examiner's strength of palpation.</div><div class=\"graphic_footnotes\">CBC: complete blood count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TSH: thyroid-stimulating hormone; CK: creatine kinase; FM: fibromyalgia; ACR: American College of Rheumatology.</div><div class=\"graphic_reference\">Adapted from: Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292:2388.</div><div id=\"graphicVersion\">Graphic 56396 Version 5.0</div></div></div>"},"56397":{"type":"graphic_table","displayName":"Microcephaly deletion and duplication syndromes","title":"Selected microdeletion and microduplication syndromes that can feature microcephaly*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected microdeletion and microduplication syndromes that can feature microcephaly*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Chromosomal location</td> <td class=\"subtitle1\">Features</td> </tr> <tr> <td>1q21.1 deletion</td> <td>Moderate/mild learning difficulties, heart defects, cataract (1q21.1 duplications associated with macrocephaly)</td> </tr> <tr> <td>1q44 subtelomeric deletion</td> <td>Callosal agenesis, severe microcephaly, epilepsy</td> </tr> <tr> <td>2q31.1 deletion</td> <td>Neurological and behavioral characteristics of MBD5 haploinsufficiency plus craniofacial dysmorphism, microcephaly, small hands and feet, hyperphagia</td> </tr> <tr> <td>5q35 microduplication (reciprocal to the Sotos syndrome/NSD1 common deletion)</td> <td>Short stature, delayed bone age, speech delay, and mild or no dysmorphism (opposite of Sotos syndrome?)</td> </tr> <tr> <td>6q25 deletion</td> <td>Callosal agenesis, facial dysmorphisms, hearing loss</td> </tr> <tr> <td>9q34 deletion</td> <td>Mental retardation, minor facial dysmorphisms, epilepsy; EHMT1 haploinsufficiency implicated</td> </tr> <tr> <td>16p11.2 deletion and duplication</td> <td>Autism and macrocephaly with deletion 16p11.2; attention deficit hyperactivity and microcephaly with duplication 16p11.2; epilepsy</td> </tr> <tr> <td>17q23.1q23.2 microdeletion</td> <td>Speech delay, microcephaly, growth retardation, dysmorphisms (heart, hands, limbs), abnormalities</td> </tr> <tr> <td>22q13.3 deletion</td> <td>Severe mental retardation and speech deficits, minimal dysmorphism (SHANK3 and other genes implicated)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Note that the clinical findings other than microcephaly often are unremarkable, so array comparative genomic hybridization (CGH) is usually required for diagnosis. Additional information on emerging genomic disorders is available at: <a href=\"https://decipher.sanger.ac.uk/application/syndrome\" target=\"_blank\">https://decipher.sanger.ac.uk/application/syndrome</a>.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Mefford HC, Sharp AJ, Baker C, et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med 2008; 359:1685. </li>&#xD;&#xA;    <li>Brunetti-Pierri N, Berg JS, Scaglia F, et al. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet 2008; 40:1466. </li>&#xD;&#xA;    <li>Shimojima K, Okamoto N, Suzuki Y, et al. Subtelomeric deletions of 1q43q44 and severe brain impairment associated with delayed myelination. J Hum Genet 2012; 57:593.</li>&#xD;&#xA;    <li>Talkowski ME, Mullegama SV, Rosenfeld JA, et al. Assessment of 2q23.1 microdeletion syndrome implactes MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am J Hum Genet 2011; 89:551.</li>&#xD;&#xA;    <li>Franco LM, de Ravel T, Graham BH, et al. A syndrome of short stature, microcephaly and speech delay is associated with duplications reciprocal to the common Sotos syndrome deletion. Eur J Hum Genet 2010; 18:258. </li>&#xD;&#xA;    <li>Kleefstra T, van Zelst-Stams WA, Nillesen WM, et al. Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype. J Med Genet 2009; 46:598. </li>&#xD;&#xA;    <li>Nagamani SC, Erez A, Eng C, et al. Interstitial deletion of 6q25.2-q25.3: a novel microdeletion syndrome associated with microcephaly, developmental delay, dysmorphic features and hearing loss. Eur J Hum Genet 2009; 17:573. </li>&#xD;&#xA;    <li>Shinawi M, Liu P, Kang SH, et al. Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioral problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet 2010; 47:332. </li>&#xD;&#xA;    <li>Ballif BC, Theisen A, Rosenfeld JA, et al. Identification of a recurrent microdeletion at 17q23.1q23.2 flanked by segmental duplications associated with heart defects and limb abnormalities. Am J Hum Genet 2010; 86:454. </li>&#xD;&#xA;    <li>Wilson HL, Crolla JA, Walker D, et al. Interstitial 22q13 deletions: genes other than SHANK3 have major effects on cognitive and language development. Eur J Hum Genet 2008; 16:1301. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 56397 Version 6.0</div></div></div>"},"56398":{"type":"graphic_figure","displayName":"Silent ischemia CHD mortality","title":"Silent ischemia increases mortality in patients with coronary risk factors","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Silent ischemia increases mortality in patients with coronary risk factors</div><div class=\"cntnt\"><img style=\"width:454px; height:299px;\" src=\"images/CARD/56398_SIlentischemiaCHDmortali.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 2682 men without known coronary heart disease (CHD) followed for 10 years, the presence of asymptomatic ST segment depression during or after exercise was a predictor of CHD mortality in high-risk men; this association was not seen in low-risk men without risk factors.</div><div class=\"graphic_reference\">Data from: Laukkanen JA, Kurl S, Lakka TA. J Am Coll Cardiol 2001; 38:72.</div><div id=\"graphicVersion\">Graphic 56398 Version 4.0</div></div></div>"},"56399":{"type":"graphic_picture","displayName":"Dog bite uninfected","title":"Uninfected dog bite","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uninfected dog bite</div><div class=\"cntnt\"><img style=\"width:443px; height:210px;\" src=\"images/EM/56399_Dogbiteuninfected.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child was bitten multiple times by a dog in the back (Panel A) and thigh (Panel B).</div><div class=\"graphic_reference\">Reproduced with permission from: Ludwig S (Ed). Bites and stings. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56399 Version 12.0</div></div></div>"},"56400":{"type":"graphic_diagnosticimage","displayName":"Intraarticular fracture of the little toe","title":"Intraarticular fracture of the little toe","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Intraarticular fracture of the little toe</div><div class=\"cntnt\"><img style=\"width:545px; height:316px;\" src=\"images/EM/56400_IA_fx_base_prox_phalanx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On the AP view (panel A), two separate fracture lines can be seen (arrows), indicating this is a comminuted fracture (ie, at least three fracture fragments). On the oblique view (panel B), the fracture fragment at the lateral base of the phalanx can be seen to include more than 25 percent of the joint surface, with a small step-off on the joint surface (arrowhead). The presence of a step-off makes this fracture more prone to complications and referral should be considered. Note also the presence of calcified arteries between the first and second metatarsal: the patient is a diabetic with peripheral neuropathy, who did not realize she had broken her toe.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 56400 Version 4.0</div></div></div>"},"56401":{"type":"graphic_picture","displayName":"Buccal hyperpigmentation","title":"Buccal hyperpigmentation due to ACTH excess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Buccal hyperpigmentation due to ACTH excess</div><div class=\"cntnt\"><img style=\"width:360px; height:230px;\" src=\"images/ENDO/56401_Buccal_hyperpigmentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lips and gums of a 32-year-old man demonstrating hyperpigmentation of the buccal mucosa along the line of dental occlusion (an area of repeated trauma) and of the gums (in the area of chronic inflammatory periodontal disease). The high plasma ACTH concentrations responsible for the hyperpigmentation were due, in this case, to primary adrenal insufficiency; similar changes can be seen in patients with ACTH-dependent Cushing's syndrome or Nelson syndrome.</div><div class=\"graphic_footnotes\">ACTH: corticotropin.</div><div class=\"graphic_reference\">Reprinted with permission from: Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia, 1996.</div><div id=\"graphicVersion\">Graphic 56401 Version 4.0</div></div></div>"},"56402":{"type":"graphic_movie","displayName":"Conduction in right bundle branch block","title":"Development of right bundle branch block","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Development of right bundle branch block</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/56402_condrbbconv.mp4\" style=\"width:408px;height:366px\"></div><img style=\"width:402px; height:348px;\" src=\"images/CARD/56402_condrbbb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sinus node generates an impulse that first activates the atria (becomes red) and then the atrioventricular node. The impulse is then conducted along the bundle of His to the left bundle (becomes red) while it fails to activate the right bundle (which remains blue). As a result, the left ventricle depolarizes normally (becomes red) while right ventricular activation is delayed and abnormal, occurring by impulses from the left ventricle. This accounts for the R' seen in the V1 and the S-wave in V6. Green represents repolarization and the T-wave on the ECG.</div><div class=\"graphic_reference\">Courtesy Entropy, Inc.</div><div id=\"graphicVersion\">Graphic 56402 Version 2.0</div></div></div>"},"56405":{"type":"graphic_table","displayName":"Clinical neurophysiology of myoclonus","title":"Clinical neurophysiology classification of myoclonus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical neurophysiology classification of myoclonus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cortical</td> <td class=\"subtitle1\">Cortical-subcortical</td> <td class=\"subtitle1\">Subcortical-nonsegmental</td> <td class=\"subtitle1\">Segmental</td> <td class=\"subtitle1\">Peripheral</td> </tr> <tr class=\"divider_bottom\"> <td><strong>EEG</strong></td> <td>Variable; some with grossly visible epileptiform discharges and slow waves</td> <td>Generalized spike and wave</td> <td>No consistent findings</td> <td>Normal</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td><strong>EMG</strong></td> <td>Bursts typically &#60;75 ms</td> <td>Bursts &#60;100 ms</td> <td>Variable burst duration</td> <td>Bursts typically &#62;100 ms</td> <td>Variable burst duration; irregular periodicity of discharges is typical</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Back-averaged EEG time-locked to EMG</strong></td> <td>Time-locked correlation almost always present; focal sharp wave 10 to 40 ms before myoclonic jerk is common</td> <td>Time-locked correlation is typical</td> <td>No association</td> <td>No association</td> <td>No association</td> </tr> <tr class=\"divider_bottom\"> <td><strong>SEPs</strong></td> <td>Enlarged cortical component in many cases</td> <td>Enlarged cortical component possible</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td><strong>Long latency EMG reflex response</strong></td> <td>Variable; enhanced long latency reflex (C reflex) typical with cortical reflex myoclonus</td> <td>Some cases have C reflex at rest</td> <td>Some cases have reflex response to sound</td> <td>Variable; some are very short latency and incompatible with supraspinal origin</td> <td>Normal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EEG: electroencephalography; EMG: surface electromyography; SEPs: somatosensory evoked potentials.</div><div class=\"graphic_reference\">Data from: Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004; 3:598.</div><div id=\"graphicVersion\">Graphic 56405 Version 5.0</div></div></div>"},"56406":{"type":"graphic_diagnosticimage","displayName":"MRI MPNST","title":"MRI MPNST","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI MPNST</div><div class=\"cntnt\"><img style=\"width:285px; height:563px;\" src=\"images/NEURO/56406_MRIMPNST.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI demonstrating an MPNST in a patient without neurofibromatosis.<br />(A) T2 imaging shows tumor (arrows) with inhomogeneous signal intensity with areas of high, intermediate and low signal in a large mass.<br />(B) T1 image of the same tumor exhibiting signal intensity similar to muscle.<br />(C) T1 imaging of the same tumor in an axial view (arrow).<br />(D) T1 postgadolinium showing minimal and somewhat irregular enhancement.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MPNST: malignant peripheral nerve sheath tumor.</div><div class=\"graphic_reference\">Courtesy of James M Gilchrist, MD.</div><div id=\"graphicVersion\">Graphic 56406 Version 4.0</div></div></div>"},"56408":{"type":"graphic_figure","displayName":"TEP access direct vision","title":"TEP access direct vision","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">TEP access direct vision</div><div class=\"cntnt\"><img style=\"width:500px; height:373px;\" src=\"images/SURG/56408_TEP_access_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Maithel SK, Schneider BE. Atlas of minimally invasive surgery. Ciné-Med, Woodbury, CT 2006. Copyright © 2006 Ciné-Med, Inc.</div><div id=\"graphicVersion\">Graphic 56408 Version 10.0</div></div></div>"},"56410":{"type":"graphic_picture","displayName":"Seborrheic dermatitis face","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:350px; height:247px;\" src=\"images/DERM/56410_Seborrheicdermatitisface.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Facial redness and scale involving the nasolabial folds and central face.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's photoguide of common skin disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56410 Version 4.0</div></div></div>"},"56411":{"type":"graphic_table","displayName":"Chemicals associated with ocular burns","title":"Chemicals commonly associated with ocular burns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemicals commonly associated with ocular burns</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n <tr>\n    <td class=\"subtitle1\">Chemical substance</td>\n    <td class=\"subtitle1\">Typical use</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\" colspan=\"2\">Alkali</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Ammonia hydroxide (anhydrous ammonia)</td>\n    <td><p>Cleansers</p>\n\t\t<p>Fertilizer</p>\n\t\t<p>Hair dyes and tints</p>\n\t\t<p>Floor strippers</p></td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Calcium carbonate or magnesium carbonate</td>\n    <td>Lime soil treatment</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Calcium hydroxide</td>\n    <td>Cement, plaster, or mortar</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\"><p>Sodium hydroxide</p>\n\t\t<p>Potassium hydroxide</p></td>\n    <td><p>Lye cleansers</p>\n\t\t<p>Oven or drain cleaners</p></td>\n  </tr>\n  <tr>\n    <td class=\"indent1\"><p>Sodium hypochlorite (70 percent)</p>\n\t\t<p>Calcium hypochlorite (70 percent)</p></td>\n    <td>Swimming pool cleaner</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Sodium hypochlorite (3 to 15 percent)*</td>\n    <td>Bleach</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Sodium tripolyphosphate</td>\n    <td>Automatic dishwasher detergent</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\" colspan=\"2\">Acids</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Acetic acid</td>\n    <td>Permanent hair wave neutralizers</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Hydrochloric acid (muriatic acid)</td>\n    <td><p>Toilet bowl cleaner</p>\n\t\t<p>Grout cleaner</p>\n\t\t<p>Rust stain remover</p>\n\t\t<p>Swimming pool cleaner</p></td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Hydrofluoric acid</td>\n    <td><p>Glass etching</p>\n\t\t<p>Rust remover</p></td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Phosphoric acid</td>\n    <td><p>Rust remover</p>\n\t\t<p>Toilet bowel cleaner</p></td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Sulfuric acid (30 to 70 percent)</td>\n    <td><p>Toilet bowl cleaner</p>\n\t\t<p>Car battery fluid</p></td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Industrial strength bleach is up to 15 percent concentration.</div><div class=\"graphic_reference\">Data from: Farjo, AA, Soong, HK. Corneal epithelium. In: Ophthalmology, 2nd ed, Yanoff, M, Duker, JS (Eds), Mosby, St. Louis, MO 2004. p. 413.</div><div id=\"graphicVersion\">Graphic 56411 Version 2.0</div></div></div>"},"56412":{"type":"graphic_figure","displayName":"Femoral intraosseous site","title":"Femoral intraosseous access site","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Femoral intraosseous access site</div><div class=\"cntnt\"><img style=\"width:345px; height:526px;\" src=\"images/EM/56412_FemoralIOsite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Entry site at the distal femur.</div><div class=\"graphic_reference\">Reproduced with permission from: Hodge Dee III. Intraosseous infusion. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56412 Version 11.0</div></div></div>"},"56413":{"type":"graphic_figure","displayName":"Action of metyrapone","title":"Action of metyrapone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Action of metyrapone</div><div class=\"cntnt\"><img style=\"width:302px; height:232px;\" src=\"images/ENDO/56413_Action_of_metyrapone.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Metyrapone inhibits cortisol production by blocking the conversion of 11-deoxycortisol to cortisol by 11-beta-hydroxylase (CYP11B1).</div><div id=\"graphicVersion\">Graphic 56413 Version 1.0</div></div></div>"},"56415":{"type":"graphic_figure","displayName":"Normal human axoneme","title":"Normal ciliary structure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal ciliary structure</div><div class=\"cntnt\"><img style=\"width:369px; height:247px;\" src=\"images/PULM/56415_Normal_human_axoneme.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram of the normal human axoneme as it can be seen in respiratory cilia or sperm flagella.</div><div class=\"graphic_reference\">From: Afzelius, BA. Genetics and pulmonary medicine. 6. Immotile cilia syndrome: past, present, and prospects for the future. Thorax 1998 53:894.</div><div id=\"graphicVersion\">Graphic 56415 Version 1.0</div></div></div>"},"56417":{"type":"graphic_waveform","displayName":"Pacer nonsensing tutorial","title":"Pacemaker malfunction - non-sensing","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pacemaker malfunction - non-sensing</div><div class=\"cntnt\"><img style=\"width:407px; height:152px;\" src=\"images/CARD/56417_Pacer_nonsensing_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The second and fourth paced QRS complexes occur earlier than expected based upon the lower rate limit of the pacemaker. The pacemaker has failed to sense the preceding native complexes, and is therefore not inhibited by them. Thus, the pacemaker will fire and stimulate the atria or ventricles at its own predetermined rate, independently of the intrinsic rhythm. The interval between the native and paced complexes is variable while the intervals of the pacing spikes is constant.</div><div id=\"graphicVersion\">Graphic 56417 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"56418":{"type":"graphic_table","displayName":"Dosing of cromolyn and nedocromil in asthma","title":"Initial dosing* of chromones (cromoglycates) in asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial dosing* of&nbsp;chromones (cromoglycates) in asthma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Dose form</td> <td class=\"subtitle1\">Availability</td> <td class=\"subtitle1\">Trade (brand)&nbsp;name</td> <td class=\"subtitle1\">Age 0 to 4</td> <td class=\"subtitle1\">Age 5 to 11</td> <td class=\"subtitle1\">Age 12 through adult</td> </tr> <tr> <td rowspan=\"4\">Cromolyn sodium (sodium cromoglycate)</td> <td> <p>Nebulizer solution: 10 mg per mL in 2 mL sterile ampules</p> </td> <td> <p>United States</p> <p>Canada</p> <p>European Union (some countries)</p> <p>Other countries&nbsp;</p> </td> <td> <p>Various generics&nbsp;</p> </td> <td> <p>&#62;2 years:&nbsp;2 mL (20 mg)&nbsp;nebulization&nbsp;4 times per day</p> <p>&nbsp;</p> </td> <td> <p>2 mL (20 mg) nebulization&nbsp;4 times per day&nbsp;</p> </td> <td> <p>2 mL (20 mg) nebulization&nbsp;4 times daily&nbsp;</p> </td> </tr> <tr> <td> <p>Metered-dose inhaler; 1 mg per puff (CFC free)&nbsp;&nbsp;</p> </td> <td> <p>European Union (some countries)</p> <p>Australia</p> <p>Other countries</p> <p><strong>Not </strong>available in US or Canada</p> </td> <td> <p>Intal CFC free</p> </td> <td>Not studied</td> <td> <p>Two&nbsp;puffs&nbsp;4 times per day</p> </td> <td> <p>Two&nbsp;puffs&nbsp;4 times per day</p> </td> </tr> <tr> <td> <p>Metered-dose inhaler; 5 mg per puff (CFC free)&nbsp;</p> </td> <td> <p>European Union (some countries)</p> <p>Australia</p> <p>Other countries</p> <p><strong>Not </strong>available in US or Canada</p> </td> <td> <p>Intal Forte CFC free</p> </td> <td>Not studied</td> <td>Two puffs&nbsp;2 to&nbsp;4 times&nbsp;per&nbsp;day</td> <td>Two puffs&nbsp;2 to 4 times per day</td> </tr> <tr> <td> <p>Powder for inhalation capsules&nbsp;with spinhaler device; 20 mg per capsule&nbsp;</p> </td> <td> <p>European Union (some countries)</p> <p>Australia</p> <p>Other countries</p> <p><strong>Not </strong>available in US or Canada</p> </td> <td> <p>Intal Spincaps Spinhaler</p> </td> <td>Not studied</td> <td>One inhalation (20 mg) 4 times per day</td> <td>One inhalation (20&nbsp;mg)&nbsp;4 times per day</td> </tr> <tr class=\"divider_top\"> <td>Nedocromil sodium</td> <td> <p>Metered-dose inhaler; 2 mg per puff&nbsp;(CFC free)</p> </td> <td> <p>European Union (some countries)</p> <p>Australia</p> <p>Other countries</p> <p><strong>Not </strong>available in US or Canada</p> </td> <td> <p>Tilade CFC free</p> </td> <td>&#62;2 years:&nbsp;Two puffs&nbsp;4 times per day<sup>&#182;</sup></td> <td>Two&nbsp;puffs&nbsp;4 times per day<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> <td>Two&nbsp;puffs&nbsp;4 times per day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CFC: chlorofluorocarbons.<br />* Usual doses for initiating treatment for asthma symptom prophylaxis are shown in the table. Dose may be adjusted up or downward based upon symptom control and allergen exposure. An additional dose may be given before anticipated trigger exposure. Dose recommendations vary by country; consult local licensed product information before use.<br />¶&nbsp;Not licensed for use in children age&nbsp;&lt;6 years in many countries where it is available.</div><div id=\"graphicVersion\">Graphic 56418 Version 10.0</div></div></div>"},"56419":{"type":"graphic_picture","displayName":"Chilblain lupus","title":"Chilblain lupus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chilblain lupus</div><div class=\"cntnt\"><img style=\"width:360px; height:192px;\" src=\"images/RHEUM/56419_Chilblain_lupus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chilblain lupus characterized by reddish-blue nodules (in this case, on the fingers) occurring in cold weather. The lesions improved after the administration of nifedipine.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 56419 Version 1.0</div></div></div>"},"56422":{"type":"graphic_picture","displayName":"Toe curls PI","title":"Toe curls","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Toe curls</div><div class=\"cntnt\"><img style=\"width:486px; height:369px;\" src=\"images/PI/56422_Toe_curls_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Curl your toes around the edge of a book. Then straighten them. Do this over and over again for 2 minutes, twice a day.</div><div id=\"graphicVersion\">Graphic 56422 Version 2.0</div></div></div>"},"56423":{"type":"graphic_diagnosticimage","displayName":"Cholesteatoma CT","title":"Axial computed tomography (CT) images of cholesteatoma","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Axial computed tomography (CT) images of cholesteatoma</div><div class=\"cntnt\"><img style=\"width:514px; height:513px;\" src=\"images/ALLRG/56423_CholesteatomaCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial CT of a small congential cholesteatoma near the eustachian tube orifice (arrows).<br />(B) Axial CT of moderate-sized congenital cholesteatoma (arrows) deep to the ossicles in the attic.<br />(C) Axial CT of a large cholesteatoma of the mastoid. Arrows outline area of destruction. Asterix shows a breach of the mastoid cortex by infection with subperiosteal abscess.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 120, Pages 603-8, Copyright &copy; 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 56423 Version 19.0</div></div></div>"},"56425":{"type":"graphic_table","displayName":"Differential of chronic fatigue","title":"Major causes of chronic fatigue","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of chronic fatigue</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n   <tr>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Psychologic\n   </td>\n   </tr>\n   <tr>\n   <td>Depression</td>\n   </tr>\n   <tr>\n   <td>Anxiety</td>\n   </tr>\n   <tr>\n   <td>Somatization disorder</td>\n   </tr>\n   <tr>\n   <td>Malnutrition or drug addiction</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Pharmacologic\n   </td>\n   </tr>\n   <tr>\n   <td>Hypnotics</td>\n   </tr>\n   <tr>\n   <td>Antihypertensives</td>\n   </tr>\n   <tr>\n   <td>Antidepressants</td>\n   </tr>\n   <tr>\n   <td>Drug abuse and drug withdrawal</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Endocrine-metabolic\n   </td>\n   </tr>\n   <tr>\n   <td>Hypothyroidism</td>\n   </tr>\n   <tr>\n   <td>Diabetes mellitus</td>\n   </tr>\n   <tr>\n   <td>Apathetic hyperthyroidism</td>\n   </tr>\n   <tr>\n   <td>Pituitary insufficiency</td>\n   </tr>\n   <tr>\n   <td>Hypercalcemia</td>\n   </tr>\n   <tr>\n   <td>Adrenal insufficiency</td>\n   </tr>\n   <tr>\n   <td>Chronic renal failure</td>\n   </tr>\n   <tr>\n   <td>Hepatic failure</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Neoplastic-hematologic\n   </td>\n   </tr>\n   <tr>\n   <td>Occult malignancy</td>\n   </tr>\n   <tr>\n   <td>Severe anemia</td>\n   </tr>\n   </table></td>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Infectious\n   </td>\n   </tr>\n   <tr>\n   <td>Endocarditis</td>\n   </tr>\n   <tr>\n   <td>Tuberculosis</td>\n   </tr>\n   <tr>\n   <td>Mononucleosis</td>\n   </tr>\n   <tr>\n   <td>Hepatitis</td>\n   </tr>\n   <tr>\n   <td>Parasitic disease</td>\n   </tr>\n   <tr>\n   <td>HIV infection</td>\n   </tr>\n   <tr>\n   <td>Cytomegalovirus</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Cardiopulmonary\n   </td>\n   </tr>\n   <tr>\n   <td>Chronic heart failure</td>\n   </tr>\n   <tr>\n   <td>Chronic obstructive pulmonary disease</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Connective tissue disease\n   </td>\n   </tr>\n   <tr>\n   <td>Rheumatoid disease</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Disturbed sleep\n   </td>\n   </tr>\n   <tr>\n   <td>Sleep apnea</td>\n   </tr>\n   <tr>\n   <td>Esophageal reflux</td>\n   </tr>\n   <tr>\n   <td>Allergic rhinitis</td>\n   </tr>\n   <tr>\n   <td>Psychologic causes (see above)</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Idiopathic (diagnosis by exclusion)\n   </td>\n   </tr>\n   <tr>\n   <td>Idiopathic chronic fatigue</td>\n   </tr>\n   <tr>\n   <td>Chronic fatigue syndrome</td>\n   </tr>\n   <tr>\n   <td>Fibromyalgia</td>\n   </tr>\n   </table></td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted from: Gorroll, AH, May, LA, Mulley, AG Jr (Eds), Primary Care Medicine: Office Evaluation and Management of the Adult Patient, 3rd ed, JB Lippincott, Philadelphia, 1995.</div><div id=\"graphicVersion\">Graphic 56425 Version 1.0</div></div></div>"},"56431":{"type":"graphic_diagnosticimage","displayName":"Fifth metacarpal shaft fracture","title":"Mid-shaft fracture of 5th metacarpal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mid-shaft fracture of 5th metacarpal</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/EM/56431_Metacarpal_shaft_fx_two_vie.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An oblique mid-shaft fracture of 5th metacarpal is seen on the anteroposterior view (left panel) and also on the oblique radiograph (right panel).</div><div class=\"graphic_reference\">Courtesy of Josh Bloom, MD, MPH.</div><div id=\"graphicVersion\">Graphic 56431 Version 2.0</div></div></div>"},"56432":{"type":"graphic_figure","displayName":"Fiberoptic nasotracheal intubation","title":"Fiberoptic nasotracheal intubation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fiberoptic nasotracheal intubation</div><div class=\"cntnt\"><img style=\"width:275px; height:635px;\" src=\"images/EM/56432_Fiberopticnasotrachintub.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After nasal application of a topical vasoconstrictor (eg, phenylephrine spray), the endotracheal tube is first inserted until the tip reaches the supraglottic area. Then the fiberoptic bronchoscope is inserted through the tube until the airway landmarks are visualized.</div><div class=\"graphic_reference\">Reproduced with permission from: King BR, Hagberg CA. Management of the difficult airway. In: Textbook of Pediatric Emergency Medicine Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56432 Version 7.0</div></div></div>"},"56434":{"type":"graphic_picture","displayName":"Linear IgA bullous dermatosis","title":"Linear IgA bullous dermatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear IgA bullous dermatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/56434_LinearIgAbullousderm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tense bullae, erosions, and crusts, often in a&nbsp;pattern described as \"clusters of jewels\" or \"strings of pearls,\" on skin of a patient with linear IgA bullous dermatosis.</div><div class=\"graphic_footnotes\">IgA: immunoglobulin A.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56434 Version 8.0</div></div></div>"},"56435":{"type":"graphic_diagnosticimage","displayName":"Sellar mass MRI III","title":"Sellar mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sellar mass</div><div class=\"cntnt\"><img style=\"width:295px; height:289px;\" src=\"images/ENDO/56435_Sellar_mass_MRI_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI shows enhancement of only the rim of a suprasellar mass (M) and of the normal pituitary inferior to it, following the administration of gadolinium. The clear distinction between the mass and the normal pituitary indicates that the mass is not a pituitary adenoma. The mass was found on surgery to be a craniopharyngioma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Peter J Snyder, MD.</div><div id=\"graphicVersion\">Graphic 56435 Version 4.0</div></div></div>"},"56436":{"type":"graphic_table","displayName":"Child-Turcotte classification","title":"Child-Turcotte classification of patients with cirrhosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Child-Turcotte classification of patients with cirrhosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Parameter </td> <td class=\"subtitle1\">A </td> <td class=\"subtitle1\">B </td> <td class=\"subtitle1\">C </td> </tr> <tr> <td>Ascites</td> <td>None</td> <td>Easily controlled</td> <td>Poorly controlled</td> </tr> <tr> <td>Bilirubin</td> <td>&#60;2 mg/dL (&#60;34.2 micromol/liter)</td> <td>2 to 3 mg/dL (34.2 to 51.3 micromol/liter)</td> <td>&#62;3 mg/dL (&#62;51.3 micromol/liter)</td> </tr> <tr> <td>Albumin</td> <td>&#62;3.5 g/dL (&#62;35 g/liter)</td> <td>3.0 to 3.5 g/dL (30 to 35 g/liter)</td> <td>&#60;3.0 g/dL (&#60;30 g/liter)</td> </tr> <tr> <td>Encephalopathy</td> <td>None</td> <td>Mild</td> <td>Advanced</td> </tr> <tr> <td>Nutritional status</td> <td>Excellent</td> <td>Good</td> <td>Poor</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56436 Version 3.0</div></div></div>"},"56437":{"type":"graphic_table","displayName":"Major causes of distal RTA","title":"Major causes of type 1 (distal) renal tubular acidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of type 1 (distal) renal tubular acidosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary</td> </tr> <tr> <td class=\"subtitle2_single\">Idiopathic (sporadic)</td> </tr> <tr> <td class=\"subtitle2_single\">Familial</td> </tr> <tr> <td class=\"indent1\">Autosomal dominant (mainly due to mutations causing defects in the kidney anion exchanger [kAE1] in distal tubule intercalated cells)</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive (mainly due to mutations causing defects in V-ATPase in distal tubule intercalated cells)</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary</td> </tr> <tr> <td class=\"subtitle2_single\">Autoimmune disorders</td> </tr> <tr> <td class=\"indent1\">Sj&#246;gren's syndrome</td> </tr> <tr> <td class=\"indent1\">Autoimmune hepatitis/primary biliary cirrhosis</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus (may be hyperkalemic)</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Ifosfamide</td> </tr> <tr> <td class=\"indent1\">Amphotericin B</td> </tr> <tr> <td class=\"indent1\">Lithium carbonate</td> </tr> <tr> <td class=\"indent1\">Ibuprofen</td> </tr> <tr> <td class=\"subtitle2_single\">Hypercalciuric conditions</td> </tr> <tr> <td class=\"indent1\">Hyperparathyroidism</td> </tr> <tr> <td class=\"indent1\">Vitamin D intoxication</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Idiopathic hypercalciuria</td> </tr> <tr> <td class=\"subtitle2_single\">Other</td> </tr> <tr> <td class=\"indent1\">Medullary sponge kidney</td> </tr> <tr> <td class=\"indent1\">Obstructive uropathy</td> </tr> <tr> <td class=\"indent1\">Renal transplant rejection</td> </tr> <tr> <td class=\"indent1\">Wilson disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56437 Version 9.0</div></div></div>"},"56438":{"type":"graphic_picture","displayName":"Urinary sediment in acute tubular necrosis","title":"Photomicrograph showing urine sediment with muddy brown granular casts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photomicrograph showing urine sediment with muddy brown granular casts</div><div class=\"cntnt\"><img style=\"width:378px; height:252px;\" src=\"images/NEPH/56438_Urine_sediment_in_ATN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing multiple muddy brown granular casts. These findings are highly suggestive of acute tubular necrosis in a patient with acute kidney injury.</div><div class=\"graphic_reference\">Courtesy of Harvard Medical School.</div><div id=\"graphicVersion\">Graphic 56438 Version 6.0</div></div></div>"},"56439":{"type":"graphic_picture","displayName":"Piper type forceps","title":"Piper forceps","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Piper forceps</div><div class=\"cntnt\"><img style=\"width:468px; height:262px;\" src=\"images/OBGYN/56439_Piper_forceps_photo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Piper forceps have long shanks that are separated and slightly curved beyond the lock in order to manage delivery of the aftercoming head in breech presentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright © Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 56439 Version 4.0</div></div></div>"},"56441":{"type":"graphic_table","displayName":"Diseases with impaired smell","title":"Disorders associated with impaired olfaction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders associated with impaired olfaction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder </td> <td class=\"subtitle1\">Percent affected </td> <td class=\"subtitle1\">Smell impairment </td> </tr> <tr> <td>Allergic and viral rhinitis</td> <td>31</td> <td>Anosmia</td> </tr> <tr> <td>Alzheimer disease</td> <td>&#62;90</td> <td>Anosmia</td> </tr> <tr> <td>Cleft palate</td> <td>&nbsp;</td> <td>Anosmia</td> </tr> <tr> <td>Diabetes mellitus</td> <td>&nbsp;</td> <td>Hyposmia to anosmia</td> </tr> <tr> <td>Down syndrome</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Old age</td> <td>5.4 to 50</td> <td>Anosmia</td> </tr> <tr> <td>Head trauma</td> <td>0.5</td> <td>Anosmia</td> </tr> <tr> <td>Hemodialysis</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Herpes virus infection</td> <td>&nbsp;</td> <td>Hyposmia to anosmia</td> </tr> <tr> <td>Human immunodeficiency virus infection</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Huntington disease</td> <td>&nbsp;</td> <td>Anosmia</td> </tr> <tr> <td>Influenza</td> <td>31</td> <td>Anosmia</td> </tr> <tr> <td>Klinefelter syndrome</td> <td>10</td> <td>Partial to total anosmia</td> </tr> <tr> <td>Kallman syndrome</td> <td>3</td> <td>Partial to total anosmia</td> </tr> <tr> <td>Korsakoff syndrome</td> <td>&nbsp;</td> <td>Anosmia</td> </tr> <tr> <td>Malnutrition, zinc deficiency</td> <td>&nbsp;</td> <td>Hyposmia to anosmia</td> </tr> <tr> <td>Nasal polyps</td> <td>&nbsp;</td> <td>Anosmia</td> </tr> <tr> <td>Olfactory neuroblastoma and meningioma</td> <td>&nbsp;</td> <td>Sudden anosmia</td> </tr> <tr> <td>Organic solvent exposure</td> <td>&nbsp;</td> <td>Hyposmia to anosmia</td> </tr> <tr> <td>Parkinson disease</td> <td>&#62;70</td> <td>Anosmia or hyposmia</td> </tr> <tr> <td>Paget disease with facial, maxillomandibular involvement</td> <td>&nbsp;</td> <td>Anosmia</td> </tr> <tr> <td>Pick disease (prefrontal and frontal lobe atrophy)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Temporal lobectomy</td> <td>&nbsp;</td> <td>Anosmia</td> </tr> <tr> <td>Schizophrenia</td> <td>&nbsp;</td> <td>Anosmia</td> </tr> <tr> <td>Shy-Drager syndrome</td> <td>&nbsp;</td> <td>Anosmia</td> </tr> <tr> <td>Sj&#246;gren's syndrome</td> <td>33</td> <td>Hyposmia to anosmia</td> </tr> <tr> <td>Aneurysm or tumor of circle of Willis</td> <td>&nbsp;</td> <td>Sudden anosmia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from Ackerman, BH, Kasbekar, N, Pharmacotherapy 1997; 17:1.</div><div id=\"graphicVersion\">Graphic 56441 Version 2.0</div></div></div>"},"56444":{"type":"graphic_table","displayName":"Rx inflammatory bowel","title":"Aminosalicylate derivative dosages* for active disease and remission maintenance in ulcerative colitis and Crohn disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aminosalicylate derivative dosages* for active disease and remission maintenance in ulcerative colitis and Crohn disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Release of active compound<sup>&#182;</sup></td> <td class=\"subtitle1\" colspan=\"2\">Ulcerative colitis</td> <td class=\"subtitle1\" colspan=\"2\">Crohn colitis</td> <td class=\"subtitle1\" colspan=\"2\">Crohn ileitis</td> </tr> <tr> <td class=\"subtitle2\">Active</td> <td class=\"subtitle2\">Maint</td> <td class=\"subtitle2\">Active</td> <td class=\"subtitle2\">Maint</td> <td class=\"subtitle2\">Active</td> <td class=\"subtitle2\">Maint</td> </tr> <tr> <td>Sulfasalazine [tablet, enteric-coated delayed release tablet]</td> <td>Converted to mesalamine in colon</td> <td>2-4</td> <td>2-4</td> <td>2-4</td> <td>NR</td> <td>NR</td> <td>ID<sup>&#916;</sup></td> </tr> <tr> <td>Asacol&#174;, Asacol HD&#174; [mesalamine tablet, delayed release]</td> <td>Release is delayed until terminal ileum and cecum, then releases as bolus in right colon.</td> <td>2.4-4.8</td> <td>2.4-4.8</td> <td>2.4-4.8</td> <td>2.4-4.8</td> <td>2.4-4.8</td> <td>2.4-4.8</td> </tr> <tr> <td>Pentasa&#174; [mesalamine capsule, extended release]</td> <td>Prolonged release throughout duodenum, jejunum, ileum, and colon. Fifty percent released in small bowel.</td> <td>4</td> <td>2-4</td> <td>4</td> <td>2-4</td> <td>4</td> <td>2-4</td> </tr> <tr> <td>Dipentum&#174; [olsalazine capsule]</td> <td>Converted to mesalamine in colon</td> <td>2-3</td> <td>1</td> <td>2-3</td> <td>1</td> <td>NR</td> <td>NR</td> </tr> <tr> <td>Rowasa&#174;, sfRowasa&#8482; [mesalamine rectal enema]</td> <td>Sigmoid colon, rectum</td> <td>4</td> <td>2-4</td> <td>4</td> <td>ID</td> <td>NR</td> <td>NR</td> </tr> <tr> <td>Apriso&#8482; [mesalamine capsule, 24 hour delayed and extended release]</td> <td>Release occurs at pH &#8805;6, then prolonged throughout colon.</td> <td>1.5-3</td> <td>1.5</td> <td>ID</td> <td>ID</td> <td>ID</td> <td>ID</td> </tr> <tr> <td>Lialda&#174;, Mezavant&#174;, Mezavant XL&#174; [mesalamine multi-maxtrix (MMX) tablet, 24 hour release]</td> <td>Release is delayed until terminal ileum, then designed to release throughout colon, including sigmoid colon and rectum.</td> <td>2.4-4.8</td> <td>2.4</td> <td>ID</td> <td>ID</td> <td>ID</td> <td>ID</td> </tr> <tr> <td>Canasa&#174; [mesalamine rectal suppository]</td> <td>Rectum</td> <td>1</td> <td>1</td> <td>ID</td> <td>ID</td> <td>NR</td> <td>NR</td> </tr> <tr> <td>Colazal&#174; [balsalazide disodium capsule]</td> <td>Converted to mesalamine in colon</td> <td>6.75</td> <td>3-6</td> <td>ID</td> <td>ID</td> <td>NR</td> <td>NR</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Maint: maintenance; ID: insufficient data; NR: not recommended.<br />* Doses shown are total grams per day and must be divided in 3 or 4 equally divided doses for certain formulations. For details, see Lexi-Comp drug information included with UpToDate and the official prescribing information.<br />¶&nbsp;Various formulations with differing release characteristics are available and vary by country. Trade names shown may be specific to US. Mesalazine is the international nonproprietary name for mesalamine.<br />Δ 2-4 grams per day in 3 or 4 equally divided doses used in practice.</div><div id=\"graphicVersion\">Graphic 56444 Version 4.0</div></div></div>"},"56446":{"type":"graphic_figure","displayName":"COPD flow rate frequency","title":"COPD flow rate and frequency","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">COPD flow rate and frequency</div><div class=\"cntnt\"><img style=\"width:579px; height:351px;\" src=\"images/PULM/56446_COPD_flow_rate_frequency.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous recordings of flow, esophageal pressure (Pes), and chest volume (the sum of rib-case and abdominal motion) in a patient with COPD receiving assist-control ventilation with a constant tidal volume. As flow increased from 30 to 60 and 90 L/min (from right to left), frequency increased from (18 to 23 and 26 breaths/min, respectively), Auto-PEEP decreased (from 15.6 to 14.4 and 13.3 cm H2O, respectively) and end-expiratory chest volume also fell. Increases in flow from 30 L/min to 60 and 90 L/min also led to decreases in the swings in Pes from 21.5 to 19.5 and 16.8 cm H2O, respectively.</div><div class=\"graphic_reference\">Adapted with permission from: Laghi, F, Segal, J, Choe, WK, Tobin, MJ. Am J Respir Crit Care Med 2001; 163:1365. Copyright &#169;2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 56446 Version 1.0</div></div></div>"},"56447":{"type":"graphic_diagnosticimage","displayName":"Pseudoalveolar sarcoidosis CT","title":"Sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis</div><div class=\"cntnt\"><img style=\"width:354px; height:250px;\" src=\"images/PULM/56447_Pseudoalveolar_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, ill-defined left perihilar consolidation, unilateral left hilar enlargement, and bilateral peripheral poorly defined nodules are present. These findings are suggestive of the pseudoalveolar form of sarcoidosis. The confluent nodules in the central region of the left lung yield the so-called galaxy sign.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56447 Version 3.0</div></div></div>"},"56450":{"type":"graphic_picture","displayName":"Penicillium marneffei papule","title":"Penicillium marneffei infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penicillium marneffei infection</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/56450_Penic_marneff_pap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous, umbilicated papules were present on the skin of this patient with <EM>Penicillium marneffei </EM>infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56450 Version 4.0</div></div></div>"},"56451":{"type":"graphic_table","displayName":"Rd for multiple myeloma","title":"Lenalidomide (Revlimid) plus dexamethasone (Rd) for multiple myeloma<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lenalidomide (Revlimid) plus dexamethasone (Rd) for multiple myeloma<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Lenalidomide*</td> <td>25 mg by mouth</td> <td>Do not break, chew, or open the capsules.</td> <td>Daily for days 1 through 21</td> </tr> <tr class=\"divider_bottom\"> <td>Dexamethasone</td> <td>40 mg by mouth, once weekly</td> <td>Take with food (after meals or with food or milk) in the morning.</td> <td>Days 1, 8, 15, and 22</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW or VERY LOW.<sup>[2]</sup></li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Routine primary prophylaxis with G-CSF is not indicated (rate of febrile neutropenia &#60;20%). The use of prophylactic antimicrobials is controversial.</li> <li>Refer to UpToDate topics on \"Treatment of the complications of multiple myeloma\" and \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Antithrombotic prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The risk of thrombosis in patients with multiple myeloma treated with the RD regimen is &#62;10%.<sup>[1]</sup> Routine antithrombotic prophylaxis is warranted.</li> <li>Refer to UpToDate topic on \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Patients with renal insufficiency experience more neutropenia with the use of lenalidomide.<sup>[3]</sup> Dose adjustment is recommended for patients with CrCl &#60;60 mL/min.<sup>[2]</sup> Suggested initial doses for patients with renal insufficiency are: <ul> <li>For patients with CrCl 30 to 60 mL/min, start at 10 mg every 24 hours.</li> <li>For patients with CrCl &#60;30 mL/min not requiring dialysis, start at 15 mg every 48 hours.</li> <li>For patients with CrCl &#60;30 mL/min requiring dialysis, start at 5 mg once daily. On dialysis days, administer the dose following dialysis.</li> </ul> </li> <li>At this time, studies have not been conducted in patients with hepatic impairment.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential, electrolytes, renal function, liver function, and M protein prior to starting each cycle.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>If platelets are &#60;30,000/microL or ANC is &#60;1000 cells/microL, hold lenalidomide and follow CBC weekly. Lenalidomide may be resumed at a reduced dose (15 mg daily) once the platelet count rises above 30,000/microL and the ANC is above 1000 cells/microL.<sup>[2]</sup> If several doses are held, reduce lenalidomide dose to 5 mg less than the previous dose.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nonhematological toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 3 or 4 nonhematologic toxicity thought to be due to lenalidomide, hold treatment and restart at a reduced dose (5 mg less than previous dose) when toxicity has resolved to &#60;grade 2.<sup>[2]</sup></li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">G-CSF: granulocyte colony-stimulating factors; CrCl: creatinine clearance; CBC: complete blood count; ANC: absolute neutrophil count.<br />* In the United States, the use of lenalidomide is subject to the REVLIMID REMS program (<A href=\"http://www.revlimidrems.com/\" target=_blank>www.REVLIMIDREMS.com</A>) developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated birth defects.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Rajkumar SV, et al. Lancet Oncol 2010; 11:29.</LI>&#xD;&#xA;<LI>Lenalidomide capsule. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).</LI>&#xD;&#xA;<LI>Niesvizky R, et al. Br J Haematol 2007; 138:640.</LI></OL></div><div id=\"graphicVersion\">Graphic 56451 Version 17.0</div></div></div>"},"56452":{"type":"graphic_table","displayName":"Drug-induced skin disorders OLT","title":"Dermatologic complications of the drugs used for immunosuppression after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dermatologic complications of the drugs used for immunosuppression after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Azathioprine</td> <td>Acne, alopecia, angioedema, isolated localized exanthem, erosive stomatitis</td> </tr> <tr> <td>Cyclosporine</td> <td>Anaphylactic reactions, edema of the face and extremities, epidermal cysts, folliculitis, gingival hyperplasia, hidradenitis, hypertrichosis, onychopathy, sebaceous hyperplasia, urticaria</td> </tr> <tr> <td>Glucocorticoids</td> <td>Acne, cushingoid appearance, ecchymosis, hypertrichosis, delayed wound healing, striae</td> </tr> <tr> <td>Mycophenolate mofetil</td> <td>Acne, edema of the face and extremities, erosive stomatitis, immune thrombocytopenia, mofetil hypersudation</td> </tr> <tr> <td>Rapamycin</td> <td>Rash, acne, leucocytoclastic vasculitis, capillary leak syndrome, immune thrombocytopenia</td> </tr> <tr> <td>Tacrolimus</td> <td>Gingival hyperplasia, immune thrombocytopenia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56452 Version 3.0</div></div></div>"},"56453":{"type":"graphic_table","displayName":"Pre-HCT screening for infection","title":"Pretransplant screening to evaluate the risk of infection in hematopoietic cell transplant donors and candidates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pretransplant screening to evaluate the risk of infection in hematopoietic cell transplant donors and candidates</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tests and evaluations</td> <td class=\"subtitle1\">Donor</td> <td class=\"subtitle1\">Candidate<br /> (allogeneic or autologous)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>History, review of systems, physical examination</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dental evaluation</strong></td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"sublist_other_start\" colspan=\"3\"><strong>Radiology</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chest radiograph</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"sublist_other_start\" colspan=\"3\"><strong>Pathogen-specific testing</strong></td> </tr> <tr> <td class=\"indent1\">CMV IgG</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Hepatitis B (HBsAg, anti-HBsAg, anti-HBc) +/- viral load*</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Hepatitis C (IgM, IgG)</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Hepatitis C viral load<sup>&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> </tr> <tr> <td class=\"indent1\">VZV IgG</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">HSV IgG</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">EBV (VCA IgG)</td> <td class=\"centered\">+</td> <td class=\"centered\">+<br /> (especially allogeneic and T cell-depleted)</td> </tr> <tr> <td class=\"indent1\">HIV-1, -2 antibodies</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">HIV-1 viral load</td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> </tr> <tr> <td class=\"indent1\">HTLV-1, -2&nbsp;antibodies</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">RPR or VDRL or a <em>Treponema pallidum </em>antibody test</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">West Nile virus antibodies<sup>&#916;</sup></td> <td class=\"centered\">+/-</td> <td class=\"centered\">-</td> </tr> <tr> <td class=\"indent1\">Serum <em>Aspergillus</em> galactomannan antigen<sup>&#9674;</sup></td> <td class=\"centered\">-</td> <td class=\"centered\">+/-</td> </tr> <tr> <td class=\"indent1\"><em>Toxoplasma gondii </em>IgG</td> <td class=\"centered\">+</td> <td class=\"centered\">+/-<br /> (allogeneic only, particularly T cell-depleted)</td> </tr> <tr> <td class=\"indent1\">Screening for TB<sup>&#167;</sup></td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus </em>nasal culture</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vancomycin-resistant <em>Enterococcus</em> rectal culture</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"sublist_other_start\" colspan=\"3\"><strong>Tests for individuals who have resided in or traveled to endemic areas</strong></td> </tr> <tr> <td class=\"indent1\"><em>Strongyloides stercoralis </em>serology<sup>&#165;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\"><em>Coccidioides</em> spp serology<sup>&#135;</sup></td> <td class=\"centered\">-</td> <td class=\"centered\">+/-<br /> (especially allogeneic and T cell-depleted)</td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma capsulatum </em>serology<sup>&#135;</sup></td> <td class=\"centered\">-</td> <td class=\"centered\">+/-<br /> (especially allogeneic and T cell-depleted)</td> </tr> <tr> <td class=\"indent1\"><em>Trypanosoma cruzi </em>serology<sup>&#134;&#916;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">+/-</td> </tr> <tr> <td class=\"indent1\">Malaria blood smears, rapid tests, and/or PCR<sup>**</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Zika virus exposure history<sup>&#182;&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The recommendations in this table are generally in keeping with the 2009 international guidelines for preventing infectious complications after hematopoietic cell transplantation<SUP>[1]</SUP>; some of our recommendations are not included in the guidelines.</div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; Ig: immunoglobulin; HBsAg: hepatitis B surface antigen; anti-HBsAg: antibodies to hepatitis B surface antigen; anti-HBc: antibodies to hepatitis B core antigen; RT-PCR: reverse transcriptase polymerase chain reaction; HIV: human immunodeficiency virus; VZV: varicella-zoster virus; HSV: herpes simplex virus; EBV: Epstein Barr virus; HTLV: human T lymphotrophic virus; VDRL: venereal disease research laboratory; TB: tuberculosis; VCA: viral capsid antigen; CBC: complete blood count; PCR: polymerase chain reaction.<br />* All HCT donors who are either anti-HBc positive or HBsAg positive and all HCT candidates who are anti-HBc positive but negative for HBsAg and anti-HBs should undergo viral load testing for hepatitis B virus. Additional recommendations for the evaluation and management of HCT candidates in the setting of positive serologic or viral load testing results from the donor or recipient can be found in the 2009 international guidelines<SUP>[1]</SUP>.<br />¶&nbsp;In addition to serologic testing for hepatitis C, all HCT candidates should undergo a careful history and physical examination for risk factors, signs, and symptoms of hepatitis C, as well as serum alanine aminotransferase (ALT) testing. Hepatitis C viral load testing should be performed in all HCT donors&nbsp;as well as in HCT candidates at increased risk for hepatitis C infection, including those who have received a transfusion with blood not tested for hepatitis C (eg, before 1992 in developed countries), history of IV or inhaled drug use, tattoos, or unexplained elevation of serum ALT. Viral load testing should also be performed in HCT candidates with positive hepatitis C serologic testing. Additional recommendations for the evaluation and management of HCT candidates in the setting of positive serologic or viral load testing results from the donor or recipient can be found in the 2009 international guidelines<SUP>[1]</SUP>.<br />Δ&nbsp;West Nile virus antibody testing and<EM> T. cruzi</EM> antibody testing of HCT donors is required in some states in the United States.<br /><FONT class=lozenge>◊</FONT> Serum <EM>Aspergillus</EM> galactomannan antigen testing should be performed in HCT candidates who have a past history of invasive aspergillosis and in others who are high-risk for invasive aspergillosis.<br />§ Screening for TB includes obtaining a history of prior active TB or exposures to individuals likely to have TB, as well as results of previous tuberculin skin tests or interferon-gamma release assays.<br />¥ The southeastern United States is an endemic region; testing should therefore be performed in individuals who have resided in or traveled to this region.&nbsp;If<EM> Strongyloides </EM>antibody testing is not available or if active disease with strongyloidiasis is suspected in a seronegative HCT candidate, three stool samples should be sent for ova and parasites.<br />‡ Reactivation of endemic mycoses following HCT is very rare, even in endemic regions.<br />† Donors or recipients who were born, received a blood transfusion, or ever lived for six months or longer in a region that is endemic for Chagas disease (eg, parts of South and Central America and Mexico) should undergo serologic testing for <EM>T. cruzi </EM>IgG. Individuals who have lived for less than six months in an endemic are but who had high-risk living conditions (eg, lived in dwellings with mud walls, unmilled logs and sticks, or a thatched roof), should also undergo serologic testing. Individuals whose mother was born in an endemic region or who has a suggestive history (eg, cardiomegaly and dysrhythmias) should be screened due to the risk of congenital transmission. Since there is no gold standard for serologic testing, screening should be performed with at least two serologic tests (enzyme immunoassay, indirect hemagglutination, indirect fluorescent antibody, or radioimmunoprecipitation assay).<br />** Donors who have traveled to a malaria-endemic area should defer donation for one year following their return. Former or current residents of endemic areas should defer donation for three years. If this is not feasible, the donor should be treated empirically for malaria prior to donation. If the donor is diagnosed with active malaria, collection of stem cells should be delayed if possible until treatment has been completed and negative confirmatory testing obtained. If this is not feasible, preemptive treatment of the HCT recipient is reasonable, although there is no evidence regarding the safety or efficacy of this approach.<br />¶¶ Potential HCT donors should be considered ineligible for HCT donation if they have been diagnosed with Zika virus infection over the past six months, resided in or traveled to an area with active mosquito-borne Zika virus transmission, or had sexual contact with a man who meets either of these criteria<SUP>[3]</SUP>. Potential umbilical cord blood donors should be considered ineligible for donation if the birth mother has been diagnosed with Zika virus infection at any point during the pregnancy, resided in or traveled to an area with active Zika virus transmission at any point during the pregnancy, or had sexual contact at any point during the pregnancy with a man who meets either of these criteria.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Testing HCT/P donors: Specific requirements. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/TissueSafety/ucm151757.htm (Accessed on December 02, 2014).</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products: Guidance for Industry, March 2016. <A href=\"http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM488582.pdf\">http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM488582.pdf</A> (Accessed on March 07, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 56453 Version 7.0</div></div></div>"},"56454":{"type":"graphic_picture","displayName":"Chorioamnionitis","title":"Chorioamnionitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chorioamnionitis</div><div class=\"cntnt\"><img style=\"width:385px; height:265px;\" src=\"images/OBGYN/56454_Chorioamnionitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross photograph of the umbilical cord and fetal surface of the placenta illustrating opaque membranous surfaces characteristic of inflammation from chorioamnionitis.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 56454 Version 2.0</div></div></div>"},"56455":{"type":"graphic_table","displayName":"Epirub cum dose cardiotox","title":"The cumulative dose of epirubicin (in mg/m<sup>2</sup>) corresponding to a 5 percent risk of developing heart failure during a follow-up time of 2.5 years after the initiation of epirubicin treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The cumulative dose of epirubicin (in mg/m<sup>2</sup>) corresponding to a 5 percent risk of developing heart failure during a follow-up time of 2.5 years after the initiation of epirubicin treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Patient characteristics</td> <td class=\"subtitle1\" colspan=\"4\">Age at epirubicin start, years</td> </tr> <tr> <td class=\"subtitle2\">40</td> <td class=\"subtitle2\">50</td> <td class=\"subtitle2\">60</td> <td class=\"subtitle2\">70</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"><em>The recommended maximum epirubicin doses are given for patients with performance status less than 2, one or more metastatic sites, and no previous adjuvant chemotherapy. Shown are the recommended maximum cumulative doses for patients with one metastasis/more than one metatasis.</em></td> </tr> <tr> <td class=\"sublist1_start\">Patients treated with first-line epirubicin as the only risk factor for HF:</td> <td class=\"indent1 divider_bottom\" rowspan=\"2\">806/844</td> <td class=\"divider_bottom\" rowspan=\"2\">739/782</td> <td class=\"divider_bottom\" rowspan=\"2\">673/722</td> <td class=\"divider_bottom\" rowspan=\"2\">609/665</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Previous antihormonal therapy*: no</p> <p>Previous CMF treatment: no</p> <p>Previous mediastinal irradiation: no</p> <p>Predisposition to heart disease<sup>&#182;</sup>: no</p> </td> </tr> <tr> <td class=\"sublist1_start\">Patients also treated previously with antihormonal drugs* for metastatic disease:</td> <td class=\"indent1 divider_bottom\" rowspan=\"2\">626/670</td> <td class=\"divider_bottom\" rowspan=\"2\">561/610</td> <td class=\"divider_bottom\" rowspan=\"2\">496/552</td> <td class=\"divider_bottom\" rowspan=\"2\">434/496</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Previous antihormonal therapy: yes</p> <p>Previous CMF treatment: no</p> <p>Previous mediastinal irradiation: no</p> <p>Predisposition to heart disease: no</p> </td> </tr> <tr> <td class=\"sublist1_start\">Patients also treated previously with CMF for metastatic disease:</td> <td class=\"indent1 divider_bottom\" rowspan=\"2\">864/883</td> <td class=\"divider_bottom\" rowspan=\"2\">828/850</td> <td class=\"divider_bottom\" rowspan=\"2\">793/818</td> <td class=\"divider_bottom\" rowspan=\"2\">759/786</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Previous antihormonal therapy: no</p> <p>Previous CMF treatment: yes</p> <p>Previous mediastinal irradiation: no</p> <p>Predisposition to heart disease: no</p> </td> </tr> <tr> <td class=\"sublist1_start\">Patients also treated previously with antihormonal drugs and CMF:</td> <td class=\"indent1 divider_bottom\" rowspan=\"2\">769/790</td> <td class=\"divider_bottom\" rowspan=\"2\">734/757</td> <td class=\"divider_bottom\" rowspan=\"2\">699/725</td> <td class=\"divider_bottom\" rowspan=\"2\">665/694</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Previous antihormonal therapy: yes</p> <p>Previous CMF treatment: yes</p> <p>Previous mediastinal irradiation: no</p> <p>Predisposition to heart disease: no</p> </td> </tr> <tr> <td class=\"sublist1_start\">Patients also treated previously with mediastinal irradiation<sup>&#916;</sup>:</td> <td class=\"indent1 divider_bottom\" rowspan=\"2\">NA/640</td> <td class=\"divider_bottom\" rowspan=\"2\">NA/581</td> <td class=\"divider_bottom\" rowspan=\"2\">NA/523</td> <td class=\"divider_bottom\" rowspan=\"2\">NA/467</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Previous antihormonal therapy: no</p> <p>Previous CMF treatment: no</p> <p>Previous mediastinal irradiation: yes</p> <p>Predisposition to heart disease: no</p> </td> </tr> <tr> <td class=\"sublist1_start\">Patients also with predisposition to heart disease<sup>&#182;</sup>:</td> <td class=\"indent1\" rowspan=\"2\">491/539</td> <td rowspan=\"2\">427/481</td> <td rowspan=\"2\">364/424</td> <td rowspan=\"2\">303/369</td> </tr> <tr> <td class=\"indent1\"> <p>Previous antihormonal therapy: no</p> <p>Previous CMF treatment: no</p> <p>Previous mediastinal irradiation: no</p> <p>Predisposition to heart disease: yes</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HF: heart failure; CMF: cyclophosphamide, methotrexate, 5-fluorouracil; NA: not available.<br />* Tamoxifen until the year 2000, when aromatase inhibitors became first choice in treatment for relapse or metastatic disease.<br />¶ History of diabetes mellitus, arterial hypertension, thyrotoxicosis, obstructive lung disease, alcoholism, or obesity.<br />Δ Data not available for one metastasis because patients will always have more than one metastasis under these circumstances.</div><div class=\"graphic_reference\">Reproduced with permission from: Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risk analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008; 100:1058. Copyright &copy; 2008 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 56455 Version 13.0</div></div></div>"},"56456":{"type":"graphic_table","displayName":"Lab monitor PN infants","title":"Laboratory monitoring of infants receiving parenteral nutrition (PN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory monitoring of infants receiving parenteral nutrition (PN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Laboratory test</td> <td class=\"subtitle1\">Frequency</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Blood</td> </tr> <tr> <td class=\"sublist1\">Electrolytes: sodium, potassium, chloride, bicarbonate</td> <td class=\"sublist_other\">Daily until stable, then serially as indicated</td> </tr> <tr> <td class=\"sublist1\">Glucose</td> <td class=\"sublist_other\">Daily until stable, then serially as indicated</td> </tr> <tr> <td class=\"sublist1\">Blood urea nitrogen (BUN), creatinine, calcium, phosphorus, magnesium, alkaline phosphatase, bilirubin, alanine aminotransferase (ALT),&nbsp;aspartate aminotransferase (AST)</td> <td class=\"sublist_other\">After the first week and then serially on an alternate week schedule as indicated</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56456 Version 4.0</div></div></div>"},"56457":{"type":"graphic_table","displayName":"Noninfectious causes of RD","title":"Noninfectious causes of neonatal respiratory distress","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Noninfectious causes of neonatal respiratory distress</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Anatomic/development defects</td></tr>\n\t\t\t\t\t\t<tr><td>Primary pulmonary hypoplasia</td></tr>\n\t\t\t\t\t\t<tr><td>Cystic adenomatoid malformation</td></tr>\n\t\t\t\t\t\t<tr><td>Tracheoesophageal fistula</td></tr>\n\t\t\t\t\t\t<tr><td>Diaphragmatic hernia</td></tr>\n\t\t\t\t\t\t<tr><td>Congenital heart disease</td></tr>\n\t\t\t\t\t\t<tr><td>Choanal atresia</td></tr>\n\t\t\t\t\t\t<tr><td>Tracheal web</td></tr>\n\t\t\t\t\t\t<tr><td>Laryngotracheomalacia</td></tr>\n\t\t\t\t\t\t<tr><td>External compression of the trachea (eg, goiter)</td></tr>\n\t\t\t\t\t\t<tr><td>Central nervous system malformation</td></tr>\n\t\t\t\t\t\t<tr><td>Hydrocephalus</td></tr>\n\t\t\t\t\t\t<tr><td>Genetic (eg, immotile cilia syndrome, surfactant protein B deficiency, urea cycle defect)</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Physiologic/pathologic disorders</td></tr>\n\t\t\t\t\t\t<tr><td>Transient tachypnea of the newborn</td></tr>\n\t\t\t\t\t\t<tr><td>Respiratory distress syndrome</td></tr>\n\t\t\t\t\t\t<tr><td>Meconium aspiration pneumonia</td></tr>\n\t\t\t\t\t\t<tr><td>Pulmonary hemorrhage</td></tr>\n\t\t\t\t\t\t<tr><td>Pulmonary edema</td></tr>\n\t\t\t\t\t\t<tr><td>Pneumothorax</td></tr>\n\t\t\t\t\t\t<tr><td>Hydrothorax/chylothorax</td></tr>\n\t\t\t\t\t\t<tr><td>Aspiration pneumonia</td></tr>\n\t\t\t\t\t\t<tr><td>Hypoglycemia</td></tr>\n\t\t\t\t\t\t<tr><td>Metabolic acidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Respiratory alkalosis</td></tr>\n\t\t\t\t\t\t<tr><td>Central nervous system injury</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 56457 Version 2.0</div></div></div>"},"56458":{"type":"graphic_table","displayName":"Signs of upper versus lower motor neuron disease","title":"Signs of upper versus lower motor neuron disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs of upper versus lower motor neuron disease</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Clinical\n   </td>\n   <td  class=\"subtitle1\">\n   UMN\n   </td>\n   <td  class=\"subtitle1\">\n   LMN\n   </td>\n   </tr>\n   <tr>\n   <td>Muscle tone</td>\n   <td>Increased</td>\n   <td>Decreased</td>\n   </tr>\n   <tr>\n   <td>Reflexes</td>\n   <td>Hyperreflexia</td>\n   <td>Hyporeflexia</td>\n   </tr>\n   <tr>\n   <td>Babinski sign</td>\n   <td>Present</td>\n   <td>Absent</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=12277&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Motor_neuron_signs.htm</title></head></div><div class=\"graphic_footnotes\">UMN: upper motor neuron; LMN: lower motor neuron.</div><div id=\"graphicVersion\">Graphic 56458 Version 2.0</div></div></div>"},"56460":{"type":"graphic_picture","displayName":"Trucut EUS apparatus","title":"Trucut needle echoendoscope","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Trucut needle echoendoscope</div><div class=\"cntnt\"><img style=\"width:540px; height:403px;\" src=\"images/GAST/56460_Trucut_EUS_apparatus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD</div><div id=\"graphicVersion\">Graphic 56460 Version 1.0</div></div></div>"},"56461":{"type":"graphic_picture","displayName":"Atopic dermatitis infantile II","title":"Atopic dermatitis: Infantile","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis: Infantile</div><div class=\"cntnt\"><img style=\"width:328px; height:447px;\" src=\"images/ALLRG/56461_Atopicdermatitisinfanti1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent erythema, microvesiculation, papules, crust, and scale on the face of an infant.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, et al (Eds), Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York 1997. Copyright © McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 56461 Version 5.0</div></div></div>"},"56462":{"type":"graphic_diagnosticimage","displayName":"Large pericardial effusion","title":"Large pericardial effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large pericardial effusion</div><div class=\"cntnt\"><img style=\"width:303px; height:264px;\" src=\"images/CARD/56462_Large_pericardial_effusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long axis precordial view shows a large anterior (APE) and posterior pericardial effusion (PPE). This distinction between this large effusion and a moderate sized one is the easily seen anterior accumulation. Since the volume of the effusion is a cube function of its dimensions, its presence circumferentially makes a large difference in it volume without a major qualitative change in appearance.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; LA: left atrium; dAo: descending aorta.</div><div id=\"graphicVersion\">Graphic 56462 Version 2.0</div></div></div>"},"56463":{"type":"graphic_picture","displayName":"Varicose veins of the thigh and calf","title":"Varicose veins of the thigh and calf","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Varicose veins of the thigh and calf</div><div class=\"cntnt\"><img style=\"width:293px; height:432px;\" src=\"images/PC/56463_Varicose_veins_thigh_calf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Varicose veins are subcutaneous dilated veins three millimeters or greater in size. These varicosities involve both saphenous and non-saphenous tributaries of the thigh and calf.</div><div class=\"graphic_reference\">Reproduced with permission from: Bickley LS and Szilagyi P. Bates' Guide to Physical Examination and History Taking, 8th Ed. Philadelphia: Lippincott Williams &amp; Wilkins 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56463 Version 3.0</div></div></div>"},"56464":{"type":"graphic_figure","displayName":"Inspiratory flow rate vs work","title":"Inspiratory flow rate effects inspiratory work","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Inspiratory flow rate effects inspiratory work</div><div class=\"cntnt\"><img style=\"width:470px; height:244px;\" src=\"images/PULM/56464_Inspiratory_flow_rate_vs_wo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of changing inspiratory flow rate on rate of inspiratory work of breathing during controlled mechanical ventilation (circles) and assist-control ventilation (squares). At all flow rates, the work of breathing was significantly greater during assist-control ventilation versus controlled ventilation. During both modes of mechanical ventilation, work increased as flow rate was decreased. Values are mean &#177; SE.</div><div class=\"graphic_reference\">Redrawn from Ward, ME, Corbeil, C, Gibbons, W, et al, Anesthesiology 1988; 69:29.</div><div id=\"graphicVersion\">Graphic 56464 Version 1.0</div></div></div>"},"56465":{"type":"graphic_figure","displayName":"Structure of a Mendelian randomization study","title":"Structure of a Mendelian randomization study","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Structure of a Mendelian randomization study</div><div class=\"cntnt\"><img style=\"width:516px; height:337px;\" src=\"images/PC/56465_struct-mendel-randomization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a Mendelian randomization study, association 1 and 2 are estimated to determine the causal effect of the exposure (ie, the intermediate factor) on the outcome. Association 3 represents the usual association estimated in traditional observational studies which may be prone to the usual biases (ie, confounding, reverse-causality).</div><div id=\"graphicVersion\">Graphic 56465 Version 2.0</div></div></div>"},"56466":{"type":"graphic_figure","displayName":"Segments of the vertebral artery","title":"Segments of the vertebral artery","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Segments of the vertebral artery</div><div class=\"cntnt\"><img style=\"width:513px; height:510px;\" src=\"images/SURG/56466_Vertebral_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vertebral artery is divided into four anatomic segments:<br /><UL>&#xD;&#xA;<LI>V1 – Origin of the vessel to the foramina of the sixth cervical (C6) transverse process.</LI>&#xD;&#xA;<LI>V2 – Intraforaminal segment from the sixth to the second cervical vertebral body (C6 to C2).</LI>&#xD;&#xA;<LI>V3 – From the second cervical (C2) foramina to the base of the skull. </LI>&#xD;&#xA;<LI>V4 – Intracerebral segment of the vertebral artery. The vertebral arteries merge to form the basilar artery and are intradural. </LI></UL></div><div id=\"graphicVersion\">Graphic 56466 Version 6.0</div></div></div>"},"56467":{"type":"graphic_table","displayName":"Differential diagnosis of DLBCL","title":"Differential diagnosis of diffuse large B-cell lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of diffuse large B-cell lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Immunophenotype</td> <td class=\"subtitle1\">Genetic features/other</td> </tr> <tr> <td>Diffuse large B-cell lymphoma</td> <td>Large, transformed B-cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation (Ki-67+) fraction.</td> <td>Generally express pan B-cell antigens (CD19, CD20, CD22, CD79a).</td> <td>The majority has genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic.</td> </tr> <tr class=\"divider_top\"> <td>Burkitt lymphoma</td> <td>Monomorphic, medium-sized cells with round nuclei, multiple nucleoli, basophilic cytoplasm, prominent cytoplasmic lipid vacuoles, and a \"starry-sky\" pattern. Ki-67+ fraction approaching 100 percent.</td> <td>Express surface IgM and B-cell-associated antigens (CD19, CD20, CD22, CD79a), as well as CD10, HLA-DR, and CD43. They lack CD5, bcl-2, and typically lack CD23.</td> <td>Strongly (but not uniformly) associated with a translocation between the long arm of chromosome 8, the site of the c-MYC oncogene (8q24), and one of three locations on Ig genes: t(8;14), t(2;8), or t(8;22).</td> </tr> <tr class=\"divider_top\"> <td>Anaplastic large cell lymphoma</td> <td>Large cells with horseshoe-shaped or embryoid nuclei, prominent nucleoli, and abundant cytoplasm. Often shows a cohesive growth pattern.</td> <td>Homogeneous and strong expression of CD30 in a membrane and golgi pattern. Usually express one or more T-cell antigens (ie, CD2, CD3, CD5, CD7). Do not express B-cell antigens.</td> <td>Two distinct subtypes: ALK positive (detected by immunostains or molecular genetics) and ALK negative.</td> </tr> <tr class=\"divider_top\"> <td>Hodgkin lymphoma</td> <td>Lymphocyte predominant or lymphocyte rich classical Hodgkin lymphoma (HL) can morphologically resemble T-cell histiocyte rich large B-cell lymphoma. The HL tumor contains a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background.</td> <td>The neoplastic cells typically express CD15 and CD30, variably express CD20, and do not express CD3 or CD45.</td> <td>There is no single cytogenetic change that is typical or diagnostic.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56467 Version 1.0</div></div></div>"},"56468":{"type":"graphic_table","displayName":"Causes elevated IgE","title":"Causes of elevated IgE","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of elevated IgE</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Common*</td> </tr> <tr> <td class=\"indent1\">Allergic disease (eg, atopic dermatitis/eczema, asthma, allergic rhinitis, food allergy, eosinophilic esophagitis, urticaria, drug allergy)</td> </tr> <tr> <td class=\"indent1\">Parasitic worm infestation (eg, helminth infection)</td> </tr> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\">Malignancy (eg, IgE myeloma, Hodgkin lymphoma)</td> </tr> <tr> <td class=\"indent1\">Primary and secondary immunodeficiencies (eg, hyperimmunoglobulin E syndrome, Wiskott-Aldrich syndrome, Nezelof syndrome, AIDS, GVHD)</td> </tr> <tr> <td class=\"indent1\">Infectious diseases (eg, allergic bronchopulmonary aspergillosis, leprosy)</td> </tr> <tr> <td class=\"indent1\">Inflammatory diseases (eg, eosinophilic granulomatosis with polyangiitis [Churg-Strauss], Kawasaki disease)</td> </tr> <tr> <td class=\"indent1\">Drug effect (eg, aztreonam, penicillin G)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; AIDS: acquired immunodeficiency syndrome; GVHD: graft-versus-host disease.<br />* Allergic disease is the most common etiology of elevated IgE in industrialized countries, whereas parasitic infection is the most common cause in developing countries.</div><div id=\"graphicVersion\">Graphic 56468 Version 8.0</div></div></div>"},"56475":{"type":"graphic_table","displayName":"Complications of Kawasaki disease","title":"Complications of Kawasaki disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of Kawasaki disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Complication</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td colspan=\"2\">Shock</td> <td>Approximately 7 percent</td> <td> <p>Associated features:</p> <ul> <li>Consumptive coagulopathy and cardiac abnormalities including impaired left ventricular systolic function, mitral regurgitation, and coronary artery abnormalities </li> <li>Higher C-reactive protein levels </li> <li>Less responsive to initial&nbsp;IVIG therapy and more commonly require additional treatment </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">Macrophage activation syndrome</td> <td>Rare</td> <td> <ul> <li>Reported rarely in children with persistent fever after IVIG treatment </li> <li>Heralded by fall in ESR due to consumptive coagulopathy; also marked by ferritin levels &#62;5000 ng/mL </li> <li>Treatment with intravenous methylprednisolone, biologic response modifiers, or cyclosporine may be needed </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Cardiac complications</td> <td>Coronary artery involvement</td> <td> <p>Nearly all patients with KD</p> <p>(Coronary artery ectasia - approximately 31 percent; coronary artery aneurysm -&nbsp;&#60;5 percent)</p> </td> <td> <p>Coronary artery aneurysms associated with:</p> <ul> <li>Age &#60;1 year or &#62;9 years </li> <li>Male sex </li> <li>Fever &#8805;14 days </li> <li>Serum sodium &#60;135 mEq/L, hematocrit &#60;35 percent, white cell count &#62;12,000/mm<sup>3</sup> </li> </ul> </td> </tr> <tr> <td>Depressed myocardial contractility</td> <td>Present in almost all patients with KD</td> <td> <ul> <li>Includes myocarditis, cardiomyopathy, and left ventricular dysfunction </li> <li>Most commonly manifested by tachycardia and an S3 gallop; uncommonly may progress to heart failure </li> <li>Normal contractility typically is restored following treatment with&nbsp;IVIG </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">Noncoronary vascular involvement</td> <td> <p>Rare (peripheral)</p> <p>Very rare (visceral)</p> </td> <td> <ul> <li>Peripheral aneurysms may present as pulsatile masses in axillae or inguinal area </li> <li>Peripheral arterial obstruction can lead to ischemia and gangrene </li> <li>Most commonly occurs in children with severe KD, including significant coronary artery involvement </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">Urinary abnormalities and renal disease</td> <td>Rare</td> <td> <ul> <li>Includes acute interstitial nephritis, mild proteinuria, acute renal failure, hemolytic-uremic syndrome, and immune complex-mediated glomerulonephritis </li> <li>IVIG may also cause acute renal injury, especially preparations using sucrose as a stabilizer </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">GI abnormalities</td> <td>Mild GI manifestations occur commonly; severe involvement is rare</td> <td> <ul> <li>Mild GI involvement includes gallbladder hydrops and cholestasis and paralytic ileus </li> <li>More severe involvement includes bile duct stenosis, appendicular vasculitis, hemorrhagic duodenitis, intestinal pseudo-obstruction, intussusception, and pancreatitis </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">Sensorineural hearing loss</td> <td>Rare</td> <td> <ul> <li>Usually transient </li> <li>Persistent sensorineural hearing loss is associated with delayed use of IVIG, prolonged thrombocytosis, anemia, and an elevated ESR</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IVIG: intravenous immune globulin; ESR: erythrocyte sedimentation rate; KD: Kawasaki disease; GI: gastrointestinal.</div><div id=\"graphicVersion\">Graphic 56475 Version 3.0</div></div></div>"},"56477":{"type":"graphic_waveform","displayName":"Detection of bolus movement","title":"MI detected bolus movement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MI detected bolus movement</div><div class=\"cntnt\"><img style=\"width:427px; height:389px;\" src=\"images/GAST/56477_Detection_of_bolus_movement.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in intraluminal impedance during swallowing and reflux. A drop in impedance identifies bolus entry in a segment followed by a recovery once the bolus exits the impedance-measuring segment. Changes in impedance progressing from proximal to distally indicate antegrade bolus movement as seen during swallowing while changes in impedance progressing distally to proximally indicate retrograde bolus movement as seen during reflux.</div><div class=\"graphic_reference\">Courtesy of Radu Tutuian, MD and Donald O Castell, MD.</div><div id=\"graphicVersion\">Graphic 56477 Version 2.0</div></div></div>"},"56479":{"type":"graphic_picture","displayName":"Laryngomalacia surgery","title":"Laryngomalacia surgery","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Laryngomalacia surgery</div><div class=\"cntnt\"><img style=\"width:484px; height:223px;\" src=\"images/PEDS/56479_Laryngomalacia_surgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Rigid laryngoscopy of laryngomalacia with redundant supraglottic tissue hiding the vocal cords. Panel B: Rigid laryngoscopy of laryngomalacia following resection of redundant tissue from epiglottis and arytenoids.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 56479 Version 1.0</div></div></div>"},"56480":{"type":"graphic_diagnosticimage","displayName":"IVUS extent coronary calcium","title":"Intracoronary ultrasound shows the extent of coronary artery calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracoronary ultrasound shows the extent of coronary artery calcification</div><div class=\"cntnt\"><img style=\"width:153px; height:298px;\" src=\"images/CARD/56480_IVUS_extent_coronary_calciu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracoronary ultrasound is useful for establishing the presence and extent of coronary artery calcification. The top panel shows a small region of calcification (arrow) while the bottom panel shows a lumen that is completely surrounded by calcium.</div><div class=\"graphic_reference\">Adapted from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995: 2:68.</div><div id=\"graphicVersion\">Graphic 56480 Version 3.0</div></div></div>"},"56481":{"type":"graphic_picture","displayName":"Viral conjunctivitis","title":"Viral conjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Viral conjunctivitis</div><div class=\"cntnt\"><img style=\"width:360px; height:241px;\" src=\"images/PC/56481_Viral_conjunctivitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Viral conjunctivitis typically presents as injection, watery or mucoserous discharge, and a burning, sandy, or gritty feeling in one eye.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD. The Eyes Have It: An interactive teaching and assessment program on vision care. WK Kellog Eye Center, University of Michigan. Copyright &#169; Jonathan D Trobe, MD.</div><div id=\"graphicVersion\">Graphic 56481 Version 3.0</div></div></div>"},"56482":{"type":"graphic_figure","displayName":"Inhalation challenge testing I","title":"Inhalation challenge testing","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Inhalation challenge testing</div><div class=\"cntnt\"><img style=\"width:456px; height:387px;\" src=\"images/PULM/56482_Inhalation_challenge_testin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Types of specific asthmatic reactions after specific inhalation challenge testing: immediate, early late, isolated late, and dual (immediate and late). Mean and standard deviation of percent change in FEV1 (ordinate) are shown as a function of time (abscissa) from the challenge test.</div><div class=\"graphic_reference\">From Perrin et al, J Allergy Clin Immunol 1991;87:630.</div><div id=\"graphicVersion\">Graphic 56482 Version 1.0</div></div></div>"},"56483":{"type":"graphic_picture","displayName":"Muscle biopsy DM IF","title":"Vascular involvement in DM","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vascular involvement in DM</div><div class=\"cntnt\"><img style=\"width:195px; height:302px;\" src=\"images/RHEUM/56483_Muscle_biopsy_DM_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Muscle biopsy in a patient with dermatomyositis showing vascular C5b-9 deposition in the perimysial blood vessels.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 56483 Version 1.0</div></div></div>"},"56484":{"type":"graphic_table","displayName":"Drug therapy acute and recurrent pericarditis","title":"Drug therapy in acute and recurrent pericarditis for adult patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug therapy in acute and recurrent pericarditis for adult patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Anti-inflammatory dose</td> <td class=\"subtitle1\">Duration of therapy*<br /> (anti-inflammatory dose)</td> <td class=\"subtitle1\">Tapering*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">For initial combination treatment of most patients:</td> </tr> <tr> <td class=\"indent1\">Aspirin<sup>&#182;</sup></td> <td>650 to 1000 mg orally three times daily</td> <td>One to two weeks</td> <td>Weekly decrease once patient is symptom-free and CRP has normalized</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Ibuprofen<sup>&#182;</sup></td> <td>600 to 800 mg orally three times daily<sup>&#916;</sup></td> <td>One to two weeks</td> <td>Weekly decrease once patient is symptom-free and CRP has normalized</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Indomethacin<sup>&#182;</sup></td> <td>25 to 50 mg orally three times daily</td> <td>One to two weeks</td> <td>Weekly decrease once patient is symptom-free and CRP has normalized</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><strong>PLUS</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Colchicine<sup>&#9674;</sup><sup>&#167;</sup></td> <td>0.5 to 0.6 mg orally two times daily</td> <td> <p>Three months (acute)</p> Six months or longer (recurrent)</td> <td>Usually not tapered<sup>&#165;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">For initial combination therapy of patients following myocardial infarction:</td> </tr> <tr> <td class=\"indent1\">Aspirin<sup>&#182;</sup></td> <td>650 to 1000 mg orally three times daily</td> <td>One to two weeks</td> <td>Weekly decrease once patient is symptom-free and CRP has normalized</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><strong>PLUS</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Colchicine<sup>&#9674;</sup><sup>&#167;</sup></td> <td>0.5 to 0.6 mg orally two times daily</td> <td> <p>Three months (acute)</p> Six months or longer (recurrent)</td> <td>Usually not tapered<sup>&#165;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">For refractory cases or patients with a contraindication to NSAID therapy:</td> </tr> <tr> <td class=\"indent1\">Prednisone</td> <td>0.25 to 0.5 mg/kg/day</td> <td> <p>Two weeks (acute)</p> Two to four weeks (recurrent)</td> <td>Gradual tapering over three months; refer to UpToDate topic review of treatment of acute pericarditis, section on glucocorticoids</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"indent1\">Colchicine<sup>&#9674;</sup><sup>&#167;</sup></td> <td>0.5 to 0.6 mg orally two times daily</td> <td>Three months</td> <td>Usually not tapered<sup>&#165;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CRP: C-reactive protein; NSAID: nonsteroidal anti-inflammatory drug.<br />* Duration and tapering of therapy (except colchicine) should be tailored according to resolution of symptoms and normalization of markers of inflammation; refer to topic reviews for approach.<br />¶ Proton pump inhibitor (eg, omeprazole) gastrointestinal protection may be indicated.<br />Δ Some patients may require ibuprofen every six hours (four times daily), in which case the dose should not exceed 600 mg every six hours.<br /><FONT class=lozenge>◊</FONT> 0.5 mg colchicine is not available in the US. It is widely available elsewhere.<br />§ Colchicine dose should be reduced to 0.5 to 0.6 mg once daily in patients &lt;70 kg.<br />¥ The duration of colchicine therapy for recurrent or refractory pericarditis is at least six months.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lange RA, Hillis LD. Clinical practice. Acute pericarditis. N Engl J Med 2004; 351:2195.</li>&#xD;&#xA;    <li>Maisch B, Seferovic PM, Ristic AD, et al. Guidelines on the diagnosis and management of pericardial disease: The task force on the diagnosis and management of pericardial disease of the European Society of Cardiology. European Heart Journal 2004; 25:587.</li>&#xD;&#xA;    <li>Imazio M, Brucato A, Trinchero R, et al. Individualized therapy for pericarditis. Expert Rev Cardiovasc Ther 2009; 7:965.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 56484 Version 14.0</div></div></div>"},"56487":{"type":"graphic_diagnosticimage","displayName":"Contrast MDCT panc mass","title":"Contrast MDCT of pancreatic mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contrast MDCT of pancreatic mass</div><div class=\"cntnt\"><img style=\"width:450px; height:253px;\" src=\"images/ONC/56487_Contrast_MDCT_panc_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced MDCT in coronal projection demonstrates a small mass (arrow) in the body of the pancreas, causing pancreatic ductal obstruction, with abrupt cutoff of the main pancreatic duct (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Dr. Rocio Perez-Johnston.</div><div id=\"graphicVersion\">Graphic 56487 Version 3.0</div></div></div>"},"56488":{"type":"graphic_picture","displayName":"Aphthous ulcer","title":"Aphthous ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aphthous ulcer</div><div class=\"cntnt\"><img style=\"width:381px; height:200px;\" src=\"images/PEDS/56488_Aphthousulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Martha Ann Keels, DDS, PhD.</div><div id=\"graphicVersion\">Graphic 56488 Version 2.0</div></div></div>"},"56489":{"type":"graphic_diagnosticimage","displayName":"Abdomen CT of child with B henselae","title":"Computed tomography of the abdomen in a child with visceral involvement of Bartonella henselae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of the abdomen in a child with visceral involvement of Bartonella henselae</div><div class=\"cntnt\"><img style=\"width:432px; height:313px;\" src=\"images/PEDS/56489_CSD_abdomen_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography of the abdomen showing multiple hypodense lesions in the liver and spleen of a child with prolonged fever, abdominal pain, and positive B. henselae serology.</div><div class=\"graphic_reference\">Courtesy of Sheldon L Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 56489 Version 3.0</div></div></div>"},"56490":{"type":"graphic_figure","displayName":"TB guideline phototherapy","title":"Guidelines for phototherapy in hospitalized infants of 35 or more weeks gestation","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Guidelines for phototherapy in hospitalized infants of 35 or more weeks gestation</div><div class=\"cntnt\"><img style=\"width:554px; height:406px;\" src=\"images/PEDS/56490_TSBguidelinephototherapy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Use TB. Do not subtract direct reacting or conjugated bilirubin. Risk factors include isoimmune hemolytic diseases, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin &lt;3 g/dL (if measured). For well infants 35 to 37 6/7 weeks, can adjust TB levels for intervention around the medium risk line. It is an option to intervene at lower TB levels for infants closer to 35 weeks and at higher TB levels for those closer to 37 6/7 weeks. It is an option to provide conventional phototherapy in hospital or at home at TB levels 2 to 3 mg/dL (35 to 50 mmol/L) below those shown, but home phototherapy should not be used in any infant with risk factors. Note that these guidelines are based on limited evidence and the levels shown are approximations. The guidelines refer to the use of intensive phototherapy, which should be used when the TB exceeds the line indicated for each category. Infants are designated as \"higher risk\" because of the potential negative effects of the conditions listed on albumin binding of bilirubin, the blood-brain barrier, and the susceptibility of the brain cells to damage by bilirubin.</div><div class=\"graphic_footnotes\">TB: total serum or plasma bilirubin; G6PD: glucose-6-phosphate dehydrogenase.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 114, Pages 297-316, Copyright &copy; 2004 by the AAP.</div><div id=\"graphicVersion\">Graphic 56490 Version 19.0</div></div></div>"},"56491":{"type":"graphic_figure","displayName":"Tumescence and REM sleep","title":"Association of nocturnal erections with REM sleep","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Association of nocturnal erections with REM sleep</div><div class=\"cntnt\"><img style=\"width:478px; height:273px;\" src=\"images/ENDO/56491_Tumescence_and_REM_sleep.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Penile tumescence during the different stages of sleep. Nocturnal erections occurred during periods of REM sleep (columns).</div><div class=\"graphic_footnotes\">REM: rapid eye movement.</div><div class=\"graphic_reference\">Data from: Karacan I, Williams RL, Thornby JI, Salis PJ.&nbsp; Sleep-related penile tumescence as a function of age. Am J Psychiatry 1975; 132:932.</div><div id=\"graphicVersion\">Graphic 56491 Version 2.0</div></div></div>"},"56492":{"type":"graphic_table","displayName":"Nonresectoscopic ablation","title":"Nonresectosopic endometrial ablation methods (available in the United States)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonresectosopic endometrial ablation methods (available in the United States)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Ablation method (device names)</td> <td class=\"subtitle1\" rowspan=\"2\">Endometrial preparation</td> <td class=\"subtitle1\" rowspan=\"2\">Device diameter (mm)</td> <td class=\"subtitle1\" rowspan=\"2\">Treatment time (min)</td> <td class=\"subtitle1\" colspan=\"2\">Sounded uterine length (cm)*</td> <td class=\"subtitle1\" colspan=\"3\">Treatment in women with submucosal leiomyomas</td> </tr> <tr> <td class=\"subtitle2\">Minimum</td> <td class=\"subtitle2\">Maximum</td> <td class=\"subtitle2\">Diameter (cm)</td> <td class=\"subtitle2\">Published evidence</td> <td class=\"subtitle2\">Women with leiomyomas included in trials for US FDA approval</td> </tr> <tr> <td>Bipolar radiofrequency (Novasure&#174;)</td> <td>None</td> <td>7.5</td> <td>1 to 2</td> <td>6<sup>&#182;</sup></td> <td>10</td> <td>&#60;3</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>Microwave (Microwave Endometrial Ablation)</td> <td>Hormonal suppression</td> <td>8.5</td> <td>3 to 5</td> <td>6</td> <td>12</td> <td>&#8804;3</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Hot liquid filled balloon (ThermaChoice&#174;)</td> <td>Hormonal suppression or uterine curettage</td> <td>5</td> <td>8</td> <td>6</td> <td>10</td> <td>&#8804;3</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>Cryoablation (Her Option&#174;)</td> <td>Hormonal suppression</td> <td>5.5</td> <td>6 to 18</td> <td>4</td> <td>10</td> <td>Not applicable</td> <td>No</td> <td>No</td> </tr> <tr> <td>Circulating hot water (Hydro ThermAblator&#174;)</td> <td>Hormonal suppression</td> <td>7.8</td> <td>11</td> <td>6</td> <td>10.5</td> <td>&#8804;4</td> <td>Yes</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDA: Food and Drug Administration.<br />* Sounded uterine length is from the external cervical os to the uterine fundus.<br />&para; For bipolar radiofrequency ablation, the minimim cornu to cornu distance is 2.5 cm.</div><div class=\"graphic_reference\">Modified with permission from: ACOG Practice Bulletin No. 81: Endometrial Ablation. Obstet Gynecol 2007; 109:1233. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56492 Version 12.0</div></div></div>"},"56493":{"type":"graphic_algorithm","displayName":"Algorithm HIT","title":"Approach to the patient with suspected heparin-induced thrombocytopenia","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Approach to the patient with suspected heparin-induced thrombocytopenia</div><div class=\"cntnt\"><img style=\"width:511px; height:329px;\" src=\"images/HEME/56493_Algorithm_HIT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heparin-induced thrombocytopenia (HIT) should be suspected when there is thrombocytopenia, thrombosis with thrombocytopenia, a platelet count that has fallen by &ge;50 percent, or necrotic skin lesions at injection sites in a patient started on heparin within the preceding 5 to 10 days. The diagnosis is initially made on clinical grounds because assays with the highest sensitivity and specificity may not be readily available and have a slow turnaround time. Refer to UpToDate HIT topics for further information regarding presumptive diagnosis of HIT.</div><div class=\"graphic_footnotes\">HIT: heparin-induced thrombocytopenia; HIPA: heparin-induced platelet aggregation assay; heparin-PF4 Ab: heparin-platelet factor 4 antibody.<br />* Observation should be chosen only if patient is at high risk for bleeding. Otherwise, treatment (anticoagulation with the agents listed) is preferred until the platelet count has returned to normal, at which time treatment with a vitamin K antagonist can be given. Refer to UpToDate HIT topics for details.</div><div id=\"graphicVersion\">Graphic 56493 Version 7.0</div></div></div>"},"56494":{"type":"graphic_picture","displayName":"Chigger larva","title":"Larval stage of Trombicula alfreddugesi (450x)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Larval stage of Trombicula alfreddugesi (450x)</div><div class=\"cntnt\"><img style=\"width:432px; height:380px;\" src=\"images/PC/56494_Chigger_larva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The larval stage of <EM>Trombicula alfreddugesi </EM>is the most common chigger to affect humans in the United States. Larvae demonstrate only six legs (rather than the eight of mature forms) and a light coat of hairs.</div><div class=\"graphic_reference\">Courtesy of JF Butler, Professor Emeritus, University of Florida.</div><div id=\"graphicVersion\">Graphic 56494 Version 2.0</div></div></div>"},"56497":{"type":"graphic_diagnosticimage","displayName":"Color Doppler images of two-vessel umbilical cord","title":"Color Doppler images of two-vessel umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Color Doppler images of two-vessel umbilical cord</div><div class=\"cntnt\"><img style=\"width:504px; height:576px;\" src=\"images/OBGYN/56497_US2vesselcorded2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal three-vessel umbilical cord. Color Doppler shows presence of two umbilical arteries, one on each side of the bladder.<br />(B) Two-vessel umbilical cord. Color Doppler images show alternating single artery and vein.<br />(C) Two-vessel umbilical cord. Transverse view at the level of the fetal bladder shows an artery on only one side of the fetal bladder.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 56497 Version 9.0</div></div></div>"},"56498":{"type":"graphic_diagnosticimage","displayName":"Supracristal VSD subcostal 2D and color still frame","title":"Supracristal VSD subcostal 2D and color still frame","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Supracristal VSD subcostal 2D and color still frame</div><div class=\"cntnt\"><img style=\"width:546px; height:396px;\" src=\"images/CARD/56498_Supracristal_VSD_subcost_2D.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paired subcostal parasagittal images of a supracristal ventricular septal defect (VSD, arrow) located just beneath the pulmonary valve.</div><div class=\"graphic_footnotes\">PA: pulmonary artery; RV: right ventricle; IVS: trabecular portion of the intraventricular septum; LVOT: left ventricular outflow tract; LA: left atrium; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 56498 Version 3.0</div></div></div>"},"56499":{"type":"graphic_table","displayName":"Phenytoin poisoning - Rapid overview","title":"Phenytoin poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phenytoin poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">General</td> </tr> <tr> <td>Phenytoin is an anticonvulsant; fosphenytoin is a prodrug of phenytoin</td> </tr> <tr> <td>Neurological signs are by far the most common manifestation of phenytoin overdose</td> </tr> <tr> <td>Rapid IV administration can cause hypotension, bradyarrhythmia, and possibly asystole</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td>Mild poisoning: horizontal nystagmus, unsteady gait, worsening coordination</td> </tr> <tr> <td>Severe poisoning: slurred speech; depressed mental status (possibly coma)</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory/diagnostic evaluation</td> </tr> <tr> <td class=\"sublist1_start\">Phenytoin toxicity</td> </tr> <tr> <td class=\"sublist1\">Obtain phenytoin serum concentration</td> </tr> <tr> <td class=\"sublist1\">Obtain serum albumin if phenytoin concentration and clinical findings inconsistent; hypoalbuminemia predisposes to toxicity</td> </tr> <tr> <td class=\"sublist1_start\">Routine testing in poisoned patients</td> </tr> <tr> <td class=\"sublist1\">Fingerstick glucose if mental status altered</td> </tr> <tr> <td class=\"sublist1\">Acetaminophen and salicylate concentrations if possible suicide attempt</td> </tr> <tr> <td class=\"sublist1\">ECG to assess for poisoning by drugs that effect QRS or QTc intervals</td> </tr> <tr> <td class=\"sublist1\">Pregnancy test in women of childbearing years</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Administer activated charcoal (1 g/kg up to 50 g) for symptomatic acute ingestions, unless airway is not protected or other contraindications exist</td> </tr> <tr> <td>Administer activated charcoal (1 g/kg up to 50 g) for asymptomatic patients who report significant ingestions if less than 1 to 2 hours after ingestion</td> </tr> <tr> <td>Provide supportive care as needed</td> </tr> <tr> <td class=\"subtitle1_single\">Disposition</td> </tr> <tr> <td>Patients with acute toxicity or moderate to severe symptoms from chronic toxicity should be hospitalized</td> </tr> <tr> <td>Children may manifest signs of phenytoin toxicity at lower serum concentrations than adults and thus are more likely to require admission</td> </tr> <tr> <td>Patients with chronic toxicity may be discharged if they can ambulate safely and have someone to monitor them and assist with their activities of daily living until toxicity has resolved</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56499 Version 4.0</div></div></div>"},"56501":{"type":"graphic_table","displayName":"Aspiration risk factors","title":"Conditions that predispose to aspiration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions that predispose to aspiration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Altered consciousness</td> </tr> <tr> <td class=\"indent1\">Alcoholism, seizures, head trauma, general anesthesia, drug overdose</td> </tr> <tr> <td class=\"subtitle1_single\">Dysphagia</td> </tr> <tr> <td class=\"indent1\">Esophageal disorders including stricture, neoplasm, diverticula, tracheoesophageal fistula, incompetent cardiac sphincter, achalasia<span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">, oropharyngeal obstruction, xerostomia</span></td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic disorder</td> </tr> <tr> <td class=\"indent1\"><span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">Cerebrovascular accident, multiple sclerosis, Parkinson disease, myasthenia gravis, pseudobulbar palsy, amyotrophic lateral sclerosis</span></td> </tr> <tr> <td class=\"subtitle1_single\">Mechanical disruption of the usual defense barriers</td> </tr> <tr> <td class=\"indent1\">Nasogastric tube, endotracheal intubation, tracheostomy, upper gastrointestinal endoscopy, bronchoscopy</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Protracted vomiting, gastric outlet obstruction, large-volume nasogastric tube feedings, pharyngeal anesthesia, general debility, recumbent position, ascites, gastroparesis, ileus<span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">, glottic insufficiency (eg, vocal cord paralysis)</span></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56501 Version 5.0</div></div></div>"},"56503":{"type":"graphic_diagnosticimage","displayName":"CT guided biopsy Ewing sarcoma","title":"CT-guided biopsy of Ewing sarcoma of the right ilium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT-guided biopsy of Ewing sarcoma of the right ilium</div><div class=\"cntnt\"><img style=\"width:390px; height:262px;\" src=\"images/ONC/56503_CT_biopsy_Ewings_sarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT-guided needle biopsy of a large pelvic Ewings sarcoma involving the right ilium (arrow) of a 28-year-old man. The core biopsy needle can be seen here approaching the lesion posteriorly (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Thomas DeLaney, MD.</div><div id=\"graphicVersion\">Graphic 56503 Version 4.0</div></div></div>"},"56504":{"type":"graphic_table","displayName":"ASD treatment resources","title":"Online resources for providers and families of children with autism spectrum disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Online resources for providers and families of children with autism spectrum disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Resource</td> <td class=\"subtitle1\">Description</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Agency for Healthcare Research and Quality (AHRQ) Consumer Summary: Therapies for Children with Autism Spectrum Disorder</strong></p> <p><a href=\"http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&#38;productID=1974\" spellcheck=\"true\" target=\"_blank\">effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&#38;productID=1974</a></p> </td> <td>Provides information for families about the possible benefits and side effects of treatments for children with ASD</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>American Academy of Pediatrics National Center for Medical Home Implementation</strong></p> <a href=\"http://www.medicalhomeinfo.org/\" target=\"_blank\">www.medicalhomeinfo.org</a></td> <td>Provides information for families and providers, including a resource toolkit (for purchase)</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Autism Society of America</strong></p> <a href=\"http://www.autism-society.org/\" target=\"_blank\">www.autism-society.org</a></td> <td>Provides information about treatment, education, and advocacy</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Autism Speaks Family Services Tool Kits</strong></p> <a href=\"http://www.autismspeaks.org/family-services/tool-kits\" target=\"_blank\">www.autismspeaks.org/family-services/tool-kits</a></td> <td>Provides tool kits to help with blood draws, dental visits, transitions, toilet training, education planning, etc</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Autism Speaks 100 Day Kits</strong></p> <ul> <li>&nbsp;For newly diagnosed families of young children </li> </ul> <p>&nbsp;<a href=\"http://www.autismspeaks.org/family-services/tool-kits/100-day-kit\" spellcheck=\"true\">www.autismspeaks.org/family-services/tool-kits/100-day-kit</a></p> <ul> <li>For school-age children </li> </ul> <p>&nbsp;<a href=\"http://www.autismspeaks.org/family-services/tool-kits/100-day-kit-school-age\">www.autismspeaks.org/family-services/tool-kits/100-day-kit-school-age</a></p> </td> <td>Provide information for families to make the best possible use of the 100 days following diagnosis of ASD</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>The Centers for Disease Control and Prevention's Autism Information Center</strong></p> <a href=\"http://www.cdc.gov/ncbddd/autism/treatment.html\" target=\"_blank\">www.cdc.gov/ncbddd/autism/treatment.html</a></td> <td>Provides information about treatment of ASD</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>First Signs</strong></p> <p><a href=\"http://www.firstsigns.org/\" target=\"_blank\">www.firstsigns.org</a></p> <a href=\"http://www.firstsigns.org/asd_video_glossary/asdvg_about.htm\" target=\"_blank\">www.firstsigns.org/asd_video_glossary/asdvg_about.htm</a></td> <td>Provides information for providers and parents, including video clips showing early red flags for ASD</td> </tr> <tr> <td> <p><strong>The United Kingdom's National Autistic Society</strong></p> <a href=\"http://www.nas.org.uk/\" target=\"_blank\">www.nas.org.uk</a></td> <td>Provides information about ASD, services, and activities</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ASD: autism spectrum disorder. </div><div id=\"graphicVersion\">Graphic 56504 Version 10.0</div></div></div>"},"56505":{"type":"graphic_table","displayName":"Clues viral CNS infections children","title":"Clinical clues to viral infections of the central nervous system in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical clues to viral infections of the central nervous system in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\" colspan=\"2\">Relative frequency of meningitis versus encephalitis*</td> <td class=\"subtitle1\">Potential clinical clues</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Enteroviruses</td> </tr> <tr> <td class=\"indent2\">Coxsackie A and B viruses</td> <td class=\"centered\" colspan=\"2\">Meningitis &#62; Encephalitis</td> <td>Herpangina, hand-foot-mouth disease, conjunctivitis, pharyngitis, pleurodynia, myopericarditis, rash</td> </tr> <tr> <td class=\"indent2\">Echoviruses</td> <td class=\"centered\" colspan=\"2\">Meningitis &#62; Encephalitis</td> <td>Rash</td> </tr> <tr> <td class=\"indent2\">Polioviruses</td> <td class=\"centered\" colspan=\"2\">Meningitis &#62; Encephalitis</td> <td>Flaccid paralysis</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Arthropod-borne viruses (arboviruses)</td> </tr> <tr> <td class=\"indent2\">West Nile virus</td> <td class=\"centered\" colspan=\"2\">Encephalitis &#62; Meningitis</td> <td>Rash; mosquito exposure</td> </tr> <tr> <td class=\"indent2\">St. Louis encephalitis virus</td> <td class=\"centered\" colspan=\"2\">Meningitis&nbsp;= Encephalitis</td> <td>Mosquito exposure</td> </tr> <tr> <td class=\"indent2\">La Crosse (California) encephalitis virus</td> <td class=\"centered\" colspan=\"2\">Meningitis&nbsp;= Encephalitis</td> <td>Mosquito exposure</td> </tr> <tr> <td class=\"indent2\">Eastern equine encephalitis virus</td> <td class=\"centered\" colspan=\"2\">Encephalitis &#62; Meningitis</td> <td>Mosquito exposure</td> </tr> <tr> <td class=\"indent2\">Western equine encephalitis virus</td> <td class=\"centered\" colspan=\"2\">Meningitis&nbsp;= Encephalitis</td> <td>Mosquito exposure</td> </tr> <tr> <td class=\"indent2\">Powassan virus</td> <td class=\"centered\" colspan=\"2\">Encephalitis &#62; Meningitis</td> <td>Tick exposure</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Herpesviruses</td> </tr> <tr> <td class=\"indent2\">Herpes simplex type 1</td> <td class=\"centered\" colspan=\"2\">Encephalitis &#62; Meningitis</td> <td>Oral lesions</td> </tr> <tr> <td class=\"indent2\">Herpes simplex type 2</td> <td class=\"centered\" colspan=\"2\">Meningitis&nbsp;&#62; Encephalitis</td> <td>Genital lesions, sacral radiculopathy (urinary retention, constipation, paresthesia, weakness)</td> </tr> <tr> <td class=\"indent2\">Cytomegalovirus</td> <td class=\"centered\" colspan=\"2\">Encephalitis &#62; Meningitis</td> <td>Immunocompromised host</td> </tr> <tr> <td class=\"indent2\">Varicella zoster virus</td> <td class=\"centered\" colspan=\"2\">Meningitis&nbsp;&#62; Encephalitis</td> <td>Vesicular rash; shingles</td> </tr> <tr> <td class=\"indent2\">Epstein-Barr virus</td> <td class=\"centered\" colspan=\"2\">Encephalitis &#62; Meningitis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Other viruses</td> </tr> <tr> <td class=\"indent2\">Human immunodeficiency virus</td> <td class=\"centered\" colspan=\"2\">Meningitis&nbsp;= Encephalitis</td> <td>Intravenous drug use, risky sexual behavior</td> </tr> <tr> <td class=\"indent2\">Rabies virus</td> <td class=\"centered\" colspan=\"2\">Encephalitis &#62; Meningitis</td> <td>Animal exposure; prodrome of nonspecific symptoms (fever, headache, malaise, myalgia, cough, sore throat, nausea, vomiting)</td> </tr> <tr> <td class=\"indent2\">Lymphocytic choriomeningitis virus</td> <td class=\"centered\" colspan=\"2\">Meningitis&nbsp;&#62; Encephalitis</td> <td>Rodent pets or contact with rodent droppings or urine</td> </tr> <tr> <td class=\"indent2\">Influenza virus</td> <td class=\"centered\" colspan=\"2\">Encephalitis &#62; Meningitis</td> <td>Classic influenza symptoms: fever, cough, vomiting, headache, diarrhea</td> </tr> <tr> <td class=\"indent2\">Mumps virus</td> <td class=\"centered\" colspan=\"2\">Meningitis&nbsp;&#62; Encephalitis</td> <td>Painful parotitis; occurs in unvaccinated or incompletely vaccinated individuals</td> </tr> <tr> <td class=\"indent2\">Measles virus</td> <td class=\"centered\" colspan=\"2\">Meningitis&nbsp;&#62; Encephalitis</td> <td>Conjunctivitis, coryza, cough; occurs in unvaccinated or incompletely vaccinated individuals</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56505 Version 5.0</div></div></div>"},"56508":{"type":"graphic_diagnosticimage","displayName":"Proximal phalanx oblique fracture AP radiograph","title":"Oblique fracture of the proximal phalanx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique fracture of the proximal phalanx</div><div class=\"cntnt\"><img style=\"width:384px; height:534px;\" src=\"images/EM/56508_Prox_phalanx_oblique_fx_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows an oblique fracture of the proximal phalanx (white arrow). Oblique fractures may be stable if the periosteal sleeve is intact.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 56508 Version 3.0</div></div></div>"},"56512":{"type":"graphic_figure","displayName":"Total body water","title":"Total body water and its major subdivisions as a function of age","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Total body water and its major subdivisions as a function of age</div><div class=\"cntnt\"><img style=\"width:535px; height:338px;\" src=\"images/PEDS/56512_Total_body_water.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics 1961; 28:169.</div><div id=\"graphicVersion\">Graphic 56512 Version 2.0</div></div></div>"},"56514":{"type":"graphic_picture","displayName":"Rheumatoid nodule","title":"Rheumatoid nodule","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Rheumatoid nodule</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/56514_Rheumatoid_nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rheumatoid vasculitis tends to occur in patients with aggressive, erosive arthritis associated with rheumatoid nodules.</div><div class=\"graphic_reference\">Courtesy of John Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 56514 Version 2.0</div></div></div>"},"56515":{"type":"graphic_figure","displayName":"Ankle block","title":"Ankle block","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Ankle block</div><div class=\"cntnt\"><img style=\"width:535px; height:564px;\" src=\"images/SURG/56515_Ankleblocks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ankle block anesthetizes four branches of the sciatic nerve (superficial peroneal, deep peroneal, posterior tibial, and sural nerves) and one cutaneous branch of the femoral nerve (saphenous nerve). Each nerve is independently anesthetized.<br />The deep peroneal nerve innervates the first webspace of the foot. The dorsalis pedis artery is palpated and the needle inserted just lateral to the extensor hallucis longus tendon.<br />The superficial peroneal nerve supplies the skin over the dorsum of the foot and is blocked by subcutanous infiltration over the dorsum of the foot starting from the injection site for the deep peroneal nerve (above).<br />The posterior tibial nerve provides sensation to the calcaneus and sole of the foot. It is anesthetized by injecting local anesthetic behind the medial malleolus.<br />The sural nerve provides cutaneous sensation over the lateral ankle, foot, and fifth toe and is adjacent to&nbsp;the small saphenous vein. It is blocked by injecting local anesthetic behind the lateral malleolus.<br />The saphenous nerve supplies sensation to the skin over the medial aspect of the ankle and foot. It is blocked by injecting a ring of local anesthetic around the great saphenous vein.</div><div id=\"graphicVersion\">Graphic 56515 Version 6.0</div></div></div>"},"56516":{"type":"graphic_figure","displayName":"Types ascitic fluid infection","title":"Natural history of ascitic fluid infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Natural history of ascitic fluid infection</div><div class=\"cntnt\"><img style=\"width:382px; height:302px;\" src=\"images/GAST/56516_Types_ascitic_fluid_infecti.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between spontaneous bacterial peritonitis and its variants as shown by the short-term, untreated natural history of the different conditions.</div><div class=\"graphic_reference\">Adapted from McHutchison JG, Runyon BA. Spontaneous bacterial peritonitis. In: Gastrointestinal and Hepatic Infections, Surawicz CM, Owen RL (Eds), WB Saunders, Philadelphia, 1994, p. 455.</div><div id=\"graphicVersion\">Graphic 56516 Version 2.0</div></div></div>"},"56518":{"type":"graphic_table","displayName":"Immunohistochemistry CUP","title":"Immunohistochemical and histochemical stains useful in the differential diagnosis of poorly differentiated neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunohistochemical and histochemical stains useful in the differential diagnosis of poorly differentiated neoplasms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor type</td> <td class=\"subtitle1\">Immunohistochemical staining</td> </tr> <tr class=\"divider_bottom\"> <td>Carcinoma</td> <td> <p>Positive: Pankeratin, AE 1/3, CAM 5.2, OSCAR, EMA</p> <p>Negative: CD 45</p> Variable: CK 7, CK 20, S-100, vimentin</td> </tr> <tr class=\"divider_bottom\"> <td>Colorectal carcinoma</td> <td> <p>Positive: CK 20, CDX-2</p> Negative: CK 7</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Lung carcinoma</td> </tr> <tr> <td class=\"indent1\">Adenocarcinoma</td> <td>Positive: TTF-1, napsin A, CK 7, mucicarmine, PAS-D</td> </tr> <tr> <td class=\"indent1\">Squamous cell carcinoma</td> <td> <p>Positive: p 40, p 63, CK 5/6, desmoglein</p> Negative: CK 7 (usually)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Small-cell carcinoma</td> <td> <p>Positive: TTF-1, high proliferative rate (Ki-67, MIB-1)</p> Variable: Chromogranin, synaptophysin</td> </tr> <tr class=\"divider_bottom\"> <td>Neuroendocrine carcinoma</td> <td>Positive: Chromogranin, synaptophysin, epithelial stains</td> </tr> <tr class=\"divider_bottom\"> <td>Germ cell tumor</td> <td>Positive: HCG, AFP, Oct4 transcription factor, placental alkaline phosphatase, epithelial stains</td> </tr> <tr class=\"divider_bottom\"> <td>Hepatocellular carcinoma</td> <td> <p>Positive: Hep par 1, CEA, AFP, glypican 3</p> Negative: CK 7, CK 20</td> </tr> <tr class=\"divider_bottom\"> <td>Renal cell carcinoma</td> <td> <p>Positive: Pan keratin, CAM 5.2, Pax-8, CK 7, vimentin, RCC, CD 10</p> Negative: CK 20, CEA</td> </tr> <tr class=\"divider_bottom\"> <td>Prostate carcinoma</td> <td> <p>Positive: PSA, prostatic acid phosphatase</p> Negative: CK 7, 20</td> </tr> <tr class=\"divider_bottom\"> <td>Pancreas carcinoma</td> <td> <p>Positive: CA 19-9, CK 7, CDX-2, CK 17</p> Variable: CK 20</td> </tr> <tr class=\"divider_bottom\"> <td>Breast carcinoma</td> <td> <p>Positive: ER, PR, Her-2-neu, CK 7, gross cystic fluid protein 15, epithelial stains, GATA 3, mammaglobin</p> Negative: CK 20</td> </tr> <tr> <td>Ovarian carcinoma</td> <td> <p>Positive: CK 7, WT-1, Pax-8, ER</p> Negative: CK 20, CDX-2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EMA: epithelial membrane antigen; CD: luster of differentiation; CK: cytokeratin; S-100: S-100 protein; CDX: caudal type homeo box transcription factor 2; TTF-1: thyroid transcription factor-1; PAS-D: Periodic Acid Schiff with diastase predigestion; NSE: neuron-specific enolase; HCG: human chorionic gonadotropin; AFP: &alpha;-fetoprotein; Hep par: hepatocyte paraffin 1 monoclonal antibody; CEA: carcinoembryonic antigen; Pax: paired box gene; RCC: renal cell carcinoma; PSA: prostate-specific antigen; CA: carbohydrate antigen 19-9; ER: estrogen receptor; PR: progesterone receptor; WT-1: Wilm's tumor-1 protein.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Thunnissen E, Kerr KM, Herth FJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012; 76:1.</li>&#xD;&#xA;    <li>Pelosi G, Rossi G, Bianchi F, et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 2011; 6:1039.</li>&#xD;&#xA;    <li>http://www.immunoquery.com (Accessed on September 30, 2014).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 56518 Version 10.0</div></div></div>"},"56519":{"type":"graphic_picture","displayName":"IUD PI","title":"Tcu-380A (Paragard®) intrauterine contraceptive device","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Tcu-380A (Paragard&#174;) intrauterine contraceptive device</div><div class=\"cntnt\"><img style=\"width:468px; height:287px;\" src=\"images/PI/56519_IUD_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This device consists of a T-shaped polyethylene frame with 380 mm2 of exposed surface consisting of fine copper wire wound around the vertical stem and each of the horizontal arms. There is a 3-mm ball at the base of the stem to decrease the risk of cervical perforation [1]. A white or clear polyethylene monofilament string is knotted through this ball.</div><div id=\"graphicVersion\">Graphic 56519 Version 1.0</div></div></div>"},"56521":{"type":"graphic_algorithm","displayName":"Pathophysiology of MAS","title":"Pathophysiology of meconium aspiration syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of meconium aspiration syndrome</div><div class=\"cntnt\"><img style=\"width:396px; height:331px;\" src=\"images/PEDS/56521_Pathophysiology_MAS_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Joseph A Garcia-Prats, MD.</div><div id=\"graphicVersion\">Graphic 56521 Version 7.0</div></div></div>"},"56522":{"type":"graphic_table","displayName":"Normal values impedance pH","title":"Normal values for combined impedance-pH monitoring based on 95th percentile data in healthy volunteers off and on acid-suppressive therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal values for combined impedance-pH monitoring based on 95th percentile data in healthy volunteers off and on acid-suppressive therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle1\"> <p>Off therapy</p> <p>(N = 60)</p> </td> <td class=\"subtitle1\"> <p>On therapy (PPI twice daily)</p> <p>(N = 20)</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Esophageal pH data</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Percent&nbsp;time pH &#60;4</td> <td>Total</td> <td>6.7%</td> <td>1.3%</td> </tr> <tr> <td>Upright</td> <td>9.7%</td> <td>2.2%</td> </tr> <tr> <td>Recumbent</td> <td>2.1%</td> <td>0.0%</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Esophageal MII-data</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Nr. reflux episodes</td> <td>Total</td> <td>73</td> <td>48</td> </tr> <tr> <td>Acid</td> <td>55</td> <td>12</td> </tr> <tr> <td>Non-acid</td> <td>27</td> <td>44</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPI: proton pump inhibitor; MII: multichannel intraluminal impedance. </div><div class=\"graphic_reference\">Data from:<br> 1. Shay, S, Tutuian, R, Sifrim, D, et al. Twenty-Four Hour Ambulatory Simultaneous Impedance and pH Monitoring: A Multicenter Report of Normal Values From 60 Healthy Volunteers. Am J Gastroenterol 2004; 99:1037.<br> 2. Tutuian, R, Mainie, I, Agrawal, A, et al. Normal values for ambulatory 24-h combined impedance-pH monitoring on acid suppressive therapy. Gastroenterology 2006; 130 Suppl 2:A171.</div><div id=\"graphicVersion\">Graphic 56522 Version 2.0</div></div></div>"},"56523":{"type":"graphic_figure","displayName":"Free light chains serum","title":"Serum free light chains","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Serum free light chains</div><div class=\"cntnt\"><img style=\"width:524px; height:516px;\" src=\"images/HEME/56523_Free_light_chains_serum.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows simultaneous measurements of free serum kappa (horizontal axis) and lambda (vertical axis) light chains. The dashed line indicates a 1:1 kappa/lambda ratio (weight basis). Results are shown for 282 normal subjects (+), 120 patients with kappa light chain myeloma (closed circles), 140 patients with lambda light chain myeloma (closed triangles), 31 patients with renal impairment from non light chain disorders (open squares), and 28 subjects with non-secretory myeloma (open circles). Note that monoclonality could be detected in many of the latter group using this technique.</div><div class=\"graphic_reference\">Data from:&nbsp;Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361:489.</div><div id=\"graphicVersion\">Graphic 56523 Version 2.0</div></div></div>"},"56524":{"type":"graphic_table","displayName":"Effects of types of fat","title":"Type of fat intake affects cholesterol concentrations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Type of fat intake affects cholesterol concentrations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Diet enriched with</td> <td class=\"subtitle1\" rowspan=\"2\">Saturated fatty acids, g per 100 g fat</td> <td class=\"subtitle1\" rowspan=\"2\">Trans fatty acids, g per 100 g fat</td> <td class=\"subtitle1\" colspan=\"3\">Compared with butter-enriched diet</td> </tr> <tr> <td class=\"subtitle2\">LDL-C, percent</td> <td class=\"subtitle2\">HDL-C, percent</td> <td class=\"subtitle2\">TC:HDL-C, percent</td> </tr> <tr> <td>Soybean oil</td> <td>25.0</td> <td>&#60;0.5</td> <td>-12</td> <td>-3</td> <td>-6</td> </tr> <tr> <td>Semiliquid margarine</td> <td>27.0</td> <td>&#60;0.5</td> <td>-11</td> <td>-4 </td> <td>-5</td> </tr> <tr> <td>Soft margarine</td> <td>25.2</td> <td>7.4</td> <td>-9</td> <td>-4</td> <td>-2</td> </tr> <tr> <td>Shortening</td> <td>29.3</td> <td>9.9</td> <td>-7</td> <td>-4</td> <td>-1</td> </tr> <tr> <td>Stick margarine</td> <td>27.0</td> <td>20.1</td> <td>-5</td> <td>-6</td> <td>+4</td> </tr> <tr> <td>Butter</td> <td>61.7</td> <td>1.5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In an outpatient feeding study, compared with a butter-enriched diet, diets relatively higher in trans fat resulted in smaller reductions in LDL-C and larger reductions in HDL-C. The stick margarine diet, highest in trans fatty acids, resulted in a TC:HDL-C ratio that was 4% higher than the high saturated fat diet. The diets with the most favorable lipid profiles were the soybean and liquid margarine diets, characterized by low amounts of both saturated and trans fatty acids.</div><div class=\"graphic_footnotes\">LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol.</div><div class=\"graphic_reference\">Data from Lichtenstein, AH, Ausman, LM, Jalbert, SM, Schaefer, EJ, N Engl J Med 1999; 340:1933.</div><div id=\"graphicVersion\">Graphic 56524 Version 2.0</div></div></div>"},"56527":{"type":"graphic_picture","displayName":"Infiltrative basal cell carcinoma","title":"Infiltrative basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infiltrative basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/56527_Infil_basal_cell_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infiltrative or morpheaform basal cell carcinomas can present as indented, scar-like lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56527 Version 5.0</div></div></div>"},"56528":{"type":"graphic_figure","displayName":"Triple rhomboid hexagonal flap","title":"Triple rhomboid hexagonal flap","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Triple rhomboid hexagonal flap</div><div class=\"cntnt\"><img style=\"width:542px; height:322px;\" src=\"images/SURG/56528_Triplerhomboidhexagonalflap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure depicts closure of a defect with a triple rhomboid hexagonal flap. The orientation of the hexagon and the three rhomboids is adjusted to maximize laxity of the donor flap closure. In addition, the flaps can be oriented with either a clockwise or counterclockwise transposition, also depending on tissue laxity. Note that all three flaps must transpose in the same direction.</div><div id=\"graphicVersion\">Graphic 56528 Version 8.0</div></div></div>"},"56531":{"type":"graphic_diagnosticimage","displayName":"Melioidosis liver abscess","title":"Computed tomography of melioidosis liver abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of melioidosis liver abscess</div><div class=\"cntnt\"><img style=\"width:382px; height:266px;\" src=\"images/ID/56531_Melioidosis_liver_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lobulated liver abscess by CT scan in a patient with melioidosis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Bart Currie, FRACP.</div><div id=\"graphicVersion\">Graphic 56531 Version 5.0</div></div></div>"},"56532":{"type":"graphic_picture","displayName":"Infil UC microcyst variant","title":"Infiltrating urothelial carcinoma, microcystic variant","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Infiltrating urothelial carcinoma, microcystic variant</div><div class=\"cntnt\"><img style=\"width:506px; height:192px;\" src=\"images/ONC/56532_Infil_UC_microcyst_variant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) At low power (20x) the microcystic variant of infiltrating urothelial carcinoma tumor may show a striking cystic pattern. B) At high power (40x) the cysts contain necrotic material or pink secretions. The cyst lining may be flattened or absent.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 56532 Version 1.0</div></div></div>"},"56533":{"type":"graphic_picture","displayName":"MDI spacers PI","title":"Accessory devices used with metered dose inhalers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Accessory devices used with metered dose inhalers</div><div class=\"cntnt\"><img style=\"width:220px; height:490px;\" src=\"images/PI/56533_MDI_spacers_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These pictures show different types of spacers, with and without a face mask. A spacer makes it easier to use an inhaler and helps more of the medicine reach the lungs. Picture A shows an AeroChamber spacer. Picture B shows an AeroChamber spacer with a face mask. Picture C shows an InspirEase spacer.</div><div id=\"graphicVersion\">Graphic 56533 Version 4.0</div></div></div>"},"56534":{"type":"graphic_table","displayName":"Hormonal resuscitation","title":"Hormonal replacement therapy for the pediatric organ donor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hormonal replacement therapy for the pediatric organ donor</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Drug\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Dose\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Route\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Comments\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>\t<p><strong>Desmopressin</strong></p>\n\t<p>\t(DDAVP&#174;)</p>\n</td>\r\n  \r\n   <td>0.5 micrograms/hour</td>\r\n  \r\n   <td>IV</td>\r\n  \r\n   <td>\t<p>half-life 75-120 minutes</p>\n\t<p>\tTitrate to decrease urine output to 3-4 cc/kg/hour</p>\n\t<p>\tMay be beneficial in patients with an ongoing coagulopathy</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>\t<p><strong>Vasopressin</strong></p>\n\t<p>\t(Pitressin&#174;)</p>\n</td>\r\n  \r\n   <td>0.5-1 milli-units/kg/hour</td>\r\n  \r\n   <td>IV</td>\r\n  \r\n   <td>\t<p>half-life 10-35 minutes</p>\n\t<p>\tTitrate to decrease urine output to 3-4 cc/kg/hour</p>\n\t<p>\tHypertension can occur</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"4\">\r\n  \r\n   Treatment of diabetes insipidus should consist of pharmacologic management to decrease but not completely stop urine output. Replacement of urine output with 1/4 or 1/2 normal saline should be used in conjunction with pharmacologic agents to maintain serum sodium levels between 130-150 meq/L.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>\t<p><strong>Levothyroxine</strong></p>\n\t<p>\t(Synthroid&#174;)</p>\n</td>\r\n  \r\n   <td>0.8-1.4 micrograms/kg/hour</td>\r\n  \r\n   <td>IV</td>\r\n  \r\n   <td>\t<p>Bolus dose 1-5 micrograms/kg can be administered</p>\n\t<p>\tInfants and smaller children require a larger bolus and infusion dose</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>\t<p><strong>Triiodothyronine</strong></p>\n\t<p>\t(T<sub>3</sub>)</p>\n</td>\r\n  \r\n   <td>0.05-0.2 micrograms/kg/hour</td>\r\n  \r\n   <td>IV</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>\t<p><strong>Methylprednisolone</strong></p>\n\t<p>\t(Solu-Medrol&#174;)</p>\n</td>\r\n  \r\n   <td>20-30 mg/kg</td>\r\n  \r\n   <td>IV</td>\r\n  \r\n   <td>\t<p>Dose may be repeated in 8-12 hours</p>\n\t<p>\tFluid retention</p>\n\t<p>\tGlucose intolerance</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><strong>Insulin</strong></td>\r\n  \r\n   <td>0.05-0.1 units/kg/hour</td>\r\n  \r\n   <td>IV</td>\r\n  \r\n   <td>\t<p>Titrate to control blood glucose levels to 60-150 mg/dL</p>\n\t<p>\tMonitor for hypoglycemia</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"4\">\r\n  \r\n   Hormonal replacement therapy should be considered early in the course of donor management. Use of hormonal replacement therapy may allow weaning of inotropic support and assist with metabolic stability for the pediatric donor.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Reproduced with permission from: Nakagawa, TA. Pediatric donor management guidelines. NATCO, The Organization for Transplant Professionals, 2008. p.4.</div><div id=\"graphicVersion\">Graphic 56534 Version 2.0</div></div></div>"},"56535":{"type":"graphic_figure","displayName":"Pediatric airway anatomy PI","title":"Lungs in a healthy child","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Lungs in a healthy child</div><div class=\"cntnt\"><img style=\"width:550px; height:521px;\" src=\"images/PI/56535_Peds_airway_anat_PI_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is what the lungs of a healthy child look like. They sit on the left and right sides of the upper chest, inside the ribcage. When a child takes a breath, air comes in through the nose and mouth, goes down the throat, and into the main airway leading to the lungs called the \"trachea.\" The trachea branches into the left and right bronchus, which carry air to each lung.</div><div id=\"graphicVersion\">Graphic 56535 Version 7.0</div></div></div>"},"56536":{"type":"graphic_figure","displayName":"Dissection of colon and rectum","title":"Dissection of colon and rectum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dissection of colon and rectum</div><div class=\"cntnt\"><img style=\"width:377px; height:418px;\" src=\"images/SURG/56536_Intra-abd-dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mesentery in incised, exposing&#160;the superior rectal artery. Note the retroperitoneal location of&#160;the ureters and iliac vessels.</div><div id=\"graphicVersion\">Graphic 56536 Version 3.0</div></div></div>"},"56537":{"type":"graphic_figure","displayName":"Geographic distribution of six Loxosceles species in the US","title":"Geographic distribution of verified widespread populations of six native Loxosceles species in the United States","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Geographic distribution of verified widespread populations of six native Loxosceles species in the United States</div><div class=\"cntnt\"><img style=\"width:557px; height:410px;\" src=\"images/EM/56537_US_geograph_distrib_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Rick Vetter. For more information, please visit <A href=\"http://spiders.ucr.edu/\" target=_blank>http://spiders.ucr.edu/</A>. Copyright © 2011 Regents of the University of California.</div><div id=\"graphicVersion\">Graphic 56537 Version 15.0</div></div></div>"},"56539":{"type":"graphic_figure","displayName":"Female perirectal perivesical sp1","title":"Female perivesical and perirectal spaces","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female perivesical and perirectal spaces</div><div class=\"cntnt\"><img style=\"width:407px; height:346px;\" src=\"images/OBGYN/56539_Perirectal_perivesical_sp1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse diagram showing the relationships between the bladder and rectum.</div><div class=\"graphic_footnotes\">BL: bladder; VVS: vesico-vaginal space; VA: vagina; RVS: rectovaginal space; RE: rectum; RRS: retrorectal space.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 56539 Version 2.0</div></div></div>"},"56540":{"type":"graphic_table","displayName":"DDx TPLL path","title":"Differential diagnosis of T cell prolymphocytic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of T cell prolymphocytic leukemia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Entity\n   </td>\n   <td  class=\"subtitle1\">\n   Histology\n   </td>\n   <td  class=\"subtitle1\">\n   Immunophenotype\n   </td>\n   <td  class=\"subtitle1\">\n   Genetic features/Other\n   </td>\n   </tr>\n   <tr>\n   <td>T cell prolymphocytic leukemia (T-PLL)</td>\n   <td>Typically, tumor cells are \"prolymphocytes\" of medium size with moderately condensed chromatin and a visible nucleolus. Round or oval nucleus with moderately abundant agranular cytoplasm. Cytoplasmic protrusions (blebs) are common. Small cell and cerebriform variants can be seen.</td>\n   <td>\t<p>Express CD52 (strongly) and pan-T cell markers (CD2, CD3, and CD7). TdT is negative. Expression of CD4 and CD8 is variable.</p>\n\t<p>TCL1 can be demonstrated by immunohistochemistry.</p>\n</td>\n   <td>\t<p>inv(14q), t(14;14)(q11;q32), or t(X;14)(q28;q11)</p>\n\t<p>TCR genes are clonally rearranged.</p>\n</td>\n   </tr>\n   <tr>\n   <td>B cell prolymphocytic leukemia</td>\n   <td>\t<p>&#62;55 percent (and usually &#62;90 percent) of circulating white cells are \"prolymphocytes\".</p>\n\t<p>The bone marrow is infiltrated in an interstitial or nodular pattern by similar cells.</p>\n</td>\n   <td>Express bright surface IgM +/- IgD and bright CD20 as well as other B-cell antigens (CD19, CD22, CD79a, FMC7).</td>\n   <td>\t<p>t(11;14) must be excluded.</p>\n\t<p>No associated paraproteinemia.</p>\n\t<p>TCR genes are <strong>not</strong> clonally rearranged.</p>\n</td>\n   </tr>\n   <tr>\n   <td>Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL)</td>\n   <td>\t<p>\"Typical\" CLL cells are small mature appearing lymphocytes with a dense nucleus, partially aggregated chromatin, no discernible nucleoli, and a narrow border of cytoplasm.</p>\n\t<p>A minority of cells may have a prolymphocytic morphology.</p>\n</td>\n   <td>Typically express B-cell antigens (CD19, CD22, CD79a, FMC7); CD5; and CD23. Expression of CD20 and surface immunoglobulin is dim.</td>\n   <td>\t<p>Trisomy 12, deletions of 6q, 11q, 13q, and 17p</p>\n\t<p> TCR genes are <strong>not</strong> clonally rearranged.</p>\n</td>\n   </tr>\n   <tr>\n   <td>Mycosis fungoides (MF)</td>\n   <td>Small to medium-sized atypical mononuclear cells with cerebriform nuclei (Sezary cells). Variant of T-PLL has cerebriform morphology similar to that of MF.</td>\n   <td>Typically lack one or more of the following: CD2, CD3, CD5, and CD7.</td>\n   <td>\t<p>TCR genes are clonally rearranged.</p>\n\t<p>Diagnosis uses an algorithm incorporating clinical data.</p>\n</td>\n   </tr>\n   <tr>\n   <td>Adult T cell lymphoma/leukemia</td>\n   <td>Tumor morphology is variable, but often demonstrates medium-sized lymphocytes with condensed chromatin and bizarre hyperlobated nuclei (\"clover leaf\" or \"flower\" cells).</td>\n   <td>Express pan-T cell antigens (CD2, CD4, CD5), typically lack CD7, and may have dim expression of CD3.</td>\n   <td>\t<p>Positive serology or PCR for the human T-lymphotropic virus, type I (HTLV-I).</p>\n\t<p>TCR genes are clonally rearranged.</p>\n</td>\n   </tr>\n   <tr>\n   <td>T cell large granular lymphocyte leukemia</td>\n   <td>Large lymphoid cells with abundant cytoplasm containing typical azurophilic granules with a reniform or round nucleus.</td>\n   <td>Express pan-T cell antigens (CD2, CD3, CD5, CD7). Express CD8 and CD57. CD16 and CD56 expression is variable.</td>\n   <td>TCR genes are clonally rearranged.</td>\n   </tr>\n   <tr>\n   <td>Hairy cell leukemia</td>\n   <td>Variant has circulating tumor cells with morphology intermediate between hairy cells and prolymphocytes.</td>\n   <td>Strongly express pan-B cell antigens (CD19, CD20, CD22), and usually lack expression of CD5, CD10, CD21, and CD23. Characteristically express CD11c, CD25, CD103, CD123, cyclin D1, and annexin A1.</td>\n   <td>TCR genes are <strong>not</strong> clonally rearranged.</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=25170&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>DDx_TPLL_path.htm</title></head></div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; TdT: terminal deoxynucleotidyl transferase; TCL1: T cell leukemia 1; TCR: T cell receptor.</div><div id=\"graphicVersion\">Graphic 56540 Version 1.0</div></div></div>"},"56541":{"type":"graphic_picture","displayName":"Dynamometry","title":"Dynamometry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dynamometry</div><div class=\"cntnt\"><img style=\"width:233px; height:360px;\" src=\"images/EM/56541_Dynometry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamometry is the most objective measurement of grip strength and forearm muscle integrity.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 56541 Version 5.0</div></div></div>"},"56542":{"type":"graphic_picture","displayName":"Sulcus sign","title":"Sulcus sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sulcus sign</div><div class=\"cntnt\"><img style=\"width:395px; height:345px;\" src=\"images/EM/56542_Sulcus_sign_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This maneuver is used to assess glenohumoral instability. The patient is asked to relax the shoulder. One hand is placed at the acromion and one hand is placed near the antecubital fossa. Downward pressure is applied to the arm to open the subacromial space. The examiner assesses the looseness of the shoulder and the discomfort caused by the maneuver. The sulcus sign is positive when the humeral head (X) is readily displaced by 2 cm or more inferiorly (arrow). Increased humoral movement in the anterior and posterior directions demonstrates multidirectional instability.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 56542 Version 4.0</div></div></div>"},"56543":{"type":"graphic_diagnosticimage","displayName":"Positron emission mammography","title":"Positron emission mammography","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Positron emission mammography</div><div class=\"cntnt\"><img style=\"width:478px; height:429px;\" src=\"images/SURG/56543_Positron_emission_mammogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Positron emission mammography is a nuclear medicine technique being investigated for the diagnosis of breast cancer.<br> (A) Figure A demonstrates normal uptake of the radiolabeled isotope in both breasts.<br> (B) Figure B illustrates marked uptake of the isotope in the upper left breast confirming a breast cancer recurrence in a patient who presented with new left supraclavicular lymphadenopathy.</div><div id=\"graphicVersion\">Graphic 56543 Version 3.0</div></div></div>"},"56544":{"type":"graphic_table","displayName":"Patterns of cross-allergenicity","title":"Patterns of cross-allergenicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patterns of cross-allergenicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Recommendation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Trees</td> </tr> <tr> <td class=\"indent1\">Birch, Alder, Hazelnut, Hornbeam</td> <td>Use locally most important species</td> </tr> <tr> <td class=\"indent1\">European Olive, Ash, Privet, Russian Olive</td> <td>Use locally most important species</td> </tr> <tr> <td class=\"indent1\">Cedar, Cypress, Juniper, Arborvitae</td> <td>Use locally most important species</td> </tr> <tr> <td class=\"indent1\">Beech, Oak</td> <td>Use locally most important species</td> </tr> <tr> <td class=\"indent1\">Pecan, Hickory</td> <td>Use locally most important species</td> </tr> <tr> <td class=\"indent1\">Poplar, Aspen, Cottonwood</td> <td>Use locally most important species</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Grasses</td> </tr> <tr> <td class=\"indent1\">Northern pasture grasses: Timothy, Orchard, Kentucky Blue, Redtop, Meadow Fescue, Perennial Rye, and Sweet Vernal</td> <td>Usually Timothy is used to cover this group, but can use a mixture of several species</td> </tr> <tr> <td class=\"indent1\">Bermuda</td> <td>Allergenically distinct from Northern pasture grasses</td> </tr> <tr> <td class=\"indent1\">Bahia and Johnson</td> <td>Use additionally if locally important</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Weeds</td> </tr> <tr> <td class=\"indent1\">Short, Giant, False, and Western Ragweed</td> <td>Use locally most important species</td> </tr> <tr> <td class=\"indent1\">Southern and Slender Ragweed, Cocklebur, Burweed Marsh Elder</td> <td>Use additionally if locally important</td> </tr> <tr> <td class=\"indent1\">Sages, Wormwood, Mugworts</td> <td>Use locally most important species</td> </tr> <tr> <td class=\"indent1\">Pigweed, Palmer Amaranth, Western Waterhemp</td> <td>Use locally most important species</td> </tr> <tr> <td class=\"indent1\">Russian Thistle, <em>Kochia</em>, Lamb's Quarters</td> <td> <p>Use locally most important species</p> If Russian thistle and <em>Kochia</em> both prevalent, use mixture</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">House dust mites</td> </tr> <tr> <td class=\"indent1\"><em>Dermatophagoides pteronyssinus</em> and <em>Dermatophagoides farinae</em></td> <td>Use mixture if both locally important</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cockroach</td> </tr> <tr> <td class=\"indent1\">German and American cockroach</td> <td>Use mixture</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56544 Version 5.0</div></div></div>"},"56545":{"type":"graphic_table","displayName":"TC regimen for breast cancer","title":"Docetaxel (Taxotere) and cyclophosphamide (TC) adjuvant chemotherapy for breast cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Docetaxel (Taxotere) and cyclophosphamide (TC) adjuvant chemotherapy for breast cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 21 days.<br /> Total cycles: 4.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Docetaxel</strong></td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (NS) or 5 percent dextrose in water (D5W) to a final concentration of 0.3 to 0.74 mg/mL, and administer over 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td><strong>Cyclophosphamide</strong></td> <td>600 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 to 500 mL NS or D5W and administer over 30 to 60 minutes after docetaxel.</td> <td>Day 1</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hydration:</strong> Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during treatment and one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MODERATE (between 30 and 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Premedication with dexamethasone 8 mg twice daily for three days, starting one day prior to docetaxel administration, is recommended<sup>[3]</sup>. Glucocorticoid pretreatment also reduces the incidence of docetaxel-induced fluid retention. If a severe infusion reaction to docetaxel occurs (chest tightness, wheezing, hypoxia, loss of consciousness), docetaxel should be immediately discontinued. However, if the reaction is minor (eg, flushing or localized skin reaction), the infusion can be continued or it can be temporarily interrupted, and restarted at 50 percent of the initial rate once symptoms have resolved. The rate can then be increased if tolerated. Management of infusion reactions and issues related to rechallenge are discussed separately. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Docetaxel and cyclophosphamide are both classified as irritants. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> All cycles should be administered with myeloid growth factor support. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver dysfunction:</strong> Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &#62;1.5 times ULN in conjunction with alkaline phosphatase &#62;2.5 times ULN. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline renal dysfunction:</strong> Dose adjustment is not necessary for docetaxel in renal impairment. The need for cyclophosphamide dose reduction in renal insufficiency is controversial. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for known drug interactions:</strong> Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided<sup>[3]</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count on day 1 prior to each cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Serum electrolytes and liver and renal function tests every two weeks prior to each treatment cycle.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Docetaxel should only be administered if the absolute neutrophil count is greater than 1500 cells/microL. A 25 percent dose reduction of docetaxel is recommended for subsequent cycles in patients who develop severe prolonged neutropenia (less than 500 cells/microL lasting seven days or more), febrile neutropenia, or a grade 4 infection (ie, an infection with life-threatening consequences)<sup>[3]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for hepatic dysfunction:</strong> Docetaxel dose reduction may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cutaneous, mucosal, and neurologic toxicity:</strong> For severe or cumulative cutaneous reactions (erythema and desquamation), grade 3 or 4 stomatitis, or moderate neurosensory signs and/or symptoms, the dose of docetaxel should be reduced from 75 to 60 mg/m<sup>2</sup><sup>[3]</sup>. If toxicity persists, treatment should be discontinued.</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; ULN: upper limit of normal; CBC: complete blood count.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Jones SE, et al. J Clin Oncol 2006; 24:5381.</li>&#xD;&#xA;    <li>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</li>&#xD;&#xA;    <li>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 56545 Version 21.0</div></div></div>"},"56546":{"type":"graphic_picture","displayName":"Iliac conduit for endograft placement","title":"Iliac conduit for endograft placement","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Iliac conduit for endograft placement</div><div class=\"cntnt\"><img style=\"width:540px; height:505px;\" src=\"images/SURG/56546_Iliac_conduit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;illustration shows a prosthetic graft (B) sutured to the common&nbsp;iliac artery, which is looped&nbsp;(C),&nbsp;to create an&nbsp;iliac conduit, to facilitate placement of an endograft.&nbsp;The conduit is clamped distally and punctured to allow placement of a sheath (A) for endograft delivery with minimal blood loss.</div><div id=\"graphicVersion\">Graphic 56546 Version 1.0</div></div></div>"},"56547":{"type":"graphic_picture","displayName":"Chlamydia urethral Gram stain","title":"Gram stain of urethral discharge","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gram stain of urethral discharge</div><div class=\"cntnt\"><img style=\"width:360px; height:268px;\" src=\"images/ID/56547_ChlamydiaurethralGramsta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polymorphonuclear leukocytes without intracellular pathogens are characteristic of the mucopurulent discharge seen in men with chlamydial infection.</div><div class=\"graphic_reference\">Reproduced from the Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 56547 Version 2.0</div></div></div>"},"56549":{"type":"graphic_picture","displayName":"SLE membranous","title":"Light micrograph showing lupus membranous nephropathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing lupus membranous nephropathy</div><div class=\"cntnt\"><img style=\"width:378px; height:259px;\" src=\"images/NEPH/56549_SLE_Membranous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of lupus membranous nephropathy. The changes are similar to those in any form of membranous nephropathy with diffuse thickening of the glomerular capillary wall being the major abnormality (short arrows). Focal areas of mesangial expansion and hypercellularity (long arrows) are the only findings suggestive of an underlying disease such as lupus, although they can also be seen in idiopathic membranous nephropathy.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 56549 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"56550":{"type":"graphic_diagnosticimage","displayName":"Brain MRI CNS met melanoma","title":"CNS metastasis from melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CNS metastasis from melanoma</div><div class=\"cntnt\"><img style=\"width:427px; height:252px;\" src=\"images/ONC/56550_Brain_MRI_CNS_met_melnm_Ed1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial images of a brain magnetic resonance imaging (MRI) study demonstrating an intracerebral metastasis in a patient with melanoma. Following the injection of contrast (B) the lesion enhances with a ring-like pattern.<br />(A) Pre-contrast.<br />(B) Post-contrast.</div><div class=\"graphic_reference\">Courtesy of Kevin Donohoe, MD.</div><div id=\"graphicVersion\">Graphic 56550 Version 4.0</div></div></div>"},"56551":{"type":"graphic_figure","displayName":"Graf hip types","title":"Overview of the Graf hip classification types","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Overview of the Graf hip classification types</div><div class=\"cntnt\"><img style=\"width:540px; height:523px;\" src=\"images/PEDS/56551_Graf_hip_types_edit2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Donaldson JS, Feinstein KA. Imaging of developmental dysplasia of the hip. Pediatr Clin North Am 1997; 44:591.</div><div id=\"graphicVersion\">Graphic 56551 Version 6.0</div></div></div>"},"56552":{"type":"graphic_figure","displayName":"Posterior neck muscles","title":"Posterior neck muscles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior neck muscles</div><div class=\"cntnt\"><img style=\"width:450px; height:156px;\" src=\"images/PEDS/56552_Posterior_neck_muscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The posterior neck muscles include the trapezius, splenius, semispinalis, and levator scapulae. The trapezius is the flat, triangular muscle that covers the posterior portion of the neck, shoulders, and thorax. It originates from the occiput, nuchal ligament, spinous processes of C7-T12, and the supraspinal ligaments. It inserts into the lateral clavicle, acromion, and scapular spine. The splenius and semispinalis capitis arise from the lower cervical and upper thoracic vertebrae and insert on the skull. The levator scapulae originates from the upper four cervical vertebrae and inserts onto the superomedial corner of the scapula.</div><div id=\"graphicVersion\">Graphic 56552 Version 1.0</div></div></div>"},"56553":{"type":"graphic_diagnosticimage","displayName":"Tuft fracture radiographs","title":"Tuft fracture radiographs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuft fracture radiographs</div><div class=\"cntnt\"><img style=\"width:412px; height:480px;\" src=\"images/EM/56553_Finger_tuft_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiographs above show a fracture of the cancellous bone at the tip of the distal phalanx, often referred to as a tuft fracture. These fractures are generally stable and managed conservatively.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 56553 Version 4.0</div></div></div>"},"56554":{"type":"graphic_figure","displayName":"Supracondylar fracture with pucker sign","title":"Supracondylar fracture with pucker sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Supracondylar fracture with pucker sign</div><div class=\"cntnt\"><img style=\"width:432px; height:268px;\" src=\"images/EM/56554_Puckersign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient had penetration of the spike of the proximal fragment into the subcutaneous tissue. In the anteroposterior view (Panel A), there is a large puckering or defect in the skin where the distal fragment has pulled the skin inward. Laterally (Panel B), there is puckering of the skin (arrow) in the area where the spike has penetrated into the subcutaneous tissue.</div><div class=\"graphic_reference\">Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56554 Version 13.0</div></div></div>"},"56555":{"type":"graphic_table","displayName":"ASRM revised guidelines for embryo transfer","title":"American Society for Reproductive Medicine guidelines for number of embryos (fresh or frozen) to transfer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society for Reproductive Medicine guidelines for number of embryos (fresh or frozen) to transfer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristics</td> <td class=\"subtitle1\">Number of cleavage stage embryos to transfer</td> <td class=\"subtitle1\">Number of blastocysts to transfer</td> </tr> <tr> <td>&#60;35 years old, most favorable prognosis*</td> <td class=\"centered\">1 to 2 (1 recommended)</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Other women &#60;35 years old</td> <td class=\"centered\">&#8804;2</td> <td class=\"centered\">&#8804;2</td> </tr> <tr> <td>35 to 37 years old, more favorable prognosis*</td> <td class=\"centered\">&#8804;2</td> <td class=\"centered\">&#8804;2</td> </tr> <tr> <td class=\"indent1\">Other women 35 to 37 years old</td> <td class=\"centered\">&#8804;3</td> <td class=\"centered\">&#8804;2</td> </tr> <tr> <td>38 to 40 years old, more favorable prognosis*</td> <td class=\"centered\">&#8804;3</td> <td class=\"centered\">&#8804;2</td> </tr> <tr> <td class=\"indent1\">Other women 38 to 40 years old</td> <td class=\"centered\">&#8804;4</td> <td class=\"centered\">&#8804;3</td> </tr> <tr> <td>41 to 42 years old, favorable prognosis and all others</td> <td class=\"centered\">&#8804;5</td> <td class=\"centered\">&#8804;3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* (1) first IVF cycle, good embryo quality, and sufficient excess embryos available for cryopreservation or (2) previous IVF success.<br />Transfer of additional embryos may be considered for women with a less favorable prognosis or who have failed at least two IVF cycles. <br />In donor egg cycles, the age of the donor is used to determine the number of embryos to transfer.<br />Since all oocytes may not fertilize with gamete intrafallopian transfer (GIFT), one more oocyte than embryo may be transferred for each prognostic category.<br />There are insufficient data to recommend a specific limit on embryos transferred in women 43 years of age or older.</div><div class=\"graphic_reference\">Data from: ASRM Practice Committee. Guidelines on number of embryos transferred. Fertil Steril 2013; 99:44.</div><div id=\"graphicVersion\">Graphic 56555 Version 7.0</div></div></div>"},"56556":{"type":"graphic_figure","displayName":"Structure of DNA","title":"Structure of DNA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of DNA</div><div class=\"cntnt\"><img style=\"width:326px; height:521px;\" src=\"images/PC/56556_Structure_of_DNA.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56556 Version 2.0</div></div></div>"},"56557":{"type":"graphic_table","displayName":"Asbestosis histologic grades","title":"Histologic grades of asbestosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic grades of asbestosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Grade </td>\n\n      <td class=\"subtitle1\">Change</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Grade\nof severity</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">0 </td>\n\n      <td>No fibrosis associated with bronchioles</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">1 or I </td>\n\n      <td>Early fibrosis involving walls of at least one\nrespiratory bronchiole, with or without extension into septa of\nadjacent alveoli; fibrosis confined to alveolated walls of respiratory\nbronchioles and ducts and not present in more distant alveoli.\nAlveolitis and inflammation similar to that caused by cigarette smoking</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">2 or II </td>\n\n      <td>More severe fibrosis involving acinus: alveolar ducts\nand/or two or more layers of adjacent alveoli. Normal lung remains in a\nzone between adjacent bronchioles</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">3 or III </td>\n\n      <td>Fibrosis advanced and coalescent, involves entire\nacinus; all lung between at least two adjacent bronchioles is affected.\nSome alveoli are completely obliterated</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">4 or IV </td>\n\n      <td>Honeycomb remodeling and large (up to 1 cm) dilated\nspaces grossly visible in parenchyma</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Grade\nof extent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">A or 1 </td>\n\n      <td>Only occasional bronchioles are involved. Most appear\nnormal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">B or 2 </td>\n\n      <td><span style=\"font-weight: bold;\">\"</span>More\nthan occasional\" but less than half of bronchioles are involved</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">C or 3 </td>\n\n      <td>More than half of bronchioles are involved</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Developed in 1980 by a committee of the College of American Pathologists.</div><div class=\"graphic_reference\">Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org.</div><div id=\"graphicVersion\">Graphic 56557 Version 1.0</div></div></div>"},"56559":{"type":"graphic_table","displayName":"Comparison of ER by LBA and IHC","title":"Comparison of ER by ligand binding assay (LBA) and immunohistochemistry (IHC) in selected trials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of ER by ligand binding assay (LBA) and immunohistochemistry (IHC) in selected trials</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reference</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Original assay<br /> (cut off for positivity)</td> <td class=\"subtitle1\">IHC assay concordance with original assay</td> <td class=\"subtitle1\">Outcome according to biomarker</td> </tr> <tr class=\"divider_bottom\"> <td>McCarty et al, 1985</td> <td>134 patients</td> <td>LBA (&#8805;20 fmol/mg)</td> <td>89 percent</td> <td>Objective clinical response to hormonal therapy: specificity 89 percent, sensitivity 93 percent.</td> </tr> <tr class=\"divider_bottom\"> <td>Barnes et al, 1996</td> <td>170 patients</td> <td>LBA (&#8805;20 fmol/mg)</td> <td>81 percent</td> <td>Response to tamoxifen in 72 percent ER/PR positive and in 61 percent ER positive/PR negative; superior result with IHC.</td> </tr> <tr class=\"divider_bottom\"> <td>Harvey et al, 1999</td> <td>1982 patients</td> <td>LBA (&#8805;3 fmol/mg)</td> <td>71 percent</td> <td>In multivariate analysis, ER status determined by IHC was significantly better than ER status by LBA at predicting better DFS; results were similar for prediction of overall survival.</td> </tr> <tr class=\"divider_bottom\"> <td>Elledge et al, 2000</td> <td>205 patients</td> <td>LBA (&#8805;3 fmol/mg)</td> <td>90 percent</td> <td>Overall response rate 56 percent if LBA positive versus 60 percent if IHC positive. In multivariate analysis, there was significant correlation between IHC for ER and response to tamoxifen.</td> </tr> <tr class=\"divider_bottom\"> <td>Thomson et al, 2002</td> <td>332 patients</td> <td>LBA (positive if &#8805;20 fmol/mg)</td> <td>Spearman's rank correlation coefficient 0.55</td> <td>Significant interaction between IHC score of zero and lack of benefit from ovarian ablation.</td> </tr> <tr class=\"divider_bottom\"> <td>Regan et al, 2006</td> <td>571 patients</td> <td>LBA (positive if &#8805;20 fmol/mg)</td> <td>Concordance 88 percent (k = 0.66) in postmenopausal patients</td> <td>Hazard ratios were similar for association between DFS and ER status or PR status by either LBA or IHC. In premenopausal women, IHC was better than LBA for predicting DFS.</td> </tr> <tr> <td>Khoshnoud et al, 2011</td> <td>683 patients</td> <td>LBA (positive if &#8805;50 fmol/mg)</td> <td>Overall concordance rate 88 percent</td> <td>Hazard ratios were similar for association of tamoxifen use with improved recurrence free survival regardless of assay used.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DFS: disease-free survival; ER: estrogen receptor; fmol/mg: fentomoles per mg; IHC: immunohistochemical staining; LBA: ligand-binding assay; PR: progesterone receptor.</div><div class=\"graphic_reference\">Modified from: Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28:2784.</div><div id=\"graphicVersion\">Graphic 56559 Version 11.0</div></div></div>"},"56560":{"type":"graphic_table","displayName":"Irritant contact dermatitis diagnosis","title":"Diagnostic criteria for irritant contact dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for irritant contact dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Subjective major criteria</td> <td class=\"subtitle1\">Subjective minor criteria</td> </tr> <tr> <td> <ol> <li>Onset of symptoms within minutes to hours of exposure</li> <li>Pain, burning, stinging, or discomfort exceeding itching, especially early in the clinical course</li> </ol> </td> <td> <ol> <li>Onset of dermatitis within two weeks of environmental exposure</li> <li>Many people in the environment similarly affected </li> </ol> </td> </tr> <tr> <td class=\"subtitle1\">Objective major criteria</td> <td class=\"subtitle1\">Objective minor criteria</td> </tr> <tr> <td> <ol> <li>Macular erythema, hyperkeratosis, or fissuring predominating over vesicular change</li> <li>Glazed, parched, or scalded appearance of the epidermis</li> <li>The healing process proceeds without plateau upon withdrawal of exposure to substance in question</li> <li>Patch testing with known environmentally relevant allergens is negative</li> </ol> </td> <td> <ol> <li>Sharp circumspection of the dermatitis</li> <li>Evidence of gravitational influence, such as a dripping effect</li> <li>Lack of tendency for spread of dermatitis</li> <li>Vesicles juxtaposed closely to patches of erythema, erosions, bullae, or other morphological changes which suggest that small differences in concentration or contact time produce large differences in skin damage</li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission of: Informa Healthcare, from Irritant Contact Dermatitis, Jackson EM, Goldner R, New York 1990; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 56560 Version 4.0</div></div></div>"},"56561":{"type":"graphic_picture","displayName":"Stinging fire ant and local reactions to stings","title":"Stinging fire ant and local reactions to stings","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Stinging fire ant and local reactions to stings</div><div class=\"cntnt\"><img style=\"width:468px; height:310px;\" src=\"images/ALLRG/56561_Local_reactions_to_IFA_stin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture&nbsp;A depicts a stinging fire ant (<EM>Solenopsis invicta</EM>).&nbsp;Pictures&nbsp;B, C, and D reveal the different local reactions that can occur following a sting.&nbsp;Picture B reveals several wheal-and-flare reactions (arrows), which may occur within minutes after the sting.&nbsp;Pictures C and D show a sterile pustule and cutaneous late-phase allergic reaction with an excoriated sterile pustule, respectively.</div><div class=\"graphic_reference\">Reproduced with permission from: Kemp SF, deShazo RD, et al. Expanding habitat of the imported fire ant (Solenopsis invicta): A public health concern. J Allergy Clin Immunology 2000; 105:685. Copyright ©2000 The American Academy of Allergy, Asthma and Immunology.</div><div id=\"graphicVersion\">Graphic 56561 Version 3.0</div></div></div>"},"56563":{"type":"graphic_diagnosticimage","displayName":"Contrast-enhanced CT scan","title":"Hydronephrosis: contrast-enhanced CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydronephrosis: contrast-enhanced CT scan</div><div class=\"cntnt\"><img style=\"width:371px; height:483px;\" src=\"images/NEPH/56563_Contrast-enhanced_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse (A) and coronal reconstruction (B) from a contrast-enhanced scan (corticomedullary phase) showing dilated calyces, pelvis, and proximal ureter on the left side.</div><div class=\"graphic_reference\">Courtesy of Deborah A Baumgarten, MD, MPH.</div><div id=\"graphicVersion\">Graphic 56563 Version 2.0</div></div></div>"},"56565":{"type":"graphic_picture","displayName":"Robotic surg console","title":"Robot-assisted laparoscopy surgical system console","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Robot-assisted laparoscopy surgical system console</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/OBGYN/56565_Robotic_surg_console.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">da Vinci&#174; surgical system</div><div class=\"graphic_reference\">Photo courtesy of Intuitive Surgical, Inc, 2008.</div><div id=\"graphicVersion\">Graphic 56565 Version 3.0</div></div></div>"},"56567":{"type":"graphic_table","displayName":"Lysosomal storage disorders with peripheral neuropathy","title":"Lysosomal storage disorders with associated peripheral neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lysosomal storage disorders with associated peripheral neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td>Fabry disease</td> <td>XLR</td> <td>GLA</td> <td>Onset by 10 years of age, angiokeratomas, small fiber peripheral neuropathy, burning of palms and soles, hypohidrosis or anhidrosis, asymptomatic corneal dystrophy, cardiac involvement with disease progression</td> </tr> <tr> <td>Krabbe disease</td> <td>AR</td> <td>GALC</td> <td>Usual onset in first six months of life, peripheral motor sensory neuropathy, developmental delay, hypotonia, limb stiffness, optic atrophy, microcephaly, irritability</td> </tr> <tr> <td rowspan=\"3\">Metachromatic leukodystrophy</td> <td rowspan=\"3\">AR</td> <td rowspan=\"3\"> <p>ARSA</p> PSAP</td> <td>Late infant onset: usual onset at age 6 to 24 months, regression of motor skills, gait difficulty, ataxia, hypotonia, optic atrophy, peripheral neuropathy, absent or diminished deep tendon reflexes</td> </tr> <tr> <td>Juvenile onset: onset between 4 to 8 years, gait disturbance, intellectual impairment, ataxia, upper motor neuron signs, peripheral neuropathy</td> </tr> <tr> <td>Adult onset: dementia between age 16 and late adulthood, slow progressive motor dysfunction</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Niemann-Pick disease</td> </tr> <tr> <td class=\"indent1\">Niemann-Pick type A</td> <td>AR</td> <td>SMPD1</td> <td>Hepatosplenomegaly, feeding difficulties, loss of early motor skills, rapidly progressive loss of neurologic function, rare peripheral neuropathy, macular cherry red spots</td> </tr> <tr> <td class=\"indent1\">Niemann-Pick type B</td> <td>AR</td> <td>SMPD1</td> <td>Onset of hepatomegaly in infancy or childhood, thrombocytopenia, interstitial lung disease, lipid abnormalities, rare peripheral neuropathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AR: autosomal recessive; ARSA: arylsulfatase A gene; GALC: galactocerebrosidase gene; GLA: alpha galactosidase A gene; PSAP: prosaposin gene; SMPD1: sphingomyelin phosphodiesterase 1 gene; XLR: X-linked recessive.</div><div id=\"graphicVersion\">Graphic 56567 Version 6.0</div></div></div>"},"56568":{"type":"graphic_picture","displayName":"Echinostomiasis adult worm","title":"Echinostomiasis adult worm","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Echinostomiasis adult worm</div><div class=\"cntnt\"><img style=\"width:586px; height:269px;\" src=\"images/ID/56568_Enchinostomiasis_adult_worm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult of&nbsp;<EM>Echinostoma revolutum</EM>, stained with carmine. Structures illustrated in this figure include: oral sucker (OS), armed collar (CL), cirrus sac (CS), ventral sucker, or acetabulum (AC), uterus containing eggs (UT), ovary (OV), paired testes (TE), and vitelline glands (VT). This species has been recorded from humans in Taiwan.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Echinostomiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/echinostomiasis/index.html\">http://www.cdc.gov/dpdx/echinostomiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 56568 Version 6.0</div></div></div>"},"56571":{"type":"graphic_diagnosticimage","displayName":"Barretts esophagus OCT","title":"Barrett's esophagus (optical coherence tomography)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus (optical coherence tomography)</div><div class=\"cntnt\"><img style=\"width:450px; height:229px;\" src=\"images/GAST/56571_Barretts_esophagus_OCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Endoscopic view with optical coherence tomography (OCT) catheter probe placed adjacent to segment of Barrett's mucosa; (B) OCT image demonstrating multiple crypt- and band-like structures; (C) highly-magnified view of the portion of the OCT image outlined in the box in (B); (C) corresponding histological section of Barrett's mucosa.</div><div class=\"graphic_reference\">Courtesy of Shai Friedland, MD and Jacques Van Dam, MD, PhD.</div><div id=\"graphicVersion\">Graphic 56571 Version 2.0</div></div></div>"},"56573":{"type":"graphic_picture","displayName":"Mucogingivitis","title":"Mucogingivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucogingivitis</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/PEDS/56573_Mucogingivitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucogingivitis in relation to the maxillary permanent incisors in a child with Crohn disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Hardy S, Fleming P, Rowland M, et al. A prospective study of the oral manefestations of Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:886. Copyright &#169; 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 56573 Version 2.0</div></div></div>"},"56574":{"type":"graphic_picture","displayName":"Chronic farmers lung Light","title":"Chronic farmer's lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic farmer's lung</div><div class=\"cntnt\"><img style=\"width:309px; height:205px;\" src=\"images/PULM/56574_Chronic_farmers_lung_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power light micrograph from a patient with chronic farmer's lung shows bronchiolitis associated with fibrosis. Cholesterol clefts (arrow) are seen in the fibrotic region.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 56574 Version 1.0</div></div></div>"},"56575":{"type":"graphic_waveform","displayName":"M mode aortic valve HCM","title":"Aortic valve in hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic valve in hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:242px; height:343px;\" src=\"images/CARD/56575_MmodeaorticvalveHCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M mode echocardiogram shows the aortic root and aortic valve from a patient with a hypertrophic cardiomyopathy. The aortic valve shows a mid-systolic closure (arrow) or spike-dome configuration due to transient intraventricular obstruction and reduction of stroke volume.</div><div id=\"graphicVersion\">Graphic 56575 Version 2.0</div></div></div>"},"56577":{"type":"graphic_table","displayName":"Symptoms of DGI","title":"Major symptoms and signs of disseminated gonococcal infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major symptoms and signs of disseminated gonococcal infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Symptom or sign</td>\n<td class=\"subtitle1\">Percentage of patients</td>\n</tr>\n<tr>\n<td>Migratory polyarthralgia</td>\n<td>70</td>\n</tr>\n<tr>\n<td>Tenosynovitis</td>\n<td>67</td>\n</tr>\n<tr>\n<td>Dermatitis</td>\n<td>67</td>\n</tr>\n<tr>\n<td>Fever</td>\n<td>63</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Purulent arthritis</td>\n<td class=\"sublist_other_start\">42</td>\n</tr>\n<tr>\n<td class=\"sublist1\">One joint</td>\n<td class=\"sublist_other\">32</td>\n</tr>\n<tr>\n<td class=\"sublist1\">More than one joint</td>\n<td class=\"sublist_other\">10</td>\n</tr>\n<tr>\n<td>Genitourinary symptoms</td>\n<td>25</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: O'Brien, JP, Goldenberg, DL, Rice, PA, Medicine 1983; 62:395.</div><div id=\"graphicVersion\">Graphic 56577 Version 1.0</div></div></div>"},"56578":{"type":"graphic_algorithm","displayName":"Approach to the child with true vertigo","title":"Approach to the child with true vertigo","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Approach to the child with true vertigo</div><div class=\"cntnt\"><img style=\"width:614px; height:457px;\" src=\"images/EM/56578_Child_true_vertigo_algo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BPVC: benigh paroxysmal vertigo of childhood; CT: computed tomography; LP: lumbar puncture; MS: multiple sclerosis.<br> * May be first episode of recurrent condition.</div><div id=\"graphicVersion\">Graphic 56578 Version 2.0</div></div></div>"},"56581":{"type":"graphic_figure","displayName":"Anal sphincter anatomy PI","title":"Anal sphincter","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Anal sphincter</div><div class=\"cntnt\"><img style=\"width:543px; height:582px;\" src=\"images/PI/56581_Anal_sphincter_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anal sphincter is made up of two sets of muscles called the &quot;internal&quot; and &quot;external&quot; sphincters. These muscles form a ring around the anus. When these muscles are working normally, they squeeze the anus shut so that gas and bowel movements cannot leak out.</div><div id=\"graphicVersion\">Graphic 56581 Version 4.0</div></div></div>"},"56584":{"type":"graphic_picture","displayName":"Grover's histology","title":"Histology of Grover's disease (transient and persistent acantholytic dermatosis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of Grover's disease (transient and persistent acantholytic dermatosis)</div><div class=\"cntnt\"><img style=\"width:432px; height:342px;\" src=\"images/PC/56584_Grovers_histology_Edt1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology demonstrates acantholytic keratinocytes leading to suprabasilar clefting. Dyskeratotic keratinocytes extend from the mid-epidermis to the stratum corneum. Hemorrhage is noted in the intraepidermal cleft secondary to the mechanical trauma of repeated scratching (hematoxylin and eosin staining, original magnification 400x).</div><div class=\"graphic_reference\">Courtesy of Whitney High, MD.</div><div id=\"graphicVersion\">Graphic 56584 Version 3.0</div></div></div>"},"56585":{"type":"graphic_table","displayName":"Dyspepsia alarm features ","title":"Alarm features in dyspepsia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alarm features in dyspepsia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Unintentional&nbsp;weight loss</td> </tr> <tr> <td>Progressive dysphagia</td> </tr> <tr> <td>Odynophagia</td> </tr> <tr> <td>Unexplained iron deficiency anemia</td> </tr> <tr> <td>Persistent vomiting</td> </tr> <tr> <td>Palpable mass or lymphadenopathy</td> </tr> <tr> <td>Family history of upper gastrointestinal cancer</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129:1756.</div><div id=\"graphicVersion\">Graphic 56585 Version 4.0</div></div></div>"},"56586":{"type":"graphic_picture","displayName":"Vulva hematoma and catheter","title":"Vulvar hematoma with foley catheter placed","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar hematoma with foley catheter placed</div><div class=\"cntnt\"><img style=\"width:340px; height:504px;\" src=\"images/OBGYN/56586_Vulvahematomaandcatheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Emans SJ, Laufer MR. Emans, Laufer &amp; Goldstein’s Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56586 Version 8.0</div></div></div>"},"56587":{"type":"graphic_diagnosticimage","displayName":"2D TTE RV inflow","title":"Two-dimensional transthoracic echocardiogram (2D TTE) right ventricular (RV) inflow view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) right ventricular (RV) inflow view</div><div class=\"cntnt\"><img style=\"width:402px; height:291px;\" src=\"images/CARD/56587_Long_axis_view_right_heart.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal&nbsp;right ventricular (RV)&nbsp;inflow view&nbsp;from the two-dimensional echocardiogram shows the RV and atrium (RA) and the septal and&nbsp;anterior leaflets of the tricuspid valve (TV). The entrance of the coronary sinus into the RA is separated from the entrance of the inferior vena cava by the eustachian valve (EV).</div><div id=\"graphicVersion\">Graphic 56587 Version 4.0</div></div></div>"},"56588":{"type":"graphic_picture","displayName":"Exophytic squamous carcinoma","title":"Exophytic squamous cell carcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exophytic squamous cell carcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:401px; height:303px;\" src=\"images/PULM/56588_Exophytic_squamous_carcinom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A whole-mount section through an endobronchial exophytic squamous cell carcinoma of the lung.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 56588 Version 1.0</div></div></div>"},"56589":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph of pneumothorax after stab wound","title":"Chest radiograph of a pneumothorax after stab wound","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a pneumothorax after stab wound</div><div class=\"cntnt\"><img style=\"width:324px; height:321px;\" src=\"images/PULM/56589_ChestXpneomstab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain chest radiograph shows a left apicolateral pneumothorax with typical convex white visceral pleural line (yellow arrows).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56589 Version 6.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"56591":{"type":"graphic_waveform","displayName":"ECG ventricular tachycardia in ARVC","title":"12-lead electrocardiogram (ECG) showing ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy (ARVC)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy (ARVC)</div><div class=\"cntnt\"><img style=\"width:444px; height:261px;\" src=\"images/CARD/56591_Ventriculartachycardiain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy (ARVC) usually arises from the free wall of the right ventricle, resulting in a left bundle branch morphology.</div><div class=\"graphic_reference\">With permission from Podrid PJ, Kowey PR (Eds), Cardiac Arrhythmia - Mechanisms, Diagnosis, and Management, Williams &amp; Wilkins, Baltimore, 1995.</div><div id=\"graphicVersion\">Graphic 56591 Version 8.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"56592":{"type":"graphic_figure","displayName":"LH FSH lack in GnRH deficiency","title":"Lack of gonadotropin secretion in GnRH deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lack of gonadotropin secretion in GnRH deficiency</div><div class=\"cntnt\"><img style=\"width:428px; height:350px;\" src=\"images/ENDO/56592_LHFSHlackinGnRHdeficie.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum LH (blue) and FSH (red) concentrations determined at ten-minute intervals in two men with idiopathic hypogonadotropic hypogonadism. Patient A (upper figure) had microphallus, testicular volumes of one mL each, anosmia, and no history of spontaneous puberty. LH and FSH concentrations in most of his serum samples were at or below assay detection limits. Patient B (lower figure) had a normal-sized phallus, testicular volumes of 20 mL each, an intact sense of smell, and a history of partial onset of puberty with subsequent regression of sexual function. Serum testosterone concentrations (in ng/dL) at six-hour intervals are indicated by the numbers at the top of each sampling period.</div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone; LH: luteinizing hormone; FSH: follicle-stimulating hormone.</div><div class=\"graphic_reference\">Data from Spratt, DI, Carr, DB, Merriam, GR, et al, J Clin Endocrinol Metab 1987; 64:283.</div><div id=\"graphicVersion\">Graphic 56592 Version 3.0</div></div></div>"},"56593":{"type":"graphic_diagnosticimage","displayName":"Hemochromatosis MRI","title":"Hemochromatosis on magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemochromatosis on magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:382px; height:271px;\" src=\"images/GAST/56593_Hemochromatosis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">72-year-old female with hemochromatosis suggested by MRI. T1-weighted images show a black hypointense liver characteristic of iron overload (small arrows) and a similar low intensity of the spleen (large arrow).</div><div class=\"graphic_reference\">Courtesy of Martina Morrin, MD.</div><div id=\"graphicVersion\">Graphic 56593 Version 3.0</div></div></div>"},"56595":{"type":"graphic_table","displayName":"Food poisoning GI sxs","title":"Major foodborne microbes by the principal presenting gastrointestinal symptom","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major foodborne microbes by the principal presenting gastrointestinal symptom</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Major presenting symptom</td> <td class=\"subtitle1\">Likely microbes</td> <td class=\"subtitle1\">Incubation period</td> <td class=\"subtitle1\">Likely food sources</td> </tr> <tr> <td rowspan=\"3\">Vomiting</td> <td><em>S. aureus</em></td> <td>1 to 6 hours</td> <td>Prepared food, eg, salads, dairy, meat</td> </tr> <tr> <td><em>B. cereus</em></td> <td>1 to 6 hours</td> <td>Rice, meat</td> </tr> <tr> <td>Norwalk-like viruses</td> <td>24 to 48 hours</td> <td>Shellfish, prepared foods, salads, sandwiches, fruit</td> </tr> <tr> <td rowspan=\"5\">Watery diarrhea</td> <td><em>C. perfringens</em></td> <td>8 to 16 hours</td> <td>Meat, poultry, gravy</td> </tr> <tr> <td>Enterotoxigenic <em>E. coli</em></td> <td>1 to 3 days</td> <td>Fecally contaminated food or water</td> </tr> <tr> <td>Enteric viruses</td> <td>10 to 72 hours</td> <td>Fecally contaminated food or water</td> </tr> <tr> <td><em>C. parvum</em></td> <td>2 to 28 days</td> <td>Vegetables, fruit, unpasteurized milk, water</td> </tr> <tr> <td><em>C. cayetanensis</em></td> <td>1 to 11 days</td> <td>Imported berries, basil</td> </tr> <tr> <td rowspan=\"5\">Inflammatory diarrhea</td> <td><em>Campylobacter </em>spp</td> <td>2 to 5 days</td> <td>Poultry, unpasteurized milk, water</td> </tr> <tr> <td>Nontyphoidal S<em>almonella</em></td> <td>1 to 3 days</td> <td>Eggs, poultry, meat, unpasteurized milk or juice, fresh produce</td> </tr> <tr> <td>Shiga toxin-producing <em>E. coli</em></td> <td>1 to 8 days</td> <td>Ground beef, unpasteurized milk and juice, raw vegetables, water</td> </tr> <tr> <td><em>Shigella </em>spp</td> <td>1 to 3 days</td> <td>Fecal contamination of food and water</td> </tr> <tr> <td><em>V. parahemolyticus</em></td> <td>2 to 48 hours</td> <td>Raw shellfish</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Incubation period and likely food sources are shown for each.</div><div class=\"graphic_reference\">Modified from Centers for Disease Control and Prevention. Diagnosis and management of food borne illness, a primer for physicians. MMWR Recomm Rep 2001; 50:(RR-2):1.</div><div id=\"graphicVersion\">Graphic 56595 Version 2.0</div></div></div>"},"56596":{"type":"graphic_figure","displayName":"No-heparin regimen in HD","title":"Schematic diagram showing no-heparin regimen in hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Schematic diagram showing no-heparin regimen in hemodialysis</div><div class=\"cntnt\"><img style=\"width:528px; height:419px;\" src=\"images/NEPH/56596_No-heparin_regimen_in_HD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of no-heparin regimen for anticoagulation during hemodialysis. Boluses of isotonic saline are given every 15 minutes to minimize the degree of hemoconcentration and to flush fibrin strands from the dialyzer into the bubble trap.</div><div id=\"graphicVersion\">Graphic 56596 Version 5.0</div></div></div>"},"56597":{"type":"graphic_figure","displayName":"Protein intake and stones","title":"Protein load increases urine stone-forming tendency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Protein load increases urine stone-forming tendency</div><div class=\"cntnt\"><img style=\"width:406px; height:254px;\" src=\"images/NEPH/56597_Protein_intake_and_stones.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The institution of a high protein diet (2 g/kg per day) in normal men adversely effects the metabolic parameters determining the risk of calcium stone formation. There is an increase in the urinary excretion of calcium and uric acid and a reduction in that of citrate.</div><div class=\"graphic_reference\">Data from Kok, DJ, Iestra, JA, Doorenbos, CJ, Papapoulos, SE, J Clin Endocrinol Metab 1990; 71:861.</div><div id=\"graphicVersion\">Graphic 56597 Version 1.0</div></div></div>"},"56598":{"type":"graphic_table","displayName":"Resection types sarcoma MSTS","title":"Types of resection for sarcomas, Musculoskeletal Tumor Society","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of resection for sarcomas, Musculoskeletal Tumor Society</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Term</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>Radical resection</td> <td>Whole tumor-bearing compartment removed en bloc</td> </tr> <tr> <td>Wide resection</td> <td>Tumor and its pseudocapsule removed en bloc surrounded by healthy tissue within the tumor-bearing compartment</td> </tr> <tr> <td>Marginal resection</td> <td>Tumor is removed en bloc; however, the line of resection runs through the pseudocapsule of the tumor; microscopic residual disease likely</td> </tr> <tr> <td>Intralesional resection</td> <td>Tumor opened during surgery, surgical field contaminated; microscopic or macroscopic residual disease is present</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Enneking WF, Spanier SS, Malawer MM. The effect of the anatomic setting on the results of surgical procedures for soft parts sarcoma of the thigh. Cancer 1981; 47:1005.</div><div id=\"graphicVersion\">Graphic 56598 Version 3.0</div></div></div>"},"56599":{"type":"graphic_picture","displayName":"Allantoic cyst","title":"Allantoic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allantoic cyst</div><div class=\"cntnt\"><img style=\"width:357px; height:548px;\" src=\"images/OBGYN/56599_Doppler_img_allantoic_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Color flow imaging shows the umbilical arteries running around the cyst (arrows).<br />(B) Photograph of the newborn infant shows the splayed umbilical arteries and leaking of urine through the umbilicus.</div><div class=\"graphic_reference\">Reproduced with permission from: Sepulveda W, Bower S, Dhillon HK, Fisk NM. Prenatal diagnosis of congenital patent urachus and allantoic cyst: the value of color flow imaging. J Ultrasound Med 1995; 14:47. Copyright &copy; 1995 American Institute of Ultrasound in Medicine.</div><div id=\"graphicVersion\">Graphic 56599 Version 3.0</div></div></div>"},"56600":{"type":"graphic_table","displayName":"Vaughan Williams classification of antiarrhythmic drugs","title":"Vaughan Williams classification of antiarrhythmic drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vaughan Williams classification of antiarrhythmic drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class IA - slows conduction velocity (less than class IC) and prolongs APD</td> </tr> <tr> <td class=\"indent1\">Disopyramide</td> </tr> <tr> <td class=\"indent1\">Procainamide*</td> </tr> <tr> <td class=\"indent1\">Quinidine</td> </tr> <tr> <td class=\"subtitle1_single\">Class IB - has no effect on conduction velocity and may shorten APD</td> </tr> <tr> <td class=\"indent1\">Lidocaine*</td> </tr> <tr> <td class=\"indent1\">Mexiletine</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"subtitle1_single\">Class IC - slows conduction and may prolong APD (mild)</td> </tr> <tr> <td class=\"indent1\">Flecainide</td> </tr> <tr> <td class=\"indent1\">Propafenone</td> </tr> <tr> <td class=\"subtitle1_single\">Class II - blocks beta adrenergic receptors</td> </tr> <tr> <td class=\"indent1\">Beta blockers</td> </tr> <tr> <td class=\"subtitle1_single\">Class III - prolongs APD and has no effect on conduction</td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"indent1\">Dofetilide</td> </tr> <tr> <td class=\"indent1\">Ibutilide*</td> </tr> <tr> <td class=\"indent1\">Sotalol<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Dronedarone</td> </tr> <tr> <td class=\"subtitle1_single\">Class IV - calcium channel blockers</td> </tr> <tr> <td class=\"indent1\">Non-dihydropyridine calcium channel blockers (verapamil and dilitiazem)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">APD: action potential duration.<br />* Available only as an intravenous preparation in United States. Oral procainamide is available elsewhere.<br />¶ l-sotalol has beta blocking and class III activities; d-sotalol is a pure class III agent. Commercially available sotalol is a racemic (equal part) mixture.</div><div class=\"graphic_reference\">Vaughan Williams EM; Classifying antiarrhythmic actions: by facts or speculation; J Clin Pharmacol 1992; 32:964.</div><div id=\"graphicVersion\">Graphic 56600 Version 13.0</div></div></div>"},"56601":{"type":"graphic_picture","displayName":"Laryngeal inlet photograph","title":"Laryngeal inlet photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laryngeal inlet photograph</div><div class=\"cntnt\"><img style=\"width:444px; height:275px;\" src=\"images/EM/56601_Laryngealinletphoto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The epiglottis and glottis of an infant; note the apposition of the vocal cords from laryngospasm in the right-hand image.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. The pediatric airway. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56601 Version 10.0</div></div></div>"},"56602":{"type":"graphic_diagnosticimage","displayName":"PTC after hepaticojejunostomy","title":"Hepaticojejunostomy for complete transection of the common bile duct after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepaticojejunostomy for complete transection of the common bile duct after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:288px; height:323px;\" src=\"images/GAST/56602_PTC_after_hepaticojejunosto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram of a patient with a complete transection of the common bile duct treated with hepaticojejunostomy.</div><div class=\"graphic_reference\">Photo courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 56602 Version 4.0</div></div></div>"},"56603":{"type":"graphic_table","displayName":"Causes of failure to thrive","title":"Causes of failure to thrive","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of failure to thrive</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inadequate calorie intake</td> </tr> <tr> <td class=\"subtitle2_single\">Weight gain during refeeding</td> </tr> <tr> <td class=\"indent1\">Inappropriate feeding technique</td> </tr> <tr> <td class=\"indent1\">Disturbed mother/child relationship*</td> </tr> <tr> <td class=\"indent1\">Inappropriate nutrient intake- eg, excess fruit juice consumption</td> </tr> <tr> <td class=\"indent1\">Factitious food allergy</td> </tr> <tr> <td class=\"indent1\">Inadequate quantity of food</td> </tr> <tr> <td class=\"indent1\">Inappropriate food for age</td> </tr> <tr> <td class=\"indent1\">Neglect</td> </tr> <tr> <td class=\"subtitle2_single\">No weight gain during refeeding</td> </tr> <tr> <td class=\"indent1\">Psychosocial problems*</td> </tr> <tr> <td class=\"indent1\">Maternal/infant dysfunction</td> </tr> <tr> <td class=\"indent1\">Economic deprivation</td> </tr> <tr> <td class=\"indent1\">Mechanical problems- adenoidal hypertrophy, dental lesions</td> </tr> <tr> <td class=\"indent1\">Insufficient lactation in mother</td> </tr> <tr> <td class=\"indent1\">Cleft palate</td> </tr> <tr> <td class=\"indent1\">Nasal obstruction</td> </tr> <tr> <td class=\"indent1\">Sucking or swallowing dysfunction (CNS, neuromuscular, esophageal motility problems)</td> </tr> <tr> <td class=\"indent1\">Regurgitation- gastroesophageal reflux</td> </tr> <tr> <td class=\"indent1\">Malformation</td> </tr> <tr> <td class=\"indent1\">Congenital syndromes- alcohol, pheytoin, drugs</td> </tr> <tr> <td class=\"indent1\">Genetic syndromes- Turner</td> </tr> <tr> <td class=\"subtitle2_single\">Inadequate appetite or inability to eat large amounts</td> </tr> <tr> <td class=\"indent1\">Psychosocial problems- apathy*</td> </tr> <tr> <td class=\"indent1\">Cardiopulmonary disease</td> </tr> <tr> <td class=\"indent1\">Hypotonia- muscle weakness</td> </tr> <tr> <td class=\"indent1\">Anorexia of chronic infection</td> </tr> <tr> <td class=\"indent1\">Immune deficiency diseases- HIV infection</td> </tr> <tr> <td class=\"indent1\">Endocrine disorders- hypothyroidism, diabetes insipidus</td> </tr> <tr> <td class=\"indent1\">CNS tumors</td> </tr> <tr> <td class=\"indent1\">Genetic syndromes</td> </tr> <tr> <td class=\"indent1\">Metabolic conditions- lead toxicity, iron or zinc deficiency</td> </tr> <tr> <td class=\"indent1\">Anemia</td> </tr> <tr> <td class=\"indent1\">Chronic constipation</td> </tr> <tr> <td class=\"indent1\">Disturbance in appetite and satiety</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inadequate calorie absorption</td> </tr> <tr> <td class=\"subtitle2_single\">No weight gain during refeeding; increased losses</td> </tr> <tr> <td class=\"indent1\">Psychosocial problems (refeeding diarrhea, intercurrent illnesses, rumination, regurgitation)*</td> </tr> <tr> <td class=\"indent1\">Malabsorption- diarrhea (lactose intolerance, cystic fibrosis, cardiac disease, malrotation, inflammatory bowel disease, milk allergy, parasites, celiac disease)</td> </tr> <tr> <td class=\"indent1\">Vomiting or \"spitting up\" or diarrhea (gastroenteritis)</td> </tr> <tr> <td class=\"indent1\">Intestinal tract obstruction (pyloric stenosis, hernia, malrotation, intussusception, chalasia)</td> </tr> <tr> <td class=\"indent1\">Biliary atresia/cirrhosis</td> </tr> <tr> <td class=\"indent1\">CNS problems- increased intracranial pressure (subdural hematoma)</td> </tr> <tr> <td class=\"indent1\">Chronic metabolic problems (hypercalcemia, storage diseases, and inborn errors of metabolism such as galactosemia, methylmalonic acidemia, renal tubular acidosis, diabetes mellitus, adrenal insufficiency)</td> </tr> <tr> <td class=\"subtitle1_single\">Increased calorie requirements</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Cerebral palsy</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td>Chronic systemic disease (juvenile idiopathic arthritis)</td> </tr> <tr> <td>Chronic systemic infection (UTI, tuberculosis, toxoplasmosis)</td> </tr> <tr> <td>Chronic respiratory insufficiency (bronchopulmonary dysplasia)</td> </tr> <tr> <td>Congenital or acquired heart disease</td> </tr> <tr> <td>Anemia</td> </tr> <tr> <td>Toxins (lead)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Environmental causes are the most common source of problems.</div><div id=\"graphicVersion\">Graphic 56603 Version 2.0</div></div></div>"},"56604":{"type":"graphic_figure","displayName":"Amsler grid","title":"Examples of two different Amsler grids","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Examples of two different Amsler grids</div><div class=\"cntnt\"><img style=\"width:491px; height:521px;\" src=\"images/PC/56604_Amsler_grid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both are useful for monitoring central vision.</div><div class=\"graphic_reference\">Reproduced with permission from Vitreous Retina Macula Consultants of New York. http://www.vrmny.com/amsler.htm.</div><div id=\"graphicVersion\">Graphic 56604 Version 1.0</div></div></div>"},"56605":{"type":"graphic_figure","displayName":"2018 US food label: What's different? PI","title":"2018 US food label: What's different?","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">2018 US food label: What's different?</div><div class=\"cntnt\"><img style=\"width:512px; height:538px;\" src=\"images/PI/56605_NutritionlabelsodiumPI.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: U.S. Food and Drug Administration. Changes to the Nutrition Facts Label. Available at: <A href=\"https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/LabelingNutrition/ucm385663.htm\" target=_blank>https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/LabelingNutrition/ucm385663.htm</A> (Accessed on January 8, 2018).</div><div id=\"graphicVersion\">Graphic 56605 Version 7.0</div></div></div>"},"56606":{"type":"graphic_diagnosticimage","displayName":"RML RLL atelectasis-II","title":"Frontal chest radiograph reveals combined right middle and right lower lobe atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frontal chest radiograph reveals combined right middle and right lower lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/PULM/56606_RML_RLL_atelectasis-II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The interface formed by the minor fissure with the right upper lobe mimics an elevated right hemidiaphragm (arrow). The descending right pulmonary artery, right heart border and the right hemidiaphragm are engulfed by the atelectasis and are obscured.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56606 Version 2.0</div></div></div>"},"56608":{"type":"graphic_movie","displayName":"Pericardial friction rub","title":"Pericardial friction rub","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial friction rub</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/56608_Pericardfrictionrubconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:377px; height:454px;\" src=\"images/CARD/56608_Pericardialfrictionrub.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Audio file courtesy of Dr. Massimo Imazio; Figure reproduced with permission from: Bickley LS, Szilagyi P. Bates' Guide to Physical Examination and History Taking, 8th Ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56608 Version 2.0</div></div></div>"},"56611":{"type":"graphic_diagnosticimage","displayName":"Coronary artery fistula coil","title":"Coronary artery fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronary artery fistula</div><div class=\"cntnt\"><img style=\"width:374px; height:284px;\" src=\"images/CARD/56611_Coronary_artery_fistula_coi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Selective left coronary artery (LCA) angiogram (panel A) demonstrates the termination of a fistula (arrow) from the diagonal branch of the left anterior descending (LAD) artery to the right ventricle (RV). A small amount of flow is noted in the distal LAD (arrowhead). Panel B shows the deployment of Gianturco coil (arrow) at the terminal end of the fistula; in panel C a second Gianturco coil is placed (arrow). Selective LCA angiogram soon after coil deployment (panel D) shows a small residual shunt (arrow). However, a repeat selective LCA angiogram obtained 10 minutes later demonstrates no residual shunting through the coils (panel E); there is increased flow into the distal LAD (arrow) after elimination of coronary artery steal through the fistula. Selective LCA angiogram in the lateral view (panel F) confirms the absence of residual shunting through the coils (arrow) and increased flow to the distal LAD (arrowhead).</div><div id=\"graphicVersion\">Graphic 56611 Version 3.0</div></div></div>"},"56612":{"type":"graphic_table","displayName":"Differential diagnosis of acute pelvic pain","title":"Differential diagnosis of acute pelvic pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of acute pelvic pain</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Gastrointestinal </td> </tr> <tr> <td>Appendicitis</td> </tr> <tr> <td>Bowel obstruction</td> </tr> <tr> <td>Constipation</td> </tr> <tr> <td>Diverticulitis</td> </tr> <tr> <td>Fecal impaction</td> </tr> <tr> <td>Gastroenteritis</td> </tr> <tr> <td>Hirschsprung disease</td> </tr> <tr> <td>Incarcerated hernia</td> </tr> <tr> <td>Intussusception</td> </tr> <tr> <td>Irritable bowel syndrome</td> </tr> <tr> <td>Meckel's diverticulitis</td> </tr> <tr> <td>Neoplasm</td> </tr> <tr> <td>Perforated viscous</td> </tr> <tr> <td>Regional ileitis (Crohn disease)</td> </tr> <tr> <td>Ulcerative colitis</td> </tr> <tr> <td>Volvulus</td> </tr> <tr> <td class=\"subtitle1_single\">Urologic </td> </tr> <tr> <td>Cystitis</td> </tr> <tr> <td>Neoplasm</td> </tr> <tr> <td>Urethritis</td> </tr> <tr> <td>Pyelonephritis</td> </tr> <tr> <td>Calculi</td> </tr> <tr> <td class=\"subtitle1_single\">Musculoskeletal </td> </tr> <tr> <td>Abdominal wall hematoma or infection</td> </tr> <tr> <td>Trauma</td> </tr> <tr> <td>Herniated disc</td> </tr> <tr> <td>Arthritis</td> </tr> <tr> <td>Strain or sprain</td> </tr> <tr> <td>Hernia</td> </tr> <tr> <td>Neoplasm</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Gynecological </td> </tr> <tr> <td>Pregnancy complications</td> </tr> <tr> <td>Abortion</td> </tr> <tr> <td>Dysmenorrhea</td> </tr> <tr> <td>Ectopic pregnancy</td> </tr> <tr> <td>Pelvic inflammatory disease</td> </tr> <tr> <td>Endometritis</td> </tr> <tr> <td>Neoplasm</td> </tr> <tr> <td>Ovarian cyst</td> </tr> <tr> <td>Salpingitis</td> </tr> <tr> <td>Torsion of adnexa</td> </tr> <tr> <td>Rupture of ovarian cyst</td> </tr> <tr> <td>Endometriosis</td> </tr> <tr> <td>Mittelschmerz</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular </td> </tr> <tr> <td>Ischemic bowel</td> </tr> <tr> <td>Neoplasm</td> </tr> <tr> <td>Sickle cell crisis</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td>Abdominal epilepsy</td> </tr> <tr> <td>Abdominal migraine</td> </tr> <tr> <td>Depression</td> </tr> <tr> <td>Herpes zoster</td> </tr> <tr> <td>Neoplasm</td> </tr> <tr> <td class=\"subtitle1_single\">Other </td> </tr> <tr> <td>Pneumonia</td> </tr> <tr> <td>Herniated disk</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Howard FM. Acute Abdominal Pain. In: Primary Care for Women, Leppert PC, Peipert P (Eds), Lippincott Williams and Wilkins 2004. Copyright ©2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56612 Version 5.0</div></div></div>"},"56613":{"type":"graphic_picture","displayName":"Small cell ca","title":"Small cell carcinoma (poorly differentiated neuroendocrine carcinoma)","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Small cell carcinoma (poorly differentiated neuroendocrine carcinoma)</div><div class=\"cntnt\"><img style=\"width:624px; height:165px;\" src=\"images/ONC/56613_Small_cell_ca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A-B: In poorly differentiated neuroendocrine carcinoma, the cells are small, rather uniform, hyperchromatic, with nuclear molding, scant cytoplasm and inconspicuous nucleoli. C: Approximately half of small cell carcinomas are associated with areas of urothelial carcinoma and less frequently squamous cell carcinoma.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 56613 Version 1.0</div></div></div>"},"56614":{"type":"graphic_table","displayName":"LD definition IDEA","title":"Individuals with Disabilities Education Act (IDEA), 1997 definition of specific learning disability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Individuals with Disabilities Education Act (IDEA), 1997 definition of specific learning disability</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>\"The term 'specific learning disability' means those\nchildren who have a disorder in one or more of the basic psychological\nprocesses involved in understanding or in using language, spoken or\nwritten, which disorder may manifest itself in imperfect ability to\nlisten, think, speak, read, write, spell, or to do mathematical\ncalculations. The term includes such conditions as perceptual\nhandicaps, brain injury, minimal brain dysfunction, dyslexia, and\ndevelopmental aphasia. The term does not include a learning problem\nwhich is primarily the result of visual, hearing, or motor handicaps,\nof mental retardation, of emotional disturbance, or of environmental,\ncultural, or economic disadvantage.\"</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Public Law 94-142 (Federal Register, December 29, 1977, p.65083, 121a.5 and IDEA amendments of 1997, P.L. 105-17, June 4, 1997, 11 stat 37).</div><div id=\"graphicVersion\">Graphic 56614 Version 1.0</div></div></div>"},"56615":{"type":"graphic_picture","displayName":"Neonatal acne","title":"Neonatal acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neonatal acne</div><div class=\"cntnt\"><img style=\"width:400px; height:387px;\" src=\"images/DERM/56615_Neonatalacne.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and pustules on the cheeks of a three-week-old neonate.</div><div class=\"graphic_reference\">Reproduced with permission from: George A Datto, III, MD.</div><div id=\"graphicVersion\">Graphic 56615 Version 4.0</div></div></div>"},"56616":{"type":"graphic_picture","displayName":"Cutaneous lichen amyloid 3","title":"Cutaneous lichen amyloidosis in a patient with MEN2","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Cutaneous lichen amyloidosis in a patient with MEN2</div><div class=\"cntnt\"><img style=\"width:468px; height:311px;\" src=\"images/ENDO/56616_Cutaneouslichenamyloid3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin lesion is usually described as pruritic, scaly, papular, pigmented, and located in the interscapular region or on the extensor surfaces of the extremities. Amyloid deposition has been documented histologically.</div><div class=\"graphic_footnotes\">MEN2: multiple endocrine neoplasia type 2.</div><div class=\"graphic_reference\">Courtesy of Cornelis J Lips, MD.</div><div id=\"graphicVersion\">Graphic 56616 Version 2.0</div></div></div>"},"56617":{"type":"graphic_diagnosticimage","displayName":"Fistula from pancreas to skin on fistulogram","title":"Fistula from pancreas to skin on fistulogram","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fistula from pancreas to skin on fistulogram</div><div class=\"cntnt\"><img style=\"width:504px; height:358px;\" src=\"images/GAST/56617_Pancreatic_fistula_fistulog.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fistulogram through a percutaneous drain catheter demonstrates a pancreaticocutaneous fistula (arrow) connecting to the disruption in the pancreatic duct at the neck. There is retrograde and antegrade filling of the pancreatic duct through the fistula.</div><div class=\"graphic_reference\">Courtesy of Dia T Simmons, MD, Santhi Swaroop Vege, MD, and Suresh T Chari, MD.</div><div id=\"graphicVersion\">Graphic 56617 Version 3.0</div></div></div>"},"56619":{"type":"graphic_picture","displayName":"Microscopic view head louse","title":"Head louse nit","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Head louse nit</div><div class=\"cntnt\"><img style=\"width:262px; height:389px;\" src=\"images/PC/56619_Microscopy_head_lice_nit_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic view of a head louse nit attached to a strand of hair.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 56619 Version 2.0</div></div></div>"},"56620":{"type":"graphic_diagnosticimage","displayName":"Cystic Pneumocystis pneumonia","title":"Pneumocystis jiroveci pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumocystis jiroveci pneumonia</div><div class=\"cntnt\"><img style=\"width:356px; height:237px;\" src=\"images/PULM/56620_Cystic_Pneumocystis_pneumon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan from a patient treated with aerosolized pentamidine. Upper lobe ground glass opacities are interspersed with multiple small cystic spaces that diffusely permeate the lung parenchyma.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56620 Version 2.0</div></div></div>"},"56621":{"type":"graphic_algorithm","displayName":"Home treatment of acute asthma","title":"Management of asthma exacerbations: home treatment","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Management of asthma exacerbations: home treatment</div><div class=\"cntnt\"><img style=\"width:587px; height:571px;\" src=\"images/PULM/56621_Home_treatment_of_acute_ast.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ED: emergency department; MDI: metered-dose inhaler; PEF: peak expiratory flow; SABA: short-acting beta<sub>2</sub>-agonist (quick-relief inhaler).</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 56621 Version 4.0</div></div></div>"},"56622":{"type":"graphic_figure","displayName":"Venovenous ECMO","title":"Venovenous (VV) ECMO for isolated respiratory failure","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Venovenous (VV) ECMO for isolated respiratory failure</div><div class=\"cntnt\"><img style=\"width:586px; height:448px;\" src=\"images/PULM/56622_Venovenous_ECMO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram of venovenous ECMO for respiratory failure. When there is no native lung function the arterial saturation will be 75 to 85 percent. VV access: Blood is withdrawn from the IVC, circulated through the artificial membrane, and returned via the SVC to the RA.</div><div class=\"graphic_footnotes\">ECMO: extracorporeal membrane oxygenation; AO: aorta; PV: pulmonary vein; PA: pulmonary artery; LA: left atrium; LV: left ventricle; RA: right atrium; RV: right ventricle; VV: venovenous; IVC: inferior vena cava; SVC: superior vena cava.</div><div class=\"graphic_reference\">Revised and updated from: Bartlett RH, Gattinoni L. Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiol 2010; 76:534.</div><div id=\"graphicVersion\">Graphic 56622 Version 4.0</div></div></div>"},"56623":{"type":"graphic_figure","displayName":"Survival RVEF and PAP","title":"Right ventricular dysfunction predicts poor outcome only when associated with elevated pulmonary pressures","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Right ventricular dysfunction predicts poor outcome only when associated with elevated pulmonary pressures</div><div class=\"cntnt\"><img style=\"width:549px; height:331px;\" src=\"images/CARD/56623_Survival_RVEF_and_PAP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a group of 377 patients with heart failure followed for 17 months, survival rate without urgent heart transplantation is reduced only in group 4 patients who had a reduced right ventricular ejection fraction (RVEF) associated with elevated mean pulmonary artery pressure (PAP). The survival in those with either low RVEF or high PAP was the same as those without either abnormality.</div><div class=\"graphic_reference\">Data from Ghio S, Gavazzi A, Campana C, et al. J Am Coll Cardiol 2001; 37:183.</div><div id=\"graphicVersion\">Graphic 56623 Version 2.0</div></div></div>"},"56624":{"type":"graphic_figure","displayName":"Incidence of DSPN","title":"Incidence of peripheral neuropathy and rate of antiretroviral therapy use among 7362 patients in the HIV outpatient study (HOPS) cohort","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Incidence of peripheral neuropathy and rate of&nbsp;antiretroviral therapy use among 7362 patients in the HIV outpatient study (HOPS) cohort</div><div class=\"cntnt\"><img style=\"width:546px; height:292px;\" src=\"images/ID/56624_Incidence_of_DSPN.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DSPN: distal sensory peripheral neuropathy.</div><div class=\"graphic_reference\">Reproduced with permission from: Lichtenstein, KA, Armon, C, Baron, A, et al. Modification of the incidence of drug-associated symmetrical periheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005; 40:148. Copyright © 2005 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 56624 Version 2.0</div></div></div>"},"56626":{"type":"graphic_figure","displayName":"Circadian pattern AMI SCD","title":"Circadian pattern of nonfatal myocardial infarction and sudden death","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Circadian pattern of nonfatal myocardial infarction and sudden death</div><div class=\"cntnt\"><img style=\"width:489px; height:526px;\" src=\"images/CARD/56626_CircadianpatternAMISCD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A meta-analysis was performed using trials that reported the timing for an acute myocardial infarction (n = 66,635 patients) and sudden death (n = 19,390 patients). An excess number of infarctions and sudden deaths occurred in the morning between the hours of 6&nbsp;AM and 12 PM, indicating a circadian pattern to their occurrence.</div><div class=\"graphic_reference\">Data from Kangro, T, Henriksen, E, Jonason, T, et al. Am J Cardiol 1997; 79:1507.</div><div id=\"graphicVersion\">Graphic 56626 Version 2.0</div></div></div>"},"56629":{"type":"graphic_diagnosticimage","displayName":"Fetal BPD","title":"Measurement of fetal biparietal diameter","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Measurement of fetal biparietal diameter</div><div class=\"cntnt\"><img style=\"width:459px; height:451px;\" src=\"images/OBGYN/56629_Fetal_BPD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial image of the fetal head of a second trimester fetus at the level of the thalami. The thalami are symmetrical and the midline of the fetal brain is identified. The calipers are placed on the leading portions of the cranium for measurement of the biparietal diameter. This level is generally the largest transverse diameter of the cranium and is used for estimation of gestational age and fetal weight.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 56629 Version 2.0</div></div></div>"},"56630":{"type":"graphic_diagnosticimage","displayName":"Ultrasound axial image of the wrist","title":"Ultrasound axial image of the wrist","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Ultrasound axial image of the wrist</div><div class=\"cntnt\"><img style=\"width:505px; height:241px;\" src=\"images/NEURO/56630_US_axial_wrist_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an ultrasound axial image of the wrist at the distal wrist crease. The image on the left is obtained with the probe perpendicular to the flexor carpi radialis tendon (T); note that it is hyperechoic in this image. In the right image, at the same level, the probe is tilted just off the perpendicular axis by aiming the probe slightly proximal. Note that this shift of just a few degrees causes the tendon to become hypoechoic. The median nerve (N) varies less in echogenicity because the tendon exhibits a higher degree of anisotropy. Note that some of the flexor tendons below the nerve, which are not precisely parallel to the flexor carpi radialis tendon, also show marked variations in echogenicity with the slight shift of probe angle. (The numeral &quot;-1&quot; to the right indicates a depth of 1 cm, and the dot below it represents an additional 0.5 cm.)</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 56630 Version 5.0</div></div></div>"},"56631":{"type":"graphic_waveform","displayName":"Sinus tachycardia tutorial","title":"Sinus tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinus tachycardia</div><div class=\"cntnt\"><img style=\"width:281px; height:141px;\" src=\"images/CARD/56631_Sinus_tachycardia_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus tachycardia is defined as a sinus rhythm with a rate of greater than 100 beats per minute and less than approximately 160 to 180 beats per minute. In this tracing, the rate is about 130 beats per minute.</div><div id=\"graphicVersion\">Graphic 56631 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"56633":{"type":"graphic_table","displayName":"Causes of adrenal hyperandrogenism","title":"Causes of adrenal hyperandrogenism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of adrenal hyperandrogenism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary adrenal diseases</td> </tr> <tr> <td>Premature adrenarche</td> </tr> <tr> <td>Adrenal tumors (adenomas, carcinomas, bilateral macronodular adrenal hyperplasia)</td> </tr> <tr> <td class=\"subtitle1_single\">ACTH hypersecretion</td> </tr> <tr> <td>Congenital adrenal hyperplasia</td> </tr> <tr> <td>ACTH-dependent Cushing's syndrome</td> </tr> <tr> <td>Glucocorticoid resistance</td> </tr> <tr> <td>Cortisone reductase deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Hyperprolactinemia</td> </tr> <tr> <td class=\"subtitle1_single\">Exogenous</td> </tr> <tr> <td>Androgens</td> </tr> <tr> <td class=\"subtitle1_single\">Pregnancy</td> </tr> <tr> <td>Placental sulfatase deficiency (no hyperandrogenism)</td> </tr> <tr> <td>Placental aromatase deficiency (mother and female fetus virilization)</td> </tr> <tr> <td>P450 oxidoreductase deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>PAPSS2 deficiency (apparent DHEA sulfotransferase deficiency)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTH: corticotropin; DHEA: dehydroepiandrosterone.</div><div id=\"graphicVersion\">Graphic 56633 Version 7.0</div></div></div>"},"56634":{"type":"graphic_diagnosticimage","displayName":"MRI of nerve sheath B","title":"MRI of lumbar nerve sheath tumor","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">MRI of lumbar nerve sheath tumor</div><div class=\"cntnt\"><img style=\"width:540px; height:270px;\" src=\"images/ONC/56634_MRI_of_nerve_sheath_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">68-year-old male presented with significant biologic pain. Sagittal (a) and axial (b) MRI images showed a cystic lesion at L2 with linear enhancement around the periphery. The tumor was approached via an L2 laminectomy with partial laminectomies at L1 and L3 and intradural exploration. A large motor root, identified with 2 mamp stimulation was identified and dissected off of the tumor capsule. The sensory roots of origin were sharply divided and the tumor was removed en bloc.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div id=\"graphicVersion\">Graphic 56634 Version 4.0</div></div></div>"},"56637":{"type":"graphic_figure","displayName":"Mediastinal mass compartment","title":"Common diagnostic possibilities of mediastinal masses","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Common diagnostic possibilities of mediastinal masses</div><div class=\"cntnt\"><img style=\"width:527px; height:550px;\" src=\"images/PULM/56637_Mediastinal_mass_compartmen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The differential diagnosis of a mediastinal mass depends upon the anatomic compartment in which it arises.</div><div class=\"graphic_reference\">Redrawn from: Baue AE, et al. Glenn's Thoracic and Cardiovascular Surgery. 5th ed. Appleton &amp; Lange, Norwalk, CT, 1991.</div><div id=\"graphicVersion\">Graphic 56637 Version 6.0</div></div></div>"},"56639":{"type":"graphic_table","displayName":"Scleroderma fibroblasts","title":"Properties of scleroderma dermal fibroblasts in tissue culture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Properties of scleroderma dermal fibroblasts in tissue culture</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Increased</td>\n</tr>\n<tr>\n<td>Collagen I and III mRNA and protein production</td>\n</tr>\n<tr>\n<td>Proteoglycan synthesis</td>\n</tr>\n<tr>\n<td>Fibronectin synthesis</td>\n</tr>\n<tr>\n<td>Prolyl and lysyl hydroxylase enzyme activity</td>\n</tr>\n<tr>\n<td>PDGF receptor expression</td>\n</tr>\n<tr>\n<td>Production of IL-1 and IL-6</td>\n</tr>\n<tr>\n<td>Serum independent proliferation</td>\n</tr>\n<tr>\n<td>Surface expression and shedding of ICAM-1</td>\n</tr>\n<tr>\n<td>Collagenase secretion </td>\n</tr>\n<tr>\n<td>Suceptibility to anti-Fas induced apoptosis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Reduced</td>\n</tr>\n<tr>\n<td>Collagen I mRNA downregulation in collagen gel matrix culture</td>\n</tr>\n<tr>\n<td>Collagenase production</td>\n</tr>\n<tr>\n<td>Proliferative response to recombinant EGF, endothelin-1</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 56639 Version 1.0</div></div></div>"},"56641":{"type":"graphic_picture","displayName":"Neutrophilic villitis and abscess","title":"Neutrophilic villitis and abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neutrophilic villitis and abscess</div><div class=\"cntnt\"><img style=\"width:450px; height:320px;\" src=\"images/OBGYN/56641_Acute_villitis_and_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neutrophilic (acute) villitis and abscess in a case of streptococcal placentitis.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 56641 Version 3.0</div></div></div>"},"56642":{"type":"graphic_figure","displayName":"The developing fetus","title":"The developing fetus","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">The developing fetus</div><div class=\"cntnt\"><img style=\"width:542px; height:387px;\" src=\"images/OBGYN/56642_The_developing_fetus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The black bars represent the critical period during which development may be disrupted by a teratogen resulting in a major structural malformation. Cell differentiation occurs over a longer period (white bars); exposure during this period can result in minor structural malformations, growth restriction, or functional deficiency. Note, embryonic&nbsp;age is counted from fertilization, whereas menstrual age (ie, gestational age)&nbsp;is counted from the first day of the last menstrual period. Thus, an embryonic age of&nbsp;six weeks corresponds to a menstrual age (gestational age)&nbsp;of&nbsp;eight weeks. Embryonic weeks 1 to 8 are considered the&nbsp;embryonic period&nbsp;of development and are followed by the fetal period&nbsp;of development.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore K. The developing human: Clinically oriented embryology, WB Saunders, Philadelphia 1982. Copyright ©1982 Elsevier.</div><div id=\"graphicVersion\">Graphic 56642 Version 3.0</div></div></div>"},"56643":{"type":"graphic_table","displayName":"Endothelial dysfunction factors","title":"Factors that cause and interventions that improve endothelial dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that cause and interventions that improve endothelial dysfunction</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Factors associated with endothelial dysfunction</td> </tr> <tr> <td>Increased age</td> </tr> <tr> <td>Male sex </td> </tr> <tr> <td>Family history of CHD </td> </tr> <tr> <td>Smoking</td> </tr> <tr> <td>Increased serum cholesterol </td> </tr> <tr> <td>Low serum HDL-cholesterol </td> </tr> <tr> <td>Hypertension </td> </tr> <tr> <td>Increased serum homocysteine </td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td>Obesity</td> </tr> <tr> <td>High-fat meal</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Interventions that improve endothelial function</td> </tr> <tr> <td>L-arginine</td> </tr> <tr> <td>Antioxidants</td> </tr> <tr> <td>Smoking cessation</td> </tr> <tr> <td>Cholesterol lowering</td> </tr> <tr> <td>ACE inhibitors</td> </tr> <tr> <td>Exercise</td> </tr> <tr> <td>Mediterranean Diet</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56643 Version 2.0</div></div></div>"},"56644":{"type":"graphic_table","displayName":"Outcome typ atyp bronch car","title":"Long-term survival after resection of typical and atypical bronchial carcinoids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Long-term survival after resection of typical and atypical bronchial carcinoids</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"28%\"></colgroup><colgroup span=\"6\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Author, year</td> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Number of patients</td> <td class=\"subtitle1\" colspan=\"4\">Survival</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">5-year</td> <td class=\"subtitle2\" colspan=\"2\">10-year</td> </tr> <tr> <td class=\"subtitle3\">Typical</td> <td class=\"subtitle3\">Atypical</td> <td class=\"subtitle3\">Typical</td> <td class=\"subtitle3\">Atypical</td> <td class=\"subtitle3\">Typical</td> <td class=\"subtitle3\">Atypical</td> </tr> <tr> <td>Harpole H, 1992</td> <td>80</td> <td>41</td> <td>96</td> <td>40</td> <td>92</td> <td>31</td> </tr> <tr> <td>Soga J, 1999</td> <td>1595</td> <td>250</td> <td>93</td> <td>69</td> <td>82</td> <td>59</td> </tr> <tr> <td>Beasley M, 2000</td> <td>&ndash;</td> <td>106</td> <td>&ndash;</td> <td>61</td> <td>&ndash;</td> <td>35</td> </tr> <tr> <td>Gracia-Yuste M, 2000</td> <td>261</td> <td>43</td> <td>96</td> <td>72</td> <td>93</td> <td>43</td> </tr> <tr> <td>Ferguson M, 2000</td> <td>109</td> <td>26</td> <td>90</td> <td>70</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Fink G, 2001</td> <td>128</td> <td>14</td> <td>89</td> <td>75</td> <td>82</td> <td>56</td> </tr> <tr> <td>Filosso P, 2002</td> <td>82</td> <td>14</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Fiala P, 2003</td> <td>77</td> <td>19</td> <td>99</td> <td>95</td> <td>87</td> <td>74</td> </tr> <tr> <td>Kaplan B, 2003</td> <td>144</td> <td>62</td> <td>79*</td> <td>63*</td> <td>60*</td> <td>37*</td> </tr> <tr> <td>Cardillo G, 2004</td> <td>121</td> <td>42</td> <td>90</td> <td>79</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Rea F, 2007</td> <td>174</td> <td>78</td> <td>&ndash;</td> <td>&ndash;</td> <td>93</td> <td>64</td> </tr> <tr> <td>Machuca T, 2010</td> <td>110</td> <td>16</td> <td>91</td> <td>56</td> <td>89</td> <td>47</td> </tr> <tr> <td>Filosso PL, 2013</td> <td>83</td> <td>43</td> <td>91</td> <td>69</td> <td>86</td> <td>43</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Disease-specific survival.</div><div id=\"graphicVersion\">Graphic 56644 Version 8.0</div></div></div>"},"56645":{"type":"graphic_algorithm","displayName":"Asymptomatic microhematuria","title":"Algorithm for isolated asymptomatic microscopic hematuria in children","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Algorithm for isolated asymptomatic microscopic hematuria in children</div><div class=\"cntnt\"><img style=\"width:459px; height:567px;\" src=\"images/PEDS/56645_Asymptomatic_microhematuria.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RBC: red blood cell.<br />* Urinalysis.</div><div class=\"graphic_reference\">Modified with permission from: Patel HP, Bissler JJ. Hematuria in children. Pediatr Clin North Am 2001; 48:1519. Copyright © 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 56645 Version 3.0</div></div></div>"},"56646":{"type":"graphic_picture","displayName":"Aspiration following central venous catheter placement","title":"Aspiration following central venous catheter placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspiration following central venous catheter placement</div><div class=\"cntnt\"><img style=\"width:432px; height:217px;\" src=\"images/EM/56646_Central_line_aspiratn_flush.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following placement of the catheter, blood should be aspirated from each port and then each port should be flushed.</div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 56646 Version 4.0</div></div></div>"},"56647":{"type":"graphic_diagnosticimage","displayName":"Normal AP and lateral elbow radiograph child","title":"AP and lateral radiographs of the normal elbow and anatomic landmarks","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">AP and lateral radiographs of the normal elbow and anatomic landmarks</div><div class=\"cntnt\"><img style=\"width:460px; height:283px;\" src=\"images/EM/56647_XrayAPlateralelbowedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anteroposterior (AP) radiograph of a normal elbow of a child. <br />(B) Normal lateral radiograph. The radial head and neck are seen on both AP and lateral views of the elbow. The olecranon process of the ulna is best seen on the lateral view. On the lateral radiograph, the radial head is superimposed over the coronoid process of the ulna.</div><div class=\"graphic_reference\">Reproduced with permission from: Bachman D, Santora S. Orthopedic trauma. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56647 Version 17.0</div></div></div>"},"56648":{"type":"graphic_figure","displayName":"Weight gain with glitazones","title":"Weight gain with thiazolidinediones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Weight gain with thiazolidinediones</div><div class=\"cntnt\"><img style=\"width:327px; height:317px;\" src=\"images/ENDO/56648_Weight_gain_with_glitazones.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Weight increased in both a time- and dose-dependent fashion in patients with type 2 diabetes who were treated with different thiazolidinediones for six months.</div><div class=\"graphic_footnotes\">T200, T400, and T600: troglitazone 200, 400, and 600 mg daily, respectively; P15 and P45: pioglitazone 15 and 45 mg daily, respectively; R4 and R8: rosiglitazone 4 and 8 mg daily, respectively.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23:1605.</LI>&#xD;&#xA;<LI>Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000; 283:1695.</LI>&#xD;&#xA;<LI>Schwartz S, Raskin P, Fonseca V, Graveline JF.&nbsp;Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998; 338:861. </LI>&#xD;&#xA;<LI>Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes.&nbsp;Diabetes Care 2000; 23:1067.</LI></OL></div><div id=\"graphicVersion\">Graphic 56648 Version 3.0</div></div></div>"},"56649":{"type":"graphic_figure","displayName":"Causes of see saw nystagmus","title":"Causes of see-saw nystagmus in 42 patients","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Causes of see-saw nystagmus in 42 patients</div><div class=\"cntnt\"><img style=\"width:425px; height:286px;\" src=\"images/PC/56649_Causes_of_see_saw_nystagmus.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">The numbers in parentheses associated with the pie graph represent the percent of patients with each cause.</div><div id=\"graphicVersion\">Graphic 56649 Version 1.0</div></div></div>"},"56650":{"type":"graphic_table","displayName":"Predictors of survival","title":"Predictors of survival in patients with advanced cancer under palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of survival in patients with advanced cancer under palliative care</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Index Survival</td> <td class=\"subtitle1\">Value</td> <td class=\"subtitle1\">Median</td> <td class=\"subtitle1\">References</td> </tr> <tr> <td rowspan=\"3\">Karnofsky Performance Status</td> <td>10 to 20 </td> <td>7 to 16 days </td> <td rowspan=\"3\">Evans 1985, Maltoni 1994, Maltoni 1995, Reuben 1998, Morita 1999, Llobera 2000, Bruera 1992</td> </tr> <tr> <td>30 to 40</td> <td>8 to 50 days</td> </tr> <tr> <td>&#62;50</td> <td>50 to 90 days</td> </tr> <tr> <td>Anorexia</td> <td>Present</td> <td>&#60;58 days</td> <td>Maltoni 1995, Llobera 2000, Bruera 1992</td> </tr> <tr> <td>Confusion</td> <td>Present</td> <td>&#60;38 days</td> <td>Llobera 2000, Bruera 1992</td> </tr> <tr> <td>Dysphagia</td> <td>Present</td> <td>&#60;30 days</td> <td>Maltoni 1995</td> </tr> <tr> <td>Dyspnea</td> <td>Present</td> <td>&#60;30 days</td> <td>Maltoni 1995</td> </tr> <tr> <td>Xerostomia</td> <td>Present</td> <td>&#60;50 days</td> <td>Bruera 1992</td> </tr> <tr> <td>Physician estimate</td> <td>3 months</td> <td>30 days </td> <td>Parkes 1972, Heyse-Moore 1987, Christakis 2000</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56650 Version 4.0</div></div></div>"},"56651":{"type":"graphic_figure","displayName":"Calculation Fick cardiac output","title":"Calculation of AV oxygen difference and cardiac output using the Fick method","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Calculation of AV oxygen difference and cardiac output using the Fick method</div><div class=\"cntnt\"><img style=\"width:498px; height:120px;\" src=\"images/PULM/56651_Calculation_Fick_cardiac_ou.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oxygen consumption is estimated from a nomogram based on age, sex, height, and weight. In addition, oxygen consumption can be measured directly using exhaled breath analysis.</div><div class=\"graphic_footnotes\">Hgb: serum hemoglobin (g/dL)<br> SaO2: arterial oxygen saturation (percent) measured from arterial blood<br> SvO2: mixed venous oxygen saturation (percent) measured from the pulmonary artery in the absence of a shunt or calculated using MvO2 = [3 SVC saturation + IVC saturation] divided by 4 if a left to right shunt is present.<br> Constant values: 1.34 mL O2 per gram Hgb; 10 dL per L.</div><div id=\"graphicVersion\">Graphic 56651 Version 3.0</div></div></div>"},"56652":{"type":"graphic_diagnosticimage","displayName":"Lymphangioleiomyomatosis PA","title":"Lymphangioleiomyomatosis in a young woman","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphangioleiomyomatosis in a young woman</div><div class=\"cntnt\"><img style=\"width:357px; height:351px;\" src=\"images/PULM/56652_Lymphangioleiomyomatosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows hyperexpanded lungs permeated by fine reticular and nodular opacities. The right pleural effusion is due to a chylothorax.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56652 Version 4.0</div></div></div>"},"56653":{"type":"graphic_diagnosticimage","displayName":"Stage III sarcoidosis PA","title":"Sarcoidosis, stage 3","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis, stage 3</div><div class=\"cntnt\"><img style=\"width:349px; height:346px;\" src=\"images/PULM/56653_Stage_III_sarcoidosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows reticular and nodular opacities involving both lungs diffusely. The lung volumes are preserved. Enlarged central pulmonary arteries suggest pulmonary arterial hypertension.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56653 Version 4.0</div></div></div>"},"56655":{"type":"graphic_picture","displayName":"Nocardia 1","title":"<EM>Nocardia </EM>pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Nocardia </EM>pattern</div><div class=\"cntnt\"><img style=\"width:410px; height:518px;\" src=\"images/ID/56655_Nocardia_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) <EM>Nocardia</EM> organisms with typical characteristic Chinese letter pattern. <br />(B)&nbsp;Grocott methenamine silver stain with <EM>Nocardia</EM> organisms.</div><div class=\"graphic_reference\">Reproduced with permission from: Cagle PT, MD. Color Atlas and Text of Pulmonary Pathology. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56655 Version 4.0</div></div></div>"},"56656":{"type":"graphic_movie","displayName":"TEE PFO with contrast","title":"Transesophageal echocardiography with contrast of a patent foramen ovale","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography with contrast of a patent foramen ovale</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/56656_TEEPFOcontrastvid.mp4\" style=\"width:320px;height:236px\"></div><img style=\"width:412px; height:429px;\" src=\"images/CARD/56656_TEEPFOcontrastimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sequence of images from a transesophageal echocardiography shows the right and left atrium during diastole (panel A); a flap of the atrial septum is seen covering the foramen ovale. There is opacification of the right atrium immediately after the injection of agitated saline (panel B). Panel C shows the contrast passing from the right atrium (RA) into the left atrium (LA) through a patent foramen ovale (PFO) (dashed arrow). Panel D shows a large amount of contrast within the LA (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 56656 Version 3.0</div></div></div>"},"56658":{"type":"graphic_table","displayName":"DYT locus symbols for dystonia","title":"DYT locus symbols for dystonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DYT locus symbols for dystonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Locus</td> <td class=\"subtitle1\">Designation</td> <td class=\"subtitle1\">Mode of inheritance</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Chromosome, mutation and gene product</td> </tr> <tr> <td>DYT1</td> <td>Dystonia 1, torsion</td> <td>AD</td> <td>Typically begins in childhood; onset in limb often with progression to generalized dystonia</td> <td>9q34; GAG deletion in TOR1A gene causes abnormality in ATP-binding protein, torsinA</td> </tr> <tr> <td>DYT2</td> <td>Dystonia 2, torsion</td> <td>AR</td> <td>Childhood onset, generalized or segmental; Gypsy families</td> <td>Unknown chromosome, gene product</td> </tr> <tr> <td>DYT3</td> <td>X-linked dystonia-parkinsonism (Lubag)</td> <td>X-linked recessive</td> <td>Segmental or generalized dystonia with parkinsonism; predominantly in males from Panay island in Philippines</td> <td>Xq13.1; TAF1 gene</td> </tr> <tr> <td>DYT4</td> <td>Whispering dysphonia</td> <td>AD</td> <td>Laryngeal and cervical dystonia described in one Australian family</td> <td>19p13.3; mutations in the TUBB4A gene</td> </tr> <tr> <td rowspan=\"2\">DYT5 </td> <td>Dopa-responsive dystonia/parkinsonism</td> <td>AD</td> <td>Dystonia with or without parkinsonism; dramatic response to levodopa</td> <td>14q22; GCH1 locus; mutations in GTP cyclohydrolase I gene</td> </tr> <tr> <td>Segawa syndrome</td> <td>AR</td> <td>Dystonia with or without parkinsonism; diurnal variation, with worst symptoms in evening; marked response to levodopa</td> <td>11p15.5; mutations in the tyrosine hydroxylase gene; tyrosine hydroxylase deficiency</td> </tr> <tr> <td>DYT6</td> <td>Dystonia 6, torsion</td> <td>AD</td> <td>Adolescent onset dystonia of mixed type; mostly segmental dystonia; mixed limb, cervical, cranial; Amish-Mennonite, German, Irish, Italian families</td> <td>8p11.21; mutations in the THAP1 gene</td> </tr> <tr> <td>DYT7</td> <td>Dystonia 7, torsion</td> <td>AD</td> <td>Adult onset focal dystonia with cervical dystonia, limb dystonia, dysphonia, or blepharospasm; German family</td> <td>18p; gene and product unknown</td> </tr> <tr> <td>DYT8</td> <td>Paroxysmal nonkinesigenic dyskinesia 1</td> <td>AD</td> <td>Episodes of dystonia/choreoathetosis not precipitated by exercise or activity</td> <td>2q35; myofibrillogenesis regulator (MR1 gene)</td> </tr> <tr> <td>DYT9 (allelic with DYT18)</td> <td>Paroxysmal choreoathetosis with episodic spasticity and ataxia</td> <td>AD</td> <td>Episodes of dystonia, diplopia, and paresthesia with spastic paraplegia between attacks</td> <td>1p34.2; mutations in the SLC2A1 gene that encodes the glucose transporter type 1</td> </tr> <tr> <td>DYT10</td> <td>Episodic kinesigenic dyskinesia 1 (paroxysmal kinesigenic dyskinesia)</td> <td>AD</td> <td>Episodic choreoathetosis and dystonia brought on by exercise/activity</td> <td>16p11.2; mutations in the PRRT2 gene</td> </tr> <tr> <td>DYT11</td> <td>Myoclonus-dystonia</td> <td>AD</td> <td>Myoclonic jerks associated with variable features of dystonia; very alcohol responsive</td> <td>7q; epsilon-sarcoglycan gene (SGCE)</td> </tr> <tr> <td>DYT12</td> <td>Rapid onset dystonia- parkinsonism</td> <td>AD</td> <td>Onset of dystonia and parkinsonism over days to months</td> <td>19q; ATP1A3 gene that encodes the Na+/K+ -ATPase alpha3 subunit</td> </tr> <tr> <td>DYT13</td> <td>Dystonia 13, torsion</td> <td>AD</td> <td>Early adult onset multifocal and segmental dystonia with cervical, cranial, and arm dystonia</td> <td>1p; gene and product unknown</td> </tr> <tr> <td>DYT14</td> <td>Dopa responsive dystonia (now included under DYT5)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>DYT15</td> <td>Dystonia 15, myoclonic</td> <td>AD</td> <td>Myoclonus and dystonia</td> <td>18p11; gene and product unknown</td> </tr> <tr> <td>DYT16</td> <td>Dystonia 16</td> <td>AR</td> <td>Early onset generalized dystonia; some cases with parkinsonism unresponsive to levodopa</td> <td>2q31.3; PRKRA gene</td> </tr> <tr> <td>DYT17</td> <td>Dystonia 17, torsion</td> <td>AR</td> <td>Adolescent onset in neck with regional spread</td> <td>20p11.2-q13.12; gene and product unknown</td> </tr> <tr> <td>DYT18 (allelic with DYT9)</td> <td>Paroxysmal exercise-induced dyskinesia with or without epilepsy and/or hemolytic anemia (GLUT1 deficiency syndrome 2)</td> <td>AD</td> <td>Episodes of dystonia, diplopia, paresthesias with spastic paraplegia between attacks</td> <td>1p34.2; mutations in the SLC2A1 gene that encodes the glucose transporter type 1</td> </tr> <tr> <td>DYT19</td> <td>Episodic kinesigenic dyskinesia 2 (paroxysmal kinesigenic dyskinesia)</td> <td>AD</td> <td>Episodic choreoathetosis and dystonia brought on by exercise/activity</td> <td>16q13-q22.1; gene and product unknown</td> </tr> <tr> <td>DYT20</td> <td>Paroxysmal nonkinesigenic dyskinesia 2</td> <td>AD</td> <td>Spontaneous episodes of dystonia</td> <td>2q31; gene and product unknown</td> </tr> <tr> <td>DYT21</td> <td>Dystonia 21</td> <td>AD</td> <td>Adolescent to adult onset; generalized or multifocal</td> <td>2q14.3-q21.3; gene and product unknown</td> </tr> <tr> <td>DYT23</td> <td>Dystonia 23</td> <td>AD</td> <td>Adult onset cervical dystonia</td> <td>9q34, ?CIZ1 gene</td> </tr> <tr> <td>DYT24</td> <td>Dystonia 24</td> <td>AD</td> <td>Adult onset craniocervical dystonia affecting the neck, laryngeal muscles, and arms</td> <td>11p14.2, ANO3 gene</td> </tr> <tr> <td>DYT25</td> <td>Dystonia 25</td> <td>AD</td> <td>Adult onset cervical dystonia with regional spread</td> <td>18p11.21, GNAL gene</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: autosomal dominant; AR: autosomal recessive; ATP: adenosine triphosphate.</div><div id=\"graphicVersion\">Graphic 56658 Version 13.0</div></div></div>"},"56660":{"type":"graphic_waveform","displayName":"ECG subarachnoid hemorrhage","title":"T wave abnormalities following stroke","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">T wave abnormalities following stroke</div><div class=\"cntnt\"><img style=\"width:548px; height:391px;\" src=\"images/CARD/56660_ECG_subarachnoid_hemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inverted, symmetric T waves are seen on the EKG of a patient with subarachnoid hemorrhage. Normal serum cardiac enzymes concentrations as well as subsequent normalization of the T waves attest to the neurogenic origin of the EKG pattern.</div><div id=\"graphicVersion\">Graphic 56660 Version 3.0</div></div></div>"},"56661":{"type":"graphic_figure","displayName":"Measurement of intra-abdominal pressure","title":"Measurement of intra-abdominal pressure","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Measurement of intra-abdominal pressure</div><div class=\"cntnt\"><img style=\"width:524px; height:634px;\" src=\"images/SURG/56661_IABPtransducersetup.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">1. Clamp the drainage tube of the Foley (bladder) catheter.<br />2. Instill up to 60 cc sterile saline into the bladder via the aspiration port of the Foley catheter. Be certain the catheter is filled with fluid.<br />3. The pressure transducer can be held in place using an elastic strap as shown in the figure, or alternatively, it can be attached to an intravenous pole at the height of the midaxillary line. Attach a pressure transducer to an 18-gauge needle, and insert into the aspiration port. With some newer-style Foley catheters, a needle-less connection system can be used.<br />4. Zero the transducer at the level of the midaxillary line.<br />5. With the patient in the supine position, ensure that abdominal muscle contractions are absent, and measure the bladder pressure at end-expiration.</div><div id=\"graphicVersion\">Graphic 56661 Version 6.0</div></div></div>"},"56663":{"type":"graphic_algorithm","displayName":"Approach psychosis child","title":"Approach to acute onset psychosis in children","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Approach to acute onset psychosis in children</div><div class=\"cntnt\"><img style=\"width:600px; height:576px;\" src=\"images/EM/56663_Approach_psychosis_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematosus.<BR>* Attempt verbal deescalation. Progress to physical restraints, as needed. Check rapid blood glucose, provide empiric oxygen therapy. Administer chemical restraint as needed (see text).<BR><FONT class=bullet>•</FONT> Other laboratory studies should be obtained if a diagnosis has not been made at this point and may include a complete blood count, liver enzymes (eg, aspartate aminotransferase [AST], alanine aminotransferase [ALT], lactate dehydrogenase [LDH], alkaline phosphatase), liver function tests (total protein, albumin, total and direct bilirubin, prothrombin time, and activated thromboplastin time) ammonia, serum electrolytes, serum&nbsp;blood urea nitrogen&nbsp;and creatinine, and thyroid function tests. Additional testing for inborn errors of metabolism, or SLE is indicated in selected patients with specific physical findings (see text).<BR>Δ Implicated medications include corticosteroids, amoxicillin, clarithromycin, erythromycin, isoniazid, topiramate, and phenytoin.</div><div id=\"graphicVersion\">Graphic 56663 Version 3.0</div></div></div>"},"56664":{"type":"graphic_table","displayName":"Tendinopathy phases","title":"Tendinosis phases of pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tendinosis phases of pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Phase I</td>\n<td>Mild pain after exercise activity, resolves within 24 hours</td>\n</tr>\n\n<tr>\n<td>Phase II</td>\n<td>Pain after exercise activity, exceeds 48 hours, resolves with warm-up</td>\n</tr>\n\n<tr>\n<td>Phase III</td>\n<td>Pain with exercise activity that does not alter activity</td>\n</tr>\n\n<tr>\n<td>Phase IV</td>\n<td>Pain with exercise activity that alters activity</td>\n</tr>\n\n<tr>\n<td>Phase V</td>\n<td>Pain caused by heavy activities of daily living</td>\n</tr>\n\n<tr>\n<td>Phase VI</td>\n<td><p>Intermittent pain at rest that does not disturb sleep</p><p>Pain caused by light activities of daily living</p></td>\n</tr>\n\n<tr>\n<td>Phase VII</td>\n<td>Constant rest pain (dull aching) and pain that disturbs sleep</td>\n</tr>\n\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Nirschl, RP. Elbow tendinosis/Tennis elbow. Clinics in sports medicine 1992; 11:851. Copyright &#169;1992 Elsevier.</div><div id=\"graphicVersion\">Graphic 56664 Version 1.0</div></div></div>"},"56665":{"type":"graphic_figure","displayName":"T cell antigen receptor","title":"The T cell antigen receptor","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">The T cell antigen receptor</div><div class=\"cntnt\"><img style=\"width:562px; height:228px;\" src=\"images/ALLRG/56665_T-cell_antigen_receptor.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The core of the receptor complex is a heterodimer composed of either alpha (α) and beta (β) chains or gamma (γ) and delta (δ). These molecules are members of the immunoglobulin gene superfamily. Each contains two immunoglobulin-like domains with intrachain disulfide bridges. The two chains are also disulfide linked to each other. The cytoplasmic domains of these chains are short, and signaling is carried out by associated molecules.</div><div class=\"graphic_footnotes\">S&ndash;S: disulfide bond.</div><div id=\"graphicVersion\">Graphic 56665 Version 4.0</div></div></div>"},"56667":{"type":"graphic_figure","displayName":"Tonsil dissector","title":"Hurd tonsil dissector and retractor","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Hurd tonsil dissector and retractor</div><div class=\"cntnt\"><img style=\"width:533px; height:151px;\" src=\"images/PC/56667_Tonsil_dissector.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56667 Version 3.0</div></div></div>"},"56668":{"type":"graphic_table","displayName":"Drugs that induce ILD","title":"Examples of drugs and biologics that can cause interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of drugs and biologics that can cause interstitial lung disease</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Antibiotics</td> </tr> <tr> <td class=\"indent1\">Ethambutol</td> </tr> <tr> <td class=\"indent1\">Minocycline</td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin, acute and chronic</td> </tr> <tr> <td class=\"subtitle1_single\">Anti-inflammatory agents</td> </tr> <tr> <td class=\"indent1\">Abatacept&nbsp;</td> </tr> <tr> <td class=\"indent1\">Azathioprine*</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide*</td> </tr> <tr> <td class=\"indent1\">Gold</td> </tr> <tr> <td class=\"indent1\">Interleukin-1 blockers (anakinra)</td> </tr> <tr> <td class=\"indent1\">Leflunomide</td> </tr> <tr> <td class=\"indent1\">Methotrexate*</td> </tr> <tr> <td class=\"indent1\">Nonsteroidal antiinflammatory agents</td> </tr> <tr> <td class=\"indent1\">Penicillamine</td> </tr> <tr> <td class=\"indent1\">Rituximab (anti-CD20 monoclonal antibody)</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> </tr> <tr> <td class=\"indent1\">Thalidomide*</td> </tr> <tr> <td class=\"indent1\">Tocilizumab</td> </tr> <tr> <td class=\"indent1\">Tumor-necrosis factor-alpha blockers</td> </tr> <tr> <td class=\"subtitle1_single\">Anti-arrhythmic agents</td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"indent1\">Tocainide</td> </tr> <tr> <td class=\"subtitle1_single\">Antineoplastic&nbsp;agents</td> </tr> <tr> <td class=\"sublist2_start\">Alkylating agents</td> </tr> <tr> <td class=\"sublist2\">Busulfan</td> </tr> <tr> <td class=\"sublist2\">Chlorambucil</td> </tr> <tr> <td class=\"sublist2\">Cyclophosphamide*</td> </tr> <tr> <td class=\"sublist2\">Melphalan</td> </tr> <tr> <td class=\"sublist2\">Procarbazine</td> </tr> <tr> <td class=\"sublist2_start\">Antibiotics</td> </tr> <tr> <td class=\"sublist2\">Bleomycin sulfate</td> </tr> <tr> <td class=\"sublist2\">Mitomycin C</td> </tr> <tr> <td class=\"sublist2_start\">Antimetabolites</td> </tr> <tr> <td class=\"sublist2\">Azathioprine*</td> </tr> <tr> <td class=\"sublist2\">Cytosine arabinoside</td> </tr> <tr> <td class=\"sublist2\">Methotrexate*</td> </tr> <tr> <td class=\"sublist2_start\">Nitrosoureas</td> </tr> <tr> <td class=\"sublist2\">BCNU (carmustine)</td> </tr> <tr> <td class=\"sublist2\">CCNU (lomustine)</td> </tr> <tr> <td class=\"sublist2\">Methyl-CCNU (semustine)</td> </tr> <tr> <td class=\"sublist2_start\">Other</td> </tr> <tr> <td class=\"sublist2\">Alpha interferon</td> </tr> <tr> <td class=\"sublist2\">Docetaxel</td> </tr> <tr> <td class=\"sublist2\">Etoposide (VP-16)</td> </tr> <tr> <td class=\"sublist2\">Gefitinib</td> </tr> <tr> <td class=\"sublist2\">Nilutamide</td> </tr> <tr> <td class=\"sublist2\">Paclitaxel</td> </tr> <tr> <td class=\"sublist2\">Temsirolimus</td> </tr> <tr> <td class=\"sublist2\">Thalidomide*</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drug-induced systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Hydantoins</td> </tr> <tr> <td class=\"indent1\">Hydralazine</td> </tr> <tr> <td class=\"indent1\">Isoniazid</td> </tr> <tr> <td class=\"indent1\">Penicillamine</td> </tr> <tr> <td class=\"indent1\">Procainamide</td> </tr> <tr> <td class=\"subtitle1_single\">Illicit drugs</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Heroin</td> </tr> <tr> <td class=\"indent1\">Methadone</td> </tr> <tr> <td class=\"indent1\">Propoxyphene</td> </tr> <tr> <td class=\"indent1\">Talc</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Bacille Calmette-Guerin (BCG)</td> </tr> <tr> <td class=\"indent1\">Bromocriptine</td> </tr> <tr> <td class=\"indent1\">Drugs inducing pulmonary infiltrates and eosinophilia</td> </tr> <tr> <td class=\"indent1\">L-tryptophan</td> </tr> <tr> <td class=\"indent1\">Oxygen</td> </tr> <tr> <td class=\"indent1\">Radiation</td> </tr> <tr> <td class=\"indent1\">Statins</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Drugs that are used as both antineoplastic and anti-inflammatory agents.</div><div class=\"graphic_reference\">Adapted from: Rosenow EC III, Martin WJ II. Drug-induced interstitial lung disease. In: Interstitial Lung Disease, Schwarz MI, King TE Jr, (Eds), Mosby Year Book, St. Louis, 1993, p.255-270.</div><div id=\"graphicVersion\">Graphic 56668 Version 3.0</div></div></div>"},"56669":{"type":"graphic_diagnosticimage","displayName":"Paratracheal mass MRI II","title":"Paratracheal mass due to primary lung adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paratracheal mass due to primary lung adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:360px; height:265px;\" src=\"images/PULM/56669_Paratracheal_mass_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial T1-weighted section demonstrates a right paratracheal mass. There are irregular margins with the lung parenchyma, consistent with either a pulmonary primary tumor or invasion of lung by a mediastinal tumor.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56669 Version 2.0</div></div></div>"},"56670":{"type":"graphic_picture","displayName":"Eyelid changes in atopic keratoconjunctivitis","title":"Eyelid changes in atopic keratoconjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eyelid changes in atopic keratoconjunctivitis</div><div class=\"cntnt\"><img style=\"width:380px; height:267px;\" src=\"images/RHEUM/56670_AKC_eyelid_changes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe thickening and a scaly and indurated appearance is typical of atopic keratoconjunctivitis.</div><div id=\"graphicVersion\">Graphic 56670 Version 4.0</div></div></div>"},"56672":{"type":"graphic_picture","displayName":"Renal atheroembolus histology","title":"Renal atheroembolus histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal atheroembolus histology</div><div class=\"cntnt\"><img style=\"width:396px; height:276px;\" src=\"images/NEPH/56672_Atheroemboli.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of an atheroembolus in a muscular renal artery showing cleft-like spaces (arrow) due to washout of the cholesterol crystals during histologic processing.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 56672 Version 2.0</div></div></div>"},"56673":{"type":"graphic_picture","displayName":"Skin biopsy NSF CD34 cells II","title":"Low power image showing immunohistochemical staining for CD34 of a skin biopsy from a patient with nephrogenic systemic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low power image showing immunohistochemical staining for CD34 of a skin biopsy from a patient with nephrogenic systemic fibrosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/NEPH/56673_Skin_biopsy_NSF_CD34_cell1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lower magnification of the same image shows a dense network of CD34+ dendritic processes (brown) among thickened collagen bundles (magenta).</div><div class=\"graphic_reference\">With permission from: Shawn E Cowper, MD.</div><div id=\"graphicVersion\">Graphic 56673 Version 3.0</div></div></div>"},"56675":{"type":"graphic_table","displayName":"Causes of secondary adrenal insufficiency","title":"Causes of secondary adrenal insufficiency in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of secondary adrenal insufficiency in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pituitary disorders</td> </tr> <tr> <td class=\"subtitle2_single\">Congenital</td> </tr> <tr> <td class=\"indent1\">PROP1 gene mutation</td> </tr> <tr> <td class=\"indent1\">POU1F1 (PIT1) gene mutation</td> </tr> <tr> <td class=\"indent1\">TBX19 (TPIT) gene mutation</td> </tr> <tr> <td class=\"indent1\">POMC gene mutation</td> </tr> <tr> <td class=\"indent1\">Idiopathic isolated ACTH deficiency</td> </tr> <tr> <td class=\"subtitle2_single\">Acquired</td> </tr> <tr> <td class=\"indent1\">Brain tumor</td> </tr> <tr> <td class=\"indent1\">Brain hemorrhage</td> </tr> <tr> <td class=\"indent1\">Brain surgery</td> </tr> <tr> <td class=\"indent1\">Cranial radiation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PROP1: prophet of PIT1; PIT1: pituitary-specific transcription factor 1; TBX19: T-box factor, pituitary; POMC: pro-opiomelanocortin (the precursor molecule for ACTH, melanocortin, and β-endorphin); ACTH: adrenocorticotropic hormone.</div><div id=\"graphicVersion\">Graphic 56675 Version 17.0</div></div></div>"},"56676":{"type":"graphic_picture","displayName":"Cortical cataract","title":"Cortical cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cortical cataract</div><div class=\"cntnt\"><img style=\"width:289px; height:260px;\" src=\"images/PC/56676_Cortical_cataract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slit-lamp photo of a cortical cataract reveals white spoke-like opacities in the outer layers of the lens (arrows).</div><div class=\"graphic_reference\">Courtesy of Deborah S Jacobs, MD.</div><div id=\"graphicVersion\">Graphic 56676 Version 2.0</div></div></div>"},"56678":{"type":"graphic_table","displayName":"Symptoms and sequelae of date rape","title":"Possible symptoms and sequelae of date or acquaintance rape","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible symptoms and sequelae of date or acquaintance rape</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Disturbances in sleep (eg, taking more than 20 minutes to fall asleep, nightmares)</td> </tr> <tr> <td>Decrease in appetite; less interest in eating</td> </tr> <tr> <td>Somatic reactions (eg, chronic pelvic pain, recurrent abdominal pain, chronic headache, multiple physical complaints)</td> </tr> <tr> <td>Depressive symptoms</td> </tr> <tr> <td>Suicidality</td> </tr> <tr> <td>Anxiety</td> </tr> <tr> <td>Signs of posttraumatic stress disorder (emotional numbing, diminished interest in everyday activities, detachment from others)</td> </tr> <tr> <td>Psychiatric or behavior problems that usually are found in the other gender (eg, eating disorders in boys or fighting in girls)</td> </tr> <tr> <td>School failure</td> </tr> <tr> <td>Decreased self-esteem, self-worth, and/or confidence in their sense of judgment</td> </tr> <tr> <td>Difficulty maintaining relationships</td> </tr> <tr> <td>Sexual dysfunction</td> </tr> <tr> <td>Alcohol or substance use</td> </tr> <tr> <td>Decreased sexual negotiation skills (may lead to pregnancy or sexually transmitted infections)</td> </tr> <tr> <td>For male victims: Fragility of sense of masculinity and confusion about sexual orientation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56678 Version 5.0</div></div></div>"},"56679":{"type":"graphic_figure","displayName":"Pelvic nerve plexus","title":"Nerve plexus of the pelvis","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Nerve plexus of the pelvis</div><div class=\"cntnt\"><img style=\"width:595px; height:553px;\" src=\"images/EM/56679_Pelvicnerveplexusedit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Autonomic nerves are demonstrated. The superior hypogastric plexus is a continuation of the aortic (intermesenteric) plexus. It divides into left and right hypogastric nerves as it enters the pelvis. The hypogastric and pelvic splanchnic nerves merge to form the inferior hypogastric plexuses, which thus consist of both sympathetic and parasympathetic fibers. Autonomic (sympathetic) fibers also enter the pelvis via the sympathetic trunks and periarterial plexuses.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56679 Version 11.0</div></div></div>"},"56680":{"type":"graphic_diagnosticimage","displayName":"Unstable forearm fracture","title":"Unstable midshaft forearm fracture","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Unstable midshaft forearm fracture</div><div class=\"cntnt\"><img style=\"width:525px; height:353px;\" src=\"images/EM/56680_Unstable_forearm_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Very unstable complete midshaft forearm fracture in a 14-year-old child. This fracture required open reduction and internal fixation in the operating Room. Both bones are 100 percent displaced dorsally and 50 percent displaced laterally. There is no intact periosteum.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 56680 Version 3.0</div></div></div>"},"56681":{"type":"graphic_figure","displayName":"Tamoxifen in osteoporosis","title":"Tamoxifen increases bone density in postmenopausal women","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Tamoxifen increases bone density in postmenopausal women</div><div class=\"cntnt\"><img style=\"width:491px; height:217px;\" src=\"images/ENDO/56681_Tamoxifen_in_osteoporosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Change in bone mineral density in the lumbar spine and hip in postmenopausal women treated with tamoxifen or placebo. Tamoxifen was associated with an increase in bone density at both sites.</div><div class=\"graphic_reference\">Data from: Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.&nbsp;J Clin Oncol 1996; 14:78.</div><div id=\"graphicVersion\">Graphic 56681 Version 3.0</div></div></div>"},"56684":{"type":"graphic_picture","displayName":"Tinea cruris","title":"Tinea cruris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea cruris</div><div class=\"cntnt\"><img style=\"width:302px; height:337px;\" src=\"images/PC/56684_Tinea_cruris.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tinea cruris infection caused by&nbsp;<EM>Trichophyton rubrum</EM> involving the crural fold and medial aspect of the right thigh.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 56684 Version 3.0</div></div></div>"},"56687":{"type":"graphic_table","displayName":"Laboratory findings in vitamin D deficiency","title":"Biochemical manifestations of different stages of vitamin D deficiency, as compared with deficiencies of calcium or phosphorus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biochemical manifestations of different stages of vitamin D deficiency, as compared with deficiencies of calcium or phosphorus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Plasma Ca<sup>++</sup></td> <td class=\"subtitle1\">Plasma PO<sub>4</sub></td> <td class=\"subtitle1\">ALP</td> <td class=\"subtitle1\">PTH</td> <td class=\"subtitle1\">25(OH)-D</td> <td class=\"subtitle1\">1,25(OH)<sub>2</sub>-D</td> <td class=\"subtitle1\">X-ray changes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Vitamin D deficiency</td> </tr> <tr> <td class=\"indent1\">Early</td> <td>N or &#8595;</td> <td>N or &#8595;</td> <td>&#8593;</td> <td>&#8593;</td> <td>&#8595;</td> <td>N</td> <td>Osteopenia</td> </tr> <tr> <td class=\"indent1\">Moderate</td> <td>N or &#8595;</td> <td>&#8595;</td> <td>&#8593;&#8593;</td> <td>&#8593;&#8593;</td> <td>&#8595;&#8595;</td> <td>&#8593;</td> <td>Rachitic changes +</td> </tr> <tr> <td class=\"indent1\">Severe</td> <td>&#8595;&#8595;</td> <td>&#8595;&#8595;</td> <td>&#8593;&#8593;&#8593;</td> <td>&#8593;&#8593;&#8593;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8593; or N or &#8595;</td> <td>Rachitic changes ++</td> </tr> <tr> <td><strong>Calcium deficiency</strong></td> <td>N or &#8595;</td> <td>&#8595;</td> <td>&#8593;&#8593;</td> <td>&#8593;</td> <td>N</td> <td>&#8593;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Phosphorus deficiency</strong></td> <td>N or &#8593;</td> <td>&#8595;&#8595;</td> <td>&#8593;&#8593;</td> <td>N or &#8595;</td> <td>N</td> <td>&#8593;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N: normal; ALP: alkaline phosphatase; PTH: parathyroid hormone; 25(OH)D: 25-hydroxyvitamin D; 1,25(OH)<sub>2</sub>D: 1,25-dihydroxyvitamin D.<br></div><div class=\"graphic_reference\">Data from: Levine MA, Zapalowski C, Kappy MS. Disorders of calcium, phosphate, parathyroid hormone, and Vitamin D. In: Kappy MS, Allen DB, and Geffner ME (Eds). Principles and Practice of Pediatric Endocrinology. Charles C. Thomas Co, Springfield, 2005.</div><div id=\"graphicVersion\">Graphic 56687 Version 4.0</div></div></div>"},"56689":{"type":"graphic_figure","displayName":"Anatomy of the stomach","title":"Anatomy of the stomach","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Anatomy of the stomach</div><div class=\"cntnt\"><img style=\"width:539px; height:414px;\" src=\"images/SURG/56689_Anatomy-of-the-stomach.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relationship of the stomach to surrounding structures is depicted in the figure. The arterial supply to the stomach is derived primarily from the celiac axis. The celiac axis arises from the proximal abdominal aorta and typically branches into the common hepatic, splenic, and left gastric arteries. The common hepatic artery usually gives rise to the gastroduodenal artery (in approximately 75 percent of people), which, in turn, branches off into the right gastroepiploic artery and the anterior and posterior superior pancreaticoduodenal arteries, which supply the pancreas. The right gastroepiploic artery joins with the left gastroepiploic artery, which emanates from the splenic artery in 90 percent of patients. The right gastric artery branches from the hepatic artery and anastomoses with the left gastric artery along the lesser curvature of the stomach. Because of its highly redundant blood supply, stomach ischemia is rare.</div><div id=\"graphicVersion\">Graphic 56689 Version 5.0</div></div></div>"},"56690":{"type":"graphic_diagnosticimage","displayName":"Miliary TB pulmonary lesions","title":"Extensive miliary pulmonary lesions in disseminated tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extensive miliary pulmonary lesions in disseminated tuberculosis</div><div class=\"cntnt\"><img style=\"width:396px; height:278px;\" src=\"images/ID/56690_Miliary_TB_pulm_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive miliary pulmonary lesions in a young child with disseminated tuberculosis. The child presented in a shock-like state with extreme respiratory distress, weight loss, and fever. After appropriate treatment, the child had a full recovery and a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 56690 Version 5.0</div></div></div>"},"56691":{"type":"graphic_figure","displayName":"PIV seasonality","title":"Reported percentages of positive parainfluenza virus tests in the United States, July 1990 to June 2004","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Reported percentages of positive parainfluenza virus tests in the United States, July 1990 to June 2004</div><div class=\"cntnt\"><img style=\"width:595px; height:451px;\" src=\"images/ID/56691_PIV_seasonality.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The percentage of tests positive for parainfluenza virus (PIV) serotypes 1, 3, 2, and 4 reported to the National Respiratory and Enteric Viruses Surveillance System (NREVSS) in the United States, by week, July 1990 to June 2004. The percentage of antigen detection tests positive for respiratory syncytial virus (RSV) reported to NREVSS is shown for comparison. (Note that RSV and PIV-4 have different axis scales than the other PIV serotypes.)</div><div class=\"graphic_reference\">Reproduced from: Fry AM, Curns AT, Harbour K, et al. Seasonal trends of human parainfluenza viral infections: United States, 1990-2004. Clin Infect Dis 2006; 43:1016-22.</div><div id=\"graphicVersion\">Graphic 56691 Version 5.0</div></div></div>"},"56692":{"type":"graphic_table","displayName":"ANCA accuracy in GN in children","title":"ANCA results for pauci-immune crescentic glomerulonephritis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ANCA results for pauci-immune crescentic glomerulonephritis in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1\">Clinical presentation</td>\n\n\t\t\t\t\t\t<td class=\"subtitle1\">Prevalence of PI-CGN</td>\n\n\t\t\t\t\t\t<td class=\"subtitle1\">PPV for PI-CGN</td>\n\n\t\t\t\t\t\t<td class=\"subtitle1\">NPV for PI-CGN</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Rapidly progressive glomerulonephritis*</td>\n\n\t\t\t\t\t\t<td>48 percent (10/21)</td>\n\n\t\t\t\t\t\t<td>98 percent</td>\n\n\t\t\t\t\t\t<td>80 percent</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Hematuria, proteinuria, and creatinine &#62;3 mg/dL</td>\n\n\t\t\t\t\t\t<td>16 percent (6/38)</td>\n\n\t\t\t\t\t\t<td>90 percent</td>\n\n\t\t\t\t\t\t<td>95 percent</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Hematuria, proteinuria, and creatinine 1.5-3 mg/dL</td>\n\n\t\t\t\t\t\t<td>15 percent (6/39)</td>\n\n\t\t\t\t\t\t<td>89 percent</td>\n\n\t\t\t\t\t\t<td>95 percent</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Hematuria, proteinuria, and creatinine &#60;1.5 mg/dL</td>\n\n\t\t\t\t\t\t<td>1 percent (1/162)</td>\n\n\t\t\t\t\t\t<td>30 percent</td>\n\n\t\t\t\t\t\t<td>100 percent</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=35069&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ANCA_accuracy_in_GN_in_chil.htm</title></head></div><div class=\"graphic_lgnd\">Estimated positive predictive values (PPV) and negative predictive values (NPV) of ANCA results for pauci-immune crescentic glomerulonephritis (PI-CGN) in children (&lt;18 years old) with different clinical presentation using an assay approach (that has a 72.5 percent sensitivity and a 98.4 percent specificity).</div><div class=\"graphic_footnotes\">* This clinical presentation presumed from renal biopsy showing &gt;50 percent of glomeruli with crescents.</div><div class=\"graphic_reference\">Adapted from: Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int 1998; 53:796.</div><div id=\"graphicVersion\">Graphic 56692 Version 2.0</div></div></div>"},"56693":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber echo endocarditis tricuspid valve","title":"Apical 4 chamber echocardiogram showing tricuspid valve infective endocarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical 4 chamber echocardiogram showing tricuspid valve infective endocarditis</div><div class=\"cntnt\"><img style=\"width:276px; height:509px;\" src=\"images/CARD/56693_Endocarditis_tricuspid_valv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four chamber view (panel A) shows irregular masses, which are bulky vegetations (veg) due to endocarditis, attached to the tricuspid leaflets and prolapsing into an enlarged right atrium (RA) which bulges (via the interatrial septum, arrow) into the left atrium (LA). The enlarged right sided chambers makes the presence of severe tricuspid insufficiency highly likely. The M-mode of a vegetation of the septal leaflet of the tricuspid valve is seen in panel B; the mass has a large excursion because it is highly mobile, large, and prolapses into the right atrium. The phonocardiogram (PCG) shows a diastolic (DM) and systolic murmur (SM) which are variable due to the mobility of the vegetations.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; MV: mitral valve.</div><div id=\"graphicVersion\">Graphic 56693 Version 3.0</div></div></div>"},"56694":{"type":"graphic_diagnosticimage","displayName":"Osteosarc osteoartic allograft","title":"Reconstruction of a distal femur defect following resection for osteosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reconstruction of a distal femur defect following resection for osteosarcoma</div><div class=\"cntnt\"><img style=\"width:243px; height:419px;\" src=\"images/ONC/56694_Osteosarc_osteoartic_allogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AP radiograph shows the osteoarticular allograft stabilized with a plate and screws.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Francis J Hornicek, MD, PhD.</div><div id=\"graphicVersion\">Graphic 56694 Version 3.0</div></div></div>"},"56695":{"type":"graphic_figure","displayName":"Alk phos range child","title":"Reference range for serum alkaline phosphatase activity in children and adolescents","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Reference range for serum alkaline phosphatase activity in children and adolescents</div><div class=\"cntnt\"><img style=\"width:512px; height:386px;\" src=\"images/PEDS/56695_Alk_phos_range_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal ranges for serum alkaline phosphatase activity for boys (blue) and girls (red).</div><div class=\"graphic_reference\">Data from: NIH Clinical reference laboratory, available at: www.cc.nih.gov/ccc/pedweb/pedsstaff/pedlab.html.</div><div id=\"graphicVersion\">Graphic 56695 Version 3.0</div></div></div>"},"56696":{"type":"graphic_table","displayName":"Definitions and classification of stent restenosis","title":"Definitions and classification of stent restenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions and classification of stent restenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Angiographic restenosis and classification</td> </tr> <tr> <td class=\"indent1\">Diameter stenosis &#8805;50%</td> </tr> <tr> <td class=\"sublist2_start\">Type I focal: &#8804;10 mm in length</td> </tr> <tr> <td class=\"sublist2\">IA articulation or gap</td> </tr> <tr> <td class=\"sublist2\">IB margin</td> </tr> <tr> <td class=\"sublist2\">IC focal body</td> </tr> <tr> <td class=\"sublist2\">ID multifocal</td> </tr> <tr> <td class=\"indent1\">Type 2 diffuse: &#62;10 mm intrastent</td> </tr> <tr> <td class=\"indent1\">Type 3 proliferative: &#62;10 mm extending beyond the stent margins</td> </tr> <tr> <td class=\"indent1\">Type 4 total occlusion: Restenotic lesions with TIMI flow grade of 0</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical restenosis: Assessed objectively as requirement for ischemia-driven repeat revascularization</td> </tr> <tr> <td class=\"indent1\">Diameter stenosis &#8805;50% <strong>and</strong> one of the following:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Positive history of recurrent angina pectoris, presumably related to target vessel </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to target vessel </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Abnormal results of any invasive functional diagnostic test (eg, coronary flow velocity reserve, FFR &#60;0.80); IVUS minimum cross-sectional area &#60;4 mm<sup>2</sup> (and &#60;6.0 mm<sup>2</sup> for left main stem) has been found to correlate with abnormal FFR and need for subsequent TLR<sup>[1-3]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>TLR with diameter stenosis &#8805;70% even in absence of the above ischemic signs or symptoms </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TIMI: thrombolysis in myocardial infarction; ECG: electrocardiography; FFR: fractional flow reserve; IVUS: intravascular ultrasound; TLR: target lesion revascularization.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Abizaid AS, Mintz GS, Mehran R, et al. Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings: importance of lumen dimensions. Circulation 1999; 100:256. </li>&#xD;&#xA;    <li>Jasti V, Ivan E, Yalamanchili V, et al. Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis. Circulation 2004; 110:2831. </li>&#xD;&#xA;    <li>Doi H, Maehara A, Mintz GS, et al. Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trials. Circ Cardiovasc Interv 2008; 1:111. </li>&#xD;&#xA;</ol>&#xD;&#xA;Original table modified for this publication. From: Dangas G, Claessen B, Caixeta A, et al. In-Stent Restenosis in the Drug-Eluting Stent Era. J Am Coll Card 2010; 56:1897. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 56696 Version 5.0</div></div></div>"},"56697":{"type":"graphic_picture","displayName":"Supraspinatus isometric strength test","title":"Supraspinatus isometric strength test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Supraspinatus isometric strength test</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/56697_Supraspinatus_iso_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Stephen M Simons, MD.</div><div id=\"graphicVersion\">Graphic 56697 Version 1.0</div></div></div>"},"56698":{"type":"graphic_picture","displayName":"Nordic lower descent","title":"Nordic lower: Descent","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Nordic lower: Descent</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/EM/56698_Nordic_lower_descent_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During the Nordic lower exercise, descent should be steady and gradual. This is often a difficult exercise for those with a weak posterior chain.</div><div class=\"graphic_reference\">Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.</div><div id=\"graphicVersion\">Graphic 56698 Version 2.0</div></div></div>"},"56699":{"type":"graphic_picture","displayName":"Molluscum neck","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:432px; height:269px;\" src=\"images/DERM/56699_Molluscum_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the linear configuration of lesions resulting from autoinoculation.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56699 Version 2.0</div></div></div>"},"56701":{"type":"graphic_table","displayName":"Sulfonylureas","title":"Sulfonylureas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sulfonylureas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug </td> <td class=\"subtitle1\">Duration of biologic effect, hour </td> <td class=\"subtitle1\">Usual daily dose, mg </td> <td class=\"subtitle1\">Dosing per day </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">First-generation sulfonylureas </td> </tr> <tr> <td class=\"indent1\">Acetohexamide </td> <td>12 to 18</td> <td>500 to 750</td> <td>Once or divided</td> </tr> <tr> <td class=\"indent1\">Chlorpropamide (Diabinese) </td> <td>24 to 72</td> <td>250 to 500</td> <td>Once</td> </tr> <tr> <td class=\"indent1\">Tolbutamide (Orinase) </td> <td>14 to 16</td> <td>1000 to 2000</td> <td>Once or divided</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Second-generation sulfonylureas </td> </tr> <tr> <td class=\"sublist2_start\">Glipizide </td> <td rowspan=\"3\">14 to 16 </td> <td rowspan=\"2\">2.5 to 10 </td> <td rowspan=\"2\">Once or divided </td> </tr> <tr> <td class=\"sublist2\">(Glucotrol) </td> </tr> <tr> <td class=\"sublist2\">(Glucotrol XL) </td> <td>5 to 10</td> <td>Once</td> </tr> <tr> <td class=\"sublist2_start\">Gliclazide </td> <td rowspan=\"3\">24 </td> <td rowspan=\"3\">40 to 240 </td> <td rowspan=\"3\">Once </td> </tr> <tr> <td class=\"sublist2\">(Diamicron R) </td> </tr> <tr> <td class=\"sublist2\">(Diamicron MR) </td> </tr> <tr> <td class=\"sublist2_start\">Glyburide (Glibenclamide) </td> <td rowspan=\"4\">20 to 24+ </td> <td rowspan=\"4\">2.5 to 10 </td> <td rowspan=\"4\">Once </td> </tr> <tr> <td class=\"sublist2\">(Diabeta) </td> </tr> <tr> <td class=\"sublist2\">(Micronase) </td> </tr> <tr> <td class=\"sublist2\">(Glynase) </td> </tr> <tr> <td class=\"indent1\">Glimepiride (Amaryl) </td> <td>24+</td> <td>2 to 4</td> <td>Once</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56701 Version 2.0</div></div></div>"},"56702":{"type":"graphic_diagnosticimage","displayName":"CPAM type 1 CT scan","title":"Computed tomography type 1 congenital pulmonary airway malformation (CPAM)*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography type 1 congenital pulmonary airway malformation (CPAM)*</div><div class=\"cntnt\"><img style=\"width:288px; height:458px;\" src=\"images/PEDS/56702_CCAM_type_1_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography of the chest of&nbsp;a one-year-old patient with type 1 congenital pulmonary airway malformation (CPAM). A single, large (5 x 5 x 4 cm), air-filled cyst is demonstrated in the right upper lobe.</div><div class=\"graphic_footnotes\">* CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).</div><div class=\"graphic_reference\">Courtesy of Christopher M Oermann, MD.</div><div id=\"graphicVersion\">Graphic 56702 Version 4.0</div></div></div>"},"56703":{"type":"graphic_table","displayName":"Increased risk oral infection","title":"Conditions that are associated with increased risk of infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions that are associated with increased risk of infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition </td> <td class=\"subtitle1\">Oral manifestation or complication </td> <td class=\"subtitle1\">Dental management </td> </tr> <tr> <td>Childhood cancers</td> <td>Decreased immune function, leading to gingival inflammation and alveolar bone loss</td> <td>Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhexidine</td> </tr> <tr> <td>Chemotherapeutic immunosuppression</td> <td>Oral ulceration; infection by opportunistic organisms</td> <td>Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhexidine</td> </tr> <tr> <td>Graft-versus-host disease</td> <td>Mucositis, xerostomia, oral pain</td> <td>Artificial saliva, chemotherapeutic agents to reduce plaque, pain control measures</td> </tr> <tr> <td>HIV infection</td> <td>Severe acute and chronic gingival and periodontal inflammation, exceeding that expected for local irritants present</td> <td>Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhexidine</td> </tr> <tr> <td>Diabetes mellitus</td> <td>Increased gingival and periodontal inflammation and increased risk of odontogenic infections</td> <td>Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhoxidine</td> </tr> <tr> <td>Congenital heart disease</td> <td>Cyanotic friable oral tissues; ingress of microorganisms implicated in subacute bacterial endocarditis</td> <td>Adherence to American Heart Association guidelines for prevention of infective endocarditis<sup>[1]</sup></td> </tr> <tr> <td>In-dwelling catheters/central lines</td> <td>Risk of infection of device from oral bacteremia introduced by dental treatment</td> <td>Adherence to American Heart Association guidelines for prevention of infective endocarditis<sup>[1]</sup></td> </tr> <tr> <td>Sickle cell anemia</td> <td>Nonspecific oral findings, but at increased risk for infection secondary to dental treatment in some cases</td> <td>Prophylaxis with appropriate antibiotic when needed for dental treatment</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">1. Wilson, W, Taubert, KA, Gewitz, M, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association:&nbsp;A guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.</div><div class=\"graphic_reference\">Reproduced with permission from Casamassimo, PS. Pediatr Clin North Am 2000; 47:1149. Copyright 2000 W.B. Saunders Co.</div><div id=\"graphicVersion\">Graphic 56703 Version 2.0</div></div></div>"},"56707":{"type":"graphic_figure","displayName":"PG functions and inhibition","title":"Prostanoid synthesis and inhibition","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Prostanoid synthesis and inhibition</div><div class=\"cntnt\"><img style=\"width:476px; height:418px;\" src=\"images/RHEUM/56707_PG_functions_and_inhibition.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depiction of prostanoid synthesis and actions and potential levels of inhibition: 1. Aspirin and other nonsteroidal antiinflammatory drugs; 2. Alternative fatty acid substrates; 3. Glucocorticoids and selective PGHS-2 (COX-2) inhibitors; 4. Prostanoid receptor antagonists; 5. Nitric oxide synthase inhibitors, antihistamines; 6. Monoclonal antibodies to adhesion molecules.</div><div id=\"graphicVersion\">Graphic 56707 Version 1.0</div></div></div>"},"56708":{"type":"graphic_picture","displayName":"Sulfa crystals","title":"Photomicrograph showing urine sediment of a patient with sulfonamide crystalluria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photomicrograph showing urine sediment of a patient with sulfonamide crystalluria</div><div class=\"cntnt\"><img style=\"width:378px; height:252px;\" src=\"images/NEPH/56708_Sulfa_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing sulfonamide crystals with a needle-shaped appearance. Other forms that may be seen include rosettes and a shock of wheat appearance.</div><div class=\"graphic_reference\">Courtesy of Harvard Medical School.</div><div id=\"graphicVersion\">Graphic 56708 Version 3.0</div></div></div>"},"56709":{"type":"graphic_table","displayName":"Criteria for gestational HTN","title":"Criteria for gestational hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for gestational hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>New onset of systolic blood pressure &#8805;140 mmHg</td> </tr> <tr> <td><strong>OR</strong></td> </tr> <tr> <td>Diastolic blood pressure &#8805;90 mmHg</td> </tr> <tr> <td><strong>AND</strong> no proteinuria or signs of end-organ damage</td> </tr> <tr> <td>Developing <strong>AFTER</strong> the 20<sup>th</sup> week of gestation in women known to be normotensive before pregnancy; blood pressure should be elevated on at least two occasions at least six hours apart</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56709 Version 4.0</div></div></div>"},"56710":{"type":"graphic_figure","displayName":"Aneurysmal bone cyst sites","title":"Skeletal distribution of aneurysmal bone cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skeletal distribution of aneurysmal bone cyst</div><div class=\"cntnt\"><img style=\"width:247px; height:605px;\" src=\"images/PEDS/56710_Aneurysmal_bone_cyst_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56710 Version 2.0</div></div></div>"},"56711":{"type":"graphic_table","displayName":"CF nutrition tests","title":"Laboratory monitoring of nutritional status for children with cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory monitoring of nutritional status for children with cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Recommended frequency</td> <td class=\"subtitle1\" rowspan=\"2\">Tests</td> </tr> <tr> <td class=\"subtitle2\">At diagnosis</td> <td class=\"subtitle2\">Annually</td> <td class=\"subtitle2\">Other</td> </tr> <tr> <td>Beta carotene</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>At physician's discretion</td> <td>Serum levels</td> </tr> <tr> <td>Vitamin A</td> <td class=\"centered\">X*</td> <td class=\"centered\">X</td> <td>Also check serum retinol binding protein and retinyl esters in patients with liver disease</td> <td>Vitamin A (retinol)</td> </tr> <tr> <td>Vitamin D</td> <td class=\"centered\">X*</td> <td class=\"centered\">X</td> <td>&nbsp;</td> <td>25-OH-D</td> </tr> <tr> <td>Vitamin E</td> <td class=\"centered\">X*</td> <td class=\"centered\">X</td> <td>&nbsp;</td> <td>&#945;-tocopherol</td> </tr> <tr> <td>Vitamin K</td> <td class=\"centered\">X*</td> <td class=\"centered\">&nbsp;</td> <td>If patient has hemoptysis or hematemesis; in patients with liver disease</td> <td>PIVKA-II (preferably) or prothrombin time</td> </tr> <tr> <td>Essential fatty acids</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Consider checking in infants or those with FTT</td> <td> <p>Triene:tetraene ratio</p> or Linoleic acid (as moles percent of total serum phospholipid fatty acids)</td> </tr> <tr> <td>Calcium/bone status</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td>Begin DXA at age&nbsp;eight years if risk factors are present<sup>&#182;</sup> and repeat every&nbsp;one to&nbsp;two years depending on results (see text)</td> <td>Calcium, phosphorus, intact PTH, DXA scan</td> </tr> <tr> <td>Iron</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td>Consider in-depth evaluation for patients with poor appetite</td> <td> <p>Hemoglobin, hematocrit</p> Serum transferrin receptor (sTfR)</td> </tr> <tr> <td>Zinc</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Consider six-month supplementation trial and follow growth</td> <td>No acceptable measurement</td> </tr> <tr> <td>Sodium</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Consider checking if exposed to heat stress and becomes dehydrated</td> <td>Serum sodium; spot urine sodium if total body sodium depletion suspected</td> </tr> <tr> <td>Protein stores</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td>Check in patients with nutritional failure or those at risk</td> <td>Albumin</td> </tr> <tr> <td>Oral glucose tolerance test<sup>&#916;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td>&nbsp;</td> <td>HgbA1c &#8805;6.5 percent or fasting plasma glucose &#8805;126 mg/dL support the diagnosis of CFRD but are not sufficiently sensitive to use for screening</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">25-OH-D: 25-hydroxyvitamin D; PIVKA: proteins induced by vitamin K absence or antagonism; FTT: failure to thrive; Intact PTH: intact parathyroid hormone; DXA: dual energy x-ray absorptiometry; HgbA1c: hemoglobin A1c.<br />* For infants diagnosed by neonatal screening these should be measured approximately&nbsp;two months after starting vitamin supplementation, and annually thereafter.<br />¶&nbsp;Risk factors for bone disease include body mass index (BMI) &lt;10th percentile for age, FEV1 &lt;50 percent predicted, glucocorticoid use of ≥5 mg daily for ≥90 days/year, delayed puberty, or a history of fractures.<br />Δ Testing for cystic fibrosis-related diabetes (CFRD) using the oral glucose tolerance test (OGTT) should be performed annually in patients 10 years and older, and also in patients who develop symptoms of CFRD.</div><div class=\"graphic_reference\">Modified with permission from: Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35:246. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.<br />Additional recommendations on bone health from: Aris RM, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90:1888.</div><div id=\"graphicVersion\">Graphic 56711 Version 16.0</div></div></div>"},"56712":{"type":"graphic_table","displayName":"Infectious causes of cervical nodes","title":"Infectious causes of cervical lymphadenitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious causes of cervical lymphadenitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Presentation </td> <td class=\"subtitle1\">Common </td> <td class=\"subtitle1\">Uncommon </td> <td class=\"subtitle1\">Rare </td> </tr> <tr> <td>Acute bilateral</td> <td> <p>Rhinovirus</p> <p>Epstein-Barr virus*<sup>&#182;</sup></p> <p>Cytomegalovirus*<sup>&#182;</sup></p> <p>Herpes simplex virus</p> <p>Adenovirus</p> <p>Enterovirus</p> <p><em>Mycoplasma pneumoniae</em></p> <p>Group A <em>Streptococcus</em></p> <p><em>Arcanobacterium haemolyticum</em></p> <p>Influenza</p> </td> <td> <p>Roseola<sup>&#182;</sup></p> <p>Parvovirus B19<sup>&#182;</sup></p> </td> <td> <p><em>Corynebacterium diphtheriae</em></p> <p>Rubella<sup>&#182;</sup></p> <p>Measles</p> <p>Mumps<sup>&#182;</sup></p> </td> </tr> <tr> <td>Acute unilateral</td> <td> <p><em>Staphylococcus aureus</em></p> <p>Group A <em>Streptococcus</em></p> <p>Anaerobic bacteria</p> </td> <td> <p>Group B <em>Streptococcus</em></p> <p>Tularemia*</p> <p>Alpha <em>Streptococcus</em></p> <p><em>Pasteurella multocida</em></p> <p><em>Yersinia pestis</em><sup>&#182;</sup></p> <p>Gram-negative bacilli</p> </td> <td> <p><em>Yersinia enterocolitica</em>*</p> <p>Anthrax</p> </td> </tr> <tr> <td>Chronic unilateral</td> <td> <p>Nontuberculous mycobacteria</p> <p>Cat scratch disease</p> </td> <td> <p>Toxoplasmosis<sup>&#182;</sup></p> <p>Tuberculosis<sup>&#182;</sup></p> <p>Actinomycosis</p> </td> <td> <p><em>Nocardia brasiliensis</em></p> <p>Aspergillosis</p> <p>Sporotrichosis</p> </td> </tr> <tr> <td>Chronic bilateral</td> <td> <p>Epstein-Barr virus<sup>&#182;</sup></p> <p>Cytomegalovirus<sup>&#182;</sup></p> </td> <td> <p>HIV<sup>&#182;</sup></p> <p>Toxoplasmosis<sup>&#182;</sup></p> <p>Tuberculosis<sup>&#182;</sup></p> <p>Syphilis<sup>&#182;</sup></p> </td> <td> <p>Brucellosis<sup>&#182;</sup></p> <p>Histoplasmosis<sup>&#182;</sup></p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus. <br />* Infection can persist and become more chronic in appearance.<br />¶&nbsp;Often associated with generalized lymphadenopathy.</div><div id=\"graphicVersion\">Graphic 56712 Version 8.0</div></div></div>"},"56713":{"type":"graphic_picture","displayName":"Long finger extension test","title":"Long finger extension test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Long finger extension test</div><div class=\"cntnt\"><img style=\"width:353px; height:238px;\" src=\"images/EM/56713_Long_finger_extension_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient maintains extension of the wrist (30 degrees) and fingers while the examiner presses down on the dorsum of the long finger. Pain with this maneuver suggests radial nerve irritation.</div><div id=\"graphicVersion\">Graphic 56713 Version 4.0</div></div></div>"},"56714":{"type":"graphic_diagnosticimage","displayName":"Eisenmengers PA","title":"Eisenmenger reaction in patient with longstanding atrial septal defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eisenmenger reaction in patient with longstanding atrial septal defect</div><div class=\"cntnt\"><img style=\"width:341px; height:303px;\" src=\"images/PULM/56714_Eisenmengers_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows centralization of pulmonary vascular flow with aneurysmal configuration of the main and hilar pulmonary arteries as well as arteriosclerotic calcifications in these vessels.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56714 Version 3.0</div></div></div>"},"56716":{"type":"graphic_figure","displayName":"Time to oxygen desaturation","title":"Time to oxygen desaturation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Time to oxygen desaturation</div><div class=\"cntnt\"><img style=\"width:393px; height:393px;\" src=\"images/EM/56716_Time_to_desaturation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoxygenation prolongs the period between paralysis with succinlycholine and oxygen desaturation in all patients, but to varying degrees depending on patient attributes. This diagram shows the time to desaturation for several different clinical conditions.</div><div class=\"graphic_reference\">Reproduced with permission from: Benumof JL, Dagg R, Benumof R. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous succinylcholine. Anesthesiology 1997; 87:979. Copyright © 1997 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56716 Version 12.0</div></div></div>"},"56718":{"type":"graphic_table","displayName":"Multistep approach treatment infertility PCOS","title":"Multistep approach to treatment of anovulatory infertility associated with polycystic ovary syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Multistep approach to treatment of anovulatory infertility associated with polycystic ovary syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Cost</td> <td class=\"subtitle1\">Multiple pregnancy risk</td> </tr> <tr> <td>First line</td> <td>Weight loss for high body mass index</td> <td>Low</td> <td>Not increased</td> </tr> <tr> <td>First line</td> <td>Clomiphene or letrozole with or without metformin</td> <td>Low</td> <td>Low</td> </tr> <tr> <td>Second line</td> <td>Follicle-stimulating hormone injections</td> <td>High</td> <td>High, includes high-order multiples</td> </tr> <tr> <td>Second line</td> <td>Ovarian drilling</td> <td>High</td> <td>Not increased</td> </tr> <tr> <td>Third line</td> <td>In vitro fertilization</td> <td>Very high</td> <td>High but reducible with single embryo transfer</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56718 Version 10.0</div></div></div>"},"56722":{"type":"graphic_picture","displayName":"Congenital myocardial infarction","title":"Congenital myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Congenital myocardial infarction</div><div class=\"cntnt\"><img style=\"width:559px; height:429px;\" src=\"images/OBGYN/56722_Congenital_myocardial_infar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Papillary muscle with orangophillic discoloration in the center, classic for myocardial infarcts in the fetus, which tend to be multifocal and non-coronary in distribution.<br />(B) Wavy fibers, relatively recent myocardial infarction.<br />(C) Calcified focus in papillary muscle, which may be seen in Trisomy 21 or 13 or as evidence of a remote myocardial infarction.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 56722 Version 3.0</div></div></div>"},"56724":{"type":"graphic_picture","displayName":"Unilateral leukocoria","title":"Unilateral leukocoria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unilateral leukocoria</div><div class=\"cntnt\"><img style=\"width:390px; height:218px;\" src=\"images/PEDS/56724_Leukocoria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parents of this 18-month-old child noticed a difference between the two eyes in a family photograph and alerted their pediatrician. The child was subsequently referred to an ophthalmologist and diagnosed with retinoblastoma in the left eye, which is directly visible through the pupil as an abnormal white reflex (leukocoria).</div><div class=\"graphic_reference\">Courtesy of Paul L Kaufman, MD and Richard A Saunders, MD.</div><div id=\"graphicVersion\">Graphic 56724 Version 2.0</div></div></div>"},"56727":{"type":"graphic_figure","displayName":"Sharp curettage","title":"Sharp curette inserted into uterine cavity","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Sharp curette inserted into uterine cavity</div><div class=\"cntnt\"><img style=\"width:543px; height:358px;\" src=\"images/OBGYN/56727_Sharp_curettage.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 56727 Version 1.0</div></div></div>"},"56728":{"type":"graphic_picture","displayName":"Beta thalassemia trait","title":"Beta thalassemia trait","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Beta thalassemia trait</div><div class=\"cntnt\"><img style=\"width:439px; height:288px;\" src=\"images/HEME/56728_Beta_thalassemia_trait.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear from a patient with beta thalassemia trait. The field shows numerous hypochromic and microcytic red cells (thin arrows), some of which are also target cells (blue arrows).</div><div class=\"graphic_reference\">Courtesy of Stanley Schrier, MD</div><div id=\"graphicVersion\">Graphic 56728 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"56729":{"type":"graphic_figure","displayName":"Stepwise approach managing asthma in youths ≥12 years and adults","title":"Stepwise approach for managing asthma in youths ≥12 years of age and adults","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Stepwise approach for managing asthma in youths &ge;12 years of age and adults</div><div class=\"cntnt\"><img style=\"width:612px; height:595px;\" src=\"images/PULM/56729_Stepwise_asthma_12_and_up.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up. Zileuton is a less desirable alternative due to limited studies as adjunctive therapy and the need to monitor liver function. Theophylline requires monitoring of serum concentration levels. In step 6, before oral systemic glucocorticoids are introduced, a trial of high-dose ICS + LABA + either LTRA, theophylline, or zileuton may be considered, although this approach has not been studied in clinical trials. Step 1, 2, and 3 preferred therapies are based on evidence A; step 3 alternative therapy is based on evidence A for LTRA, evidence B for theophylline, and evidence D for zileuton. Step 4 preferred therapy is based on evidence B, and alternative therapy is based on evidence B for LTRA and theophylline and evidence D for zileuton. Step 5 preferred therapy is based on evidence B. Step 6 preferred therapy is based on (EPR-2 1997) and evidence B for omalizumab. Immunotherapy for steps 2 to 4 is based on evidence B for house dust mites, animal danders, and pollens; evidence is weak or lacking for molds and cockroaches. Evidence is strongest for immunotherapy with single allergens. The role of allergy in asthma is greater in children than in adults. Clinicians who administer immunotherapy or omalizumab should be prepared and equipped to identify and treat anaphylaxis that may occur.<br /><strong>Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy.</strong></div><div class=\"graphic_footnotes\">SABA: inhaled short-acting beta<sub>2</sub>-agonist; PRN: \"as needed\"; LTRA: leukotriene receptor antagonist; LABA: long-acting inhaled beta<sub>2</sub>-agonist; EIB: exercise-induced bronchospasm.<br />* Cromolyn has limited availability.</div><div class=\"graphic_reference\">Updated and reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 56729 Version 7.0</div></div></div>"},"56734":{"type":"graphic_picture","displayName":"Scissor technique","title":"Scissor technique for opening the mouth during endotracheal intubation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scissor technique for opening the mouth during endotracheal intubation</div><div class=\"cntnt\"><img style=\"width:350px; height:514px;\" src=\"images/EM/56734_Scissor_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thumb of the operator's right hand pushes the lower incisors (or mandibular gum) caudad while the index finger (placed posterior to the thumb) pushes the upper incisors (or maxillary gum) cephalad.</div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 56734 Version 1.0</div></div></div>"},"56735":{"type":"graphic_table","displayName":"Okuda staging system for HCC","title":"Okuda staging system for hepatocellular carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Okuda staging system for hepatocellular carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Positive</td> <td class=\"subtitle1\">Negative</td> </tr> <tr> <td>Tumor size*</td> <td>&#62;50%</td> <td>&#60;50%</td> </tr> <tr> <td>Ascites</td> <td>Clinically detectable</td> <td>Clinically absent</td> </tr> <tr> <td>Albumin</td> <td>&#60;3 mg/dL</td> <td>&#62;3 mg/dL</td> </tr> <tr> <td>Bilirubin</td> <td>&#62;3 mg/dL</td> <td>&#60;3 mg/dL</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Stage</td> </tr> <tr> <td>I</td> <td colspan=\"2\">No positive</td> </tr> <tr> <td>II</td> <td colspan=\"2\">One or two positives</td> </tr> <tr> <td>III</td> <td colspan=\"2\">Three or four positives</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Okuda system is commonly used for staging hepatocellular carcinoma. Survival correlates with the Okuda stage in untreated patients (8.3, 2.0, and 0.7 months for stages I, II, and III, respectively). </div><div class=\"graphic_footnotes\">* Largest cross-sectional area of tumor to largest cross-sectional area of the liver.</div><div class=\"graphic_reference\">Adapted from: Okuda K, Ohtuiki T, Obata H, et al. Cancer 1985; 56:918.</div><div id=\"graphicVersion\">Graphic 56735 Version 3.0</div></div></div>"},"56737":{"type":"graphic_waveform","displayName":"Digitalis effect tutorial","title":"Digitalis effect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Digitalis effect</div><div class=\"cntnt\"><img style=\"width:398px; height:115px;\" src=\"images/CARD/56737_Digitalis_effect_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ST segment is depressed and concave upward.</div><div id=\"graphicVersion\">Graphic 56737 Version 4.0</div></div></div>"},"56738":{"type":"graphic_table","displayName":"MTX ectopic pregnancy protocol","title":"Methotrexate treatment protocol for tubal or interstitial ectopic pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methotrexate treatment protocol for tubal or interstitial ectopic pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Pretreatment testing and instructions </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">hCG concentration </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Transvaginal ultrasound </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Blood group and Rh(D) typing; give anti Rh(D) immune globulin (Rho[D] immune globulin) 300 mcg IM, if indicated </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Complete blood count </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Liver and renal function tests </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Discontinue folic acid supplements </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Counsel patient to avoid nonsteroidal anti-inflammatory medications, recommend acetaminophen if an analgesic is needed </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Advise patient to refrain from sexual intercourse and strenuous exercise</td> </tr> <tr> <td class=\"subtitle1\">Treatment day </td> <td class=\"subtitle1\">Single-dose protocol </td> <td class=\"subtitle1\">Multiple-dose protocol </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">1 </td> <td>hCG concentration</td> <td>hCG concentration</td> </tr> <tr> <td> <p>Methotrexate 50 mg/m<sup>2</sup>&nbsp;BSA IM</p> <p>A calculator useful for determining BSA from patient height and body weight is available separately in UpToDate</p> </td> <td>Methotrexate 1 mg/kg body weight IM or IV</td> </tr> <tr> <td class=\"indent1\">2 </td> <td>&nbsp;</td> <td>Leucovorin 0.1 mg/kg orally</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">3 </td> <td rowspan=\"3\">&nbsp; </td> <td>hCG</td> </tr> <tr> <td>If &#60;15 percent hCG decline from Day 1 to 3, give&nbsp;methotrexate 1 mg/kg IM or IV</td> </tr> <tr> <td>If &#8805;15 percent decline from Day 1 to 3, begin weekly hCG</td> </tr> <tr> <td class=\"indent1\">4 </td> <td>hCG</td> <td>Leucovorin 0.1 mg/kg orally*</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">5 </td> <td rowspan=\"3\">&nbsp; </td> <td>hCG</td> </tr> <tr> <td>If &#60;15 percent decline from Day 3 to 5 methotrexate, give&nbsp;methotrexate 1 mg/kg IM or IV</td> </tr> <tr> <td>If &#8805;15 percent decline from day 3 to 5, begin weekly hCG</td> </tr> <tr> <td class=\"indent1\">6 </td> <td>&nbsp;</td> <td>Leucovorin 0.1 mg/kg orally*</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">7 </td> <td>hCG</td> <td>hCG</td> </tr> <tr> <td>If &#60;15 percent hCG decline from Day 4 to 7, give additional dose of methotrexate 50 mg/m<sup>2</sup> IM</td> <td>If &#60;15 percent decline from Day 5 to 7 methotrexate, give&nbsp;methotrexate 1 mg/kg IM or IV</td> </tr> <tr> <td>If &#8805;15 percent hCG decline from Day 4 to 7, draw hCG concentration weekly until hCG is undetectable</td> <td>If &#8805;15 percent decline from Day 5 to 7, begin weekly hCG</td> </tr> <tr> <td class=\"indent1\">8 </td> <td>&nbsp;</td> <td>Leucovorin 0.1 mg/kg orally*</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">14 </td> <td>hCG</td> <td>hCG</td> </tr> <tr> <td>If &#60;15 percent hCG decline from Day 7 to 14, give additional dose of&nbsp;methotrexate 50 mg/m<sup>2</sup> IM</td> <td>If &#60;15 percent hCG decline from Day 7 to 14, give additional dose of&nbsp;methotrexate 1 mg/kg IM (give&nbsp;leucovorin 0.1 mg/kg&nbsp;orally on Day 15)</td> </tr> <tr> <td>If &#8805;15 percent hCG decline from Day 7 to 14, check hCG weekly until undetectable</td> <td>If &#8805;15 percent hCG decline from Day 7 to 14, check hCG weekly until undetectable</td> </tr> <tr> <td class=\"indent1\">21 and 28 </td> <td>If&nbsp;three doses have been given and there is a &#60;15 percent hCG decline from Day 21 to 28, proceed with laparoscopic surgery</td> <td>If&nbsp;five doses have been given and there is a &#60;15 percent hCG decline from Day 14 to 21, proceed with laparoscopic surgery</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Laparoscopy </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">If severe abdominal pain or an acute abdomen suggestive of tubal rupture occurs </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">If ultrasonography reveals greater than 300 mL pelvic or other intraperitoneal fluid </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin beta-subunit; BSA: body surface area; IV: intravenously; IM: intramuscularly.<br />* Leucovorin is given only if methotrexate was given on the previous day. Leucovorin may also be administered IM.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Barnhart KT. Clinical practice. Ectopic pregnancy.&nbsp;N Engl J Med 2009; 361:379.</LI>&#xD;&#xA;<LI>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 94: Medical management of ectopic pregnancy. Obstet Gynecol 2008; 111:1479.</LI></OL></div><div id=\"graphicVersion\">Graphic 56738 Version 5.0</div></div></div>"},"56739":{"type":"graphic_picture","displayName":"Lymphedema stageI AB","title":"Lymphedema stage I","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lymphedema stage I</div><div class=\"cntnt\"><img style=\"width:504px; height:446px;\" src=\"images/ONC/56739_Lymphedema_stageI_AB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stage I lymphedema. A) Right lower extremity. B) Right upper extremity.</div><div class=\"graphic_reference\">Courtesy of Tammy Mondry, DPT, MSRS, CLT-LANA.</div><div id=\"graphicVersion\">Graphic 56739 Version 2.0</div></div></div>"},"56740":{"type":"graphic_waveform","displayName":"Exercise test ST seg changes","title":"Exercise induced ST segment depression","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exercise induced ST segment depression</div><div class=\"cntnt\"><img style=\"width:406px; height:156px;\" src=\"images/CARD/56740_Exercise_test_ST_seg_change.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computer averaging shows the degree of ST segment depression (noted in mm below each QRS complex) in lead V6 prior to, during, and after exercise. Both horizontal and downsloping ST segment depressions are observed.</div><div id=\"graphicVersion\">Graphic 56740 Version 2.0</div></div></div>"},"56743":{"type":"graphic_figure","displayName":"Anatomy of ureters - male pelvis","title":"Anatomy of ureters - male pelvis, cross section","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Anatomy of ureters - male pelvis, cross section</div><div class=\"cntnt\"><img style=\"width:511px; height:463px;\" src=\"images/SURG/56743_Ureters-male-sup-view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the anatomy of the male pelvis and the cross sectional relationship of the ureters to the adjacent structures.</div><div id=\"graphicVersion\">Graphic 56743 Version 1.0</div></div></div>"},"56744":{"type":"graphic_table","displayName":"Thrombolytic regimens STEMI","title":"Preferred thrombolytic regimens for acute ST elevation myocardial infarction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preferred thrombolytic regimens for acute ST elevation myocardial infarction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Recommended IV regimen*</td> <td class=\"subtitle1\">Advantages and limitations</td> </tr> <tr> <td rowspan=\"3\">Alteplase (accelerated regimen)</td> <td>15 mg bolus</td> <td rowspan=\"3\">Better outcomes than streptokinase in GUSTO-1 (30-day mortality 6.3 versus 7.3 percent); costlier than streptokinase; more difficult to administer because of short half-life</td> </tr> <tr> <td><strong>then</strong> 0.75 mg/kg (maximum 50 mg) over 30 minutes</td> </tr> <tr> <td><strong>then</strong> 0.5 mg/kg (maximum 35 mg) over the next 60 minutes</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Tenecteplase</td> <td>Single bolus over five to ten seconds based upon body weight:</td> <td rowspan=\"6\">As effective as alteplase in ASSENT-2 with less noncerebral bleeding and need for transfusion; easier to administer (single bolus due to longer half-life) both in and out of hospital; these advantages make tenecteplase the drug of choice in many US hospitals</td> </tr> <tr> <td class=\"indent1\">&#60;60 kg: 30 mg</td> </tr> <tr> <td class=\"indent1\">60 to 69 kg: 35 mg</td> </tr> <tr> <td class=\"indent1\">70 to 79 kg: 40 mg</td> </tr> <tr> <td class=\"indent1\">80 to 89 kg: 45 mg</td> </tr> <tr> <td class=\"indent1\">&#8805;90 kg: 50 mg</td> </tr> <tr class=\"divider_top\"> <td>Reteplase</td> <td>10 units over two minutes then repeat 10 unit bolus at 30 minutes</td> <td>Similar outcomes as alteplase but easier to administer</td> </tr> <tr class=\"divider_top\"> <td>Streptokinase</td> <td>1.5 million units over 30 to 60 minutes</td> <td>Generally a much less costly option than other fibrinolytics but outcomes are inferior. Neutralizing antibodies develop, which can diminish efficacy of subsequent use. Elevated risk of hypersensitivity reaction with repeated doses. Used extensively outside North America due to lower cost. (Not available in US or CAN).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All patients are also given non enteric-coated aspirin 162 to 325 mg and, with alteplase, reteplase, and tenecteplase, unfractionated heparin as a 60 units/kg bolus (maximum 4000 units) followed by an intravenous infusion of 12 units/kg per hour (maximum 1000 units per hour) adjusted to target aPTT of 50 to 70 seconds. Heparin has not been definitively shown to improve outcomes with non-fibrin-specific agents such as streptokinase. However, heparin is recommended with streptokinase in patients who are at high risk for systemic thromboembolism (large or anterior myocardial infarction, atrial fibrillation, previous embolus, or known left ventricular thrombus).</div><div id=\"graphicVersion\">Graphic 56744 Version 4.0</div></div></div>"},"56747":{"type":"graphic_figure","displayName":"Colles splint","title":"Colles splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colles splint</div><div class=\"cntnt\"><img style=\"width:336px; height:468px;\" src=\"images/PEDS/56747_Colles_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Colles splint is used for distal forearm and wrist fractures.</div><div id=\"graphicVersion\">Graphic 56747 Version 3.0</div></div></div>"},"56749":{"type":"graphic_table","displayName":"Education at initial visit","title":"Delivery of asthma education by clinicians during patient care visits: recommendations for initial visit","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Delivery of asthma education by clinicians during patient care visits: recommendations for initial visit</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Assessment questions</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Focus on:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Concerns</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Quality of life</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Expectations</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Goals of treatment</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Ask relevant questions from previous visit and also ask:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"What worries you most about your asthma?\"</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"What do you want to accomplish at this visit?\"</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"What do you want to be able to do that you can't do now because of your asthma?\"</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"What do you expect from treatment?\"</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"What medications have you tried?\"</td></tr><tr><td class=\"indent1\">\"What other questions do you have for me today?\"</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Information</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Teach in simple language:</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"sublist2_start\">What is asthma?</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">A chronic lung disease. The airways are very sensitive. They become inflamed and narrow; breathing becomes difficult.</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2_start\">Asthma treatments: two types of medicines are needed:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Long-term control: medications that prevent symptoms, often by reducing inflammation</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Quick relief: short-acting bronchodilator relaxes muscles around airways</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Bring all medications to every appointment.</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\" rowspan=\"2\">When to seek medical advice. Provide appropriate telephone number.</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\"> Skills</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Teach and demonstrate:</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"indent1\">Inhaler and spacer/holding chamber use. Check performance.</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2_start\">Self-monitoring skills that are tied to an action plan:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Recognize intensity and frequency of asthma symptoms</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Review the signs of deterioration and the need to reevaluate therapy:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist3\">Waking at night with asthma</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist3\">Increased medication use</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist3\">Decreased activity tolerance</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Use of a simple, written self-management plan</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 56749 Version 1.0</div></div></div>"},"56752":{"type":"graphic_figure","displayName":"Parathyroid location","title":"Locations of parathyroid glands","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Locations of parathyroid glands</div><div class=\"cntnt\"><img style=\"width:530px; height:382px;\" src=\"images/SURG/56752_Parathyroid_location.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most patients have four parathyroid glands: two superior and two inferior glands. The terms \"superior\" and \"inferior\" refer to a gland's embryologic origin, rather than the gland's location in the neck. The parathyroids are usually in close association with the thyroid gland. The superior parathyroid glands are usually 1 to 2 centimeters cranial to the junction of the recurrent laryngeal nerve with the inferior thyroid artery and within 1 centimeter of the entry point for the recurrent laryngeal nerve into the ligament of Berry and the cricoid cartilage. Superior parathyroid glands can be undescended or can be parapharyngeal, retropharyngeal, or retrotracheal within the middle cervical/mediastinal compartment. Enlarged parathyroid glands can travel straight down the tracheoesophageal groove or the retropharyngeal space into the chest. The two inferior parathyroid glands reside in the anterior mediastinal compartment, anterior to the recurrent laryngeal nerve. They are most often found in the thyrothymic tract or just inside the thyroid capsule on the inferior portion of the thyroid lobes. </div><div id=\"graphicVersion\">Graphic 56752 Version 10.0</div></div></div>"},"56754":{"type":"graphic_picture","displayName":"Basilar artery thrombosis","title":"Basilar artery thrombosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Basilar artery thrombosis</div><div class=\"cntnt\"><img style=\"width:504px; height:474px;\" src=\"images/NEURO/56754_Basilar_artery_thrombosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postmortem photograph of the ventral surface of the brainstem showing a dilated, thrombosed basilar artery. The thrombus extends into the anterior inferior cerebellar artery on the right. The two vertebral arteries that join to form the basilar are seen at the bottom of the photograph.</div><div id=\"graphicVersion\">Graphic 56754 Version 2.0</div></div></div>"},"56755":{"type":"graphic_picture","displayName":"Nitrazine paper for pH testing","title":"pH of vaginal discharge using nitrazine paper","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">pH of vaginal discharge using nitrazine paper</div><div class=\"cntnt\"><img style=\"width:449px; height:328px;\" src=\"images/OBGYN/56755_Nitrazine_paper_for_pH_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal.<br />(B) Bacterial vaginosis.<br />(C) Pregnant woman with premature rupture of membranes.</div><div class=\"graphic_reference\">Reproduced with permission from Aron Schuftan, MD. Copyright © Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 56755 Version 2.0</div></div></div>"},"56758":{"type":"graphic_picture","displayName":"Skin changes of chronic venous insufficiency","title":"Skin changes of chronic venous insufficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin changes of chronic venous insufficiency</div><div class=\"cntnt\"><img style=\"width:262px; height:258px;\" src=\"images/PC/56758_Skin_changes_chronic_edema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longstanding edema in this patient with chronic venous insufficiency led to moderately advanced pigment changes on the medial and lateral ankles, which extend onto the dorsum of the foot. The left medial ankle displays a healed venous ulcer below the malleolus; the right lateral ankle has a small, active, venous ulcer (arrow).</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 56758 Version 2.0</div></div></div>"},"56759":{"type":"graphic_figure","displayName":"Uterine hemi-section and myomectomy at vaginal hysterectomy","title":"Uterine hemi-section and myomectomy at vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterine hemi-section and myomectomy at vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:448px; height:308px;\" src=\"images/OBGYN/56759_Uterine_morcellation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56759 Version 3.0</div></div></div>"},"56760":{"type":"graphic_figure","displayName":"Effect of inhaled vasodilators","title":"Effect of inhaled vasodilators on blood flow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of inhaled vasodilators on blood flow</div><div class=\"cntnt\"><img style=\"width:450px; height:203px;\" src=\"images/PULM/56760_Effect_of_inhaled_vasodilat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inhaled vasodilators (green circles) preferentially dilate the pulmonary vessels (red lines) that perfuse functioning alveoli (white circles), recruiting blood flow away from poorly ventilated units (black circles). The net effect is improved ventilation/perfusion matching.</div><div id=\"graphicVersion\">Graphic 56760 Version 3.0</div></div></div>"},"56763":{"type":"graphic_diagnosticimage","displayName":"Emphysematous cholecystitis","title":"Emphysematous cholecystitis seen on computed tomographic scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Emphysematous cholecystitis seen on computed tomographic scan</div><div class=\"cntnt\"><img style=\"width:325px; height:514px;\" src=\"images/GAST/56763_Emphysematous_cholecystitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An axial image of a contrast enhanced computed tomographic (CT) scan demonstrating air within the gallbladder lumen (arrows).<br> (B) A coronal reformat of a contrast enhanced CT demonstrating air within the wall of the gallbladder (arrow).</div><div class=\"graphic_reference\">Courtesy of J Pierre Sasson, MD.</div><div id=\"graphicVersion\">Graphic 56763 Version 3.0</div></div></div>"},"56764":{"type":"graphic_picture","displayName":"Gonorrhea hemorrhagic bulla","title":"Disseminated gonococcal infection","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Disseminated gonococcal infection</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/56764_Gonorrhea_hemorrhagic_bulla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This adolescent girl developed a fever and several painful necrotic vesicles and bullae on her arms and legs. A cervical culture was positive for <em>Neisseria gonorrhoeae</em>.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 56764 Version 4.0</div></div></div>"},"56766":{"type":"graphic_figure","displayName":"Histo dx test sensitivity","title":"Overview of serology and antigen tests in acute pulmonary histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Overview of serology and antigen tests in acute pulmonary histoplasmosis</div><div class=\"cntnt\"><img style=\"width:518px; height:280px;\" src=\"images/ID/56766_Histo_dx_test_sensitivity.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Histoplasma capsulatum</EM> antigen (Ag) can be detected in patients with acute pulmonary histoplasmosis and is found more commonly in patients with severe clinical manifestations. Detection of high titers of complement fixing antibodies to the yeast or mycelia antigen precedes detection of M or H bands by immunodiffusion in most patients. However, antibodies rarely appear before the fourth week of infection and often do not reach maximal titers until the second or third month of infection.</div><div class=\"graphic_reference\">Courtesy of Joseph Wheat, MD.</div><div id=\"graphicVersion\">Graphic 56766 Version 4.0</div></div></div>"},"56767":{"type":"graphic_table","displayName":"Agents that increase BP","title":"Agents that can interfere with blood pressure control","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents that can interfere with blood pressure control</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Non-narcotic analgesics (nonsteroidal anti-inflammatory agents, selective COX-2 inhibitors, aspirin)</td> </tr> <tr> <td>Sympathomimetic agents (decongestants, diet pills, cocaine)</td> </tr> <tr> <td>Stimulants (methylphenidate, dexmethylphenidate, dextroamphetamine, amphetamine, methamphetamine)</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Oral contraceptives</td> </tr> <tr> <td>Cyclosporine</td> </tr> <tr> <td>Erythropoietin</td> </tr> <tr> <td>Natural licorice</td> </tr> <tr> <td>Herbal compounds (ephedra or ma huang)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COX-2: cyclooxygenase-2.</div><div class=\"graphic_reference\">Reprinted with permission from: Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56767 Version 12.0</div></div></div>"},"56769":{"type":"graphic_picture","displayName":"Pustular psoriasis 2","title":"Pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/OBGYN/56769_Pustular_psoriasis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 28-year-old woman developed fever, widespread erythema, and pustules at 34 weeks gestation during her first pregnancy. She was hospitalized for several months, and the eruption resolved within the first month after delivery of a normal full-term infant. A skin biopsy showed changes typical of pustular psoriasis.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 56769 Version 7.0</div></div></div>"},"56772":{"type":"graphic_diagnosticimage","displayName":"Air in fistula tract EUS","title":"Air in fistula tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Air in fistula tract</div><div class=\"cntnt\"><img style=\"width:377px; height:270px;\" src=\"images/GAST/56772_Air_in_fistula_tract_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound image showing air in a fistula tract (arrow).</div><div class=\"graphic_reference\">Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 56772 Version 3.0</div></div></div>"},"56774":{"type":"graphic_figure","displayName":"Pathogenesis of CRC","title":"Pathogenesis of colorectal cancer: adenoma-carcinoma sequence","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of colorectal cancer: adenoma-carcinoma sequence</div><div class=\"cntnt\"><img style=\"width:311px; height:326px;\" src=\"images/GAST/56774_Pathogenesis_of_CRC.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from O'Brien, MJ, Winawer, SJ, Waye, JB. Colorectal polyps. In: Management of Gastrointestinal Diseases, Winawer, SJ (Ed). Gower Medical, New York, 1992.</div><div id=\"graphicVersion\">Graphic 56774 Version 1.0</div></div></div>"},"56775":{"type":"graphic_table","displayName":"Ranson criteria pancreatitis","title":"Ranson criteria to predict severity of acute pancreatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ranson criteria to predict severity of acute pancreatitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">0 hours</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Age </td>\n\n      <td>&#62;55</td>\n\n    </tr>\n\n    <tr>\n\n      <td>White blood cell count</td>\n\n      <td>&#62;16,000/mm3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Blood glucose</td>\n\n      <td>&#62;200 mg/dL (11.1 mmol/L)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lactate dehydrogenase</td>\n\n      <td>&#62;350 U/L</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aspartate aminotransferase (AST)</td>\n\n      <td>&#62;250 U/L</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">48 hours</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Hematocrit</td>\n\n      <td>Fall by &#8805;10 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Blood urea nitrogen</td>\n\n      <td>Increase by &#8805;5 mg/dL (1.8 mmol/L) despite fluids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serum calcium</td>\n\n      <td>&#60;8 mg/dL (2 mmol/L)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>pO2</td>\n\n      <td>&#60;60 mmHg</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Base deficit</td>\n\n      <td>&#62;4 MEq/L</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fluid sequestation</td>\n\n      <td>&#62;6000 mL</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">The presence of 1 to 3 criteria represents mild pancreatitis; the mortality rate rises significantly with four or more criteria.</div><div class=\"graphic_reference\">Adapted from Ranson, JHC, Rifkind, KM, Roses, DF, et al, Surg Gynecol Obstet 1974; 139:69.</div><div id=\"graphicVersion\">Graphic 56775 Version 1.0</div></div></div>"},"56776":{"type":"graphic_picture","displayName":"Waardenburg syndrome","title":"Waardenburg syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Waardenburg syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:420px;\" src=\"images/PEDS/56776_Waardenburg_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A white forelock, broad nasal root, and dystopia canthorum in the father, and heterochromatic irides in the son affected by Waardenburg syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Nayak CS, Isaacson G. Worldwide distribution of Waardenburg syndrome. Ann Otol Rhinol Laryngol 2003; 112:817. Copyright © 2003 Annals Publishing Company.</div><div id=\"graphicVersion\">Graphic 56776 Version 6.0</div></div></div>"},"56777":{"type":"graphic_table","displayName":"Benzodiazepines chronic pain","title":"Benzodiazepines for chronic pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Benzodiazepines for chronic pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Drug</td>\n<td class=\"subtitle1\">Route of administration</td>\n<td class=\"subtitle1\">Dose</td>\n</tr>\n<tr>\n<td>Diazepam (Valium)</td>\n<td>PO/IM/PR</td>\n<td>2.5 mg Q 3 to 6 hours</td>\n</tr>\n<tr>\n<td>Lorazepam (Ativan)</td>\n<td>PO/IV/IM</td>\n<td>0.5 to 2 mg Q 3 to 6 hours</td>\n</tr>\n<tr>\n<td>Midazolam (Versed)</td>\n<td>PO/IV/SC (can be continuous infusion)</td>\n<td>1 to 3 mg Q 1 to 3 hours</td>\n</tr>\n<tr>\n<td>Clonazepam (Klonopin)</td>\n<td>PO</td>\n<td>Up to 1.5 mg/day</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 56777 Version 1.0</div></div></div>"},"56778":{"type":"graphic_table","displayName":"Periop GI pulmonary agents","title":"Perioperative management of gastrointestinal and pulmonary agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perioperative management of gastrointestinal and pulmonary agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name or class of drug</td> <td class=\"subtitle1\">Clinical considerations</td> <td class=\"subtitle1\">Recommended strategy for surgery with brief NPO state</td> <td class=\"subtitle1\">Recommended strategy for surgery with prolonged NPO state</td> </tr> <tr> <td>H2 blockers</td> <td>No known adverse effects.</td> <td>Continue therapy up to and including day of surgery.</td> <td>Continue therapy up to and including day of surgery. Substitute IV forms available for prolonged postoperative NPO state.</td> </tr> <tr> <td>Proton pump inhibitors (PPIs)</td> <td>May increase risk for <em>Clostridium difficile</em>.</td> <td>Continue therapy up to and including day of surgery.</td> <td>Continue therapy up to and including day of surgery. Substitute IV H2 blockers or IV PPIs for prolonged postoperative NPO state.</td> </tr> <tr> <td>Inhaled bronchodilators (beta agonists and anticholinergics)</td> <td>No known adverse effects.</td> <td>Continue therapy up to and including day of surgery.</td> <td>Continue therapy up to and including day of surgery. Use nebulized forms if patient unable to comply with inhalation maneuver.</td> </tr> <tr> <td>Theophylline</td> <td>No known adverse effects but very narrow range between therapeutic and toxic level.</td> <td>Discontinue the evening before surgery.</td> <td>Discontinue the evening before surgery. Resume with PO intake. Use nebulized or inhaled beta agonist or anticholinergics.</td> </tr> <tr> <td>Leukotriene inhibitors</td> <td>No known adverse effects.</td> <td>Continue therapy up to and including day of surgery.</td> <td>Continue therapy up to and including day of surgery and resume when patient able to take oral medications.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NPO: nil per os (nothing by mouth); IV: intravenous; PO: per os (by mouth).</div><div id=\"graphicVersion\">Graphic 56778 Version 5.0</div></div></div>"},"56779":{"type":"graphic_table","displayName":"Red eye treated by primary care","title":"Red eyes that may be managed by the primary care physician","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Red eyes that may be managed by the primary care physician</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Stye (hordeoleum)</td>\n</tr>\n<tr>\n<td>Chalazion</td>\n</tr>\n<tr>\n<td>Blepharitis</td>\n</tr>\n<tr>\n<td>Subconjunctival hemorrhage</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Conjunctivitis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Bacterial</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Viral</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Allergic</td>\n</tr>\n<tr>\n<td>Corneal abrasion (urgent follow-up if not better in 24 to 48 hours)</td>\n</tr>\n<tr>\n<td>Corneal foreign body (urgent follow-up if not better in 24 to 48 hours)</td>\n</tr>\n<tr>\n<td>Contect lens overwear (urgent follow-up if not better in 24 to 48 hours)</td>\n</tr>\n<tr>\n<td>Dry eye syndrome</td>\n</tr>\n<tr>\n<td>Episcleritis</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 56779 Version 1.0</div></div></div>"},"56780":{"type":"graphic_algorithm","displayName":"Secondary prevention early-onset GBS disease among newborns","title":"Secondary prevention of early-onset group B streptococcal (GBS) disease among newborns","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Secondary prevention of early-onset group B streptococcal (GBS) disease among newborns</div><div class=\"cntnt\"><img style=\"width:421px; height:477px;\" src=\"images/PEDS/56780_SecpreventearlyonsetGBS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Full diagnostic evaluation includes a blood culture, a complete blood count (CBC) including white blood cell differential and platelet counts, chest radiograph (if respiratory abnormalities are present), and lumbar puncture (if patient is stable enough to tolerate procedure and sepsis is suspected).<br />¶ Antibiotic therapy should be directed toward the most common causes of neonatal sepsis, including intravenous ampicillin for GBS and coverage for other organisms (including <EM>Escherichia coli</EM> and other gram-negative pathogens), and should take into account local antibiotic resistance patterns. Refer to UpToDate topics on management of sepsis in neonates for details on empiric antibiotic therapy.<br />Δ Consultation with obstetric providers is important to determine the level of clinical suspicion for chorioamnionitis. Chorioamnionitis is diagnosed clinically, and some of the signs are nonspecific.<br /><FONT class=lozenge>◊</FONT> Limited evaluation includes blood culture (at birth) and CBC with differential and platelets (at birth and/or at 6 to 12 hours after birth).<br />§ Refer to UpToDate topics on neonatal GBS prevention for detailed discussion of indications for GBS prophylaxis.<br />¥ If signs of sepsis develop, a full diagnostic evaluation should be conducted and antibiotic therapy initiated.<br />‡ If ≥37 weeks' gestation, observation may occur at home after 24 hours if other discharge criteria have been met, access to medical care is readily available, and a person who is able to comply fully with instructions for home observation will be present. If any of these conditions is not met, the infant should be observed in the hospital for at least 48 hours and until discharge criteria are achieved.<br />† Some experts recommend a CBC with differential and platelets at age 6 to 12 hours.</div><div class=\"graphic_reference\">Adapted from: American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW. (Ed), American Academy of Pediatrics, 2015. p.745.</div><div id=\"graphicVersion\">Graphic 56780 Version 8.0</div></div></div>"},"56781":{"type":"graphic_figure","displayName":"Adrenal steroid inhibitors","title":"Inhibitors of adrenal steroid biosynthesis or action","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Inhibitors of adrenal steroid biosynthesis or action</div><div class=\"cntnt\"><img style=\"width:475px; height:527px;\" src=\"images/ENDO/56781_Adrenal_steroid_inhibitors.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chemical structure of eight inhibitors of adrenal steroid biosynthesis or action. Mitotane is an adrenocorticolytic agent; aminoglutethimide, metyrapone, ketoconazole, trilostane, etomidate, and cyanoketone inhibit one or more of the enzymes in the steroid biosynthetic pathways; and mifepristone is a competitive antagonist of glucocorticoid binding to its cytosol receptor.</div><div id=\"graphicVersion\">Graphic 56781 Version 1.0</div></div></div>"},"56783":{"type":"graphic_movie","displayName":"MR in atrial fibrillation as heard at the apex","title":"Mitral regurgitation in atrial fibrillation as heard at the apex","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Mitral regurgitation in atrial fibrillation as heard at the apex</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/56783_mrafapexconv.mp4\" style=\"width:512px;height:458px\"></div><img style=\"width:444px; height:232px;\" src=\"images/CARD/56783_mrafapex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram and phonocardiogram of mitral regurgitation as heard at the apex. After S1 (closure of mitral and tricuspid valves), there is a harsh, holosystolic murmur of mitral regurgitation. Following S2 (closure of the aortic and pulmonic valves), there is a third heart sound (S3), which results from rapid filling of a dilated left ventricle. An early diastolic murmur is due to the large volume of blood flow from the left atrium into the left ventricle, a result of mitral regurgitation.</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 56783 Version 4.0</div></div></div>"},"56784":{"type":"graphic_diagnosticimage","displayName":"Dobutamine stress CMR predicts viable myocardium","title":"Dobutamine stress CMR predicts viable myocardium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dobutamine stress CMR predicts viable myocardium</div><div class=\"cntnt\"><img style=\"width:444px; height:216px;\" src=\"images/CARD/56784_Dobutamine_MRI_hibernat_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dobutamine stress CMR studies in a patient with total occlusion of the left anterior descending artery and a prior anterior wall myocardial infarction.<br />(Left upper panel) At rest, the short axis cine CMR at end-diastole shows normal diastolic wall thickness (*).<br />(Left lower panel) During systole (left lower panel) there is lack of systolic wall thickening (SWT) of the septum and anteroseptal portion of the anterior wall (arrow).<br />(Middle lower panel) During a dobutamine infusion, there was significant induction of SWT (arrow), indicating viable myocardium.<br />(Right lower panel) Four months after angioplasty, resting SWT of the anteroseptal region was normal.</div><div class=\"graphic_footnotes\">CMR: cardiac magnetic resonance.</div><div class=\"graphic_reference\">Reprinted with permission from: the American College of Cardiology (Journal of the American College of Cardiology) 1998; 31:1040.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 56784 Version 5.0</div></div></div>"},"56786":{"type":"graphic_waveform","displayName":"EPS tracing effects of procainamide on conduction","title":"Electrophysiology study (EPS) tracing showing the effects of procainamide on an abnormal His-Purkinje conduction system","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Electrophysiology study (EPS) tracing showing the effects of procainamide on an abnormal His-Purkinje conduction system</div><div class=\"cntnt\"><img style=\"width:610px; height:307px;\" src=\"images/CARD/56786_Effects_of_proc_on_cond.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These tracings were taken from a 58-year-old male with syncope. The baseline 12-lead electrocardiogram demonstrated sinus rhythm with prolonged atrioventricular (AV) conduction and a left bundle branch block with left axis deviation. Surface leads represented are I, II, III, and V1. Intracardiac tracings shown are the high right atrium (HRA), the distal His bundle electrogram (HIS d), the proximal His bundle electrogram (HIS 2), and the right ventricular apex (RVa). The left side of Panel A shows a baseline HV interval of 68 milliseconds. The right side of Panel A demonstrates prolongation of the HV interval to 100 milliseconds after the administration of procainamide indicating severe His-Purkinje conduction disease. Panel B (same lead schema) demonstrates high right atrial pacing at 400 milliseconds (150 beats per minute) with infra-Hisian block (arrow) after the administration of procainamide, confirming severe His-Purkinje disease.</div><div class=\"graphic_footnotes\">A: atrial depolarization; H: His bundle depolarization; msec: milliseconds; V: ventricular depolarization.</div><div class=\"graphic_reference\">Courtesy of Joseph J Germano, DO.</div><div id=\"graphicVersion\">Graphic 56786 Version 5.0</div></div></div>"},"56787":{"type":"graphic_form","displayName":"MDAS I","title":"Memorial Delirium Assessment Scale (MDAS)","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Memorial Delirium Assessment Scale (MDAS)</div><div class=\"cntnt\"><img style=\"width:606px; height:776px;\" src=\"images/ONC/56787_MDAS_I.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Breitbart, W, Rosenfield, B, Roth, A, Smith, M, Cohen, K, Passik, S. The memorial delirium assessment scale. J Pain Symptom Manage 1997; 13:128. Copyright ©1997 The US Cancer Pain Relief Committee.</div><div id=\"graphicVersion\">Graphic 56787 Version 2.0</div></div></div>"},"56788":{"type":"graphic_table","displayName":"Protocol for subcutaneous incremental challenge in patients","title":"Protocol for subcutaneous incremental challenge in patients with histories of prior reactions to local anesthetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protocol for subcutaneous incremental challenge in patients with histories of prior reactions to local anesthetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Step*</td> <td class=\"subtitle1\">Volume (mL)</td> <td class=\"subtitle1\">Dilution</td> </tr> <tr> <td class=\"centered\">1</td> <td>0.5</td> <td>Saline<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"centered\">2</td> <td>0.1 cc</td> <td>Undiluted<sup>&#9674;</sup></td> </tr> <tr> <td class=\"centered\">3</td> <td>0.5 cc</td> <td>Undiluted</td> </tr> <tr> <td class=\"centered\">4</td> <td>1.0 cc</td> <td>Undiluted</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Administered at 20- to 30-minute intervals.<br />¶ A single-blind, subcutaneous saline step may be inserted before a subcutaneous local anesthetic injection for patients in whom the reaction is suspected to be due to the injection, rather than the drug.<br />Δ After negative skin testing and a negative saline challenge (step 1), consider proceeding directly to step 4.<br /><FONT class=lozenge>◊</FONT> The concentration of the local anesthetic (usually 1 to 2%) to be used for the procedure.</div><div id=\"graphicVersion\">Graphic 56788 Version 8.0</div></div></div>"},"56789":{"type":"graphic_picture","displayName":"Amyloid goiter Congo red","title":"Amyloid goiter: Microscopic section with Congo red stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amyloid goiter: Microscopic section with Congo red stain</div><div class=\"cntnt\"><img style=\"width:360px; height:271px;\" src=\"images/ENDO/56789_Amyloid_goiter_Congo_red.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic section (Congo red and hematoxylin and eosin stains, magnification x 100) of the thyroid from a patient with an amyloid goiter stained with Congo red shows green birefringence under polarized light microscopy. Note deposition of amyloid material surrounding a thyroid follicule (F) and in the perivascular (V) space.</div><div class=\"graphic_reference\">Courtesy of Stephanie L Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 56789 Version 2.0</div></div></div>"},"56791":{"type":"graphic_table","displayName":"Chylous ascites features","title":"Characteristics of ascitic fluid in chylous ascites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of ascitic fluid in chylous ascites</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_left\">Color</td>\n<td>Milky and cloudy</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Triglyceride level</td>\n<td>Above 200 mg/dL</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Cell count</td>\n<td>Above 500 (predominance of lymphocytes)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Total protein</td>\n<td>Between 2.5 - 7.0 g/dL</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">SAAG</td>\n<td>Below 1.1 g/dL*</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Cholesterol</td>\n<td>Low (ascites/serum ratio &#60;1)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Lactate dehydrogenase</td>\n<td>Between 110 - 200 IU/liter</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Culture</td>\n<td>Positive in selected cases of tuberculosis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Adenosine deaminase</td>\n<td>Elevated in cases of tuberculosis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Cytology</td>\n<td>Positive in malignancy</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Glucose</td>\n<td>Under 100 mg/dL</td>\n</tr>\n<tr>\n<td class=\"subtitle1_left\">Amylase</td>\n<td>Elevated (&#62;40 IU/liter) in cases of acute or chronic pancreatitis</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">SAAG: serum-ascites albumin gradient; IU: international units.<br>* Level above 1.1 g/dL in chylous ascites secondary to cirrhosis.</div><div id=\"graphicVersion\">Graphic 56791 Version 1.0</div></div></div>"},"56792":{"type":"graphic_diagnosticimage","displayName":"Perforation partial SBO","title":"Small bowel obstruction with perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction with perforation</div><div class=\"cntnt\"><img style=\"width:390px; height:326px;\" src=\"images/GAST/56792_Perforation_partial_SBO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan demonstrating partial small bowel obstruction and perforation of the small bowel by a chicken bone (arrow). There is dilated small bowel in the left abdomen and collapsed small bowel in the right abdomen. Gas is present in the colon.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Anthony Samir, MD.</div><div id=\"graphicVersion\">Graphic 56792 Version 3.0</div></div></div>"},"56793":{"type":"graphic_diagnosticimage","displayName":"Pseudopolyps in UC BE","title":"Pseudopolyps in ulcerative colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudopolyps in ulcerative colitis</div><div class=\"cntnt\"><img style=\"width:233px; height:358px;\" src=\"images/GAST/56793_Pseudopolyps_in_UC_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast barium enema demonstrates mucosal pseudopolyps (arrows) and a stricture arising in the descending colon.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 56793 Version 2.0</div></div></div>"},"56794":{"type":"graphic_picture","displayName":"Polymorph low gr adenoCA Light","title":"Polymorphous low grade adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymorphous low grade adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:392px; height:261px;\" src=\"images/ONC/56794_Polymorph_low_gr_adenoCA_Li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of a polymorphous low grade salivary gland adenocarcinoma. A variety of histologic patterns in the same lesion characterize this tumor, commonly arising in minor salivary glands in the palate.&nbsp;Similar to adenoid cystic carcinoma, there is perineural invasion (arrow).</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 56794 Version 5.0</div></div></div>"},"56796":{"type":"graphic_table","displayName":"Pustules","title":"Differential diagnosis of pustules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of pustules</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Rosacea/perioral dermatitis</td> </tr> <tr> <td>Acne vulgaris</td> </tr> <tr> <td>Arthropod bite (fire ants)</td> </tr> <tr> <td>Drug eruption</td> </tr> <tr> <td>Eosinophilic folliculitis</td> </tr> <tr> <td>Erythema toxicum neonatorum</td> </tr> <tr> <td>Folliculitis</td> </tr> <tr> <td>Fungal or yeast infections (especially tinea capitis and Majocchi's granuloma)</td> </tr> <tr> <td>Furunculosis</td> </tr> <tr> <td>Gonorrhea (disseminated)</td> </tr> <tr> <td>Herpes simplex/zoster</td> </tr> <tr> <td>Impetigo</td> </tr> <tr> <td>Keratosis pilaris</td> </tr> <tr> <td>Neonatal pustulosis</td> </tr> <tr> <td>Pseudofolliculitis barbae</td> </tr> <tr> <td>Pustular psoriasis</td> </tr> <tr> <td>Pyoderma gangrenosum</td> </tr> <tr> <td>Syphilis</td> </tr> <tr> <td>Varicella</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56796 Version 2.0</div></div></div>"},"56797":{"type":"graphic_picture","displayName":"Erysipelas thigh","title":"Erysipelas involving the groin and thigh","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erysipelas involving the groin and thigh</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/56797_Erysipelas_thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56797 Version 4.0</div></div></div>"},"56799":{"type":"graphic_table","displayName":"Comparison of commonly infiltrated local anesthetics","title":"Comparison of commonly infiltrated local anesthetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of commonly infiltrated local anesthetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Infiltration anesthetic</td> <td class=\"subtitle1\" rowspan=\"2\">Concentration<br /> (percent)</td> <td class=\"subtitle1\" colspan=\"4\">Physiochemical properties</td> <td class=\"subtitle1\" colspan=\"2\">Maximum allowable dose*</td> <td class=\"subtitle1\">Maximum total dose*</td> </tr> <tr> <td class=\"subtitle2\">Lipid:water solubility</td> <td class=\"subtitle2\">Relative potency</td> <td class=\"subtitle2\">Onset of action<br /> (minutes)</td> <td class=\"subtitle2\">Duration<br /> (minutes)</td> <td class=\"subtitle2\">mg/kg</td> <td class=\"subtitle2\">mL/kg</td> <td class=\"subtitle2\"> <p>mg</p> (equivalent solution volume)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Lidocaine 1%</td> </tr> <tr> <td class=\"indent1\">Without epinephrine</td> <td class=\"centered\">1</td> <td class=\"centered\">2.9</td> <td class=\"centered\">2</td> <td class=\"centered\">2 to 5</td> <td class=\"centered\">50 to 120</td> <td class=\"centered\">4 to 5</td> <td class=\"centered\">0.4 to 0.5</td> <td> <p>300</p> (30 mL of 1%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">With epinephrine (1:200,000)</td> <td class=\"centered\">1</td> <td class=\"centered\">2.9</td> <td class=\"centered\">2</td> <td class=\"centered\">2 to 5</td> <td class=\"centered\">60 to 180</td> <td class=\"centered\">5 to 7</td> <td class=\"centered\">0.5 to 0.7</td> <td> <p>500</p> (50 mL of 1%)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Mepivacaine 1%</td> </tr> <tr> <td class=\"indent1\">Without epinephrine</td> <td class=\"centered\">1</td> <td class=\"centered\">0.8</td> <td class=\"centered\">2</td> <td class=\"centered\">2 to 5</td> <td class=\"centered\">50 to 120</td> <td class=\"centered\">5</td> <td class=\"centered\">0.5</td> <td> <p>300</p> (30 mL of 1%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">With epinephrine<sup>&#182;</sup> (1:200,000)</td> <td class=\"centered\">1</td> <td class=\"centered\">0.8</td> <td class=\"centered\">2</td> <td class=\"centered\">2 to 5</td> <td class=\"centered\">60 to 180</td> <td class=\"centered\">5 to 7</td> <td class=\"centered\">0.5 to 0.7</td> <td> <p>500</p> (50 mL of 1%)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Bupivacaine 0.25%</td> </tr> <tr> <td class=\"indent1\">Without epinephrine</td> <td class=\"centered\">0.25</td> <td class=\"centered\">27.5</td> <td class=\"centered\">8</td> <td class=\"centered\">5 to 10</td> <td class=\"centered\">240 to 480</td> <td class=\"centered\">2 to 2.5</td> <td class=\"centered\">0.8</td> <td> <p>175</p> (70 mL of 0.25%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">With epinephrine (1:200,000)</td> <td class=\"centered\">0.25</td> <td class=\"centered\">27.5</td> <td class=\"centered\">8</td> <td class=\"centered\">5 to 10</td> <td class=\"centered\">240 to 480</td> <td class=\"centered\">3</td> <td class=\"centered\">1.2</td> <td> <p>225</p> (90 mL of 0.25%)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"9\"><strong>Procaine 1%</strong><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Without epinephrine</td> <td class=\"centered\">1</td> <td class=\"centered\">0.6</td> <td class=\"centered\">1</td> <td class=\"centered\">5 to 10</td> <td class=\"centered\">60 to 90</td> <td class=\"centered\">7 to 10</td> <td class=\"centered\">0.7 to 1</td> <td> <p>500</p> (50 mL of 1%)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Maximum total dose for intradermal-subcutaneous infiltration anesthesia may vary according to site of administration and concommitant use of vasoconstrictors. The maximum dosing values in this table are at the lower end of what many experts regard as safe. Lower doses and concentrations than what are listed are generally used for children, debilitated patients or those with cardiac disease. Note that preparations of infiltrated local anesthestics are available in concentrations <strong>other</strong> than those shown in table. Maximum allowable and maximum total volumes shown apply <strong>only</strong> to the specific concentration of the preparation in table. Toxicity may occur with doses within the suggested range, especially with inadvertent vascular injection.<br />&para; Not commercially available, provider must mix.<br />&Delta; Not commercially available in the United States or Canada.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>McCreight A, Stephan M. Local and regional anesthesia. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008.</li>&#xD;&#xA;    <li>McGee DL. Anesthetic and analgesic technique. In: Roberts and Hedges Clinical Procedures in Emergency Medicine, 5th edition, Roberts JR, Hedges JR (Eds), Saunders Elsevier, Philadelphia 2010.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 56799 Version 17.0</div></div></div>"},"56801":{"type":"graphic_table","displayName":"Manifestations opioid toxicity","title":"Clinical manifestations of opioid toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of opioid toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">System</td> <td class=\"subtitle1\">Manifestations</td> </tr> <tr> <td>Pulmonary</td> <td>Respiratory depression, noncardiogenic pulmonary edema</td> </tr> <tr> <td>Cardiovascular</td> <td>Orthostatic hypotension, peripheral vasodilation, dysrhythmias</td> </tr> <tr> <td>Neurologic</td> <td>Analgesia, euphoria, dysphoria, miosis, mydriasis, seizures</td> </tr> <tr> <td>Gastrointestinal</td> <td>Nausea, vomiting, constipation</td> </tr> <tr> <td>Dermatologic</td> <td>Flushing, pruritus</td> </tr> <tr> <td>Reproductive</td> <td>Amenorrhea, anovulation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56801 Version 2.0</div></div></div>"},"56802":{"type":"graphic_table","displayName":"Air embolism conditions","title":"Conditions associated with air embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with air embolism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Surgical procedures</td>\n</tr>\n<tr>\n<td>Neurosurgery (craniotomy, shunt placement)</td>\n</tr>\n<tr>\n<td>Otolaryngological procedures</td>\n</tr>\n<tr>\n<td>Orthopedic surgery (arthroscopy, endoprosthesis placement)</td>\n</tr>\n<tr>\n<td>Ob-Gyn procedures (hysteroscopy/laparoscopy, cesarean section)</td>\n</tr>\n<tr>\n<td>Cardiothoracic surgery (cardiopulmonary bypass, lung resection, YAG laser resection, lung transplantation, needle biopsy of lung)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Intravenous catheterization</td>\n</tr>\n<tr>\n<td>Central lines</td>\n</tr>\n<tr>\n<td>Hemodialysis</td>\n</tr>\n<tr>\n<td>CABG/angioplasty</td>\n</tr>\n<tr>\n<td>Pacemaker or defibrillator placement</td>\n</tr>\n<tr>\n<td>Radiofrequency cardiac ablation</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Radiologic procedures</td>\n</tr>\n<tr>\n<td>Intravenous contrast injection</td>\n</tr>\n<tr>\n<td>Arthrography</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Trauma</td>\n</tr>\n<tr>\n<td>Head and neck injuries</td>\n</tr>\n<tr>\n<td>Penetrating and blunt chest trauma</td>\n</tr>\n<tr>\n<td>Blunt abdominal trauma</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Positive pressure ventilation</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Decompression sickness</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 56802 Version 1.0</div></div></div>"},"56806":{"type":"graphic_figure","displayName":"Uncommon fast slow AVNRT","title":"Uncommon fast-slow variant of atrioventricular nodal reentrant tachycardia (AVNRT)","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Uncommon fast-slow variant of atrioventricular nodal reentrant tachycardia (AVNRT)</div><div class=\"cntnt\"><img style=\"width:488px; height:236px;\" src=\"images/CARD/56806_UncommonfastslowAVNRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagrammatic representation in the circuit (left panel) and the ladder diagram (right panel) of the uncommon form of AVNRT (fast-slow variant). Antegrade conduction is through the fast (F) pathway and retrograde conduction is through the slow (S) pathway. Because of slow retrograde activation of the atrium, the P wave occurs after the QRS complex with a long RP interval and relatively short PR interval before the next QRS complex.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 56806 Version 4.0</div></div></div>"},"56807":{"type":"graphic_picture","displayName":"Acute generalized exanthematous pustulosis (AGEP)","title":"Acute generalized exanthematous pustulosis (AGEP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute generalized exanthematous pustulosis (AGEP)</div><div class=\"cntnt\"><img style=\"width:396px; height:354px;\" src=\"images/ALLRG/56807_AGEP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent nonfollicular pustules superimposed on edematous erythema in a 46-year-old woman with AGEP. A skin biopsy showed intracorneal pustules with numerous neutrophils and neutrophilic infiltration of the epidermis and upper dermis.</div><div class=\"graphic_reference\">Copyright &copy; Vincent CB Lin, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 56807 Version 14.0</div></div></div>"},"56808":{"type":"graphic_figure","displayName":"Oxygenation at different altitudes","title":"Oxygenation at different altitudes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oxygenation at different altitudes</div><div class=\"cntnt\"><img style=\"width:364px; height:318px;\" src=\"images/EM/56808_High_alt_oxygen.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increasing altitude results in a decrease in inspired oxygen (PiO<sub>2</sub>), arterial oxygen<sub>2</sub> (PaO<sub>2</sub>), and arterial oxygen saturation (SaO<sub>2</sub>). Note that the difference between PiO<sub>2</sub> and PaO<sub>2</sub> narrows at high altitudes because of increased ventilation, and that SaO<sub>2</sub> is well maintained while awake until over 3000 meters.</div><div class=\"graphic_reference\">Reproduced with permission from: Hackett, PH, Roach, RC. High-Altitude Medicine. In: Wilderness Medicine, 5th ed, Auerbach, PS (Ed), Mosby, Philadelphia 2007. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 56808 Version 2.0</div></div></div>"},"56809":{"type":"graphic_picture","displayName":"Prophylactic hemoclip Endosc","title":"Prophylactic hemoclip placement prior to colonic polypectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prophylactic hemoclip placement prior to colonic polypectomy</div><div class=\"cntnt\"><img style=\"width:301px; height:340px;\" src=\"images/GAST/56809_Prophylactic_hemoclip_Endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hemoclip has been placed prophylactically to ligate a long thin polyp stalk prior to snare transection.</div><div class=\"graphic_reference\">Courtesy of Uwe Seitz, MD, Sabine Bohnacker, MD, and Nib Soehendra, MD.</div><div id=\"graphicVersion\">Graphic 56809 Version 2.0</div></div></div>"},"56810":{"type":"graphic_picture","displayName":"Porphyria cutanea tarda 3","title":"Porphyria cutanea tarda: bullous skin lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Porphyria cutanea tarda: bullous skin lesion</div><div class=\"cntnt\"><img style=\"width:432px; height:250px;\" src=\"images/HEME/56810_Porphy_cut_tar_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullous lesion on the hand of a patient with porphyria cutanea tarda. Erythema, erosions, and crusting are also seen.</div><div class=\"graphic_reference\">Courtesy of Karl E Anderson, MD, FACP.</div><div id=\"graphicVersion\">Graphic 56810 Version 2.0</div></div></div>"},"56811":{"type":"graphic_table","displayName":"Drug resistance data 2010","title":"Rate of resistance to second-line drugs for countries with high burden of multidrug-resistant tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rate of resistance to second-line drugs for countries with high burden of multidrug-resistant tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Method*</td> <td class=\"subtitle1\">MDR-TB cases tested for second-line drug resistance</td> <td class=\"subtitle1\">XDR cases among MDR-TB cases tested</td> <td class=\"subtitle1\">Proportion of MDR cases that were XDR (percent)</td> </tr> <tr> <td><strong>Armenia</strong></td> <td>2007</td> <td>Survey</td> <td>199</td> <td>8</td> <td>4 (1.8-7.8)</td> </tr> <tr> <td><strong>Azerbaijan, Baku</strong></td> <td>2007</td> <td>Survey</td> <td>431</td> <td>55</td> <td>12.8 (9.8-16.3)</td> </tr> <tr> <td><strong>Bangladesh<sup>&#182;</sup><sup>&#916;</sup></strong></td> <td>2008</td> <td>Surveillance</td> <td>168</td> <td>1</td> <td>0.6</td> </tr> <tr> <td><strong>China<sup>&#182;</sup></strong></td> <td>2008</td> <td>Survey</td> <td>270</td> <td>30</td> <td>11.1 (7.6-15.5)</td> </tr> <tr> <td><strong>Estonia</strong></td> <td>2008</td> <td>Surveillance</td> <td>72</td> <td>9</td> <td>12.5</td> </tr> <tr> <td><strong>Georgia</strong></td> <td>2006</td> <td>Survey</td> <td>70</td> <td>3</td> <td>4.3 (0.9-12)</td> </tr> <tr> <td><strong>India, Gujarat state<sup>&#182;</sup></strong></td> <td>2006</td> <td>Survey</td> <td>216</td> <td>7</td> <td>3.2 (1.2-6.6)</td> </tr> <tr> <td><strong>Kazakhstan</strong></td> <td>2008</td> <td>Surveillance</td> <td>373</td> <td>16</td> <td>4.3</td> </tr> <tr> <td><strong>Latvia</strong></td> <td>2008</td> <td>Surveillance</td> <td>128</td> <td>19</td> <td>14.8</td> </tr> <tr> <td><strong>Lithuania</strong></td> <td>2003 to 2006</td> <td>Surveillance</td> <td>173</td> <td>25</td> <td>14.5</td> </tr> <tr> <td><strong>Moldova</strong></td> <td>2006</td> <td>Survey</td> <td>47</td> <td>3</td> <td>6.4 (1.3-17.5)</td> </tr> <tr> <td><strong>Russia, Tomsk oblast<sup>&#182;</sup></strong></td> <td>2003 to 2005</td> <td>Surveillance</td> <td>458</td> <td>30</td> <td>6.6</td> </tr> <tr> <td><strong>South Africa<sup>&#182;</sup></strong></td> <td>2008</td> <td>Surveillance</td> <td>5451</td> <td>573</td> <td>10.5</td> </tr> <tr> <td><strong>Tajikistan, Dushanbe and Rudaki</strong></td> <td>2009</td> <td>Survey</td> <td>100</td> <td>21</td> <td>21 (13.5-30.3)</td> </tr> <tr> <td><strong>Ukraine, Donetsk oblast</strong></td> <td>2006</td> <td>Survey</td> <td>20</td> <td>3</td> <td>15 (3.2-37.9)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data are n or % (95% CI).</div><div class=\"graphic_footnotes\">MDR: multidrug resistant; TB: tuberculosis; XDR: extensively drug resistant.<br />* Data derived from continuous surveillance systems versus from periodic drug-resistance surveys.<br />¶ Countries with a high burden of tuberculosis, for which representative data for prevalence of XDR disease were available; XDR prevalence data were not available for any of the remaining high-burden countries.<br />Δ Damien Foundation Area, previously treated cases only.</div><div class=\"graphic_reference\">Reproduced from: Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375:1830. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 56811 Version 5.0</div></div></div>"},"56812":{"type":"graphic_picture","displayName":"Thrush PI","title":"Thrush","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thrush</div><div class=\"cntnt\"><img style=\"width:359px; height:236px;\" src=\"images/PI/56812_Thrush.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thrush sometimes causes white patches to form on the tongue.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 56812 Version 1.0</div></div></div>"},"56813":{"type":"graphic_algorithm","displayName":"Management overview suspected acute coronary syndrome in ED","title":"Overview of approach to patients with suspected acute myocardial infarction in the emergency department","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Overview of approach to&nbsp;patients with suspected acute myocardial infarction in the emergency department</div><div class=\"cntnt\"><img style=\"width:546px; height:584px;\" src=\"images/CARD/56813_Schema_manage_suspAMI_ed5.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Initial laboratory work&nbsp;may vary by institution, but often&nbsp;includes: serum cardiac biomarkers, CBC with platelet count, PT and INR, aPTT, basic electrolytes, magnesium, BUN, creatinine, blood glucose, and serum lipid profile.</div><div id=\"graphicVersion\">Graphic 56813 Version 6.0</div></div></div>"},"56814":{"type":"graphic_picture","displayName":"Parasternal long view probe position","title":"Parasternal long view probe position","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Parasternal long view probe position</div><div class=\"cntnt\"><img style=\"width:504px; height:333px;\" src=\"images/EM/56814_Paraster_long_view_probe_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows proper probe position for obtaining the parasternal long axis view.</div><div class=\"graphic_reference\">Courtesy of Manoj Pariyadath, MD.</div><div id=\"graphicVersion\">Graphic 56814 Version 1.0</div></div></div>"},"56815":{"type":"graphic_picture","displayName":"Facial atopic dermatitis","title":"Atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/56815_Facial_atopic_dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slightly lichenified dermatitic plaques are present on the face. Erythema is subtle in this dark-skinned patient.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56815 Version 3.0</div></div></div>"},"56817":{"type":"graphic_table","displayName":"Secondary factors renal failure","title":"Secondary factors and progression of chronic renal failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary factors and progression of chronic renal failure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Intraglomerular hypertension and hypertrophy</td>\n</tr>\n<tr>\n<td>Phosphate retention, with interstitial CaPO4 deposition</td>\n</tr>\n<tr>\n<td>Increased prostaglandin synthesis</td>\n</tr>\n<tr>\n<td>Hyperlipidemia, especially in the nephrotic syndrome</td>\n</tr>\n<tr>\n<td>Metabolic acidosis</td>\n</tr>\n<tr>\n<td>Proteinuria</td>\n</tr>\n<tr>\n<td>Tubulointerstitial disease</td>\n</tr>\n<tr>\n<td>Retained \"uremic\" toxins</td>\n</tr>\n<tr>\n<td>Filtered iron in nephrotic syndrome</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 56817 Version 1.0</div></div></div>"},"56818":{"type":"graphic_figure","displayName":"Standard alcoholic drink","title":"What is a standard drink?","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">What is a standard drink?</div><div class=\"cntnt\"><img style=\"width:604px; height:644px;\" src=\"images/GAST/56818_Standard_alcoholic_drink_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">oz. = ounces.<br />* It can be difficult to estimate the number of standard drinks in a single mixed drink made with hard liquor. Depending on factors such as the type of spirits and the recipe, a mixed drink can contain from one to three or more standard drinks.</div><div class=\"graphic_reference\">Reproduced with content from: National Institutes on Alcohol Abuse and Alcoholism. Rethinking Drinking: Alcohol and your health. Available at: <a href=\"http://rethinkingdrinking.niaaa.nih.gov/\" target=\"_blank\">http://rethinkingdrinking.niaaa.nih.gov</a>.</div><div id=\"graphicVersion\">Graphic 56818 Version 3.0</div></div></div>"},"56821":{"type":"graphic_table","displayName":"Evaluation bronchiectasis 1","title":"Evaluation of bronchiectasis-1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of bronchiectasis-1</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Specific examples/features</td> <td class=\"subtitle1\">Diagnostic tests</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Acquired bronchial obstruction</td> </tr> <tr> <td class=\"indent1\">Foreign-body aspiration</td> <td>Peanut; chicken bone; tooth; grass inflorescence, etc</td> <td>Chest imaging; flexible bronchoscopy</td> </tr> <tr> <td class=\"indent1\">Tumors</td> <td>Laryngeal papillomatosis; airway adenoma; endobronchial teratoma</td> <td>Chest imaging; flexible bronchoscopy</td> </tr> <tr> <td class=\"indent1\">Hilar adenopathy</td> <td>Tuberculosis; histoplasmosis; sarcoidosis</td> <td>PPD; chest imaging; flexible bronchoscopy</td> </tr> <tr> <td class=\"indent1\">COPD</td> <td>Chronic bronchitis</td> <td>Pulmonary function tests; serum alpha-1 antitrypsin level</td> </tr> <tr> <td class=\"indent1\">Rheumatic disease</td> <td>Relapsing polychondritis (RP); tracheobronchial amyloidosis</td> <td>Clinical syndrome of RP/cartilage biopsy; biopsy for amyloid</td> </tr> <tr> <td class=\"indent1\">Mucoid impaction</td> <td>Allergic bronchopulmonary aspergillosis; bronchocentric granulomatosis (BG); postoperative mucoid impaction</td> <td>Total and aspergillus specific IgE; specific aspergillus IgG; Aspergillus skin test; chest imaging; biopsy for BG</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Congenital anatomic defects that may cause bronchial obstruction</td> </tr> <tr> <td class=\"indent1\">Tracheobronchial</td> <td>Bronchomalacia; bronchial cyst; cartilage deficiency (Williams-Campbell syndrome); tracheobronchomegaly (Mounier-Kuhn syndrome); ectopic bronchus; tracheoesophageal fistula</td> <td>Chest CT imaging</td> </tr> <tr> <td class=\"indent1\">Vascular</td> <td>Pulmonary (intralobar) sequestration; pulmonary artery aneurysm</td> <td>Chest CT imaging</td> </tr> <tr> <td class=\"indent1\">Lymphatic</td> <td>Yellow-nail syndrome</td> <td>History of dystrophic, slow growing nails</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPD: purified protein derivative (tuberculin skin test); COPD: chronic obstructive pulmonary disease; RP: relapsing polychondritis; BG: bronchocentric granulomatosis; CT: computerized tomography.</div><div id=\"graphicVersion\">Graphic 56821 Version 5.0</div></div></div>"},"56822":{"type":"graphic_diagnosticimage","displayName":"Diverticulitis US","title":"Diverticulitis on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diverticulitis on ultrasound</div><div class=\"cntnt\"><img style=\"width:330px; height:576px;\" src=\"images/GAST/56822_Diverticulitis_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound images showing a hypoechoic region adjacent to the sigmoid colon representing a diverticular abscess (ABSZ top panel). Regression was demonstrated after five days of conservative treatment (bottom).</div><div class=\"graphic_reference\">Courtesy of Christoph F Dietrich, MD.</div><div id=\"graphicVersion\">Graphic 56822 Version 3.0</div></div></div>"},"56823":{"type":"graphic_diagnosticimage","displayName":"Lipoma EUS","title":"Gastrointestinal lipoma","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Gastrointestinal lipoma</div><div class=\"cntnt\"><img style=\"width:468px; height:347px;\" src=\"images/GAST/56823_Lipoma_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endosonographic view of a lipoma. Note the hyperechoic and homogenous character, and originating from the submucosal layer.</div><div class=\"graphic_reference\">Courtesy of Mary Lee Krinsky, DO, and Kenneth Binmoeller, MD.</div><div id=\"graphicVersion\">Graphic 56823 Version 3.0</div></div></div>"},"56825":{"type":"graphic_figure","displayName":"Lower extremity rotational alignment","title":"Rotational alignment of the lower extremity","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Rotational alignment of the lower extremity</div><div class=\"cntnt\"><img style=\"width:455px; height:633px;\" src=\"images/PEDS/56825_Lower-extremity-rotational-alignment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rotational alignment of the lower extremity is determined by the position of the foot, the rotation of the tibia in relation to the transcondylar axis of the femur (tibial torsion), and the rotation of the neck of the femur in relation to the transcondylar axis of the femur (femoral anteversion).</div><div id=\"graphicVersion\">Graphic 56825 Version 2.0</div></div></div>"},"56826":{"type":"graphic_table","displayName":"Vascular structures 2","title":"Vascular structures most commonly seen in nonmelanocytic tumors<sup>[1-3]</sup>","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Vascular structures most commonly seen in nonmelanocytic tumors<sup>[1-3]</sup></div><div class=\"cntnt\"><img style=\"width:672px; height:723px;\" src=\"images/DERM/56826_Vascular_structures_2_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The presence of a given vessel morphology is not exclusive to a particular diagnosis. For example, arborizing vessels are commonly seen in basal cell carcinoma, but they can also be seen in melanoma and intradermal nevi. Another example would be that although hairpin vessels are commonly associated with seborrheic keratoses, they can also be seen in melanoma. With that said, this table highlights vessels that are most commonly associated with nonmelanocytic tumors.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J Am Acad Dermatol 2010; 63:377. </li>&#xD;&#xA;    <li>Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part I. Melanocytic skin tumors. J Am Acad Dermatol 2010; 63:361. </li>&#xD;&#xA;    <li>Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004; 140:1485. </li>&#xD;&#xA;    <li>Pan Y, Chamberlain AJ, Bailey M, et al. Dermatoscopy aids in the diagnosis of the solitary red scaly patch or plaque-features distinguishing superficial basal cell carcinoma, intraepidermal carcinoma, and psoriasis. J Am Acad Dermatol 2008; 59:268. </li>&#xD;&#xA;    <li>Braun RP, Rabinovitz HS, Krischer J, et al. Dermoscopy of pigmented seborrheic keratosis: a morphological study. Arch Dermatol 2002; 138:1556. </li>&#xD;&#xA;    <li>Ka VS, Clark-Loeser L, Marghoob AA. Vascular pattern in seborrheic keratoses and melanoma. Dermatol Surg 2004; 30:75. </li>&#xD;&#xA;    <li>Altamura D, Menzies SW, Argenziano G, et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol 2010; 62:67. </li>&#xD;&#xA;    <li>Zalaudek I, Giacomel J, Argenziano G, et al. Dermoscopy of facial nonpigmented actinic keratosis. Br J Dermatol 2006; 155:951. </li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 56826 Version 8.0</div></div></div>"},"56827":{"type":"graphic_picture","displayName":"IgG4-related sialadenitis","title":"IgG4-related sialadenitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">IgG4-related sialadenitis</div><div class=\"cntnt\"><img style=\"width:432px; height:407px;\" src=\"images/RHEUM/56827_IgG4_related_sialadenitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 26-year-old woman with three months of bilateral submandibular gland swelling. Her condition, once misdiagnosed as Sjögren's syndrome or termed \"Mikulicz disease\" or \"Küttner tumor,\" is now known as IgG4-related sialadenitis. IgG4-related sialadenitis is part of the larger spectrum of IgG4-related systemic disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Khosroshahi A, Stone J. IgG4-related systemic disease: the age of discovery. Curr Opinion Rheum 2011; 23:72. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56827 Version 6.0</div></div></div>"},"56828":{"type":"graphic_figure","displayName":"Construction of a loop ileostomy - defunctionalized distal limb","title":"Construction of a loop ileostomy - defunctionalized distal limb","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of a loop ileostomy - defunctionalized distal limb</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/SURG/56828_Loop-ileostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a loop ileostomy with a defunctionalized distal limb. The ileotomy is made circumferentially and 20 percent of the back wall of the ileum is intact, maintaining a bridge between the functional proximal limb&#160;and the defunctionalized distal limb. Only the proximal limb is everted.</div><div id=\"graphicVersion\">Graphic 56828 Version 1.0</div></div></div>"},"56830":{"type":"graphic_table","displayName":"Granulomatous liver dz meds","title":"Medications associated with granulomatous liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with granulomatous liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Allopurinol</td>\n</tr>\n<tr>\n<td>BCG</td>\n</tr>\n<tr>\n<td>Carbamazepine</td>\n</tr>\n<tr>\n<td>Chlorpropramide</td>\n</tr>\n<tr>\n<td>Diltiazem</td>\n</tr>\n<tr>\n<td>Gold</td>\n</tr>\n<tr>\n<td>Halothane</td>\n</tr>\n<tr>\n<td>Hydralazine</td>\n</tr>\n<tr>\n<td>Interferon alfa</td>\n</tr>\n<tr>\n<td>Mebendazole</td>\n</tr>\n<tr>\n<td>Methyldopa</td>\n</tr>\n<tr>\n<td>Nitrofurantoin</td>\n</tr>\n<tr>\n<td>Phenylbutazone</td>\n</tr>\n<tr>\n<td>Phenytoin</td>\n</tr>\n<tr>\n<td>Procainamide</td>\n</tr>\n<tr>\n<td>Quinidine</td>\n</tr>\n<tr>\n<td>Sulfa drugs</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 56830 Version 1.0</div></div></div>"},"56831":{"type":"graphic_table","displayName":"Knodell score","title":"Knodell score (histology activity index score) of liver biopsy specimens for necrosis, inflammation, and fibrosis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Knodell score (histology activity index score) of liver biopsy specimens for necrosis, inflammation, and fibrosis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">I. Periportal&#177; bridging necrosis</td> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">II. Intralobular degeneration and focal necrosis&#182;</td> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">III. Portal inflammation</td> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">IV. Fibrosis</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td>None</td> <td>0</td> <td>None</td> <td>0</td> <td>No portal inflammation</td> <td>0</td> <td>No fibrosis</td> <td>0</td> </tr> <tr> <td>Mild piecemeal necrosis</td> <td>1</td> <td>Mild (acidophilic bodies, ballooning degeneration and/or scattered foci of hepatocellular necrosis in &#60;1/3 of lobules or nodules</td> <td>1</td> <td>Mild (sprinkling of inflammatory cells in &#60;1/3 of portal tracts)</td> <td>1</td> <td>Fibrous portal expansion</td> <td>1</td> </tr> <tr> <td>Moderate piecemeal necrosis (involves less than 50 percent of the circumference of most portal tracts)</td> <td>3</td> <td>Moderate (involvement of 1/3 to 2/3 of lobules or nodules)</td> <td>3</td> <td>Moderate (increased inflammatory cells in 1/3 to 2/3 of portal tracts)</td> <td>3</td> <td>Bridging fiborisis (portal-portal or portal-central linkage)</td> <td>3</td> </tr> <tr> <td>Marked piecemeal necrosis (involves more than 50 percent of the circumference of most portal tracts)</td> <td>4</td> <td>Marked (involvement of &#62;2/3 of lobules or nodules)</td> <td>4</td> <td>Marked (dense packing of inflammatory cells in &#62;2/3 of portal tracts)</td> <td>4</td> <td>Cirrhosis&#916;</td> <td>4</td> </tr> <tr> <td>Moderate piecemeal necrosis plus bridging necrosis&#9674;</td> <td>5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Marked piecemeal necrosis plus bridging necrosis&#9674;</td> <td>6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Multilobular necrosis&#167;</td> <td>10</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The histology activity index score is the combined scores for necrosis, inflammation, and fibrosis.<br />¶&nbsp;Degeneration-acidophilic bodies, ballooning; focal necrosis-scattered foci of hepatocellular necrosis.<br />Δ Loss of normal hepatic lobular architecture with fibrous septae separating and surrounding nodules.<br />◊ Bridging is defined as ≥2 bridges in the liver biopsy specimen; no distinction is made between portal-portal and portal-central linkage.<br />§ Two or more contiguous lobules with panlobular necrosis.</div><div class=\"graphic_reference\">Adapted from Knodell RG, et al. Hepatology 1981; 1:431.</div><div id=\"graphicVersion\">Graphic 56831 Version 4.0</div></div></div>"},"56832":{"type":"graphic_picture","displayName":"Anthrax CSF Gram stain","title":"Gram stain of cerebrospinal fluid containing <EM>Bacillus anthracis</EM>, displaying the characteristic \"boxcar-shaped\" morphology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gram stain of cerebrospinal fluid containing <EM>Bacillus anthracis</EM>, displaying the characteristic \"boxcar-shaped\" morphology</div><div class=\"cntnt\"><img style=\"width:323px; height:375px;\" src=\"images/ID/56832_Gramsstaincsf.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from The Lancet Infectious Diseases, Vol. 5, Sejvar JJ, Tenover FC, Stephens DS, Management of antrax meningitis, pp. 287-95, Copyright © 2005, with permission from Elsevier.</div><div id=\"graphicVersion\">Graphic 56832 Version 6.0</div></div></div>"},"56833":{"type":"graphic_table","displayName":"Relapsing fever Borrelia spp","title":"Borrelia species causing tick-borne relapsing fever","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Borrelia species causing tick-borne relapsing fever</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Species</td> <td class=\"subtitle1\">Tick vector</td> <td class=\"subtitle1\">Geographic distribution</td> </tr> <tr> <td><em>Borrelia hermsii</em></td> <td><em>Ornithodoros hermsi</em></td> <td>Western North America</td> </tr> <tr> <td><em>B. turicatae</em></td> <td><em>O. turicata</em></td> <td>Southwestern North America and northern Mexico</td> </tr> <tr> <td><em>B. venezuelensis</em></td> <td><em>O. rudis</em></td> <td>Central America and northern South America</td> </tr> <tr> <td><em>B. hispanica</em></td> <td><em>O. erraticus</em></td> <td>Iberian peninsula and northwestern Africa</td> </tr> <tr> <td><em>B. crocidurae</em></td> <td><em>O. erraticus</em></td> <td>North Africa and Mediterranean region</td> </tr> <tr> <td><em>B. duttonii</em></td> <td><em>O. moubata</em></td> <td>Central, eastern and southern Africa</td> </tr> <tr> <td><em>B. persica</em></td> <td><em>O. tholozani</em></td> <td>Western China, India, central Asia, Middle East</td> </tr> <tr> <td><em>B. latyschewii</em></td> <td><em>O. tartakovskyi</em></td> <td>Tajikistan, Uzbekistan</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56833 Version 4.0</div></div></div>"},"56834":{"type":"graphic_picture","displayName":"Cystine crystals","title":"Urine sediment showing cystine crystals","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urine sediment showing cystine crystals</div><div class=\"cntnt\"><img style=\"width:378px; height:256px;\" src=\"images/NEPH/56834_Cystine_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing hexagonal cystine crystals that are essentially pathognomonic of cystinuria.</div><div class=\"graphic_reference\">Courtesy of Harvard Medical School.</div><div id=\"graphicVersion\">Graphic 56834 Version 2.0</div></div></div>"},"56836":{"type":"graphic_picture","displayName":"Suction vulva hematoma","title":"Suction/irrigation system for debridement of large vulvar hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Suction/irrigation system for debridement of large vulvar hematoma</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/OBGYN/56836_Suction_vulva_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Marc Laufer, MD.</div><div id=\"graphicVersion\">Graphic 56836 Version 1.0</div></div></div>"},"56837":{"type":"graphic_table","displayName":"Causes of chronic diarrhea in children","title":"Causes of chronic diarrhea in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of chronic diarrhea in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diet-induced</td> </tr> <tr> <td class=\"subtitle2_single\">Functional diarrhea (chronic nonspecific diarrhea)</td> </tr> <tr> <td class=\"indent1\">Excessive intake of juice/osmotically active carbohydrates</td> </tr> <tr> <td class=\"indent1\">Inadequate dietary fat</td> </tr> <tr> <td class=\"indent1\">Idiopathic</td> </tr> <tr> <td class=\"subtitle2_single\">Other dietary triggers&nbsp;</td> </tr> <tr> <td class=\"indent1\">Lactose intolerance&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sucrase deficiency&nbsp;</td> </tr> <tr> <td class=\"indent1\">Food allergies (IgE- and non-IgE-mediated)&nbsp;&#8212; see \"abnormal immune response\" below</td> </tr> <tr> <td class=\"subtitle1_single\">Enteric infection</td> </tr> <tr> <td class=\"subtitle2_single\">Postenteritis syndrome</td> </tr> <tr> <td class=\"subtitle2_single\">Parasites</td> </tr> <tr> <td class=\"indent1\">Giardia lamblia</td> </tr> <tr> <td class=\"indent1\">Cryptosporidia parvum</td> </tr> <tr> <td class=\"indent1\">Cyclospora cayetanensis</td> </tr> <tr> <td class=\"indent1\">Isospora belli</td> </tr> <tr> <td class=\"indent1\">Microsporidia</td> </tr> <tr> <td class=\"indent1\">Entamoeba histolytica</td> </tr> <tr> <td class=\"indent1\">Strongyloides, Ascaris, Trichuris species</td> </tr> <tr> <td class=\"subtitle2_single\">Bacteria</td> </tr> <tr> <td class=\"indent1\">E. coli -- multiple types (enteroaggregative, enteropathogenic, enterotoxigenic, enteroadherent)</td> </tr> <tr> <td class=\"indent1\">Salmonella, Shigella, Yersinia, Campylobacter&nbsp;</td> </tr> <tr> <td class=\"indent1\">Clostridium difficile&nbsp;</td> </tr> <tr> <td class=\"indent1\">Mycobacterium avium complex</td> </tr> <tr> <td class=\"indent1\">Mycobacterium tuberculosis</td> </tr> <tr> <td class=\"subtitle2_single\">Viruses</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Rotavirus</td> </tr> <tr> <td class=\"indent1\">Enteric adenovirus</td> </tr> <tr> <td class=\"indent1\">Astrovirus</td> </tr> <tr> <td class=\"indent1\">Torovirus</td> </tr> <tr> <td class=\"indent1\">Human Immunodeficiency Virus (HIV)</td> </tr> <tr> <td class=\"subtitle1_single\">Syndromic persistent diarrhea (common in&nbsp;resource-limited countries)</td> </tr> <tr> <td>Associated with malnutrition</td> </tr> <tr> <td class=\"subtitle1_single\">Immune deficiency</td> </tr> <tr> <td>Primary immune deficiencies</td> </tr> <tr> <td>Secondary immune deficiencies (HIV)</td> </tr> <tr> <td class=\"subtitle1_single\">Abnormal immune response</td> </tr> <tr> <td>Celiac disease</td> </tr> <tr> <td>Food&nbsp;protein-induced enteropathy (FPIES) or food protein-induced proctocolitis/enteritis* (eg, due to cow's&nbsp; milk)</td> </tr> <tr> <td>Autoimmune disorders</td> </tr> <tr> <td>Autoimmune enteropathy (including IPEX and APS-1)</td> </tr> <tr> <td>Graft versus host disease</td> </tr> <tr> <td>Microscopic lymphocytic or&nbsp;collagenous colitis&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory bowel disease (more common in&nbsp;resource-rich countries)</td> </tr> <tr> <td>Ulcerative Colitis</td> </tr> <tr> <td>Crohn disease</td> </tr> <tr> <td>Early onset inflammatory bowel disease (ulcerative colitis or Crohn disease presenting prior to six years of age)</td> </tr> <tr> <td class=\"subtitle1_single\">Protein losing gastroenteropathy</td> </tr> <tr> <td>Lymphangiectasia (primary or secondary)</td> </tr> <tr> <td>Other diseases affecting the gastrointestinal mucosa</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital persistent diarrhea (rare)</td> </tr> <tr> <td>Microvillus inclusion disease (Microvillus atrophy)</td> </tr> <tr> <td>Intestinal epithelial dysplasia (Tufting enteropathy)</td> </tr> <tr> <td>Congenital chloride diarrhea</td> </tr> <tr> <td>Congenital sodium diarrhea</td> </tr> <tr> <td>Glucose-galactose malabsorption&nbsp;</td> </tr> <tr> <td>Congenital disaccharidase (sucrase-isomaltase, etc) deficiencies</td> </tr> <tr> <td>Congenital bile acid malabsorption</td> </tr> <tr> <td class=\"subtitle1_single\">Neuroendocrine tumors</td> </tr> <tr> <td>Gastrinoma (Zollinger-Ellison syndrome)</td> </tr> <tr> <td>VIPoma (Verner-Morrison syndrome)</td> </tr> <tr> <td>Mastocytosis</td> </tr> <tr> <td class=\"subtitle1_single\">Factitious diarrhea</td> </tr> <tr> <td>Laxative abuse</td> </tr> <tr> <td>Manipulation of stool samples</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>IgE: immunoglobulin E; IPEX: immune dysregulation, polyendocrinopathy, enteropathy, X-linked; APS-1: Autoimmune polyendocrine syndrome type 1. <br />* The term, \"food protein-induced proctocolitis/enteritis\"&nbsp;is now preferred. Previously used terms (eg, milk protein intolerance, cow's milk sensitivity, and soy intolerance) are no longer recommended. The new terminology helps to distinguish these non-IgE-mediated disorders from classical food allergies/hypersensitivities that are mediated by IgE. It also distinguishes them from food intolerances that do not involve immunologic mechanisms (eg, lactose intolerance).&nbsp;&nbsp;</FONT> </div><div id=\"graphicVersion\">Graphic 56837 Version 10.0</div></div></div>"},"56838":{"type":"graphic_table","displayName":"Poisons amenable to forced diuresis","title":"Agents for which forced diuresis may enhance elimination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents for which forced diuresis may enhance elimination</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Barium</td> </tr> <tr> <td>Bromides</td> </tr> <tr> <td>Calcium&nbsp;</td> </tr> <tr> <td>Chromium</td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Cyclophosphamide</td> </tr> <tr> <td>Fluoride&nbsp;</td> </tr> <tr> <td>5-Fluorouracil</td> </tr> <tr> <td>Iodide</td> </tr> <tr> <td>Isoniazid&nbsp;</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Meprobamate</td> </tr> <tr> <td>Potassium</td> </tr> <tr> <td>Thallium</td> </tr> <tr> <td>Tritium</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56838 Version 2.0</div></div></div>"},"56839":{"type":"graphic_figure","displayName":"Grasping technique","title":"Grasping technique","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Grasping technique</div><div class=\"cntnt\"><img style=\"width:452px; height:244px;\" src=\"images/PULM/56839_Proper_grasping_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Firm and atraumatic grasping of a smooth and rounded foreign body with a foreign body forceps (A &amp; B). Traumatic and unsecured grasping with an alligator forceps (C &amp; D).</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 56839 Version 2.0</div></div></div>"},"56840":{"type":"graphic_picture","displayName":"Mycoplasma lung histopathology","title":"<em>Mycoplasma</em> pneumonia histopathology","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><em>Mycoplasma</em> pneumonia histopathology</div><div class=\"cntnt\"><img style=\"width:504px; height:361px;\" src=\"images/ID/56840_Mycoplasmlunghisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of a biopsy specimen shows severe inflammation of the mucosa and submucosal interstitium of a membranous bronchiole. An exudate of inflammatory cells is present in the airway lumen. The adjacent parenchyma shows only mild inflammation.</div><div class=\"graphic_reference\">Reproduced with permission from: Pulmonary infection. In: Diseases of the Lung: Radiologic and Pathologic Correlations, Müller NL, Fraser RS, Lee KS, Johkoh T (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56840 Version 9.0</div></div></div>"},"56841":{"type":"graphic_table","displayName":"Virology of the common cold","title":"Epidemiologic and clinical features of viruses that cause the common cold in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiologic and clinical features of viruses that cause the common cold in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Virus</td> <td class=\"subtitle1\">Proportion of cases</td> <td class=\"subtitle1\">Predominant months of circulation*</td> <td class=\"subtitle1\">Other clinical syndromes</td> </tr> <tr> <td>Rhinoviruses<br /> (more than 100 serotypes)</td> <td>30 to 50 percent</td> <td>Present year round with a peak in September and a smaller peak in March and April</td> <td>&nbsp;</td> </tr> <tr> <td>Respiratory syncytial virus</td> <td>5 percent</td> <td>November to March</td> <td>Bronchiolitis</td> </tr> <tr> <td>Influenza viruses</td> <td>5 to 15 percent</td> <td>Winter months, with peak in February</td> <td> <p>Influenza</p> <p>Croup</p> Pneumonia</td> </tr> <tr> <td>Parainfluenza viruses</td> <td>5 percent</td> <td>September to January with peak in October and November</td> <td>Croup</td> </tr> <tr> <td>Adenoviruses</td> <td>&#60;5 percent</td> <td>September to May</td> <td>Pharyngoconjunctival fever</td> </tr> <tr> <td>Enteroviruses<br /> (echoviruses and coxsackieviruses)</td> <td>&#60;5 percent</td> <td>Present year round, with a peak during the summer</td> <td> <p>Aseptic meningitis (nonpolio enteroviruses)</p> Herpangina (coxsackievirus type A)</td> </tr> <tr> <td>Coronaviruses</td> <td>10 to 15 percent</td> <td>November to February</td> <td> <p>Pneumonia</p> Croup</td> </tr> <tr> <td>Human metapneumovirus</td> <td>Unknown</td> <td>Late winter and early spring</td> <td> <p>Pneumonia</p> Bronchitis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In the northern hemisphere.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Heikkinen T, Järvinen A. The common cold. Lancet 2003; 361:51. </LI>&#xD;&#xA;<LI>Kirkpatrick GL. The common cold. Prim Care 1996; 23:657. </LI>&#xD;&#xA;<LI>Pappas DE, Hendley JO. The common cold. In: Principles and Practice of Pediatric Infectious Diseases, 3<SUP>rd</SUP> ed, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, Philadelphia 2008. p.203. </LI></OL></div><div id=\"graphicVersion\">Graphic 56841 Version 5.0</div></div></div>"},"56846":{"type":"graphic_picture","displayName":"Postinfectious GN IF","title":"Postinfectious glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postinfectious glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/56846_Postinfectious_GN_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy shows granular deposition of complement in the glomerular tuft in postinfectious glomerulonephritis. Immunoglobulin G (IgG) can also be seen in the same distribution.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 56846 Version 2.0</div></div></div>"},"56847":{"type":"graphic_table","displayName":"Birth weight percentiles by gestational age","title":"Birth weight percentiles by gestational age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Birth weight percentiles by gestational age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16.6%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Week of gestation</td> <td class=\"subtitle1\">5<sup>th</sup> percentile</td> <td class=\"subtitle1\">10<sup>th</sup> percentile</td> <td class=\"subtitle1\">50<sup>th</sup> percentile</td> <td class=\"subtitle1\">90<sup>th</sup> percentile</td> <td class=\"subtitle1\">95<sup>th</sup> percentile</td> </tr> <tr> <td class=\"centered\">24</td> <td class=\"centered\">539</td> <td class=\"centered\">567</td> <td class=\"centered\">680</td> <td class=\"centered\">850</td> <td class=\"centered\">988</td> </tr> <tr> <td class=\"centered\">25</td> <td class=\"centered\">540</td> <td class=\"centered\">584</td> <td class=\"centered\">765</td> <td class=\"centered\">938</td> <td class=\"centered\">997</td> </tr> <tr> <td class=\"centered\">26</td> <td class=\"centered\">580</td> <td class=\"centered\">637</td> <td class=\"centered\">872</td> <td class=\"centered\">1080</td> <td class=\"centered\">1180</td> </tr> <tr> <td class=\"centered\">27</td> <td class=\"centered\">650</td> <td class=\"centered\">719</td> <td class=\"centered\">997</td> <td class=\"centered\">1260</td> <td class=\"centered\">1467</td> </tr> <tr> <td class=\"centered\">28</td> <td class=\"centered\">740</td> <td class=\"centered\">822</td> <td class=\"centered\">1138</td> <td class=\"centered\">1462</td> <td class=\"centered\">1787</td> </tr> <tr> <td class=\"centered\">29</td> <td class=\"centered\">841</td> <td class=\"centered\">939</td> <td class=\"centered\">1290</td> <td class=\"centered\">1672</td> <td class=\"centered\">2070</td> </tr> <tr> <td class=\"centered\">30</td> <td class=\"centered\">952</td> <td class=\"centered\">1068</td> <td class=\"centered\">1455</td> <td class=\"centered\">1883</td> <td class=\"centered\">2294</td> </tr> <tr> <td class=\"centered\">31</td> <td class=\"centered\">1080</td> <td class=\"centered\">1214</td> <td class=\"centered\">1635</td> <td class=\"centered\">2101</td> <td class=\"centered\">2483</td> </tr> <tr> <td class=\"centered\">32</td> <td class=\"centered\">1232</td> <td class=\"centered\">1380</td> <td class=\"centered\">1833</td> <td class=\"centered\">2331</td> <td class=\"centered\">2664</td> </tr> <tr> <td class=\"centered\">33</td> <td class=\"centered\">1414</td> <td class=\"centered\">1573</td> <td class=\"centered\">2053</td> <td class=\"centered\">2579</td> <td class=\"centered\">2861</td> </tr> <tr> <td class=\"centered\">34</td> <td class=\"centered\">1632</td> <td class=\"centered\">1793</td> <td class=\"centered\">2296</td> <td class=\"centered\">2846</td> <td class=\"centered\">3093</td> </tr> <tr> <td class=\"centered\">35</td> <td class=\"centered\">1871</td> <td class=\"centered\">2030</td> <td class=\"centered\">2549</td> <td class=\"centered\">3119</td> <td class=\"centered\">3345</td> </tr> <tr> <td class=\"centered\">36</td> <td class=\"centered\">2117</td> <td class=\"centered\">2270</td> <td class=\"centered\">2797</td> <td class=\"centered\">3380</td> <td class=\"centered\">3594</td> </tr> <tr> <td class=\"centered\">37</td> <td class=\"centered\">2353</td> <td class=\"centered\">2500</td> <td class=\"centered\">3025</td> <td class=\"centered\">3612</td> <td class=\"centered\">3818</td> </tr> <tr> <td class=\"centered\">38</td> <td class=\"centered\">2564</td> <td class=\"centered\">2706</td> <td class=\"centered\">3219</td> <td class=\"centered\">3799</td> <td class=\"centered\">3995</td> </tr> <tr> <td class=\"centered\">39</td> <td class=\"centered\">2737</td> <td class=\"centered\">2877</td> <td class=\"centered\">3374</td> <td class=\"centered\">3941</td> <td class=\"centered\">4125</td> </tr> <tr> <td class=\"centered\">40</td> <td class=\"centered\">2863</td> <td class=\"centered\">3005</td> <td class=\"centered\">3499</td> <td class=\"centered\">4057</td> <td class=\"centered\">4232</td> </tr> <tr> <td class=\"centered\">41</td> <td class=\"centered\">2934</td> <td class=\"centered\">3082</td> <td class=\"centered\">3600</td> <td class=\"centered\">4167</td> <td class=\"centered\">4340</td> </tr> <tr> <td class=\"centered\">42</td> <td class=\"centered\">2941</td> <td class=\"centered\">3099</td> <td class=\"centered\">3686</td> <td class=\"centered\">4290</td> <td class=\"centered\">4474</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Table constructed using United States National Center for Health Statistics data from 2011 for live-born singleton neonates between 500 and 6000 grams without malformations. Gestational age was based on the obstetric estimate of gestational age included in the revised 2003 United States birth certificate, which, when available, incorporates ultrasound dating information.</div><div class=\"graphic_reference\">From: Duryea EL, Hawkins JS, McIntire DD, et al. A revised birth weight reference for the United States. Obstet Gynecol 2014; 124:16. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2014&amp;issue=07000&amp;article=00005&amp;type=abstract\" target=\"_blank\">10.1097/AOG.0000000000000345</a>. Copyright &copy; 2014 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 56847 Version 7.0</div></div></div>"},"56850":{"type":"graphic_figure","displayName":"Epidemiology of Campylobacter","title":"Incidence of Campylobacter enteritis in the United States, by age ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incidence of Campylobacter enteritis in the United States, by age </div><div class=\"cntnt\"><img style=\"width:388px; height:272px;\" src=\"images/ID/56850_Epidemiology_of_Campylobact.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reported campylobacter isolations by age and sex in the United States from 1982 to 1986. There is a high incidence in early childhood (with a peak in the first three months) and a pronounced secondary peak in young adults, a feature not seen with salmonella or shigella infection.</div><div class=\"graphic_reference\">Redrawn from Tauxe RV. Epidemiology of Campylobacter enteritis in the United States, American Society for Microbiology, Washington, DC, 1992, p. 9.</div><div id=\"graphicVersion\">Graphic 56850 Version 2.0</div></div></div>"},"56856":{"type":"graphic_table","displayName":"AIP signs and symptoms","title":"Acute intermittent porphyria incidence of signs and symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute intermittent porphyria incidence of signs and symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"75%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td>Abdominal pain</td> <td>85 to 95 percent</td> </tr> <tr> <td>Vomiting</td> <td>43 to 88 percent</td> </tr> <tr> <td>Constipation</td> <td>48 to 84 percent</td> </tr> <tr> <td>Muscle weakness</td> <td>42 to 60 percent</td> </tr> <tr> <td>Psychiatric symptoms</td> <td>40 to 58 percent</td> </tr> <tr> <td>Limb, head, neck, or chest pain</td> <td>50 to 52 percent</td> </tr> <tr> <td>Hypertension</td> <td>36 to 54 percent</td> </tr> <tr> <td>Tachycardia</td> <td>28 to 80 percent</td> </tr> <tr> <td>Convulsion</td> <td>10 to 20 percent</td> </tr> <tr> <td>Sensory loss</td> <td>9 to 38 percent</td> </tr> <tr> <td>Fever</td> <td>9 to 37 percent</td> </tr> <tr> <td>Respiratory paralysis</td> <td>9 to 14 percent</td> </tr> <tr> <td>Diarrhea</td> <td>5 to 12 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine</EM>, Anderson KE, Bloomer JR, Bonkovsky HL, et al, Recommendations for the diagnosis and treatment of the acute porphyrias, Vol 142, Pg 439. Copyright © 2005 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 56856 Version 9.0</div></div></div>"},"56857":{"type":"graphic_waveform","displayName":"Mechanism of torsades de pointes","title":"Mechanism of torsades de pointes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanism of torsades de pointes</div><div class=\"cntnt\"><img style=\"width:412px; height:360px;\" src=\"images/CARD/56857_Mech_torsades_de_pointes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top panels A-F are examples of epicardial isochrone maps obtained from the surface of the anterior left ventricular (LV) wall and free wall of the right ventricle (RV) during an episode of quinidine-induced torsades de pointes. Each map corresponds to a QRS deflection of the surface ECG and simultaneous monophasic action potential (MAP). Early afterpotentials (EADs) result in triggered activity (panels A-C) which is followed by a long episode of spiral-like reentry (panels D-F). Panel C shows the first reentrant wave which is not stationary, but gradually shifts upward and to the right. This is associated with a gradual decrease in the QRS complex amplitude.</div><div class=\"graphic_reference\">Reprinted with permission from the American College of Cardiology. Journal of the American College of Cardiology, 1997; 29:831.</div><div id=\"graphicVersion\">Graphic 56857 Version 3.0</div></div></div>"},"56858":{"type":"graphic_diagnosticimage","displayName":"Radiograph of hip prosthesis aseptic loosening","title":"Radiograph of hip prosthesis aseptic loosening","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Radiograph of hip prosthesis aseptic loosening</div><div class=\"cntnt\"><img style=\"width:504px; height:412px;\" src=\"images/RADIOL/56858_Aseptic_pros_loose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aseptic loosening of hip prosthesis. Frontal radiograph of the pelvis shows radiolucent areas greater than 2 mm in width (arrows) surrounding the proximal shaft of the left femoral prosthesis, consistent with loosening.</div><div class=\"graphic_reference\">Courtesy of Cecilia M Jude, MD, and Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 56858 Version 3.0</div></div></div>"},"56860":{"type":"graphic_picture","displayName":"Scoliosis PI","title":"Scoliosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scoliosis</div><div class=\"cntnt\"><img style=\"width:266px; height:406px;\" src=\"images/PI/56860_ScoliosisPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Signs of scoliosis include 1 shoulder that is higher than the other, a shoulder blade that sticks out, and a skin fold or crease at the waist.</div><div class=\"graphic_reference\">Courtesy of Dr. Susan Scherl.</div><div id=\"graphicVersion\">Graphic 56860 Version 1.0</div></div></div>"},"56862":{"type":"graphic_picture","displayName":"Scabies infant foot 2","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:432px; height:321px;\" src=\"images/DERM/56862_Scabies_infant_foot_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous and hyperpigmented papules and crusts on the foot of&nbsp;a child with scabies.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56862 Version 7.0</div></div></div>"},"56863":{"type":"graphic_algorithm","displayName":"Quick start method","title":"Quick-start (same-day start) approach to initiation of new birth control method: Pill, patch, ring, DMPA injection, implant","html":"<div class=\"graphic\"><div style=\"width: 686px\" class=\"figure\"><div class=\"ttl\">Quick-start (same-day start) approach to initiation of new birth control method: Pill, patch, ring, DMPA injection, implant</div><div class=\"cntnt\"><img style=\"width:666px; height:680px;\" src=\"images/PEDS/56863_Quick_start_method.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DMPA: depot medroxyprogesterone acetate; LMP: last menstrual period.<br />* Refer to UpToDate content on early pregnancy and pregnancy termination.<br />&para; Patient should use a barrier back-up method such as condoms for the first week after starting a new method.<br />&Delta; Unprotected sex includes episodes of sex in which a method of contraception was used but may not have been effective (eg, breakage of condom, multiple skipped pills).<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate content on emergency contraception.<br />&sect; For women using ulipristal for emergency contraception, progestin-containing contraception (ie, the pill, patch, ring, injection, and implant) should not be used for 5 days following ulipristal. For women taking levonorgestrel or combined estrogen-progestin emergency contraception, the new contraceptive method can be started after the emergency contraception<sup>&loz;</sup>.<br />&yen; If the patient would like the contraceptive implant, some providers prefer to offer a single injection of DMPA today and ask the patient to return for the implant within 5 days of the first day of her next menstrual period (to avoid the need for implant removal if the repeat urine pregnancy test is positive).</div><div class=\"graphic_reference\">Modified from: RHEDI/The Center for Reproductive Health Education In Family Medicine, Montefiore Medical Center, New York City. Available at: <A href=\"http://www.rhedi.org/clinicians.php\">http://www.rhedi.org/clinicians.php</A>. Accessed on July 7, 2016. </div><div id=\"graphicVersion\">Graphic 56863 Version 7.0</div></div></div>"},"56864":{"type":"graphic_figure","displayName":"Lifestyle and survival","title":"Lifestyle factors and survival","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Lifestyle factors and survival</div><div class=\"cntnt\"><img style=\"width:514px; height:213px;\" src=\"images/CARD/56864_Lifestyle_and_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Additional years of life according to age associated with adoption or maintenance of a favorable physical-activity (&#8805;4.5 metabolic equivalents, or METS) level and other characteristics between 1962 or 1966 and 1977, as estimated from mortality rates among 10,269 male Harvard alumni from 1977 through 1985. Prolongation of life was greater in younger men and with cessation of smoking, alone or particularly with exercise. The effect of each individual factor was adjusted for differences in other factors.</div><div class=\"graphic_footnotes\">HTN: hypertension.</div><div class=\"graphic_reference\">Data from Paffenberger RS Jr, Hyde RT, Wing AL, et al. N Engl J Med 1993; 328:538.</div><div id=\"graphicVersion\">Graphic 56864 Version 2.0</div></div></div>"},"56865":{"type":"graphic_table","displayName":"Etiologies of painful ejaculation","title":"Etiologies of painful ejaculation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of painful ejaculation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inflammation</td> </tr> <tr> <td>Urethritis</td> </tr> <tr> <td>Prostatitis</td> </tr> <tr> <td>Epididymitis</td> </tr> <tr> <td>Orchitis</td> </tr> <tr> <td>Abdominal abscess</td> </tr> <tr> <td>Penile prosthesis</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr> <td>Bladder cancer</td> </tr> <tr> <td>Intraabdominal tumors</td> </tr> <tr> <td>Prostate cancer</td> </tr> <tr> <td class=\"subtitle1_single\">Benign</td> </tr> <tr> <td>Inguinal hernia</td> </tr> <tr> <td>Vesical calculi</td> </tr> <tr> <td>Benign prostatic hyperplasia</td> </tr> <tr> <td>Urethral stricture</td> </tr> <tr> <td>Pelvic musculature spasm</td> </tr> <tr> <td class=\"subtitle1_single\">Surgical</td> </tr> <tr> <td>Radical prostatectomy</td> </tr> <tr> <td>Transurethral resection of the prostate (TURP)</td> </tr> <tr> <td>Vasectomy</td> </tr> <tr> <td>Hernia repair</td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td>Tricyclic antidepressants</td> </tr> <tr> <td>Selective serotonin reuptake inhibitors (SSRIs)</td> </tr> <tr> <td>Monoaminoxidase inhibitors (MAOIs)</td> </tr> <tr> <td>Antipsychotics</td> </tr> <tr> <td class=\"subtitle1_single\">Psychogenic</td> </tr> <tr> <td>Psychiatric</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56865 Version 6.0</div></div></div>"},"56866":{"type":"graphic_algorithm","displayName":"Assessing the risk of postoperative pulmonary complications","title":"Assessing the risk of postoperative pulmonary complications","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Assessing the risk of postoperative pulmonary complications</div><div class=\"cntnt\"><img style=\"width:492px; height:630px;\" src=\"images/PC/56866_Risk_postop_pulm_complicati.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ASA: American Society of Anesthesiologists; PFTs: pulmonary function tests; COPD: chronic obstructive pulmonary disease.</div><div id=\"graphicVersion\">Graphic 56866 Version 3.0</div></div></div>"},"56871":{"type":"graphic_picture","displayName":"Manual neck distraction test","title":"Manual neck distraction test for cervical radiculopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manual neck distraction test for cervical radiculopathy</div><div class=\"cntnt\"><img style=\"width:336px; height:504px;\" src=\"images/PC/56871_Manual_Neck_Tract_Test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The head and neck are placed in the neutral position. With the examiners hands firmly grasping the angle of the jaw and the base of the skull, traction is applied in the upward vertical direction. A positive result is a diminution of the patient's radicular symptoms.</div><div class=\"graphic_reference\">Photo courtesy of Bruce Anderson, MD.</div><div id=\"graphicVersion\">Graphic 56871 Version 3.0</div></div></div>"},"56872":{"type":"graphic_table","displayName":"IC BPS clinical presentation","title":"Clinical symptoms at the diagnosis of interstitial cystitis/bladder pain syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical symptoms at the diagnosis of interstitial cystitis/bladder pain syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Patients (percent)</td> </tr> <tr> <td>Urinary urgency</td> <td class=\"centered\">57 to 98</td> </tr> <tr> <td>Daytime frequency</td> <td class=\"centered\">84 to 97</td> </tr> <tr> <td>Pain</td> <td class=\"centered\">66 to 94</td> </tr> <tr> <td>Nocturia</td> <td class=\"centered\">44 to 90</td> </tr> <tr> <td>Pain with voiding/dysuria</td> <td class=\"centered\">71 to 98</td> </tr> <tr> <td>Suprapubic pain</td> <td class=\"centered\">39 to 71</td> </tr> <tr> <td>Perineal pain</td> <td class=\"centered\">25 to 56</td> </tr> <tr> <td>Patient sensation of bladder spasms</td> <td class=\"centered\">50 to 74</td> </tr> <tr> <td>Pubic pressure</td> <td class=\"centered\">60 to 71</td> </tr> <tr> <td>Dyspareunia</td> <td class=\"centered\">46 to 80</td> </tr> <tr> <td>Depression</td> <td class=\"centered\">55 to 67</td> </tr> <tr> <td>Gross hematuria</td> <td class=\"centered\">14 to 33</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Teichman JM, Parsons CL. Contemporary clinical presentation of interstitial cystitis. Urology 2007; 69:41. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 56872 Version 2.0</div></div></div>"},"56873":{"type":"graphic_picture","displayName":"Erythema multiforme path","title":"Skin biopsy in erythema multiforme - H&E","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin biopsy in erythema multiforme - H&amp;E</div><div class=\"cntnt\"><img style=\"width:396px; height:320px;\" src=\"images/DERM/56873_Erythema_multiforme_path.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidermal cell apoptosis, basal cell vacuolar degeneration, lymphocytic exocytosis, and a dermal lymphocytic infiltrate are present.</div><div class=\"graphic_reference\">Reproduced with permission from: Mills, SE. Histology For Pathologists, Third Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &#169; 2007. Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56873 Version 1.0</div></div></div>"},"56874":{"type":"graphic_diagnosticimage","displayName":"Supracondylar fracture line","title":"Supracondylar fracture line","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Supracondylar fracture line</div><div class=\"cntnt\"><img style=\"width:413px; height:252px;\" src=\"images/EM/56874_Supracondylar_fx_line.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Orientation of fracture lines. A) The typical transverse fracture line originates just above the epicondyles and courses through the supracondylar area (arrows). B) In the lateral projection, the fracture line is usually also transverse.</div><div class=\"graphic_reference\">Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56874 Version 11.0</div></div></div>"},"56876":{"type":"graphic_table","displayName":"Options for diabetes treatment","title":"Summary of glucose-lowering interventions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of glucose-lowering interventions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Expected decrease in A1C with monotherapy (%)</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Step 1: Initial therapy</td> </tr> <tr> <td class=\"indent1\">Lifestyle change to decrease weight and increase activity</td> <td>1.0 to 2.0</td> <td>Broad benefits</td> <td>Insufficient for most within first year owing to inadequate weight loss and weight regain</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Metformin (usually 1700 to 2000 mg per day)</td> <td>1.0 to 2.0</td> <td>Weight neutral</td> <td>GI side effects, contraindicated with renal insufficiency (eGFR &#60;30 mL/min)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Step 2: Additional therapy</td> </tr> <tr> <td class=\"indent1\">Insulin (usually with a single daily injection of intermediate- or long-acting insulin initially)</td> <td>1.5 to 3.5</td> <td>No dose limit, rapidly effective, improved lipid profile</td> <td>One to four injections daily, monitoring, weight gain, hypoglycemia, analogues are expensive</td> </tr> <tr> <td class=\"indent1\">Sulfonylurea (shorter-acting agents preferred)</td> <td>1.0 to 2.0</td> <td>Rapidly effective</td> <td>Weight gain, hypoglycemia (especially with glibenclamide or chlorpropamide)</td> </tr> <tr> <td class=\"indent1\">GLP-1 agonist (daily to weekly injections)</td> <td>0.5 to 1.0</td> <td>Weight loss, reduced cardiovascular mortality (liraglutide, semaglutide) in patients with established CVD</td> <td>Requires injection, frequent GI side effects, long-term safety not established, expensive</td> </tr> <tr> <td class=\"indent1\">Thiazolidinedione</td> <td>0.5 to 1.4</td> <td>Improved lipid profile (pioglitazone), potential decrease in MI (pioglitazone)</td> <td>Fluid retention, HF, weight gain, bone fractures, potential increase in MI (rosiglitazone) and bladder cancer (pioglitazone)</td> </tr> <tr> <td class=\"indent1\">Glinide</td> <td>0.5 to 1.5<sup>&#182;</sup></td> <td>Rapidly effective</td> <td>Weight gain, three times/day dosing, hypoglycemia</td> </tr> <tr> <td class=\"indent1\">SGLT2 inhibitor</td> <td>0.5 to 0.7</td> <td>Weight loss, reduction in systolic blood pressure, reduced cardiovascular mortality in patients with established CVD</td> <td>Vulvovaginal candidiasis, urinary tract infections, bone fractures, lower limb amputations, acute kidney injury, DKA, long-term safety not established</td> </tr> <tr> <td class=\"indent1\">DPP-4 inhibitor</td> <td>0.5 to 0.8</td> <td>Weight neutral</td> <td>Long-term safety not established, expensive, possible increased risk of HF with saxagliptin</td> </tr> <tr> <td class=\"indent1\">Alpha-glucosidase inhibitor</td> <td>0.5 to 0.8</td> <td>Weight neutral</td> <td>Frequent GI side effects, three times/day dosing</td> </tr> <tr> <td class=\"indent1\">Pramlintide</td> <td>0.5 to 1.0</td> <td>Weight loss</td> <td>Three injections daily, frequent GI side effects, long-term safety not established, expensive</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">A1C: glycated hemoglobin; GI: gastrointestinal; eGFR: estimated glomerular filtration rate; GLP-1: glucagon-like protein-1; CVD: cardiovascular disease; MI: myocardial infarction; HF: heart failure; SGLT2: sodium-glucose co-transporter 2; DKA: diabetic ketoacidosis; DPP-4: dipeptidyl peptidase-4.<br />* Initiation is contraindicated with eGFR &lt;30 mL/min and not recommended with eGFR 30 to 45 mL/min.<br />&para; Repaglinide is more effective in lowering A1C than nateglinide.</div><div class=\"graphic_reference\">Modified with permission from: Nathan DM, Buse JB, Davidson MB, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203. Copyright &copy; 2009 American Diabetes.</div><div id=\"graphicVersion\">Graphic 56876 Version 10.0</div></div></div>"},"56878":{"type":"graphic_picture","displayName":"Skin biopsy adult Stills","title":"Skin biospy from adult onset Still's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin biospy from adult onset Still's disease</div><div class=\"cntnt\"><img style=\"width:368px; height:246px;\" src=\"images/RHEUM/56878_Skin_biopsy_adult_Stills.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This skin biopsy demonstrates some mild perivascular inflammation and dermal edema in an area of skin involved with the rash of adult Still's disease.</div><div class=\"graphic_reference\">Courtesy of Lisa Mandl, MD.</div><div id=\"graphicVersion\">Graphic 56878 Version 1.0</div></div></div>"},"56879":{"type":"graphic_picture","displayName":"Dermatomyositis - heliotrope eruption","title":"Heliotrope eruption in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heliotrope eruption in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/56879_Derm_heliotrope_erupt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous erythema is present on the periorbital skin in this patient with dermatomyositis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56879 Version 4.0</div></div></div>"},"56880":{"type":"graphic_picture","displayName":"Botulinum toxin - platysmal bands","title":"Botulinum toxin injection for platysmal bands","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Botulinum toxin injection for platysmal bands</div><div class=\"cntnt\"><img style=\"width:511px; height:236px;\" src=\"images/DERM/56880_Botulin_toxin_platys_bands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These platysmal bands on the neck (A) were much less evident after treatment wtih botulinum toxin (B).</div><div id=\"graphicVersion\">Graphic 56880 Version 1.0</div></div></div>"},"56881":{"type":"graphic_figure","displayName":"Laparoscopic cholecystectomy in pregnant women","title":"Laparoscopic cholecystectomy in pregnant women","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic cholecystectomy in pregnant women</div><div class=\"cntnt\"><img style=\"width:372px; height:518px;\" src=\"images/SURG/56881_Lap_chole_pregnancy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Entry into the peritoneal cavity can be gained through the left upper quadrant or via a supraumbilical port (shown in red in the figure).<br> <ul> <li>For left upper quadrant access, a Veress needle is inserted. Gastric decompression with an orogastric tube prior to needle insertion minimizes the risk of gastric perforation. The needle should be angled approximately 15 degrees caudad to minimize the risk of splenic injury. </li> <li>Placement of a supraumbilical port 6 cm above the fundus with a Hasson technique is another entry method that reduces the risk of organ perforation. </li> </ul> Additional ports required for performing laparoscopic cholecystectomy include two 5 mm ports in the right upper quadrant and an 11 mm port in the epigastrium (shown in black in the figure).</div><div id=\"graphicVersion\">Graphic 56881 Version 5.0</div></div></div>"},"56882":{"type":"graphic_figure","displayName":"High altitude PI","title":"High altitude categories","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">High altitude categories</div><div class=\"cntnt\"><img style=\"width:541px; height:676px;\" src=\"images/PI/56882_High-altitude-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Doctors rank different altitudes as high, very high, or extreme based on the effects those altitudes have on the body. This graphic shows what can happen if you travel or climb to these altitudes.</div><div id=\"graphicVersion\">Graphic 56882 Version 3.0</div></div></div>"},"56883":{"type":"graphic_figure","displayName":"Colonizing flora head and neck","title":"Diagrammatic illustration of the anatomic relationship of head and neck structures and distribution of the indigenous microflora","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagrammatic illustration of the anatomic relationship of head and neck structures and distribution of the indigenous microflora</div><div class=\"cntnt\"><img style=\"width:388px; height:510px;\" src=\"images/ID/56883_Colonizing_flora_head_and_n.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Roscoe, DL, Chow, AW. Normal flora and mucosal immunity of the head and neck. In: Infectious Syndromes of the Head and Neck, Infect Dis Clin N Am, Vol. 2, Chow, AW, Moellering, RC (Eds), WB Saunders, Philadelphia 1988. p. 5. Copyright &#169; 1988 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 56883 Version 1.0</div></div></div>"},"56884":{"type":"graphic_figure","displayName":"CCr v KtV by transporter type","title":"Graphs showing weekly creatinine clearance and Kt/V among CAPD patients according to transporter type","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Graphs showing weekly creatinine clearance and Kt/V among CAPD patients according to transporter type</div><div class=\"cntnt\"><img style=\"width:533px; height:270px;\" src=\"images/NEPH/56884_Ccr_v_KtV_by_transporter_ty.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Weekly CCr and Kt/V among CAPD patients according to transporter type (L, LA, HA, and H are low, low-average, high-average, high transporters, respectively). The weekly Kt/V is relatively independent of transporter type, while the weekly CCr increases progressively from low to high transporters.</div><div class=\"graphic_footnotes\">CCr: creatinine clearance; CAPD: chronic ambulatory peritoneal dialysis.</div><div class=\"graphic_reference\">Data from Vonesh EF, Moran J. Discrepancies between urea Kt/V versus normalized creatinine clearance.&nbsp;Perit Dial Int 1997; 17:13.</div><div id=\"graphicVersion\">Graphic 56884 Version 4.0</div></div></div>"},"56885":{"type":"graphic_table","displayName":"Degree blood loss and symptoms","title":"Symptoms related to blood loss with postpartum hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms related to blood loss with postpartum hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Blood loss, %(mL) </td> <td class=\"subtitle1\">Blood pressure, mmHg </td> <td class=\"subtitle1\">Signs and symptoms </td> </tr> <tr> <td>10 to 15 (500 to 1000)</td> <td>Normal</td> <td>Palpitations, lightheadedness, mild increase in heart rate</td> </tr> <tr> <td>15 to 25 (1000 to 1500)</td> <td>Slightly low</td> <td>Weakness, sweating, tachycardia (100 to 120 beats/minute)</td> </tr> <tr> <td>25 to 35 (1500 to 2000)</td> <td>70 to 80</td> <td>Restlessness, confusion, pallor, oliguria, tachycardia (120 to 140&nbsp;beats/minute)</td> </tr> <tr> <td>35 to 45 (2000 to 3000)</td> <td>50 to 70</td> <td>Lethargy, air hunger, anuria, collapse, tachycardia (&#62;140 beats/minute)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Bonnar J. Massive obstetric haemorrhage. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:1.</div><div id=\"graphicVersion\">Graphic 56885 Version 4.0</div></div></div>"},"56886":{"type":"graphic_table","displayName":"Local failure STS postsurgery","title":"Local failure rate in patients with soft tissue sarcoma of the extremities treated by planned wide resection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Local failure rate in patients with soft tissue sarcoma of the extremities treated by planned wide resection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Center</td> <td class=\"subtitle1\">Number</td> <td class=\"subtitle1\">Percent</td> </tr> <tr> <td>Memorial Hospital<sup>[1]</sup></td> <td>70</td> <td>23</td> </tr> <tr> <td>University of Florida<sup>[2]</sup></td> <td>40</td> <td>15</td> </tr> <tr> <td>Swedish Sarcoma Group<sup>[3]</sup></td> <td>103</td> <td>8</td> </tr> <tr> <td>Brigham &#38; Women's Hospital<sup>[4]</sup></td> <td>24</td> <td>25</td> </tr> <tr> <td>Netherlands Cancer Institute<sup>[5]</sup></td> <td>26</td> <td>19</td> </tr> <tr> <td>Milan<sup>[6]</sup></td> <td>417</td> <td>31</td> </tr> <tr> <td>National Cancer Institute<sup>[7]</sup></td> <td>83</td> <td>0 (amputation)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16:197.</LI>&#xD;&#xA;<LI>Enneking WF, Spanier SS, Malawer MM. The effect of the Anatomic setting on the results of surgical procedures for soft parts sarcoma of the thigh. Cancer 1981; 47:1005.</LI>&#xD;&#xA;<LI>Alvegard TA, Sigurdsson H, Mouridsen H, et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol 1989; 7:1504.</LI>&#xD;&#xA;<LI>Singer S, Corson JM, Gonin R, et al. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 1994; 219:165.</LI>&#xD;&#xA;<LI>Keus RB, Rutgers EJ, Ho GH,&nbsp;et al. Limb-sparing therapy of extremity soft tissue sarcomas: treatment outcome and long-term functional results. Eur J Cancer 1994; 30A:1459.</LI>&#xD;&#xA;<LI>Azzarelli A. Surgery in soft tissue sarcomas. Eur J Cancer 1993; 29A:618.</LI>&#xD;&#xA;<LI>Potter DA, Kinsella T, Glatstein E, et al. High-grade soft tissue sarcomas of the extremities. Cancer 1986; 58:190.</LI></OL></div><div id=\"graphicVersion\">Graphic 56886 Version 3.0</div></div></div>"},"56887":{"type":"graphic_table","displayName":"Causes of horizontal diplopia","title":"Causes of acquired binocular horizontal diplopia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acquired binocular horizontal diplopia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Causes of esotropia</td> </tr> <tr> <td class=\"indent1\">Childhood strabismus syndromes (see Table 2)</td> </tr> <tr> <td class=\"indent1\">Change of angle of preexisting childhood strabismus or loss of suppression scotoma</td> </tr> <tr> <td class=\"indent1\">Decompensation of a long-standing esophoria</td> </tr> <tr> <td class=\"indent1\">Consecutive esotropia (after strabismus surgery)</td> </tr> <tr> <td class=\"indent1\">Optical (eg, optical center change in glasses, overminus in accommodative esophoria)</td> </tr> <tr> <td class=\"indent1\">Sensory esotropia (usually not associated with diplopia)</td> </tr> <tr> <td class=\"sublist2_start\">Disorders of muscle and restrictive syndromes</td> </tr> <tr> <td class=\"sublist2\">Orbital myositis (orbital pseudotumor)</td> </tr> <tr> <td class=\"sublist2\">Thyroid eye disease</td> </tr> <tr> <td class=\"sublist2\">Myasthenia gravis</td> </tr> <tr> <td class=\"sublist2\">Medial orbital wall fracture</td> </tr> <tr> <td class=\"sublist2\">Postsurgical esotropia</td> </tr> <tr> <td class=\"sublist2\">Isolated weakness of lateral rectus muscle</td> </tr> <tr> <td class=\"sublist2\">Muscle trauma</td> </tr> <tr> <td class=\"sublist2\">Progressive external ophthalmoplegia syndromes</td> </tr> <tr> <td class=\"sublist2\">Other orbital disease processes</td> </tr> <tr> <td class=\"sublist2_start\">Disorders of cranial nerves</td> </tr> <tr> <td class=\"sublist2\">Sixth nerve palsy</td> </tr> <tr> <td class=\"sublist2\">Ocular neuromyotonia</td> </tr> <tr> <td class=\"sublist2_start\">Central disorders</td> </tr> <tr> <td class=\"sublist2\">Cyclic esotropia</td> </tr> <tr> <td class=\"sublist2\">Periodic alternating esotropia</td> </tr> <tr> <td class=\"sublist2\">Divergence insufficiency or paralysis</td> </tr> <tr> <td class=\"sublist2\">Acute acquired comitant esotropia</td> </tr> <tr> <td class=\"sublist2\">Spasm of the near reflex</td> </tr> <tr> <td class=\"sublist2\">Midbrain pseudo-sixth nerve palsy</td> </tr> <tr> <td class=\"sublist2\">Thalamic esotropia</td> </tr> <tr> <td class=\"sublist2\">Acquired motor fusion deficiency</td> </tr> <tr> <td class=\"sublist2\">Hemifield slide phenomena</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Causes of exotropia</td> </tr> <tr> <td class=\"indent1\">Childhood strabismus syndromes (see Table 2)</td> </tr> <tr> <td class=\"indent1\">Change of angle of preexisting childhood strabismus or loss of suppression scotoma</td> </tr> <tr> <td class=\"indent1\">Decompensation of a long-standing exophoria</td> </tr> <tr> <td class=\"indent1\">Consecutive exotropia (after strabismus surgery)</td> </tr> <tr> <td class=\"indent1\">Optical factors</td> </tr> <tr> <td class=\"indent1\">Sensory exotropia (usually not associated with diplopia)</td> </tr> <tr> <td class=\"sublist2_start\">Disorders of the muscle</td> </tr> <tr> <td class=\"sublist2\">Orbital myositis (orbital pseudotumor)</td> </tr> <tr> <td class=\"sublist2\">Thyroid eye disease (uncommon)</td> </tr> <tr> <td class=\"sublist2\">Myasthenia gravis</td> </tr> <tr> <td class=\"sublist2\">Medial orbital wall fracture</td> </tr> <tr> <td class=\"sublist2\">Postsurgical exotropia</td> </tr> <tr> <td class=\"sublist2\">Isolated weakness of medial rectus muscle</td> </tr> <tr> <td class=\"sublist2\">Muscle trauma</td> </tr> <tr> <td class=\"sublist2\">Progressive external ophthalmoplegia syndromes</td> </tr> <tr> <td class=\"sublist2\">Other orbital disease processes</td> </tr> <tr> <td class=\"sublist2_start\">Disorders of cranial nerves</td> </tr> <tr> <td class=\"sublist2\">Third nerve palsy</td> </tr> <tr> <td class=\"sublist2\">Ocular neuromyotonia</td> </tr> <tr> <td class=\"sublist2_start\">Central disorders</td> </tr> <tr> <td class=\"sublist2\">Acquired motor fusion deficiency</td> </tr> <tr> <td class=\"sublist2\">Internuclear ophthalmoplegia (INO) (wall-eyed monocular INO syndrome and wall-eyed bilateral INO syndrome) and the one-and-a-half syndrome (paralytic Pontine exotropia)</td> </tr> <tr> <td class=\"sublist2\">Vitamin E deficiency (eg, abetalipoproteinemia)</td> </tr> <tr> <td class=\"sublist2\">Convergence insufficiency and paralysis</td> </tr> <tr> <td class=\"sublist2\">Hemifield slide phenomena</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Brazis PW, Lee AG. Acquired binocular horizontal diplopia. Mayo Clin Proc 1999; 74:907. Copyright &copy; 1999 Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 56887 Version 3.0</div></div></div>"},"56889":{"type":"graphic_diagnosticimage","displayName":"Middle phalanx fracture of proximal volar plate","title":"Middle phalanx fracture of proximal volar plate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Middle phalanx fracture of proximal volar plate</div><div class=\"cntnt\"><img style=\"width:198px; height:432px;\" src=\"images/EM/56889_Mid_phal_fx_volarplate1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraarticular fractures are commonly associated with soft tissue injuries, such as the volar plate injury depicted here.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 56889 Version 4.0</div></div></div>"},"56890":{"type":"graphic_table","displayName":"Durie Salmon staging system","title":"Durie-Salmon staging system for multiple myeloma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Durie-Salmon staging system for multiple myeloma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Stage I</td> </tr> <tr> <td>Low cell mass: &#60;0.6 x 10<sup>12</sup> cells/m<sup>2</sup>&nbsp;<strong>PLUS</strong> all of the following:</td> </tr> <tr> <td>Hgb &#62;10 g/dL</td> </tr> <tr> <td>Serum IgG &#60;5 g/dL</td> </tr> <tr> <td>Serum IgA &#60;3 g/dL</td> </tr> <tr> <td>Normal serum calcium</td> </tr> <tr> <td>Urine monoclonal protein excretion &#60;4 g/day </td> </tr> <tr> <td>No generalized lytic bone lesions</td> </tr> <tr> <td class=\"subtitle1_single\">Stage II</td> </tr> <tr> </tr> <tr> <td>Intermediate cell mass: neither stage I nor stage III</td> </tr> <tr> <td class=\"subtitle1_single\">Stage III</td> </tr> <tr> </tr> <tr> <td>High cell mass: &#62;1.2 x 10<sup>12</sup> cells/m<sup>2</sup> <strong>PLUS</strong> one of more of the following:</td> </tr> <tr> <td>Hgb &#60;8.5 g/dL</td> </tr> <tr> <td>Serum IgG &#62;7 g/dL</td> </tr> <tr> <td>Serum IgA &#62;5 g/dL</td> </tr> <tr> <td>Serum calcium &#62;12 mg/dL (3 &mu;mol/L)</td> </tr> <tr> <td>Urine monoclonal protein excretion &#62;12 g/day</td> </tr> <tr> <td>Advanced lytic bone lesions</td> </tr> <tr> <td class=\"subtitle1_single\">Stage III is subclassified&nbsp;as IIIA&nbsp;or IIIB based on serum creatinine</td> </tr> <tr> <td>A. Serum creatinine &#60;2 mg/dL (177 &mu;mol/L)</td> </tr> <tr> <td>B. Serum creatinine &#8805;2 mg/dL</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hgb: hemoglobin; IgG: immunoglobulin G; IgA: immunoglobulin A</div><div id=\"graphicVersion\">Graphic 56890 Version 3.0</div></div></div>"},"56891":{"type":"graphic_figure","displayName":"Iatrogenic distal impaction","title":"Potential complications of foreign body extraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Potential complications of foreign body extraction</div><div class=\"cntnt\"><img style=\"width:311px; height:294px;\" src=\"images/PULM/56891_Iatrogenic_distal_impaction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Accidental wedging of the foreign body into a distal position.</div><div id=\"graphicVersion\">Graphic 56891 Version 1.0</div></div></div>"},"56894":{"type":"graphic_figure","displayName":"Muscle compartments of the thigh","title":"Muscle compartments of the thigh","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Muscle compartments of the thigh</div><div class=\"cntnt\"><img style=\"width:521px; height:575px;\" src=\"images/SURG/56894_Right-thigh-compartments-mid-thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thigh has three muscle compartments: <ul> <li>Anterior compartment (pink) &#8212; Sartorius and quadriceps muscles (rectus femoris, vastus lateralis, vastus intermedius, vastus medialis). The femoral nerve and superficial femoral artery supply these muscles. </li> <li>Medial compartment (green) &#8212; Pectineus, obturator externus, gracilis and adductor muscles (longus, brevis, magnus, minimus). The obturator nerve innervates the medial compartment. </li> <li>Posterior compartment (blue) &#8212; Biceps femoris, semimembranous and semitendinous muscles. The sciatic nerve innervates the posterior compartment. The deep femoral artery supplies the posterior compartment. </li> </ul></div><div id=\"graphicVersion\">Graphic 56894 Version 3.0</div></div></div>"},"56895":{"type":"graphic_figure","displayName":"Principles of Doppler sonography","title":"Principles of Doppler sonography","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Principles of Doppler sonography</div><div class=\"cntnt\"><img style=\"width:504px; height:409px;\" src=\"images/OBGYN/56895_Principles_Dopp_sono_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dev Maulik, MD, PhD.</div><div id=\"graphicVersion\">Graphic 56895 Version 3.0</div></div></div>"},"56896":{"type":"graphic_figure","displayName":"Thoracic lymph nodes - Anterior view","title":"Thoracic lymph nodes - Anterior view","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Thoracic lymph nodes - Anterior view</div><div class=\"cntnt\"><img style=\"width:474px; height:528px;\" src=\"images/SURG/56896_Thoracic-lymph-nodes-anterior-view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the location of the mediastinal nodes viewed anteriorly, in relationship to the heart, great vessels, and lungs.</div><div id=\"graphicVersion\">Graphic 56896 Version 1.0</div></div></div>"},"56897":{"type":"graphic_diagnosticimage","displayName":"Pheochromocytoma MRI","title":"Pheochromocytoma in the adrenal gland","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Pheochromocytoma in the adrenal gland</div><div class=\"cntnt\"><img style=\"width:554px; height:298px;\" src=\"images/ENDO/56897_Pheochromocytoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI findings in adrenal pheochromocytomas.<br />(A) Sagittal MRI demonstrates a mass (arrow) displacing the inferior vena cava anteriorly (arrowhead). This caval displacement is typically seen with tumors arising in the adrenal gland.<br />(B) Coronal MRI of the abdomen demonstrates a large mass in the right adrenal bed (arrow), lying immediately superior to the kidney. The low signal intensity in the center is caused by hemorrhage into the tumor.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 56897 Version 4.0</div></div></div>"},"56898":{"type":"graphic_picture","displayName":"Babesia microti thin smear","title":"<EM>Babesia microti </EM>parasites in red blood cells","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Babesia microti </EM>parasites in red blood cells</div><div class=\"cntnt\"><img style=\"width:504px; height:475px;\" src=\"images/ID/56898_Babesiamicrotithinsmear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) <EM>Babesia microti</EM><SUP>[1]</SUP>&nbsp;— This thin peripheral blood smear (Giemsa stain; x1000) shows <EM>B. microti</EM>. Several erythrocytes contain multiple parasites, including a diagnostic tetrad form (arrow). (B) Malaria (for comparison)<SUP innerHtml>[2]</SUP> —&nbsp;Peripheral smear from a patient with malaria shows intra-erythrocytic ring forms (trophozoites; arrows). (C) Normal<SUP>[2]</SUP> — High-power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of:<br> 1. Harriet Provine<br> 2. Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 56898 Version 3.0</div></div></div>"},"56899":{"type":"graphic_table","displayName":"Influenza symptoms PI","title":"Is it a cold or the flu?","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Is it a cold or the flu?</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cold</td> <td class=\"subtitle1\">Flu</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Symptoms</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td>Rare</td> <td>Usual; high (100&#176;F to 102&#176;F; occasionally higher, especially in young children); lasts&nbsp;3 to 4 days</td> </tr> <tr> <td class=\"indent1\">Headache</td> <td>Rare</td> <td>Common</td> </tr> <tr> <td class=\"indent1\">General aches, pains</td> <td>Slight</td> <td>Usual; often severe</td> </tr> <tr> <td class=\"indent1\">Fatigue, weakness</td> <td>Sometimes</td> <td>Usual; can last up to&nbsp;2 to 3 weeks</td> </tr> <tr> <td class=\"indent1\">Extreme exhaustion</td> <td>Never</td> <td>Usual; at the beginning of the illness</td> </tr> <tr> <td class=\"indent1\">Stuffy nose</td> <td>Common</td> <td>Sometimes</td> </tr> <tr> <td class=\"indent1\">Sneezing</td> <td>Usual</td> <td>Sometimes</td> </tr> <tr> <td class=\"indent1\">Sore throat</td> <td>Common</td> <td>Sometimes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chest discomfort, cough</td> <td>Mild to moderate; hacking cough</td> <td>Common; can become severe</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: National Institutes of Health. (http://www.niaid.nih.gov/publications/cold/sick.pdf).</div><div id=\"graphicVersion\">Graphic 56899 Version 6.0</div></div></div>"},"56900":{"type":"graphic_picture","displayName":"Multifocal cutaneous lesions","title":"Multifocal cutaneous lesions","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Multifocal cutaneous lesions</div><div class=\"cntnt\"><img style=\"width:504px; height:320px;\" src=\"images/ID/56900_Multifocal_cutaneous_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: da Rosa AC, Scroferneker ML, Vettorato R, et al. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52:451. Copyright © 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 56900 Version 3.0</div></div></div>"},"56901":{"type":"graphic_movie","displayName":"Dissection of the ascending aorta on TEE","title":"Dissection of the ascending aorta on transesophageal echocardiography","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dissection of the ascending aorta on transesophageal echocardiography</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/56901_teeaaodiconv.mp4\" style=\"width:383px;height:276px\"></div><img style=\"width:458px; height:250px;\" src=\"images/CARD/56901_teeaaodi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a large dissection involving the ascending aorta (Ao) and the aortic valves. The false lumen (FL) impinges upon the aortic valve leaflets and impairs their function. Spontaneous echo contrast can be seen within the false lumen, a result of turbulent blood flow.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 56901 Version 3.0</div></div></div>"},"56903":{"type":"graphic_picture","displayName":"Reduce lower limb fatigue standing","title":"Reduce lower limb fatigue while standing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reduce lower limb fatigue while standing</div><div class=\"cntnt\"><img style=\"width:345px; height:449px;\" src=\"images/RHEUM/56903_reduce_low_limb_fatig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If the patient's job or task requires prolonged standing at one site, placing a 12-inch long 2x4 inch board on the floor, then placing one foot on and off of it at intervals, alternating feet, can reduce lower limb fatigue.</div><div class=\"graphic_reference\">Courtesy of Sharon Alzner, MPT.</div><div id=\"graphicVersion\">Graphic 56903 Version 1.0</div></div></div>"},"56904":{"type":"graphic_figure","displayName":"Transducer position apical 2 ch","title":"Transducer position for apical two-chamber view of the left ventricle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transducer position for apical two-chamber view of the left ventricle</div><div class=\"cntnt\"><img style=\"width:430px; height:278px;\" src=\"images/CARD/56904_Transducer_position_apical.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transducer position and beam plane for imaging the heart from the apex impulse location. This view is the two-dimensional two-chamber apical view; it is similar to a right anterior oblique angiogram of the left ventricle (LV) in that the inferior wall (IW) and anterolateral walls (A-LW) are border forming.</div><div id=\"graphicVersion\">Graphic 56904 Version 2.0</div></div></div>"},"56906":{"type":"graphic_figure","displayName":"Fetal response to stress","title":"Sequence of fetal response to stress","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Sequence of fetal response to stress</div><div class=\"cntnt\"><img style=\"width:531px; height:424px;\" src=\"images/OBGYN/56906_Fetal_response_to_stress.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the depicted sequence is an approximation and the actual course may vary depending upon the characteristics of the chronic deprivation and the individual fetal ability to cope.</div><div class=\"graphic_reference\">Reproduced with permission from Maulik D. Doppler velocimetry for fetal surveillance: Adverse perinatal outcome and fetal hypoxia. In: Maulik D (Ed), Doppler Ultrasound in Obstetrics and Gynecology, 1997; 349 New York, Springer Verlag. Copyright © 1997 Springer-Verlag.</div><div id=\"graphicVersion\">Graphic 56906 Version 2.0</div></div></div>"},"56907":{"type":"graphic_picture","displayName":"Microscopy cord hematoma","title":"Microscopy cord hematoma","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Microscopy cord hematoma</div><div class=\"cntnt\"><img style=\"width:507px; height:331px;\" src=\"images/OBGYN/56907_Microscopy_cord_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic section through localized umbilical cord hematoma revealing extravasated blood surrounding the umbilical vein.</div><div id=\"graphicVersion\">Graphic 56907 Version 3.0</div></div></div>"},"56908":{"type":"graphic_figure","displayName":"Collimaters comp a","title":"Schema of collimator and compensators","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schema of collimator and compensators</div><div class=\"cntnt\"><img style=\"width:427px; height:362px;\" src=\"images/ONC/56908_Collimaters_comp_a.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">By passing each beam through an aperture shaped to correspond to the cross-sectional area of the lesion in the beam's bird's eye view, the cross-section of each proton beam is conformed to the corresponding silhouette of the lesion (collimation). By interposing specific materials in the beam's path, energy attenuation is achieved to account for the effects of sloping skin surfaces and tissue non-homogeneities (compensation).</div><div id=\"graphicVersion\">Graphic 56908 Version 1.0</div></div></div>"},"56909":{"type":"graphic_picture","displayName":"Grades pan duct adenoCA","title":"Histology of pancreatic ductal adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Histology of pancreatic ductal adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:521px; height:198px;\" src=\"images/ONC/56909_Grades_pan_duct_adenoCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Well differentiated (grade 1) carcinoma invading fat. B) Poorly differentiated (grade 3) carcinoma is desmoplastic and has prominent fibrous stroma. Hematoxylin and Eosin.</div><div class=\"graphic_reference\">Courtesy of Daniel S Longnecker, MD.</div><div id=\"graphicVersion\">Graphic 56909 Version 3.0</div></div></div>"},"56910":{"type":"graphic_picture","displayName":"Discoid lupus PI","title":"Discoid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Discoid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:584px; height:334px;\" src=\"images/PI/56910_Discoid_lupus_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Discoid lupus causes raised red areas (\"plaques\") and scars on the skin. Picture A shows a person's ear, and picture B shows a person's cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56910 Version 7.0</div></div></div>"},"56911":{"type":"graphic_diagnosticimage","displayName":"Kawasaski multiple CA aneurysms","title":"Kawasaski disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kawasaski disease</div><div class=\"cntnt\"><img style=\"width:283px; height:350px;\" src=\"images/CARD/56911_Kawasaski_multiple_CA_aneur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Selective right coronary artery angiogram in a three-year-old boy with Kawasaki disease demonstrates multiple saccular aneurysms.</div><div id=\"graphicVersion\">Graphic 56911 Version 3.0</div></div></div>"},"56912":{"type":"graphic_diagnosticimage","displayName":"Adult TB case 2 lateral view","title":"Classic adult TB case 2 lateral","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Classic adult TB case 2 lateral</div><div class=\"cntnt\"><img style=\"width:504px; height:395px;\" src=\"images/ID/56912_ClassicadultTBcase2late.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 40-year-old automobile mechanic with pulmonary tuberculosis, chest radiograph lateral view.</div><div class=\"graphic_reference\">Courtesy of John Bernardo, MD.</div><div id=\"graphicVersion\">Graphic 56912 Version 4.0</div></div></div>"},"56913":{"type":"graphic_diagnosticimage","displayName":"Penumbra sign","title":"Penumbra sign in osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penumbra sign in osteomyelitis</div><div class=\"cntnt\"><img style=\"width:260px; height:396px;\" src=\"images/ID/56913_Penumbra_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging (MRI) scan shows the penumbra sign (a transitional zone with relatively high signal intensity between abscess and sclerotic bone marrow on T1-weighted MRI).</div><div class=\"graphic_reference\">Reproduced with permission from: Shih HN, Shih LY, Wong YC. Diagnosis and treatment of subacute osteomyelitis. J Trauma 2005; 58:83. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56913 Version 11.0</div></div></div>"},"56914":{"type":"graphic_diagnosticimage","displayName":"Bladder obstruction","title":"Obstruction of the urinary bladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Obstruction of the urinary bladder</div><div class=\"cntnt\"><img style=\"width:444px; height:517px;\" src=\"images/NEPH/56914_Bladder_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Transverse (left) and sagittal (right) ultrasound images of a distended, post-void bladder.<br />(B) Same bladder after placement of Foley catheter. The balloon of the catheter is visible (arrowheads).</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 56914 Version 3.0</div></div></div>"},"56916":{"type":"graphic_table","displayName":"ESC bridging therapy","title":"European Society of Cardiology guideline summary: Bridging therapy in patients with mechanical valves who require interruption of warfarin therapy for noncardiac surgery or other procedure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Society of Cardiology guideline summary: Bridging therapy in patients with mechanical valves who require interruption of warfarin therapy for noncardiac surgery or other procedure</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Risk stratification for thromboembolism risk is essential. High risk is defined as one or more of the following; the risk increases with the number of risk factors present:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1_start\" colspan=\"1\">\n   &#8226; Risk factors for thromboembolism, especially if multiple. Risk factors include:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   1. Atrial fibrillation\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   2. A prior history of thromboembolism\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   3. Heart failure or a left ventricular ejection fraction &#8804;30 percent\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   4. A hypercoagulable state\n   </td>\n   </tr>\n   <tr>\n   <td>&#8226; A mechanical valve in the mitral position.</td>\n   </tr>\n   <tr>\n   <td   colspan=\"1\">\n   &#8226; Mechanical valves known to be associated with a high risk of valve thrombosis if the INR is low (Lillehei Kaster, Omniscience, Starr Edwards).\n   </td>\n   </tr>\n   <tr>\n   <td   colspan=\"1\">\n   &#8226; Surgery for cancer or an infection, both of which can be associated with a hypercoagulable state.\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   The following approach is recommended based upon risk stratification for both thromboembolism and the risk of bleeding, which varies with the site of surgery:\n   </td>\n   </tr>\n   <tr>\n   <td   colspan=\"1\">\n   &#8226; For very high-risk patients, anticoagulation should not be interrupted if possible.\n   </td>\n   </tr>\n   <tr>\n   <td   colspan=\"1\">\n   &#8226; Interruption of anticoagulation is not necessary for many minor surgical procedures, including dental extraction, and for procedures where bleeding can be easily controlled. In such patients, the INR should be lowered to a goal of 2.0 and surgical homeostasis should be meticulous.\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1_start\">\n   &#8226; If anticoagulation must be interrupted:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   1. The patient should be admitted to the hospital and warfarin discontinued\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   2. Intravenous unfractionated heparin (goal aPTT 1.5 to 2.0) should be started as the INR gradually falls. The safety of subcutaneous low molecular weight heparin started at home has not been established.\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   3. Heparin and warfarin should be resumed as soon as possible after surgery; heparin is continued until the INR is within the goal therapeutic range.\n   </td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=4612&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ESC_bridging_therapy.htm</title></head></div><div class=\"graphic_reference\">Data from: Butchart EG, Gohlke-Barwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26:2463.</div><div id=\"graphicVersion\">Graphic 56916 Version 2.0</div></div></div>"},"56918":{"type":"graphic_table","displayName":"Quick sources of sugar for children PI","title":"Quick sources of sugar to treat low blood sugar in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Quick sources of sugar to treat low blood sugar in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>3 or 4 glucose tablets</td> </tr> <tr> <td>&#189; cup of juice or regular soda (not sugar-free)</td> </tr> <tr> <td>2 tablespoons of raisins</td> </tr> <tr> <td>1 tablespoon of sugar</td> </tr> <tr> <td>1 tablespoon of honey, jelly, or syrup</td> </tr> <tr> <td>Hard candies, such as 6 lifesavers</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These sources of sugar act quickly to treat low blood sugar levels. If your child has diabetes and uses insulin, you or your child should carry at least 1 of these items at all times. You should also leave quick sources of sugar at your child's school, and with babysitters and coaches.</div><div id=\"graphicVersion\">Graphic 56918 Version 2.0</div></div></div>"},"56921":{"type":"graphic_diagnosticimage","displayName":"Intussusception with small bowel obstruction","title":"Intussusception","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intussusception</div><div class=\"cntnt\"><img style=\"width:337px; height:432px;\" src=\"images/GAST/56921_Intussusception_SBO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film of a child with intussusception shows small intestinal obstruction. Notable are a dilated small bowel and the absence of colonic gas.</div><div class=\"graphic_reference\">Courtesy of Nancy Fitzgerald, MD and Taylor Chung, MD.</div><div id=\"graphicVersion\">Graphic 56921 Version 3.0</div></div></div>"},"56922":{"type":"graphic_table","displayName":"AHA lesion classification","title":"Criteria for American Heart Association lesion classification system and correspondence with classification of gross arterial specimens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for American Heart Association lesion classification system and correspondence with classification of gross arterial specimens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">AHA grade</td> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Comments and corresponding gross classification</td> </tr> <tr> <td>0</td> <td>Normal artery with or without adaptive intimal thickening; no hold</td> <td>Normal tissue</td> </tr> <tr> <td>1</td> <td>Isolated MFCs containing lipid; no extracellular lipid; variable adaptive intimal thickening grossly with lipid staining</td> <td>Initial atherosclerotic lesion, sometimes visible grossly with lipid staining</td> </tr> <tr> <td>2</td> <td>Numerous MFCs, often in layers, with fine particles of extracellular lipid; no distinct pools of extracellular lipid: variable adaptive intimal thickening</td> <td>Fatty streak, visible grossly with III staining</td> </tr> <tr> <td>3</td> <td>Numerous MFCs with &#8805; pools of extracellular lipid; no well-defined core of extracellular lipid</td> <td>Fatty plaque, raised fatty streak, intermediate lesion, or transitional lesion</td> </tr> <tr> <td>4</td> <td>Numerous MFGs plus well-defined core of extracellular lipid, but with luminal surface covered by relatively normal intima</td> <td>Atheroma, fibrous plaque, or raised lesion</td> </tr> <tr> <td>5</td> <td>Numerous MFCs, well-defined core or multiple cores of extracellular lipid, plus reactive fibrotic cap, vascularization, or calcium</td> <td>Fibroartherema, fibrous plaque, or raised lesion</td> </tr> <tr> <td>6</td> <td>All of the above plus surface defect, hematoma, hemorrhage, or thrombosis</td> <td>Complicated lesion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MFC: macrophage foam cell; AHA: American Heart Association.</div><div id=\"graphicVersion\">Graphic 56922 Version 2.0</div></div></div>"},"56923":{"type":"graphic_diagnosticimage","displayName":"ICD lead systems chest film","title":"Different ICD lead systems","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Different ICD lead systems</div><div class=\"cntnt\"><img style=\"width:553px; height:314px;\" src=\"images/CARD/56923_ICDleadsystemsChestfilm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiographs of two different implantable cardioverter-defibrillator (ICD) systems. Left panel shows an ICD epicardial lead system. Epicardial sensing electrodes are located on the left ventricle (arrow) and the three epicardial patch electrodes are located on the right atrium, and the inferior and lateral walls of the left ventricle. Right panel shows a dual coil transvenous ICD lead system with a pulse generator in the pectoral region.</div><div class=\"graphic_reference\">Courtesy of Douglas Kopp, MD.</div><div id=\"graphicVersion\">Graphic 56923 Version 3.0</div></div></div>"},"56924":{"type":"graphic_picture","displayName":"Verruca vulgaris","title":"Verruca vulgaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Verruca vulgaris</div><div class=\"cntnt\"><img style=\"width:369px; height:276px;\" src=\"images/DERM/56924_Verruca_vulgaris.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple common warts are evident on the hand.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 56924 Version 3.0</div></div></div>"},"56925":{"type":"graphic_diagnosticimage","displayName":"Empyema with calcifications","title":"Empyema with calcifications","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Empyema with calcifications</div><div class=\"cntnt\"><img style=\"width:536px; height:256px;\" src=\"images/PULM/56925_Empyema_with_calcifications.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Empyema due to previous pneumothorax therapy for cavitary tuberculosis. Left: Chest radiograph shows large right sided pleural mass with a sharp border towards the lung and obtuse angles of interface towards the chest wall. Slight caudad \"drooping\" is visible. Pleural calcifications are present. The right costophrenic sulcus is obscured. Right: CT scan shows a large loculated collection of liquid in the right hemithorax with obvious calcifications of the visceral and parietal pleura. Restrictive changes are evident and account for the small size of the right hemithorax. The thickness of the extrapleural fat in the posterolateral aspect of the right hemithorax is increased when compared to the left side. This compensates for the low lung volume on the right side.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56925 Version 3.0</div></div></div>"},"56926":{"type":"graphic_picture","displayName":"Pustular psoriasis - plaques","title":"Pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/56926_Pustular_psoriasis_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous small pustules are present on erythematous plaques.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Callen, MD, FACP.</div><div id=\"graphicVersion\">Graphic 56926 Version 2.0</div></div></div>"},"56928":{"type":"graphic_diagnosticimage","displayName":"Supravalvar aortic stenosis","title":"Anatomy of supravalvar AS","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Anatomy of supravalvar AS</div><div class=\"cntnt\"><img style=\"width:469px; height:216px;\" src=\"images/CARD/56928_Supravalvar_aortic_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Imaging studies demonstrate supravalvar aortic stenosis (AS) in a patient with Williams syndrome. Left image: A transesophageal echocardiogram shows tubular narrowing and thickening of the aortic walls above the sinuses of Valsalva (arrow). Right image: Aortic root angiography shows a typical tubular deformity (arrow).</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle.</div><div class=\"graphic_reference\">Modified with permission from Youn HJ, Chung WS, Hong SJ. Demonstration of supravalvar aortic stenosis by different cardiac imaging modalities in Williams syndrome. Heart 2002; 88:438. Copyright © 2002 BMJ Publishing Group.</div><div id=\"graphicVersion\">Graphic 56928 Version 3.0</div></div></div>"},"56931":{"type":"graphic_waveform","displayName":"ECG atrial tachycardia with paroxysmal AV block","title":"ECG of atrial tachycardia with resultant paroxysmal complete AV block","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">ECG of atrial tachycardia with resultant paroxysmal complete AV block</div><div class=\"cntnt\"><img style=\"width:522px; height:311px;\" src=\"images/CARD/56931_ECG_atrial_tachy_with_AV_bl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The continous lead II electrocardiogram (ECG) tracing initially shows a regular tachycardia at a rate of 160; the QRS complex is wide with a terminal S wave compatible with a right bundle branch block. There is gradual slowing of the rate with the development of atrioventricular (AV) nodal block; ultimately a series of nonconducted P waves (arrows) are seen and there is one escape ventricular premature beat (*). After a second ventricular premature beat (+), sinus rhythm is restored.</div><div class=\"graphic_reference\">Reproduced with permission by Samuel Levy, MD.</div><div id=\"graphicVersion\">Graphic 56931 Version 4.0</div></div></div>"},"56933":{"type":"graphic_picture","displayName":"Hip aspiration","title":"Hip aspiration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip aspiration</div><div class=\"cntnt\"><img style=\"width:310px; height:323px;\" src=\"images/EM/56933_Hip_aspiration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aspiration of the hip joint is performed to confirm acute synovitis or septic arthritis. The patient is placed in the lateral decubitus position with the hips and knees flexed to 90º. A 3.5 inch (9 cm), 22-gauge spinal needle is inserted perpendicular to the skin,&nbsp;2.5 cm (1 in)&nbsp;above the superior trochanter. 1 mL of local anesthetic is injected around the periosteum.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 56933 Version 3.0</div></div></div>"},"56936":{"type":"graphic_figure","displayName":"Heart anatomy PI","title":"Normal heart","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal heart</div><div class=\"cntnt\"><img style=\"width:337px; height:333px;\" src=\"images/PI/56936_Heart_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a drawing of a normal heart. The heart has 4 chambers: right atrium, left atrium, right ventricle, and left ventricle. Blood flows from the right atrium to the right ventricle through the tricuspid valve. Blood flows from the left atrium to the left ventricle through the mitral valve.</div><div id=\"graphicVersion\">Graphic 56936 Version 2.0</div></div></div>"},"56937":{"type":"graphic_picture","displayName":"Notalgia paresthetica","title":"Notalgia paresthetica","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Notalgia paresthetica</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/56937_Notalgia_paresthetica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hyperpigmented, lichenified plaque is present on the right medial upper back.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 56937 Version 3.0</div></div></div>"},"56938":{"type":"graphic_diagnosticimage","displayName":"Type 3 odontoid fracture","title":"Odontoid fracture type III","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Odontoid fracture type III</div><div class=\"cntnt\"><img style=\"width:509px; height:353px;\" src=\"images/EM/56938_Odontoid_fx_type3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type III odontoid fractures travel through the upper portion of the body of C2. They are mechanically unstable, since they allow the dens and the occiput to move as a unit.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 56938 Version 2.0</div></div></div>"},"56940":{"type":"graphic_picture","displayName":"Insulinoma insulin stain","title":"Insulinoma","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Insulinoma</div><div class=\"cntnt\"><img style=\"width:462px; height:178px;\" src=\"images/ENDO/56940_Insulinoma_insulin_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insulin staining of normal pancreas (left panel) and an insulin-secreting pancreatic tumor (right panel) (x 40).</div><div class=\"graphic_reference\">Courtesy of F John Service, MD.</div><div id=\"graphicVersion\">Graphic 56940 Version 1.0</div></div></div>"},"56942":{"type":"graphic_picture","displayName":"Novel nebulizer designs","title":"Novel nebulizer designs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Novel nebulizer designs</div><div class=\"cntnt\"><img style=\"width:393px; height:568px;\" src=\"images/PULM/56942_Nebulizers_new_designs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These devices are designed to release more aerosol during inspiration and less during expiration.</div><div id=\"graphicVersion\">Graphic 56942 Version 3.0</div></div></div>"},"56943":{"type":"graphic_picture","displayName":"Pulmonary capillaritis DAH II","title":"Pulmonary capillaritis in diffuse alveolar hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary capillaritis in diffuse alveolar hemorrhage</div><div class=\"cntnt\"><img style=\"width:360px; height:242px;\" src=\"images/PULM/56943_Pulmonary_capillaritis_DA1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in pulmonary capillaritis showing marked broadening of the alveolar septa caused by edema and necrosis. There is a striking infiltration of neutrophils in the alveolar septa (arrows), with many of those cells undergoing fragmentation and appearing pyknotic. The alveolar spaces are packed with red blood cells (diffuse alveolar hemorrhage) as well as some neutrophils.</div><div class=\"graphic_reference\">Courtesy of Marvin I Schwarz, MD.</div><div id=\"graphicVersion\">Graphic 56943 Version 2.0</div></div></div>"},"56944":{"type":"graphic_diagnosticimage","displayName":"Para Hisian pacing lead","title":"Para Hisian pacing lead","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Para Hisian pacing lead</div><div class=\"cntnt\"><img style=\"width:504px; height:263px;\" src=\"images/CARD/56944_Para_Hisian_pacing_lead.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient #6. Right anterior oblique (RAO) and left anterior oblique (LAO) fluoroscopic projections showing leads position during the &quot;ablate and pace&quot; procedure and Hisian pacing; 1 = quadripolar Hisian mapping catheter; 2 = screw-in bipolar lead positioned in close proximity to the His-bundle; 3 = bipolar passive fixation positioned in right ventricular apex.</div><div class=\"graphic_reference\">Reproduced with permission from: Occhetta E, Bortnik M, Magnani A, et al. Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, blinded, randomized study versus apical right ventricular pacing. J Am Coll Cardiol 2006; 47:1938. Copyright ©2006 American College of Cardiology Foundation.</div><div id=\"graphicVersion\">Graphic 56944 Version 3.0</div></div></div>"},"56945":{"type":"graphic_picture","displayName":"Excision and debridement using hydrosurgery system","title":"Excision and debridement using hydrosurgery system","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Excision and debridement using hydrosurgery system</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/SURG/56945_Excision_and_debridement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hydrosurgery system, such as the VersaJet, can be used to excise nonviable tissue around the digits and web spaces and other areas that are difficult to reach with Goulian or Weck knives.</div><div id=\"graphicVersion\">Graphic 56945 Version 4.0</div></div></div>"},"56946":{"type":"graphic_picture","displayName":"Peripheral IV placement 7","title":"Peripheral IV placement: Saline flush","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Peripheral IV placement: Saline flush</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/EM/56946_Peripheral_IV_placement_7.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once appropriate IV tubing is attached and the catheter is secured, flush it with isotonic saline.</div><div class=\"graphic_reference\">Courtesy of Robert Frank, MD.</div><div id=\"graphicVersion\">Graphic 56946 Version 2.0</div></div></div>"},"56947":{"type":"graphic_waveform","displayName":"Atrial flutter Entrainment","title":"Entrainment in typical atrial flutter with right atrial pacing with the rate of recording by the ECG machine being slowed by one-half","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Entrainment in&nbsp;typical atrial flutter with right atrial pacing with the rate of recording by the ECG machine being slowed by one-half</div><div class=\"cntnt\"><img style=\"width:480px; height:173px;\" src=\"images/CARD/56947_Atrial_flutter_Entrainment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The spontaneous rhythm, in which the flutter waves are not clearly apparent, is shown in the left side of panel A. The right atrium is then paced at just under 400 beats/min; entrainment is achieved at the asterisk when there is a sudden change in atrial morphology as the flutter rate matched the pacing rate. Cessation of pacing led to conversion to sinus rhythm (panel B).</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 56947 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"56949":{"type":"graphic_diagnosticimage","displayName":"Posterior cephalocele B","title":"Posterior cephalocele","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Posterior cephalocele</div><div class=\"cntnt\"><img style=\"width:572px; height:414px;\" src=\"images/OBGYN/56949_Posterior_cephalocele_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial view of the posterior encephalocele. The arrows point to the cranial defect.</div><div id=\"graphicVersion\">Graphic 56949 Version 3.0</div></div></div>"},"56952":{"type":"graphic_waveform","displayName":"Intermediate case 3 with answer","title":"Prolonged QT interval due to hypocalcemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prolonged QT interval due to hypocalcemia</div><div class=\"cntnt\"><img style=\"width:421px; height:99px;\" src=\"images/CARD/56952_Intermediate_case_3_with_an.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The QT interval in this case is quite prolonged (0.50 sec) at a heart rate of 55 beats/min. The rate corrected QT (QTc) interval can be calculated from: QT interval ÷ sqrt (RR interval). The RR interval is 1.05 sec leading to a QTc of 0.48 sec which is longer than the normal value of ≤0.44 sec. A long QT interval with a &quot;stretched out&quot; ST segment and normal T wave is most consistent with hypocalcemia. In contrast, hypercalcemia shortens the QT, hyponatremia usually has no effect on the ECG, and hypokalemia prolongs repolarization with flattened or broad T waves and prominent U waves.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 56952 Version 2.0</div></div></div>"},"56954":{"type":"graphic_picture","displayName":"CML blood smear","title":"Chronic myeloid leukemia blood smear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic myeloid leukemia blood smear</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/HEME/56954_CML_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic peripheral blood smear of chronic myeloid leukemia shows basophilia and granulocytosis with neutrophils and immature granulocytes.</div><div class=\"graphic_reference\">Reproduced with permission from: McClatchey, KD, MD, DDS. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright ©2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 56954 Version 3.0</div></div></div>"},"56956":{"type":"graphic_figure","displayName":"Portion-size estimator","title":"Portion-size estimator","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Portion-size estimator</div><div class=\"cntnt\"><img style=\"width:533px; height:697px;\" src=\"images/PC/56956_Portion-size_estimator.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56956 Version 2.0</div></div></div>"},"56959":{"type":"graphic_table","displayName":"Associations retinal vasculitis","title":"Disorders associated with retinal vasculitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders associated with retinal vasculitis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Systemic disorders</td> </tr> <tr> <td>Beh&#231;et's syndrome</td> </tr> <tr> <td>Crohn disease</td> </tr> <tr> <td>Giant cell arteritis</td> </tr> <tr> <td>HLA-B27-associated conditions</td> </tr> <tr> <td>Multiple sclerosis</td> </tr> <tr> <td>Polyarteritis nodosa</td> </tr> <tr> <td>Relapsing polychondritis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Whipple's disease</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious disorders</td> </tr> <tr> <td>Acute retinal necrosis</td> </tr> <tr> <td>Amoebiasis</td> </tr> <tr> <td>Brucellosis</td> </tr> <tr> <td>Candidiasis</td> </tr> <tr> <td>Cat scratch disease</td> </tr> <tr> <td>Coccidiomycosis</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td>Hepatitis</td> </tr> <tr> <td>Herpes simplex</td> </tr> <tr> <td>Herpes zoster</td> </tr> <tr> <td>Human immunodeficiency virus</td> </tr> <tr> <td>Leptospirosis</td> </tr> <tr> <td>Lyme disease</td> </tr> <tr> <td>Ricketsia</td> </tr> <tr> <td>Syphilis</td> </tr> <tr> <td>Toxocariasis</td> </tr> <tr> <td>Toxoplasmosis</td> </tr> <tr> <td>Tuberculosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Ocular disorders</td> </tr> <tr> <td>Birdshot retinochoroidopathy</td> </tr> <tr> <td>Eales' disease</td> </tr> <tr> <td>Pars planitis</td> </tr> <tr> <td>Retinal arteriolitis</td> </tr> <tr> <td>Sympathetic ophthalmia</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div id=\"graphicVersion\">Graphic 56959 Version 4.0</div></div></div>"},"56960":{"type":"graphic_picture","displayName":"Pancreatic neuroendocrine neoplasm Gross","title":"Pancreatic neuroendocrine neoplasm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic neuroendocrine neoplasm</div><div class=\"cntnt\"><img style=\"width:435px; height:288px;\" src=\"images/ENDO/56960_IsletcelltumorGross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross specimen of a pancreatic neuroendocrine neoplasm that has been surgically removed. The type of tumor cannot be determined from gross examination.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 56960 Version 2.0</div></div></div>"},"56961":{"type":"graphic_figure","displayName":"Efficacy of ePTFE and ORC in preventing adhesions","title":"Efficacy of ePTFE and ORC in preventing adhesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efficacy of ePTFE and ORC in preventing adhesions</div><div class=\"cntnt\"><img style=\"width:380px; height:272px;\" src=\"images/OBGYN/56961_Efficacy_of_gortex_vs_inter.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Expanded polytetra-fluorothylene (Gore-Tex Surgical Membrane) is superior to oxidized regenerated cellulose (Interceed TC7) in preventing adhesions.</div><div class=\"graphic_footnotes\">* Expanded polytetrafluoroethylene (ePTFE).<br>&#8226; Oxidized regenerated cellulose (ORC).</div><div class=\"graphic_reference\">Reproduced with permission from: Haney, AF, Hesla, J, Hurst, BS, et al.</div><div id=\"graphicVersion\">Graphic 56961 Version 2.0</div></div></div>"},"56962":{"type":"graphic_figure","displayName":"Distribution vector ticks","title":"Approximate distribution of vector tick species for human monocytotropic ehrlichiosis and human granulocytotropic anaplasmosis","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Approximate distribution of vector tick species for human monocytotropic ehrlichiosis and human granulocytotropic anaplasmosis</div><div class=\"cntnt\"><img style=\"width:538px; height:493px;\" src=\"images/ID/56962_Distribution_vector_ticks.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Champman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis -- United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.</div><div id=\"graphicVersion\">Graphic 56962 Version 2.0</div></div></div>"},"56963":{"type":"graphic_picture","displayName":"Pseudomonas aeruginosa on MacConkey agar","title":"<EM>Pseudomonas aeruginosa </EM>on MacConkey agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Pseudomonas aeruginosa </EM>on MacConkey agar</div><div class=\"cntnt\"><img style=\"width:334px; height:240px;\" src=\"images/ID/56963_Gramstainsputum8Canswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compare the mucoid (above) and non-mucoid (below) strains of <EM>Pseudomonas aeruginosa</EM>. Patients with cystic fibrosis often have mucoid <EM>P. aeruginosa </EM>in their sputum.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 56963 Version 3.0</div></div></div>"},"56964":{"type":"graphic_picture","displayName":"Sputum Ziehl Neelsen stain","title":"Sputum stained by Ziehl-Neelsen","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Sputum stained by Ziehl-Neelsen</div><div class=\"cntnt\"><img style=\"width:496px; height:358px;\" src=\"images/ID/56964_SputstainbyZiehlNeelsen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sputum, decontaminated and concentrated, and stained using the Ziehl-Neelsen method.</div><div class=\"graphic_reference\">Courtesy of John Bernardo, MD.</div><div id=\"graphicVersion\">Graphic 56964 Version 4.0</div></div></div>"},"56966":{"type":"graphic_figure","displayName":"MHC class I and II structure","title":"Structure of MHC class I and II","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Structure of MHC class I and II</div><div class=\"cntnt\"><img style=\"width:479px; height:442px;\" src=\"images/NEPH/56966_MHC_class_I_and_II_structur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Since the principal role of MHC encoded proteins is the presentation of peptide antigen, all such proteins have an antigen-binding groove. The floor of the groove is provided by a beta sheet region upon which rests two alpha helical regions. MHC class I and II proteins differ in the details of structure and function. The large figures show the MHC molecules viewed &quot;face on&quot; as they would be encountered by T cell receptors. The inset figures depict the MHC molecules as viewed &quot;side on.&quot;</div><div id=\"graphicVersion\">Graphic 56966 Version 1.0</div></div></div>"},"56967":{"type":"graphic_picture","displayName":"Ectopic ureter through vaginoscope","title":"Ectopic ureter through vaginal introitus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ectopic ureter through vaginal introitus</div><div class=\"cntnt\"><img style=\"width:346px; height:292px;\" src=\"images/OBGYN/56967_Ectopic_ureter_thru_vaginos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Urethra. (B) An asymmetric ridge of tissue was <SPAN style=\"COLOR: black\">observed&nbsp;coursing the length of vagina from the level of the cervix to the introitus. (C) Note the smooth contiguous rim of hymenal tissue, which remained unchanged after vaginoscopy</SPAN>.</div><div id=\"graphicVersion\">Graphic 56967 Version 3.0</div></div></div>"},"56968":{"type":"graphic_picture","displayName":"Balance PI","title":"Balance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balance</div><div class=\"cntnt\"><img style=\"width:297px; height:432px;\" src=\"images/PI/56968_Balance_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Use a wobble board or balance disk to improve knee strength and balance ability. If a wobble board or balance disk is not available, try balancing on the affected leg while lifting the unaffected leg off the ground; do not hold onto any support. Hold this position for a count of 5 to 10. Rest and repeat 10 to 15 times. To increase the difficulty, raise the unaffected leg into the air.</div><div id=\"graphicVersion\">Graphic 56968 Version 3.0</div></div></div>"},"56969":{"type":"graphic_figure","displayName":"Burch suture placement","title":"Suture placement in endopelvic fascia for Burch procedure (retropubic colposuspension)","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Suture placement in endopelvic fascia for Burch procedure (retropubic colposuspension)</div><div class=\"cntnt\"><img style=\"width:527px; height:299px;\" src=\"images/OBGYN/56969_Burch_suture_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Robinson, D, Norton, PA. Diagnosis and Management of Urinary Incontinence. In: Gynecologic Surgery. Mann, WJ, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.715.</div><div id=\"graphicVersion\">Graphic 56969 Version 2.0</div></div></div>"},"56970":{"type":"graphic_diagnosticimage","displayName":"Double decidual sign","title":"Double decidual sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Double decidual sign</div><div class=\"cntnt\"><img style=\"width:354px; height:303px;\" src=\"images/OBGYN/56970_Double_decidual_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal image demonstrating the double decidual sac sign in the endometrium.</div><div class=\"graphic_footnotes\">G: gestational sac.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 56970 Version 3.0</div></div></div>"},"56973":{"type":"graphic_picture","displayName":"Atypical adenom hyperpl light","title":"Atypical adenomatous hyperplasia of the prostate ","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Atypical adenomatous hyperplasia of the prostate </div><div class=\"cntnt\"><img style=\"width:550px; height:277px;\" src=\"images/ONC/56973_Atypical_adenom_hyperpl_lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right panel: hematoxylin- and eosin-stained section of a prostate biopsy showing atypical adenomatous hyperplasia, with its characterstic small crowded glands mimicking prostatic adenocarcinoma. However, minimal cytologic atypia and patchy basal cells (arrowheads) are present. Left panel: Immunohistocehmical staining with 34bE12 demonstrates basal cells (arrowheads) in an area of atypical adenomatous hyperplasia.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 56973 Version 2.0</div></div></div>"},"56975":{"type":"graphic_table","displayName":"Genes involved DSD B","title":"Genes known to be involved in disorders of sex development (DSD) (continued)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genes known to be involved in disorders of sex development (DSD) (continued)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">OMIM No.</td> <td class=\"subtitle1\">Locus</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Gonad</td> <td class=\"subtitle1\">Mullerian structures</td> <td class=\"subtitle1\">External genitalia</td> <td class=\"subtitle1\">Associated features/variant phenotypes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">46,XX DSD</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"9\">Disorders of gonadal (ovarian) development</td> </tr> <tr> <td class=\"indent2\">SRY</td> <td>TF</td> <td>480000</td> <td>Yp11.3</td> <td>Translocation</td> <td>Testis or ovotestis</td> <td>&ndash;</td> <td>Male or ambiguous</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">SOX9</td> <td>TF</td> <td>608160</td> <td>17q24</td> <td>dup17q24</td> <td>Not determined</td> <td>&ndash;</td> <td>Male or ambiguous</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"9\">Androgen excess</td> </tr> <tr> <td class=\"indent2\">HB2 HSD</td> <td>Enzyme</td> <td>201810</td> <td>1p13</td> <td>AR</td> <td>Ovary</td> <td>+</td> <td>Clitoromegaly</td> <td>CAH, primary adrenal failure, partial androgenization caused by dehydroepiandrosterone sulfate</td> </tr> <tr> <td class=\"indent2\">CYP21A2</td> <td>Enzyme</td> <td>201910</td> <td>6p21-23</td> <td>AR</td> <td>Ovary</td> <td>+</td> <td>Ambiguous</td> <td>CAH, phenotypic spectrum from severe salt-losing forms associated with adrenal failure to simple virilizing forms with compensated adrenal function, 17-hydroxyprogesterone</td> </tr> <tr> <td class=\"indent2\">CYP11B1</td> <td>Enzyme</td> <td>202010</td> <td>8q21-22</td> <td>AR</td> <td>Ovary</td> <td>+</td> <td>Ambiguous</td> <td>CAH, hypertension caused by 11-deoxycortisol and 11-deoxycorticosterone</td> </tr> <tr> <td class=\"indent2\">POR (P450 oxidoreductase)</td> <td>CYP enzyme electron donor</td> <td>124015</td> <td>7q11.2</td> <td>AR</td> <td>Ovary</td> <td>+</td> <td>Ambiguous</td> <td>Mixed features of 21-hydroxylase deficiency, 17 &#945;-hydroxylase/17,20-lyase deficiency, and aromatase deficiency; associated with Antley Bixler craniosynostosis</td> </tr> <tr> <td class=\"indent2\">CYP19</td> <td>Enzyme</td> <td>107910</td> <td>15q21</td> <td>AR</td> <td>Ovary</td> <td>+</td> <td>Ambiguous</td> <td>Maternal androgenization during pregnancy, absent breast development at puberty, except in partial cases</td> </tr> <tr> <td class=\"indent2\">Glucocorticoid receptor</td> <td>Nuclear receptor TF</td> <td>138040</td> <td>5q31</td> <td>AR</td> <td>Ovary</td> <td>+</td> <td>Ambiguous</td> <td>Adrenocorticotropin, 17-hydroxyprogesterone and cortisol; failure of dexamethasone suppression (patient heterozygous for a mutation in CYP21)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Chromosomal rearrangements likely to include key genes are included.</div><div class=\"graphic_footnotes\">OMIM: Online Mendelian Inheritance in Man; TF: transcription factor; AD: autosomal dominant (often do novo mutation); AR: autosomal recessive; Y: Y-chromosomal; X: X-chromosomal.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 118, Pages e488-e500, Copyright © 2006 by the AAP.</div><div id=\"graphicVersion\">Graphic 56975 Version 14.0</div></div></div>"},"56976":{"type":"graphic_diagnosticimage","displayName":"Advanced asbestosis CXR","title":"Advanced asbestosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced asbestosis</div><div class=\"cntnt\"><img style=\"width:332px; height:371px;\" src=\"images/PULM/56976_Advanced_asbestosis_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note characteristic features: fibrotic bands superimposed on a background of widespread irregular opacities, shaggy heart border and septal thickening, extensive pleural changes, and blunted costophrenic angles.</div><div class=\"graphic_reference\">Am J Respir Crit Care Med 2004; 170:692; www.atsjournals.org</div><div id=\"graphicVersion\">Graphic 56976 Version 3.0</div></div></div>"},"56978":{"type":"graphic_picture","displayName":"Cutibacterium shoulder","title":"<EM>Cutibacterium</EM> (formerly <EM>Propionibacterium</EM>) shoulder infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Cutibacterium</EM> (formerly <EM>Propionibacterium</EM>) shoulder infection</div><div class=\"cntnt\"><img style=\"width:288px; height:307px;\" src=\"images/ID/56978_Propionibacterium_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bruising pattern along the surgical incision, often seen with <EM>Cutibacterium</EM> shoulder infections.</div><div class=\"graphic_reference\">Courtesy of Daniel J Sexton, MD.</div><div id=\"graphicVersion\">Graphic 56978 Version 3.0</div></div></div>"},"56979":{"type":"graphic_diagnosticimage","displayName":"RPL CT and MRI findings B","title":"MRI images in Reversible posterior leukoencephalopathy syndrome (RPLS) (B)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI images in Reversible posterior leukoencephalopathy syndrome (RPLS) (B)</div><div class=\"cntnt\"><img style=\"width:396px; height:453px;\" src=\"images/NEURO/56979_RPL_CT_and_MRI_findings_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffusion-weighted image (DWI) (A) shows slight hyperintensity within the hyperintense regions seen on FLAIR image. The corresponding ADC map (B) shows hyperintensity in these regions, suggestive of facilitated water diffusion and vasogenic edema. Follow-up study obtained two weeks later shows resolution of the hyperintense lesions on T2-weighted (C) and FLAIR (D) images.</div><div class=\"graphic_footnotes\">ADC: apparent diffusion coefficient; FLAIR: fluid-attenuated inversion recovery. </div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 56979 Version 4.0</div></div></div>"},"56982":{"type":"graphic_table","displayName":"Classification glaucoma children","title":"Etiologic classification of pediatric glaucoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologic classification of pediatric glaucoma</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Primary infantile or congenital glaucoma (open angle)</td> </tr> <tr> <td class=\"subtitle1_single\">Juvenile glaucoma</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary glaucoma</td> </tr> <tr> <td class=\"subtitle2_single\">Angle anomaly</td> </tr> <tr> <td class=\"indent1\">Sturge-Weber</td> </tr> <tr> <td class=\"indent1\">Klippel-Trenaunay-Weber</td> </tr> <tr> <td class=\"indent1\">Aniridia</td> </tr> <tr> <td class=\"indent1\">Neurocrestopathies</td> </tr> <tr> <td class=\"indent1\">Lowe syndrome</td> </tr> <tr> <td class=\"indent1\">Neurofibromatosis</td> </tr> <tr> <td class=\"indent1\">Marfan's syndrome</td> </tr> <tr> <td class=\"indent1\">Pierre-Robin sequence</td> </tr> <tr> <td class=\"indent1\">Rubinstein-Taybi syndrome</td> </tr> <tr> <td class=\"indent1\">Epidermal nevus syndrome</td> </tr> <tr> <td class=\"indent1\">Trisomy 13</td> </tr> <tr> <td class=\"indent1\">Skeletal dysplasia</td> </tr> <tr> <td class=\"indent1\">Diamond-Blackfan syndrome</td> </tr> <tr> <td class=\"indent1\">Oculodermal melanocytosis</td> </tr> <tr> <td class=\"indent1\">Stickler syndrome</td> </tr> <tr> <td class=\"indent1\">Rubella</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Secondary glaucoma (continued)</td> </tr> <tr> <td class=\"subtitle2_single\">Lens-iris diaphragm abnormalities</td> </tr> <tr> <td class=\"indent1\">Aphakia*</td> </tr> <tr> <td class=\"indent1\">Weill-Marchesani syndrome</td> </tr> <tr> <td class=\"indent1\">Homocystinuria</td> </tr> <tr> <td class=\"indent1\">Persistent fetal vasculature</td> </tr> <tr> <td class=\"indent1\">Ectopia lentis*</td> </tr> <tr> <td class=\"indent1\">Retinopathy of prematurity</td> </tr> <tr> <td class=\"subtitle2_single\">Inflammation (uveitis)*</td> </tr> <tr> <td class=\"indent1\">Idiopathic</td> </tr> <tr> <td class=\"indent1\">Juvenile idiopathic arthritis</td> </tr> <tr> <td class=\"indent1\">Sarcoid</td> </tr> <tr> <td class=\"indent1\">Rubella</td> </tr> <tr> <td class=\"subtitle2_single\">Tumors*</td> </tr> <tr> <td class=\"indent1\">Retinoblastoma</td> </tr> <tr> <td class=\"indent1\">Juvenile xanthogranuloma</td> </tr> <tr> <td class=\"indent1\">Histiocytosis X</td> </tr> <tr> <td class=\"indent1\">Leukemia</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Secondary glaucoma (continued)</td> </tr> <tr> <td class=\"subtitle2_single\">Trauma*</td> </tr> <tr> <td class=\"indent1\">Hyphema</td> </tr> <tr> <td class=\"indent1\">Angle recession</td> </tr> <tr> <td class=\"indent1\">Traumatic trabeculitis</td> </tr> <tr> <td class=\"indent1\">Lens induced</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs*</td> </tr> <tr> <td class=\"indent1\">Steroid induced</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These types of glaucomas are sometimes referred to as acquired childhood glaucomas.</div><div id=\"graphicVersion\">Graphic 56982 Version 4.0</div></div></div>"},"56984":{"type":"graphic_figure","displayName":"Variations in hepatic arterial supply","title":"Variations in hepatic arterial supply","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variations in hepatic arterial supply</div><div class=\"cntnt\"><img style=\"width:441px; height:600px;\" src=\"images/SURG/56984_Hepatic_arterial_supply.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figures A through E&nbsp;illustrate the most common variations of hepatic artery anatomy.</div><div id=\"graphicVersion\">Graphic 56984 Version 2.0</div></div></div>"},"56985":{"type":"graphic_diagnosticimage","displayName":"Normal fifth metatarsal apophysis","title":"Apophysis of the fifth metatarsal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apophysis of the fifth metatarsal</div><div class=\"cntnt\"><img style=\"width:229px; height:360px;\" src=\"images/EM/56985_Normal5thapophysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Orientation of the apophysis of the fifth metatarsal is parallel to the shaft and should not be confused with a fracture. (This patient also has an undisplaced, transverse fracture.)</div><div class=\"graphic_reference\">Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 56985 Version 12.0</div></div></div>"},"56986":{"type":"graphic_picture","displayName":"Epi MPEC hemostasis NBVV","title":"Combination therapy for a nonbleeding visible vessel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Combination therapy for a nonbleeding visible vessel</div><div class=\"cntnt\"><img style=\"width:377px; height:563px;\" src=\"images/GAST/56986_Epi_MPEC_hemostasis_NBVV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing a deformed gastric antrum with three circumferential ulcers (arrowheads) near the pylorus (panels A-C). One of the ulcers contains a nonbleeding visible vessel (arrow), which was treated by a combination of epinephrine injection and multipolar electrocoagulation (panels D-E). Panel F shows the coagulated vessel after treatment.</div><div class=\"graphic_reference\">Courtesy of Dennis M Jensen, MD, and Gustavo A Machicado, MD.</div><div id=\"graphicVersion\">Graphic 56986 Version 2.0</div></div></div>"},"56987":{"type":"graphic_table","displayName":"Series rectal foreign bod","title":"Rectal foreign bodies series","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rectal foreign bodies series</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author<br /> (year)</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Male/female</td> <td class=\"subtitle1\">Age<br /> (mean or median in years)</td> <td class=\"subtitle1\">Insertion<br /> (anal/ingestion)</td> <td class=\"subtitle1\">Extraction<br /> (transanal/ abdominal)</td> <td class=\"subtitle1\">Stoma<br /> (number)</td> <td class=\"subtitle1\">Morbidity/mortality<br /> (percent)</td> </tr> <tr> <td>Volpi (2012)<sup>[1]</sup></td> <td class=\"centered\">10</td> <td class=\"centered\">7/3</td> <td class=\"centered\">40</td> <td class=\"centered\">10/0</td> <td class=\"centered\">8/2</td> <td class=\"centered\">1</td> <td class=\"centered\">0/0</td> </tr> <tr> <td>Rodriguez (2007)<sup>[2]</sup></td> <td class=\"centered\">30</td> <td class=\"centered\">20/10</td> <td class=\"centered\">42.5</td> <td class=\"centered\">16/14</td> <td class=\"centered\">23/7</td> <td class=\"centered\">6</td> <td class=\"centered\">14/0</td> </tr> <tr> <td>Clarke (2005)<sup>[3]</sup></td> <td class=\"centered\">13</td> <td class=\"centered\">13/0</td> <td class=\"centered\">45</td> <td class=\"centered\">13/0</td> <td class=\"centered\">8/5</td> <td class=\"centered\">2</td> <td class=\"centered\">NA</td> </tr> <tr> <td>Lake (2004)<sup>[4]</sup></td> <td class=\"centered\">87</td> <td class=\"centered\">85/5</td> <td class=\"centered\">40</td> <td class=\"centered\">87/0</td> <td class=\"centered\">79/8</td> <td class=\"centered\">2</td> <td class=\"centered\">1/0</td> </tr> <tr> <td>Ruiz (2001)<sup>[5]</sup></td> <td class=\"centered\">17</td> <td class=\"centered\">14/3</td> <td class=\"centered\">46.3</td> <td class=\"centered\">17/0</td> <td class=\"centered\">10/7</td> <td class=\"centered\">5</td> <td class=\"centered\">0/0</td> </tr> <tr> <td>Biriukov (2000)<sup>[6]</sup></td> <td class=\"centered\">112</td> <td class=\"centered\">111/1</td> <td class=\"centered\">16-80</td> <td class=\"centered\">112/0</td> <td class=\"centered\">107/6</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> <tr> <td>Ooi (1998)<sup>[7]</sup></td> <td class=\"centered\">30</td> <td class=\"centered\">25/5</td> <td class=\"centered\">46</td> <td class=\"centered\">30/0</td> <td class=\"centered\">27/3</td> <td class=\"centered\">1</td> <td class=\"centered\">7/0</td> </tr> <tr> <td>Cohen (1996)<sup>[8]</sup></td> <td class=\"centered\">48</td> <td class=\"centered\">45/3</td> <td class=\"centered\">33.6</td> <td class=\"centered\">48/0</td> <td class=\"centered\">42/6</td> <td class=\"centered\">5</td> <td class=\"centered\">0/0</td> </tr> <tr> <td>Yaman (1993)<sup>[9]</sup></td> <td class=\"centered\">29</td> <td class=\"centered\">28/1</td> <td class=\"centered\">42.5</td> <td class=\"centered\">22/7</td> <td class=\"centered\">27/2</td> <td class=\"centered\">2</td> <td class=\"centered\">17/0</td> </tr> <tr> <td>Marti (1986)<sup>[10]</sup></td> <td class=\"centered\">8</td> <td class=\"centered\">NA</td> <td class=\"centered\">38</td> <td class=\"centered\">8</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">0/0</td> </tr> <tr> <td>Nehme Kingsley (1985)<sup>[11]</sup></td> <td class=\"centered\">51</td> <td class=\"centered\">51/0</td> <td class=\"centered\">19-94</td> <td class=\"centered\">51/0</td> <td class=\"centered\">50/1</td> <td class=\"centered\">0</td> <td class=\"centered\">0/0</td> </tr> <tr> <td>Barone (1983)<sup>[12]</sup></td> <td class=\"centered\">101</td> <td class=\"centered\">101/0</td> <td class=\"centered\">16-48</td> <td class=\"centered\">101/0</td> <td class=\"centered\">89/12</td> <td class=\"centered\">11</td> <td class=\"centered\">NA/1</td> </tr> <tr> <td>Crass (1981)<sup>[13]</sup></td> <td class=\"centered\">29</td> <td class=\"centered\">26/3</td> <td class=\"centered\">10-84</td> <td class=\"centered\">29/0</td> <td class=\"centered\">15/14</td> <td class=\"centered\">10</td> <td class=\"centered\">14/3</td> </tr> <tr> <td>Sohn (1977)<sup>[14]</sup></td> <td class=\"centered\">11</td> <td class=\"centered\">11/0</td> <td class=\"centered\">35</td> <td class=\"centered\">11/0</td> <td class=\"centered\">7/4</td> <td class=\"centered\">4</td> <td class=\"centered\">10/0</td> </tr> <tr> <td>Barone (1976)<sup>[15]</sup></td> <td class=\"centered\">28</td> <td class=\"centered\">26/2</td> <td class=\"centered\">16-56</td> <td class=\"centered\">28/0</td> <td class=\"centered\">23/5</td> <td class=\"centered\">5</td> <td class=\"centered\">14</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not available.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Volpi A, Panebianco A, Ialongo P, et al. Colorectal retained foreign bodies per annum introduced. Three years retrospective study at Emergency Surgery Unit. G Chir 2012; 33:411.</li>&#xD;&#xA;    <li>Rodriguez-Hermosa JI, Codina-Cazador A, Ruiz B, et al. Management of foreign bodies in the rectum. Colorectal Dis 2007; 9:543.</li>&#xD;&#xA;    <li>Clarke DL, Buccimazza I, Anderson FA, Thomson SR. Colorectal foreign bodies. Colorectal Dis 2005; 7:98.</li>&#xD;&#xA;    <li>Lake JP, Essani R, Petrone P, et al. Management of retained colorectal foreign bodies: predictors of operative intervention. Dis Colon Rectum 2004; 47:1694.</li>&#xD;&#xA;    <li>Ruiz de Castillo J, Selles Dechent R, Millan Scheiding M, et al. Colorectal trauma caused by foreign bodies introduced during sexual activity: diagnosis and management. Rev Esp Enferm Dig 2001; 93:631.</li>&#xD;&#xA;    <li>Biriukov IuV, Volkov OV, An VK, et al. Treatment of patients with foreign bodies in rectum. Khirugiia (Mosk) 2000; (7):41.</li>&#xD;&#xA;    <li>Ooi BS, Ho YH, Eu KW, et al. Management of anorectal foreign bodies: a cause of obscure anal pain. Aust N Z J Surg 1998; 68:852.</li>&#xD;&#xA;    <li>Cohen JS, Sackier JM. Management of colorectal foreign bodies. J R Coll Surg Edinb 1996; 41:312.</li>&#xD;&#xA;    <li>Yaman M, Deitel M, Burul CJ, et al. Foreign bodies in the rectum. Can J Surg 1993; 36:173.</li>&#xD;&#xA;    <li>Marti MC, Morel P, Rohner A. Traumatic lesions of the rectum. Int J Colorectal Dis 1986; 1:152.</li>&#xD;&#xA;    <li>Nehme Kingsley A, Abcarian H. Colorectal foreign bodies. Management update. Dis Colon Rectum 1985; 28:941.</li>&#xD;&#xA;    <li>Barone JE, Yee J, Nealon TF Jr. Management of foreign bodies and trauma of the rectum. Surg Gynecol Obstet 1983; 156:453.</li>&#xD;&#xA;    <li>Crass RA, Tranbaugh RF, Kudsk KA, Trunkey DD. Colorectal foreign bodies and perforation. Am J Surg 1981; 142:85.</li>&#xD;&#xA;    <li>Sohn N, Weinstein MA, Gonchar J. Social injuries of the rectum. Am J Surg 1977; 134:611.</li>&#xD;&#xA;    <li>Barone JE, Sohn N, Nealon TF Jr. Perforations and foreign bodies of the rectum: report of 28 cases. Ann Surg 1976; 184:601.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 56987 Version 4.0</div></div></div>"},"56988":{"type":"graphic_diagnosticimage","displayName":"Mainstem bronchus mass CT","title":"T3 lung cancer near carina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T3 lung cancer near carina</div><div class=\"cntnt\"><img style=\"width:275px; height:245px;\" src=\"images/PULM/56988_Mainstem_bronchus_mass_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan in a patient with bronchogenic carcinoma shows a central mass encasing the right mainstem bronchus (arrow), in close proximity to the carina. There are also speckled calcifications in the hilar mass and in subcarinal nodes (arrowhead) from previous granulomatous disease. The location of this hilar mass is consistent with a T3 tumor.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 56988 Version 3.0</div></div></div>"},"56990":{"type":"graphic_diagnosticimage","displayName":"DISH radiograph right hip","title":"Right hip involvement in diffuse idiopathic skeletal hyperostosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right hip involvement in diffuse idiopathic skeletal hyperostosis</div><div class=\"cntnt\"><img style=\"width:335px; height:304px;\" src=\"images/RHEUM/56990_DISHradiographrighthip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph of the right hip in DISH showing osteophytes that arise from the greater trochanter, the superior margin of the acetabulum, and the ilium (arrows).</div><div class=\"graphic_footnotes\">DISH: diffuse idiopathic skeletal hyperostosis.</div><div class=\"graphic_reference\">Courtesy of John Esdaile, MD.</div><div id=\"graphicVersion\">Graphic 56990 Version 3.0</div></div></div>"},"56992":{"type":"graphic_figure","displayName":"Hemodialysis PI","title":"Hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Hemodialysis</div><div class=\"cntnt\"><img style=\"width:452px; height:553px;\" src=\"images/PI/56992_Hemodialysis-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a person getting hemodialysis. Two needles are put into an &quot;access&quot; in the person's arm. Blood flows from the body to the hemodialysis machine, where it is filtered. Then the blood is returned to the body. The whole process takes about 3 to 5 hours and must be repeated 3 to 7 times a week.</div><div id=\"graphicVersion\">Graphic 56992 Version 3.0</div></div></div>"},"56993":{"type":"graphic_diagnosticimage","displayName":"Band slippage and gastric prolapse after gastric banding","title":"Band slippage and gastric prolapse after gastric banding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Band slippage and gastric prolapse after gastric banding</div><div class=\"cntnt\"><img style=\"width:286px; height:356px;\" src=\"images/SURG/56993_Band_slippage_gastric_prol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This x-ray shows a slipped gastric band creating esophageal dilatation.&nbsp;The arrow points to the band.</div><div class=\"graphic_footnotes\">AS: anterior slippage of the pouch; P: pouch; S: stomach.</div><div class=\"graphic_reference\">Courtesy of Raul J Rosenthal, MD, FACS, FASMBS.</div><div id=\"graphicVersion\">Graphic 56993 Version 3.0</div></div></div>"},"56994":{"type":"graphic_waveform","displayName":"ECG atrial tachycardia with block","title":"Single-lead electrocardiogram (ECG) showing atrial tachycardia with 2:1 atrioventricular (AV) block","html":"<div class=\"graphic normal\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing atrial tachycardia with 2:1 atrioventricular (AV) block</div><div class=\"cntnt\"><img style=\"width:464px; height:99px;\" src=\"images/CARD/56994_Atrial_tach_with_2_1_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial tachycardia with 2:1 atrioventricular (AV) block. The atrial rate is about 160 beats/min while the ventricular rate is about 80 beats/min. The nonconducted P waves (arrows) are superimposed on the ST-T segments. The P waves have a similar morphology to normal P waves suggesting that the ectopic site is near or even in the sinoatrial node. This arrhythmia may be an important sign of digoxin toxicity, but can also occur in other settings.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 56994 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"56995":{"type":"graphic_table","displayName":"Causes of myocarditis","title":"Major causes of myocarditis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of myocarditis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious causes</td> </tr> <tr> <td class=\"subtitle2_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Adenovirus</td> </tr> <tr> <td class=\"indent1\">Arborvirus</td> </tr> <tr> <td class=\"indent1\">Coxsackie B virus</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Dengue</td> </tr> <tr> <td class=\"indent1\">Echovirus</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> </tr> <tr> <td class=\"indent1\">Hepatitis B and C</td> </tr> <tr> <td class=\"indent1\">Herpesvirus</td> </tr> <tr> <td class=\"indent1\">HIV</td> </tr> <tr> <td class=\"indent1\">Influenza A and B</td> </tr> <tr> <td class=\"indent1\">Mumps</td> </tr> <tr> <td class=\"indent1\">Parvovirus</td> </tr> <tr> <td class=\"indent1\">Poliomyelitis</td> </tr> <tr> <td class=\"indent1\">Rabies</td> </tr> <tr> <td class=\"indent1\">Rubella</td> </tr> <tr> <td class=\"indent1\">Rubeola</td> </tr> <tr> <td class=\"indent1\">Vaccinia (smallpox vaccine)</td> </tr> <tr> <td class=\"indent1\">Varicella</td> </tr> <tr> <td class=\"indent1\">Variola</td> </tr> <tr> <td class=\"indent1\">Yellow fever</td> </tr> <tr> <td class=\"subtitle2_single\">Bacterial</td> </tr> <tr> <td class=\"indent1\">Bartonella</td> </tr> <tr> <td class=\"indent1\">Brucellosis</td> </tr> <tr> <td class=\"indent1\">Chlamydia</td> </tr> <tr> <td class=\"indent1\">Cholera</td> </tr> <tr> <td class=\"indent1\">Clostridial</td> </tr> <tr> <td class=\"indent1\">Diphtheria</td> </tr> <tr> <td class=\"indent1\">Gonococcal</td> </tr> <tr> <td class=\"indent1\">Haemophilus</td> </tr> <tr> <td class=\"indent1\">Legionella</td> </tr> <tr> <td class=\"indent1\">Meningococcal</td> </tr> <tr> <td class=\"indent1\">Mycoplasma</td> </tr> <tr> <td class=\"indent1\">Pneumococcal</td> </tr> <tr> <td class=\"indent1\">Psittacosis</td> </tr> <tr> <td class=\"indent1\">Salmonella</td> </tr> <tr> <td class=\"indent1\">Staphylococcal</td> </tr> <tr> <td class=\"indent1\">Streptococcal</td> </tr> <tr> <td class=\"indent1\">Tetanus</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Tularemia</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious causes (cont.)</td> </tr> <tr> <td class=\"subtitle2_single\">Spirochetal</td> </tr> <tr> <td class=\"indent1\">Leptospirosis</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> </tr> <tr> <td class=\"indent1\">Relapsing fever</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"subtitle2_single\">Mycotic</td> </tr> <tr> <td class=\"indent1\">Actinomyocosis</td> </tr> <tr> <td class=\"indent1\">Aspergillosis</td> </tr> <tr> <td class=\"indent1\">Blastomycosis</td> </tr> <tr> <td class=\"indent1\">Candidiasis</td> </tr> <tr> <td class=\"indent1\">Coccidiomycosis</td> </tr> <tr> <td class=\"indent1\">Cryptococcosis</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis</td> </tr> <tr> <td class=\"indent1\">Mucormycosis</td> </tr> <tr> <td class=\"indent1\">Nocardia</td> </tr> <tr> <td class=\"indent1\">Sporotrichosis</td> </tr> <tr> <td class=\"subtitle2_single\">Rickettsial</td> </tr> <tr> <td class=\"indent1\">Q fever</td> </tr> <tr> <td class=\"indent1\">Rocky mountain spotted fever</td> </tr> <tr> <td class=\"indent1\">Typhus</td> </tr> <tr> <td class=\"subtitle2_single\">Protozoal</td> </tr> <tr> <td class=\"indent1\">Amebiasis</td> </tr> <tr> <td class=\"indent1\">Chagas' disease (South American trypanosomiasis)</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr> <td class=\"indent1\">Sleeping sickness (African trypanosomiasis)</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis</td> </tr> <tr> <td class=\"subtitle2_single\">Helminthic</td> </tr> <tr> <td class=\"indent1\">Ascariasis</td> </tr> <tr> <td class=\"indent1\">Echinococcosis</td> </tr> <tr> <td class=\"indent1\">Filariasis</td> </tr> <tr> <td class=\"indent1\">Paragonimiasis</td> </tr> <tr> <td class=\"indent1\">Schistosomiasis</td> </tr> <tr> <td class=\"indent1\">Strongyloidiasis</td> </tr> <tr> <td class=\"indent1\">Trichinosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Noninfectious causes</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiotoxins</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">Anthracyclines</td> </tr> <tr> <td class=\"indent1\">Arsenic</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Catecholamines</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Heavy metals (copper, lead, iron)</td> </tr> <tr> <td class=\"indent1\">Methysergide</td> </tr> <tr> <td class=\"subtitle2_single\">Hypersensitivity reactions</td> </tr> <tr> <td class=\"indent1\">Antibiotics (penicillins, cephalosporins, sulfonamides)</td> </tr> <tr> <td class=\"indent1\">Clozapine</td> </tr> <tr> <td class=\"indent1\">Diuretics (thiazide, loop)</td> </tr> <tr> <td class=\"indent1\">Dobutamine</td> </tr> <tr> <td class=\"indent1\">Insect bites (bee, wasp, spider, scorpion)</td> </tr> <tr> <td class=\"indent1\">Lithium</td> </tr> <tr> <td class=\"indent1\">Methyldopa</td> </tr> <tr> <td class=\"indent1\">Snake bites</td> </tr> <tr> <td class=\"indent1\">Tetanus toxoid</td> </tr> <tr> <td class=\"subtitle2_single\">Systemic disorders</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> </tr> <tr> <td class=\"indent1\">Collagen-vascular diseases</td> </tr> <tr> <td class=\"indent1\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"indent1\">Hypereosinophilia</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease (Crohn's disease, ulcerative colitis)</td> </tr> <tr> <td class=\"indent1\">Kawasaki disease</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Thyrotoxicosis</td> </tr> <tr> <td class=\"subtitle2_single\">Radiation</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 56995 Version 4.0</div></div></div>"},"56996":{"type":"graphic_table","displayName":"Risk aggressive behavior GIST","title":"Proposed approach for defining risk of aggressive behavior in gastrointestinal stromal tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed approach for defining risk of aggressive behavior in gastrointestinal stromal tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Size*</td> <td class=\"subtitle1\">Mitotic count<sup>&#182;</sup></td> </tr> <tr> <td><strong>Very low risk</strong></td> <td>&#60;2 cm</td> <td>&#60;5 per 50 HPF</td> </tr> <tr> <td><strong>Low risk</strong></td> <td>2-5 cm</td> <td>&#60;5 per 50 HPF</td> </tr> <tr> <td rowspan=\"2\"><strong>Intermediate risk</strong></td> <td>&#60;5 cm</td> <td>6-10 per 50 HPF</td> </tr> <tr> <td>5-10 cm</td> <td>&#60;5 per 50 HPF</td> </tr> <tr> <td rowspan=\"3\"><strong>High risk</strong></td> <td>&#62;5 cm</td> <td>&#62;5 per 50 HPF</td> </tr> <tr> <td>&#62;10 cm </td> <td>Any mitotic rate</td> </tr> <tr> <td>Any size</td> <td>&#62;10 per 50 HPF</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPF: high powered fields.<br />* Size represents the single largest dimension. Admittedly this may vary somewhat before and after fixation and between observers. There is a general but poorly defined sense that perhaps the size threshold for aggressive behaviour should be 1 to 2 cm less in the small bowel than elsewhere.<br />¶ Ideally mitotic count should be standardized according to surface area examined (based on size of high power fields), but there are no agreed definitions in this regard. Despite inevitable subjectivity in recognition of mitoses and variability in the area of high power fields, such mitotic counts still prove useful.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher, CD, Berman, JJ, Corless, C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Int J Surg Pathol 2002; 10:81. Copyright &copy;2002 Westminster Publications.</div><div id=\"graphicVersion\">Graphic 56996 Version 3.0</div></div></div>"},"56997":{"type":"graphic_picture","displayName":"Intraop bladder exstrophy","title":"Intraoperative picture of a male infant during a complete primary bladder exstrophy repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraoperative picture of a male infant during a complete primary bladder exstrophy repair</div><div class=\"cntnt\"><img style=\"width:304px; height:380px;\" src=\"images/PEDS/56997_Intraop_bladder_exstrophy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 56997 Version 2.0</div></div></div>"},"56998":{"type":"graphic_diagnosticimage","displayName":"Malignant TEF CT","title":"Malignant tracheoesophageal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant tracheoesophageal fistula</div><div class=\"cntnt\"><img style=\"width:390px; height:266px;\" src=\"images/PULM/56998_Malignant_TEF_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan shows a tracheoesophageal fistula due to advanced esophageal carcinoma.</div><div id=\"graphicVersion\">Graphic 56998 Version 2.0</div></div></div>"}};